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Abstract 
This thesis describes a modular diversity-oriented synthesis approach, which exploited 
a ‘build→couple→couple→pair’ reaction sequence, to generate a library of natural 
product-like macrocycles. The use of a fluorous−tagged building block allowed the 
expedient purification of the substrates between the ‘couple→couple’ stages of the 
sequence. Building blocks were iteratively linked onto the fluorous tagged building 
block to give linear substrates bearing two terminal alkenes. These substrates were 
subjected to ring-closing metathesis to yield diverse macrocyclic scaffolds. 
Subsequent, deprotection and diversification steps yielded natural product-like 
macrocycles. Using this approach, over 13 macrocyclic scaffolds were prepared which, 
in turn, after diversification, yielded over 55 diverse macrocycles, each with unique 
scaffolds. In addition this project also saw the synthesis of the corresponding linear 
compounds.  
 
Chapter 1 discusses the importance of macrocycles in nature, how this class of 
molecules have been poorly explored and methods that have been used to explore 
chemical space. Chapter 2 describes the synthesis of the building blocks and the 
proposed method to prepare the library of diverse macrocycles. Chapter 3 explores the 
reactivity of the building blocks and developments required to improve the efficiency of 
the library synthesis. Chapter 4 describes the final library synthesis from building 
blocks to final compounds. This work aims to prepare compounds with potential 
bioactivity; however, the biological evaluation of the compounds is beyond the remit of 
the study. 
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1 Introduction 
1.1 The importance of macrocyclic small molecules 
Macrocyclic small molecules are of tremendous interest both as targets for synthetic 
chemistry and as biologically functional compounds.1 This interest has largely stemmed 
from macrocyclic natural products that exhibit interesting and diverse biological 
activity;2 macrocycles may be used as chemical tools for probing biological 
mechanisms and as starting points for drug discovery. The medicinally-relevant 
properties of macrocyclic natural products include immunosupression,3 anti-cancer and 
antibiotic activity; these activities are displayed by rapamycin 14,5 epithilone B 36,7,8 and 
erythromycin 29 respectively (Figure 1). 
 
 
Figure 1 The chemical structures of rapamycin 1, erythromycin 2 and epithilone B 3 
1.1.1 Broad structural features of macrocycles 
Macrocycles are an interesting class of molecules which bridge the gap between 
conventional small molecules and biological macromolecules;1 the molecular masses 
of macrocycles typically do not generally comply with the Lipinski ‘Rule of 5’10–12 
guidelines that have dominated medicinal chemistry. Macrocycles are considered to 
possess rings with 12 or more covalently bonded atoms.2 The cyclic structure reduces 
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the number of rotatable bonds compared to comparable acyclic molecules,13 restricting 
conformation and reducing the entropic penalty associated with binding to a protein.  
Macrocyclization also imparts topology into the molecule, often yielding two distinct 
‘faces’, allowing a large surface area of protein binding site to be targeted.11,12,13,6,14 
1.1.2 Effect of macrocyclization on biological activity 
Macrocyclization has become a significant tactic in drug discovery programmes. Table 
1 summarises selected cases where macrocyclization has had a beneficial effect on 
biological function.  The structure of the complex between the bound linear compound 
4 and BACE-1 highlighted the proximity of the two ends of the bound molecule; 
macrocyclization, to give 5, resulted in a 34-fold improvement in affinity (entry 1).  The 
researchers subsequently exploited the macrocycle 5 as a starting point for the 
discovery of compounds with low nanomolar affinity (not shown).18 The checkpoint 
kinase-1 inhibitor 7 was developed following modelling studies of a linear compound 
(not shown);19 a 440-fold increase in binding was observed relative to 6 (entry 2). The 
tetrahydroisoquinoline-3-carboxylamide 8 was identified as a micromolar inhibitor (Ki: 
15 µM) of the hepatitis C virus non-structural protein 3 (HCV-NS3).20  Crystallographic 
studies showed that, upon binding, the capping Boc group was in close proximity to the 
aromatic ring. The macrocyclic analogue 9 of the tetrahydroisoquinoline-3-
carboxylamide 8 was then prepared and displayed a ca. 70-fold improvement in 
binding (entry 3). NMR experiments revealed that the piperazinone 10 undergoes a 
considerable conformational change on binding to farnesyl transferase (FTase). The 
cyclised variant 11, which adopts a similar conformation to the bound ligand, was 
therefore prepared; its affinity for FTase was 55,000-fold higher than the comparable 
acyclic variant 10 (entry 4).21  
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Table 1 Biological activity of selected macrocycles and their acyclic counterparts  
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β-secretase 
IC50 
>100 µM 
 
IC50 
2.9 
µM 
>34  
219 
 
ChK1 
inhibition 
IC50 
4.4 µM 
 
 
IC50 
10 nM 
440 
320 
 
HCV NS3 
Protease 
Ki 
15 µM 
 
Ki 
0.015 
µM 
1000 
421 
 
FTase 
IC50 5490 nM 
 
IC50 
0.1 
nM 
55,000 
      
Macrocyclization may also be used as a tactic to control the selectivity of bioactive 
small molecules. Macrocyclization of the broad-spectrum matrix metalloproteinase 
(MMP) inhibitor 13, to give 12, resulted in significantly more selective ligands. 
Cyclisation increased inhibitory activity towards MMP8 (K i: 293 nM for 13 compared to 
17 nM for 12), whilst activity against other MMPs remained either similar or was 
reduced (in the case of MMP2 and MMP9). The macrolactone 14 was also synthesised 
and displayed increased activity towards MMP8; however the inhibition of MMP2 and 3 
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was also improved.22,23 It is likely that increased target specificity stems from the 
restricted conformation of the macrocycles compared to the acyclic variant 13. 
 
Figure 2 Comparison of selectivity of the MMP inhibitors 12, 13 and 14; Ki (nM) 
1.1.3 Effect of macrocyclization of pharmacokinetic properties  
Macrocyclization can also improve the pharmokinetic properties of small molecules. 
Although peptides can be effective inhibitors they are generally susceptible to 
enzymatic hydrolysis.24  However, in many cases, cyclisation can provide resistance to 
hydrolysis, in general by stabilising a conformation that is not targeted by 
proteases.25,26 For example, the in vitro stability of linear compound 15 and macrocycle 
16 were examined in rat plasma; after 5 h only ca. 70% of 15 remained, whereas the 
macrocycle 16 showed no detectable degradation. 
 
 
 
Figure 3 Chemical structures of peptide deformylase inhibitors 15 and 16. 16 KI 0.67 nM 
Efficacious drugs must be able to reach their protein target in vivo. Macrocyclization 
can improve membrane permeability by satisfying hydrogen bonding requirements 
intramolecularly and through reducing the number of effective rotatable bonds. 
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Veber et al. examined the contribution of molecular rigidity to oral bioavailability. It was 
found that ca. 65% of molecules that have  7 rotatable bonds achieve  20% oral 
bioavailability in rats; in contrast only ca. 25% of molecules that have  10 rotatable 
bonds only achieve <20% oral bioavalability.13 
1.2 Macrocyclization Methods 
The key step in the synthesis of most macrocycles is the ring-forming step. Polyketide 
synthases carry out this step using the terminal thioesterase to effect the concomitant 
cyclisation and release of macrocycles.27 The macrocyclization step can be problematic 
in the laboratory due to competing intermolecular reactions which can lead to low-
yields for the required product and the formation of oligomers.15,28 The rate of 
cyclization, however is extremely dependent on ring size (see Graph 1). Numerous 
methods have been developed or adapted to overcome these problems and facilitate 
macrocyclization; the main methods include macrolactonization (see Section 1.2.3), 
macrolactamization29,30,31 and ring-closing metathesis,32 often under high dilution 
conditions (see section 1.2.1). However other methods have been developed to 
facilitate ring-closure; SNAr,
33 Wittig,34 Stille,35 Buchwald—Hartwig,36 Sonogashira,37–
40Heck41,42 and Suzuki43–46 reactions. Ultimately, the choice of ring closure depends on 
the functionality accepted within the target molecule. The kinetics of ring closing is well 
understood; Illuminati measured the rates of ring closure of ω-Bromo Acids to give the 
corresponding (macro)lactones (see Graph 1).47 The study showed that whilst ring 
closing of large rings (>12) is considerably slower than small rings (4-6), it was 
considerably faster than that of medium rings (8-12). 
 
 
Graph 1 Relative rate of cyclization of ω-Bromo Acids, Br(CH2)n-2CO2H, in 99% aqueous DMSO
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1.2.1 Ring-closing metathesis 
Ring-closing metathesis (RCM) has received huge interest, and has become a 
cornerstone of synthetic organic chemistry;48,49,50 The approach is now one of the most 
utilised methods for macrocyclisation,51,49 notably in the synthesis of natural products.52 
Metathesis catalysts have been developed to improve their stability, reactivity and 
selectivity.50  The value of RCM stems from the lack of reactivity of carbon-double 
bonds under many reaction conditions (enables the synthesis of substrates), together 
with the high selectivity of the catalysts (in the cyclisation step). Ruthenium-based 
catalysts such as the Grubbs first- (17) and second- (18) generation catalysts and the 
Hoveyda—Grubbs first- (19) and second- (20) generation catalysts are most widely 
used in metathesis reactions; in particular, 19 and 20 have excellent reactivity and are 
tolerant to non-inert conditions.53 
 
Figure 4 Structures of metathesis catalysis   
The functional group created in ring-closing metathesis reactions is an alkene which 
can facilitate subsequent functionalization (e.g. via epoxidation, dihydroxylation or 
hydrogenation). The effectiveness of ring-closing metathesis is highlighted by the large 
scale synthesis of a HCV protease inhibitor BILN 2061 21.54,55 The ring-closing step 
was facilitated by the treatment of the acyclic substrate (not shown) with 0.1 mol% of a 
customised ruthenium catalyst (not shown) in toluene at reflux; this method resulted in 
>90% yield, with quantitative conversion and was scaled up to 400 kg. 
 
Figure 5 Chemical structure of BILN 2061 21 
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1.2.2 ‘Click’ Macrocyclization 
The ‘click’ cycloaddition56 reaction between alkynes and azides is another viable 
method to prepare macrocycles; however this reaction can also suffer from significant 
dimer and oligomer formation. The approach has been used to synthesis bioactive 
macrocycles; however the resultant triazole moiety is inevitably part of the final 
molecule. Peptidomimetics, including the tyrosinase inhibitor 22 have been prepared 
using ‘click’ chemistry. Treatment of the acyclic variant of 22 (not shown) with copper(I) 
bromide yielded the cyclic triazole 22 in 36% yield.57,58  
 
Figure 6 Chemical structure of tyrosinase inhibitor 22
57,58
 (IC50 = 0.6 mM) 
1.2.3 Macrolactonization  
Macrolactonization is an efficient method for the preparation of a variety of natural 
products;59 many macrocyclic natural products are macrolactones2, many of which are 
biosynthesised via polyketide synthase-catalysed cyclisation. Macrolactonization is a 
viable method for preparing macrocycles with ring size at least 12 (Graph 1). There are 
numerous methods that can facilitate macrolactonization; for example, the Mitsunobu 
reaction60 and the Yamaguchi61 method which proceeds via a mixed anhydride 
intermediate. The Yamaguchi mixed anhydride method can prove an efficient 
macrolactonization method. Erythronolide precursor 23, a parent compound of several 
antibiotics, undergoes the Yamaguchi lactonization, to yield selectively the 
corresponding 14-membered macrocycle 25, in 85% yield (Scheme 1).62 
 
Scheme 1 Macrolactonization of 23 to give erythronolide precursor 25 via the Yamaguchi esterification 
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1.3 Diversity-oriented synthesis 
Small molecules have aided enormous advances in the understanding of biological 
systems and our ability to treat disease.63,64 Synthetic approaches that allow expedient 
access to libraries of diverse small molecules are hugely valuable. Diversity-orientated 
synthesis (DOS) aims to prepare a broad distribution of compounds in chemical space. 
As DOS does not aim for a specific target molecule compared to a target-orientated 
synthesis, retrosynthetic analysis cannot be applied. DOS has gathered interest in 
recent years as a method to access libraries of skeletally diverse compounds which 
ultimately can yield chemical probes of biological systems.65–68 
 
1.3.1 Folding pathways in Diversity-Oriented Synthesis 
The folding path approach exploits common reaction conditions to convert multiple 
substrates into multiple products. Schreiber used rhodium(II)-catalyzed consecutive 
cyclisation-cycloaddition chemistry69–71 to prepare alternative densely-functionalised 
polycyclic skeletons (Scheme 2, Panel A).72 Appended to the substrates 26, 27 and 28 
were strategically-positioned α-diazo ketocarbonyl and indole moieties; upon treatment 
with a catalytic amount of rhodium(II) octanoate dimer in benzene, these substrates 
were converted into alternative products. Presumably, formation of a carbonyl ylid was 
followed by 1,3-dipolar cycloaddition with the indole to give polycyclic skeletons such 
as 29, 30 and 31. Oguri73 used the same approach to generate alkaloid-like products 
(Scheme 2, Panel B). By varying the position of the reactive groups, the scaffolds of 
the natural products aspidophytine (not shown) and the transtaganolides 34 could be 
prepared. 
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Scheme 2 Rhodium-catalysed ylid formation-cycloaddition approaches to natural product-like compounds.  
Panel A: Schreiber’s approach to indole alkaloid-like compounds.  Panel B: Oguri’s approach to 
transtaganolides. 
A multicomponent reaction, involving secondary amines 35, carbonyl compounds 36 
and triazines 37, was used to generate the substrates for a folding pathway leading to 
alkaloid-like compounds (Scheme B).74 The approach utilised a single reaction, using 
largely commercially available compounds, to synthesise the folding substrates and 
hence products. Condensation of secondary amines 35 with the carbonyl compounds 
36 generated enamines 38 in situ which underwent an inverse-electron demand 
Diels—Alder reaction with the triazine 37 to yield compounds of general structure 39. 
Expulsion of molecular nitrogen yielded 2-azadienes (40), some of which could 
undergo further reaction (e.g. Diels-Alder reaction) with functionality (sometimes known 
as σ-elements)75  elsewhere in the molecule.  
10 
 
  
Scheme 3 Generation of folding substrates using a multicomponent reaction 
The functional groups within 40 thus ultimately determined the final molecular scaffold 
obtained. Thus, with a tethered dienophile in place, an intramolecular Diels—Alder 
occurred (41a, c and d → 42, 44 and 45); in contrast, with an appropriate nucleophile, 
attack into the imine occurred (41d →49  via 45) (Scheme 4). The unreacted imine 43, 
and the resultant imines from the Diels—Alder of 41a and 41c, were substrates for a 
second three-component coupling: a Joullié—Ugi reaction. The cyclic imines 42 and 
44, and the 2-aza diene 43, were reacted with an isocyanide and carboxylic acid to 
give final compounds such as 46, 47 and 48. 
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Scheme 4 Sarah Murrison’s approach to a library of alkaloid-like compounds; a) 4 Å molecular sieves, 
toluene, imine, carboxylic acid, isocyanide, EtOH. 
1.3.2 Branching pathways in Diversity-Oriented Synthesis 
In contrast to folding pathways, branching pathways utilise complementary reactions to 
convert a common intermediate into a range of scaffolds. 
A branching pathway exploited a range of cyclization reactions to generate six 
scaffolds, two of which can be further diversified to yield four more scaffolds (Scheme 
5).76 Using a four-component Petasis reaction, Schreiber et al. were able to synthesise 
versatile cyclization precursors (such as 49). The cyclizations exploited the dense 
functionality of 49: a Pauson—Khand reaction liberated 50; a gold-catalysed cyclisation 
of an alcohol onto an alkyne liberated the acetal 54; a ruthenium-catalysed reaction 
gave the cyclohepadiene 52; and enyne metathesis, catalysed by the Hoveyda—
Grubbs 2nd generation catalyst, liberated the diene 55.  Base-induced cyclization of 49 
gave the lactone 53, which was also subjected to the same metal catalysed 
cyclizations: this approach yielded the triene 57, the cycloheptadiene 60, the 
cyclopentenone 59 and the diene 58 (Scheme 6). The reactivity of the diene 55 was 
also investigated and it was shown that hetero-Diels—Alder with 4-methyl-1,2,4-
triazoline-3,5-dione gave the adduct 56 (Scheme 5). 
12 
 
 
Scheme 5 Complementary metal-catalysed reactions leading to diverse scaffolds. 50: Co2(CO)8, Et3NO 
NH4Cl, benzene, rt; 51: Pd(PPh3)2(OAc)2 (10 mol%) benzene, 80 °C; 52:  CpRu(MeCN)3PF6 (10 mol%), 
acetone, rt; 53: NaH, toluene, rt; 54:  NaAuCl4 (10 mol%), MeOH, rt; 55:  Hoveyda—Grubbs 2
nd
 gen. cat 
(10 mol%), CH2Cl2; 56: 4-methyl-1,2,4-triazoline-3,5-dione, CH2Cl2, 
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Scheme 6 Exploitation of metal-catalysed reactions to convert 53 into diverse scaffolds. 57: 
Pd(PPh3)2(OAc)2 (10 mol%), benzene, 80 °C; 59: Co2(CO)8, Et3NO NH4Cl, benzene, rt; 60: 10 mol% 
CpRu(MeCN)3PF6 (10 mol%), acetone, rt; 58: Hoveyda—Grubbs 2nd gen. cat. (10 mol%), CH2Cl2, 
Stockman et al. have exemplified a powerful branching approach to twelve small and 
densely substituted natural product-like scaffolds (Scheme 7).77 The approach exploits 
the diverse reactivity of ketones coupled with the promiscuity of α,β-unsaturated esters. 
Treatment of 61 with hydroxylamine hydrochloride to form an oxime was followed by a 
tandem aza-Michael/1,4-prototopic shift/intramolecular [3+2] cycloaddition which gave 
the azaspirocycle 68. Amongst amine-based transformations of the central ketone of 
61, it was also shown that the ketone itself can be used as a pro-nucleophile: treatment 
of 61 with sodium hydride gave the trans-decalin 64. Furthermore, treatment of the 
ketone 61 with two equivalents of SmI2 gave the bicyclic lactone 69; however, with five 
equivalents of SmI2, the carbocycle 65 was obtained. The ketone of 61 was able to 
undergo some more conventional transformations: reduction and treatment with methyl 
lithium resulted in the secondary and tertiary alkoxides respectively and, through oxy-
Michael additions, the corresponding tetrahydropyrans 66. Treatment of 61 with methyl 
magnesium bromide liberated the expected tertiary alcohol 70. Thus the approach 
yielded a small library of diverse scaffolds; using related chemistry it was also possible 
to synthesise a key intermediate (not shown) in a synthesis of the macrocycle 
halichlorine (not shown).78 
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Scheme 7 Stockman’s approach to scaffold diversity using the reactivity of α,β-unsaturated esters and 
ketones. Conditions to initiate scaffold construction; 62, NaBH4, NH3, EtOH, Ti(OEt)4 then AcOH, 74%; 63 
PhNH2, TiCl4, CH2Cl2, 65%; 64, 70%, NaH, THF; 65, SmI2 (5 eq.), THF/MeOH, −78 °C, 70%; 66, super-
hydride, THF, 50% or MeLi, 19%; 67, glycine ethyl ester, DIPEA, 71%; 68, NH2OH•HCl, NaOAc, 
MeOH/MeCN, 60 °C, 68%; 69, SmI2 (2 eq.), THF/MeOH, −78 °C, 70%; 70, MeMgBr, 85%; 71, 
NH2OH•HCl, NaOAc, MeCN then PhMe, mw 140 °C, 12%,  or PhCl, reflux after 68, 39%; 72, NH2OH•HCl, 
NaOEt, EtOH, 12%, or NaOEt after 68, 89%; 73, NH2NHTs PhMe, reflux, 41% 
1.3.3 Oligomer-based approaches in Diversity-Oriented synthesis 
One powerful approach to synthesising a library of compounds combines elements of 
both folding and branching pathways in a so called ‘build-couple-pair’ approach.79 This 
powerful strategy involves a ‘build’ phase where monomers with specific reactivity are 
prepared and joined in a ‘couple’ phase. Finally, the oligomeric substrates are then 
‘paired’ in subsequent cyclisation reactions.80  
15 
 
This approach was harnessed in the synthesis of small, densely substituted 
heterocycles (72→77) (Scheme 8).81–84 Firstly, peptide synthesis was used to prepare 
peptides 71 which contained a masked aldehyde, an amine and a pendant nucleophile. 
Treatment of the solid supported peptides 71 with acid initiated unmasking of the latent 
aldehyde, N-acyliminium formation and interception by alternative nucleophiles (for 
example, a furan → 76: an alcohol → 73; an indole → 77; and a carboxamide → 72).  
 
Scheme 8 Meldal’s folding approach to a range of molecular scaffolds utilising N-acyliminium cyclizations; 
[a] HPLC purity  
Metathesis cascades have provided rapid routes to skeletally-diverse small molecule 
libraries.85,86 One compelling approach resulted in the preparation of over eighty distinct 
molecular scaffolds (Scheme 9). Oligomeric metathesis substrates were prepared by 
iterative attachment of unsaturated building blocks onto a fluorous-tagged linker; the 
iterative coupling reactions included the Fukuyama-Mitsunobu reaction, silaketal 
formation and esterification. Finally, treatment of the oligomers (e.g. 86 and 87) with 
ruthenium-based catalysts ‘reprogrammed’ the scaffolds of the molecules. For 
example, the ‘propagating’ cylcopentene building blocks 80 or 81 could be attached to 
a fluorous-tagged ‘initiating’ building block 78 or 79 using either a Fukuyama—
Mitsunobu reaction or silaketal (→ 82 or 83, respectively). Deprotection, and 
attachment of a ‘terminating’ building block gave metathesis substrates (for example, 
86 and 87). Finally, metathesis ‘reprogramming’ of the substrates and concomitant 
release from the fluorous tag, and if applicable removal of the silaketals, yielded the 
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final products; this approach yielded over eighty distinct scaffolds (two-thirds of which 
were novel).  
 
 
Scheme 9 Nelson’s approach to scaffold diversity exploiting metathesis cascade chemistry. Examples of 
other products prepared include 90-92 
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1.4 Diversity-oriented synthesis of macrocycles 
The ‘build-couple-pair’ approach has been applied to the synthesis of a library of 
macrocycles (Scheme 10).87 Initially, building blocks 93 and 94 were prepared 
stereoselectively. Combination of 93 and 94 led to numerous stereoisomeric 
intermediates 95. Three reactions were exploited to cyclise substrates; the SNAr 
reaction, the Huisgen [3+2] cycloaddition and ring-closing metathesis. For the SNAr 
cyclisation, intermediates 95 were treated with 2-fluoro-5-nitrophenyl carbonyl chloride 
96; deprotected to give 97; and treated with base to affect cyclisation to 8- or 9- 
membered rings 98. Similarly, acylation of the amine 95 with the azido acid 99, 
deprotection and propagarylation yielded the cycloaddition substrate 100; treatment of 
the substrate 100 with either a ruthenium- or copper-based catalyst afforded 
respectively the regioisomeric macrocycles 101 and 102; conversion of the 
intermediate 95 into a metathesis substrate 104, and treatment with Hoveyda—Grubb 
2nd generation catalyst, yielded the corresponding macrocycles 105. 
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Scheme 10 Marcaurelles’s oligomer-based approach to a library of macrocycles, of which many 
stereoisomers were prepared; a) 1) PyBOP, DIPEA, CH2Cl2, 0 °C, 15 h; 2) BH3-DMS, THF, 65 °C; b) 96, 
Et3N, CH2Cl2, 0 ˚C; c) CsF, DMF, 85 ˚C; or TBAF, NH4F; NaH, THF; d) 1) 99, PyBOP, DIPEA, CH2Cl2, rt 
then TBAF, THF, 72-93%; 2) HC≡CCH2Br, NaHMDS, THF, DMF, −78 ˚C, 91-96%; e) [Cp*Rul]4, PhMe, 70 
˚C; f) PS-CsPF6, PhMe, 55 ˚C; g) 1) DIPEA, CH2Cl2; 2) TBAF, THF, 0 ˚C; 3) NaH, allyl bromide, DMF, 0 
˚C, 50-77%; h) Hoveyda-Grubbs 2
nd
 gen cat. (10 mol%) 
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1.4.1 Bioactive Macrocyclic Compounds discovered via DOS methodologies 
Ultimately, the aim of DOS libraries is to explore biologically relevant chemical space. 
88 The macrocycles 106-110 have all been identified to be useful tools for probing 
biological mechanisms and/or are potential starting points for drug discovery (Figure 7). 
The macrocycles 106 and 108 were identified from the same DOS library and target 
different proteins: 106 was identified a micromolar histone deacetylase (HDAC) 
inhibitor (IC50 class 1: 1.5 µM; class 2: 2.8 µM; and class 3: 4.4 µM).
87 Alternatively, 
macrocycle 108 was identified as a novel lead molecule for the treatment of malaria: it 
inhibits a multidrug-resistant strain of P. falciparum parasites (Dd2) with GI50
†*0.54 
nM.89 In a similar vein, screening identified 107 as a compound active against β-cell 
apoptosis which exhibited EC50 0.78 µM.
90 Compounds 109 and 110 were identified, 
using small-molecule microarray technology, as inhibitors of the Shh signalling 
pathways which function by binding directly to the Sonic hedgehog protein.91 
 
 
Figure 7 Bioactive macrocycles identified from DOS libraries 
  
                                                 
†
 GI50 – concentration required for 50% inhibition of cell proliferation 
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1.5 Project outline and design 
In this project, it was proposed to develop a DOS strategy that would enable the 
expedient synthesis of a library of natural product-like macrocycles.  Using only a few 
reactions, it was planned to combine building blocks to yield substrates for cyclisation; 
pairing the termini of the substrate together would generate the macrocyclic scaffolds. 
The cyclic and acyclic products would then be further diversified with a range of 
capping groups. 
The envisaged ‘build-couple-couple-pair’ approach is outlined in Scheme 11; hydroxy 
acetate building blocks would be linked to a fluorous tagged building block such as 
112. After deacetylation, terminating building blocks would be appended to yield 
cyclisation substrates such as 114. Ring-closing metathesis would then be used to 
cyclise the linear substrates to yield macrocycles 115. After revealing a free amine, the 
macrocycles would subsequently be functionalised in a branching fashion by 
attachment of diversifying groups. The development and exemplification of this ‘build-
couple-couple-pair’ approach will be described in the following Chapters. Furthermore, 
the synthesis of the acyclic analogues will be described; the synthesis of these 
analogues would allow direct comparison of the biological relevance of macrocyclic 
compounds with their acyclic counterparts. 
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Scheme 11 The proposed synthetic approach exploits ‘build-couple-couple-pair’ approach. The approach 
is illustrated through the proposed synthesis of the macrocycle 117 and its acyclic counterpart 118  
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1.5.1 Fluorous-tagging technologies 
It was essential that the library be synthesised efficiently as possible; it was decided 
that fluorous-tagging be used to allow expedient purification of intermediates. These 
technologies have numerous benefits over other purification methods such as solid-
phase synthesis. The fluorous tag consists of a perfluorinated octane chain; generally 
the molecules are oils at room temperature, this allows the molecules to undergo 
homogeneous reactions and be analysed and purified by traditional methodologies 
(LC-MS, NMR, TLC, column chromatography). 
 
Picture 1 Demonstration of the fluorous tag using a fluorous tagged dye and a dye containing no fluorous 
tag. The first picture shows the columns in their unloaded states, the second photo is showing the 
compounds being loaded and eluted with 15% water in methanol; this results in the third picture where the 
un-tagged blue dye has been washed out of the mixture. The fluorous tagged compound orange dye can 
now be eluted with methanol (structures not shown).  
1.5.2 Synthetic methods to be exploited 
It was proposed to use the Fukuyama—Mitsunobu reaction, which has been shown to 
be a reliable reaction within the Nelson group, to link building blocks; in addition, 
removal of the 2-nitrobenzenesulfonyl (Ns) group, would reveal an amine for 
derivatization. It was hoped N-Ns amides and carbamates would serve as competent 
nucleophiles, allowing easy differentiation between nitrogen atoms in the deprotected 
scaffolds (Figure 8). For example, if macrocycle 119 (X = H2) was deprotected, then 
two secondary amines would be liberated which would subsequently be difficult to 
distinguish. However, with 119 (X = O), deprotection would liberate an amine and an 
amide which should be easily differentiated (to give 120). An alternative approach was 
to use trifluoromethanesulfonylamides as nucleophiles leading to macrocycles such as 
122 (X = Tf); subsequent deprotection would remove only the Ns group, thus liberating 
only one amine for conversion into final compounds (e.g. 123).  
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Figure 8 Careful selection of nucleophiles for the Fukuyama-Mitsunobu reaction would allow differentiation 
of the groups revealed upon Ns deprotection 
It was also important to select the best methods for the ring-closing steps. It was 
imperative to select an approach in which the functionality needed for cyclisation was 
stable throughout the synthesis, and the use of protecting groups was minimised. 
‘Click’ chemistry has been highlighted as being reliable for macrocyclisation;92,93 
however, a pitfall would be that all final compounds would inherit a triazole unit which 
may dominate their molecular properties. Lactonization and lactamization are proven 
methods for synthesising large rings; however the resulting functional groups 
(especially the lactones) are prone to hydrolysis in biological systems and, in any case, 
intricate protecting group chemistry would be required. Methods that rely on SNAr 
reactions would also require extensive functional group interconversion and/or the use 
of protecting groups. 
It was therefore decided that ruthenium-catalysed ring-closing metathesis would be 
used to initiate the cyclisation of the substrates: the required terminal alkenes are 
resistant to most reaction conditions and protecting group chemistry would not be 
required. The alkene product of ring-closing metathesis is both natural product-like, and 
serves to provide conformational restriction of the macrocycle.  
1.5.3 Design of building blocks and cyclisation substrates 
The design of DOS libraries requires careful consideration.94,66 It was decided to design 
final compounds that had some natural product-like features.  In addition, although the 
final molecules were unlikely to be Lipinski-‘Rule of 5’ compliant, their molecular 
properties were carefully considered. 
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1.5.4 Molecular Properties 
It is well documented that molecular properties that compounds posess can have a 
dramatic effect on their biological availability and activity.11 Lipinski set out the four 
‘rules of five’; in general a orally active compound must have no more than five 
hydrogen bond donors, no more than ten hydrogen bond acceptors, the molecular 
weight must not exceed 500 Daltons and the octanol-water partition coefficient (clogP) 
must not exceed 5. Properties such as clogP are important to predict the distribution of 
a compound in a biological system, compounds that are hydrophobic will favour areas 
such as lipid bilayers whereas hydrophilic compounds will distribute in areas such as 
blood serum. The partition coefficient can be predicted using 2 common methods clogP 
and AlogP; clogP is a fragment based approach whereas AlogP is an atom based 
approach.   
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Table 2 Potential building blocks for the synthesis of a library of diverse macrocycles 
‘Initiating’ ‘Propagating’ ‘Terminating’ Diversifying Groups 
 
   
   
   
 
   
   
 
 
The proposed ‘initiating’ building blocks were fluorous tagged 2-
nitrobenzenesulfonamides which were expected to be competent substrates in 
Fukuyama—Mitsunobu reactions.  It was proposed to append five different 
‘propagating’ building blocks (e.g. the hydroxy acetates 126-130). Deacetylation would 
then reveal an alcohol needed for a second Fukuyama—Mitsunobu reaction.  It was 
proposed to append different terminating building blocks (e.g. the N-Ns carbamates 
131 and 132, the N-Ns amides 133 and 134, and the trifluoromethanesulfonylamide 
135). Subsequent ring-closing metathesis and Ns deprotection would yield secondary 
amines such as 115 (Scheme 11). Diversification with a range of commercially 
available reagents would increase the molecular complexity and skeletal diversity.  
Some of the molecular properties of proposed final compounds are summarised in 
Table 3 (for selected compounds) and in Section 1.5.5 
  
26 
 
Table 3 Example molecular properties of a selection of potential final compounds 
entry scaffold R cLogPa mW 
1 
 
H 2.78 382.4 
 
2.66 502.6 
 
2.48 526.6 
 
3.15 450.5 
 
2.17 495.6 
2 
 
H 3.9 410.5 
 
3.78 530.6 
 
3.59 554.7 
 
4.27 478.6 
 
3.29 523.6 
[a] Calculated using ChemDraw Pro 12.0.2.1076 
1.5.5 Design of a comparative study of acycles and macrocycles 
The macrocyclization of molecules can have a profound effect on their properties 
including their biological activity (see Section 1.1.3).  To undertake a comparative study 
of the properties of macrocycles and their acyclic counterparts, we planned in addition, 
to synthesise the acyclic variants of all the proposed macrocycles. However, the 
biological evaluation of the compounds was beyond the scope of the project.  
1.5.6 Molecular properties of the proposed library  
The combination of building blocks shown in Table 3 would result in a library with 
ALogP values from 6.06 to −0.96 with an average of 2.49;95 molecular weights from 
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256.3 to 748.9 with an average of 493.5; ring sizes from 11 to 21 with the most 
common being 18; and TPSA from 70.6 to 187.3 with an average of 113.2 (see Graphs 
2, 3 and 4). However, the predicted and actual polar surface may deviate dramatically, 
due to the many conformers that macrocycles can adopt there is possibility of ‘burying’ 
the polar surface area; although it has been shown there is a strong correlation 
between the predicted versus reality.96 The molecular properties of many compounds 
did not comply with the Lipinski ‘Rule of 5’; this was expected for a library of 
macrocycles.97  
Graph 2 The distribution of molecular weights versus the atom based prediction
†
 of the logP 
 
  
                                                 
†
 Predicted using Accelrys Pipeline Pilot version 8.5 
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Graph 4 Distribution of the TPSA vs the molecular weights across the proposed library 
 
Graph 5 Distribution of ring sizes across the proposed library 
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2 Building block synthesis 
This Chapter outlines the synthesis of building blocks, for example those proposed in 
section 1.5.2. It was envisaged that there would be three types of building block:  
fluorous-tagged ‘initiating’ building blocks; ‘propagating’ building blocks; and 
‘terminating’ building blocks. 
2.1 Synthesis of initiating building blocks 
   
(Ss)-2-methylpropane-2-sulfinamide 145 and initiating building block 112 
The synthesis of the initiating building block 112 exploited the chiral auxiliary 145, 
developed by Ellman.98–101 Ozonolytic cleavage of the alkene 146 afforded the 
aldehyde 147 in 92% yield; it was found that triphenylphosphine was a much better 
reductant than Me2S because the by-product is highly crystalline, allowing facile 
purification, and the reaction proceeded rapidly at temperatures below 0 °C. The 
aldehyde 147 was condensed with (Ss)-2-methylpropane-2-sulfinamide 145, mediated 
by CuSO4, to give the sulfinimine 148 in 80% yield. 
 
Scheme 12. Preparation of sulfinimine 148  
The stereoselectivity of the addition of allyl magnesium bromide to the imine 148 
depended strongly on the reaction conditions used.  Initially, poor stereoselectivity was 
observed (ca. 40:60).  However, the stereoselectivity was markedly improved by slow 
addition of the Grignard reagent, presumably allowing better control of the temperature 
of the reaction: under these conditions, a 21:79 mixture of the separable 
diastereoisomeric products was obtained (Scheme 13).  The major sulfonamide 150 
was deprotected by methanolysis under acidic conditions to give the hydrochloride salt 
151 in 99% yield (Scheme 13). The amino alcohol 151 was converted into the 2-
nitrobenzenesulfonamide 152 in 90% yield. The fluorous-tagged silane 153 was treated 
with NBS to form the corresponding bromosilane which was reacted in situ102,103 with 
the alcohol 152 to give the silyl ether 112 in 95% yield. The synthesis was performed 
on a large scale to give 30 g of the sulfonamide 112.  
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Scheme 13. Synthesis of the initiating building block 112 
 
 
Figure 9 Structure of 
F
DIPESH
 
 
The sense of induction from the chiral auxiliary in 148 was independently determined 
using chiral HPLC (see figure 10). Surprisingly, it was found that the major 
diastereomer 150 did not have the relative configuration reported by Ellman. 
Deprotection of the major diastereomer 150 using acidic methanolysis gave the (R)-2-
aminopent-4-enol, determined by optical rotation (-10.6 vs +14.198). Further 
investigation concluded that the major diastereomer that we and Ellman et al., had 
synthesised appeared to be the same compound by comparison of optical rotation 
(+57.6 vs +57.8) and 75 MHz 13C NMR spectral data (Table 4)‡ 
  
                                                 
‡
 The signals in 150 were similarly shifted relative to those in Ellman’s major product.   
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Table 4 
13
C spectra data for the products of the addition to the sulfinimine 
150
a
 deviation Ellman major
b
 deviation 149
a
 
134.78 -0.48 ↓ 134.3 -0.18 ↓ 134.48 
118.92 -0.42 ↓ 118.5 0.95 ↑ 117.55 
65.35 -0.45 ↓ 64.9 -0.48↓ 65.38 
56.82 -0.42 ↓ 56.4 0 56.4 
56.23 -0.48 ↓ 55.8 0.11 ↑ 55.69 
37.48 -0.43 ↓ 37 0.22 ↑ 36.78 
26.24 2.26 ↑ 28.5 2.67 ↑ 25.83 
22.98 -0.48 ↓ 22.5 -0.15 ↓ 22.65 
18.63 -0.43 ↓ 18.2 0.01 ↑ 18.19 
-5.29 0.21 ↑ -5.5 0.28 ↑ -5.22 
-5.35 0.15 ↑ -5.5 0.16 ↑ -5.34 
[a] Recorded in CDCl3 at 75 MHz [b] Recorded at 100 MHz in CDCl3 
 
Graph 6 Deviations in the 
13
C NMR of 149 and 150 from the major isomer that Ellman reports.  
The racemic and enantiomerically pure amino alcohols were synthesised so that a 
quantitative method such as chiral HPLC could be used to determine the sense of 
induction. The rac-allyl glycinol was prepared from the parent allyl glycine 154; methyl 
ester formation to give 155 followed by LiAlH4 reduction to give amino alcohol 156 in 
94% yield. In a similar vein, the enantiomerically pure (R)-2-aminopent-4-enoic acid 
(R)-154 was converted into the amino-alcohol (R)-156. The amino alcohols 156, (R)-
156 and 151 were converted into the corresponding benzamides 157, (R)-157 and 158 
in 51%, 59%, and 88% yield respectively. Chiral HPLC showed good separation of the 
enantiomeric benzamides (Panel A, Figure 10) and conclusively showed that the 
amino-alcohol liberated from the major diastereomer prepared by Ellman was in fact 
the (R) isomer, and not the (S) isomer as stated. This was confirmed further through 
the determination of a crystal structure of one of the final compounds 159 (Figure 11). 
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Scheme 14 Synthesis of the molecules for chiral HPLC analysis 
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Figure 10 Chiral HPLC
§
 chromatograms of the alcohols 157, (R) 157 and 158. 
                                                 
§
 5% IPA/nHexane AD-H column 
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34 
 
 
 
Figure 11 Left: Crystal structure of (5E,3R)-3-(hydroxymethyl)-N-(pyridin-3-yl)-9-(trifluoromethane)sulfonyl-
1,2,3,4,7,8,9,10-octahydro-2,9-benzodiazacyclododecine-2-carboxamide 159. Right: Molecular structure of 
159 
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Scheme 15 Panel A Mechanism of induction of nucleophiles proposed by Ellman and Barrow. Panel B 
Revised sense of induction that is consistent with that experimentally determined. 
Transition states previously proposed by Barrow100 and Davis104 propose that the 
induction arises from the chelated chair-like transition state 161 and the open transition 
state 162 respectively; however as these transitions predict the incorrect sense of 
induction for the addition of allyl magnesium bromide. We propose that the allyl group 
is delivered as in 160 or 163. The sense of induction may be different for allylic 
nucleophiles because an SE2ʹ mechanism is possible.  
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2.2 Synthesis of propagating building blocks  
A series of hydroxy acetates was synthesised by reduction and acetylation of 
commercially-available bis-carboxylic acid derivatives. The bis-carboxylic acid 164 and 
diphenic anhydride 166 were reduced with LiAlH4 in 80% and 85% yield, respectively; 
and acetylation with acetyl chloride gave the hydroxy acetates 130 and 129 in 35% and 
49% yield (Scheme 16). The hydroxy acetates 127 and 126 were prepared by 
Francesco Marchetti. 
Scheme 16 Preparation of hydroxyl acetates 
Enzymatic desymmetrization was used to prepare the hydroxy acetate 128 from the 
diol 168 in 41% yield (Scheme 17).  Conversion of the hydroxyacetate 128 into the 
diastereoisomeric esters 169 and 170 (Scheme 18) allowed the determination of its 
enantiomeric excess (82% ee) by 500 MHz 1H NMR spectroscopy  
 
Scheme 17 Desymmetrization of 2-methyl-1,3-propanediol 
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Scheme 18 Derivatization into the diastereomeric adducts  
  
38 
 
2.3 Synthesis of terminating building blocks  
A variety of terminating building blocks were proposed in Section 1.5.2 for exploitation 
in Fukuyama—Mitsunobu reactions.  Alcohols have been synthesised (Section 2.3.1) 
which were then carbamylated with a 2-nitrobenzenesulfonyl isocyanate (Section 
2.3.3). A small series of 2-nitrobenzenesulfonyl amides and trifluoromethane 
sulfonamides was also synthesised, (Sections 2.3.2 and 2.3.4 respectively). 
2.3.1 Terminating alcohol synthesis 
A range of alcohols was prepared so that through various functional group 
interconversions a range of terminating building blocks could be obtained. The alcohol 
173 was synthesised in 71% overall yield (Scheme 19).  Allylation of 171, by treatment 
with allyl bromide and potassium carbonate, gave the aldehyde 172 which was not 
isolated; reduction with sodium borohydride gave the alcohol 173. 
 
Scheme 19 Synthesis of the salicaldehye-derived terminating building block 173 
Scheme 20 shows the preparation of building block 180. Oxidative iodination of 1,3-
dimethoxybenzene 174, by treatment with sulfuric acid, hydrogen peroxide and 
potassium iodide, gave 2,4-dimethoxyiodobenzene 175 in 70% yield.105 A copper-
catalysed Ullman-type coupling of the aryl iodide 175 with diethyl malonate using 
picolinic acid as a ligand gave the aryl malonate 176 in 70% yield.106 Subsequent 
reduction of the malonate 176 with LiAlH4 gave the diol 177 in 64% yield. Biocatalytic 
desymmetrization of the diol 177 was carried out using Candida Antarctica lipase B and 
vinyl acetate; this procedure gave the hydroxy acetate 178 in 95% yield with >99% ee. 
The enantiomeric excess was determined using chiral HPLC by comparison with the 
racemic compound synthesised from the diol 177 using acetyl chloride. The absolute 
configuration of the hydroxyacetate 181 was assigned by analogy with related 
examples107,108 such as 181. Allylation of the hydroxyacetate 178 was undertaken in 
the absence of base as it was envisioned that the acetate group could migrate across 
the 1,3-diol leading to racemisation. Firstly, allylation was attempted with silver(I) oxide 
and allyl bromide; however this method gave a complex mixture and the allyl ether 179 
could not be identified by LC-MS. A palladium(II) catalysed method was explored and 
gave the allyl ether 179 in 72% yield;109,110 potentially racemization could have been an 
issue. However submitting the hydroxyacetate 178 to the same conditions without allyl 
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ethyl carbonate showed no erosion of the enantiomeric excess, again determined by 
chiral HPLC analysis of the crude reaction. Deprotection of the acetate 179 to give the 
alcohol 180 was achieved in 99% yield using methanolic ammonia. 
 
Scheme 20 Asymmetric preparation of the chiral alcohol 180 
 
   
Figure 12  
A chiral auxiliary was exploited to prepare a handful of terminating building blocks with 
varying nucleophilic groups (133, 198 and 202). The aldol product 183 was prepared in 
the reaction between the boron enolate of 182 and 4-pentenal. The boron enolate was 
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prepared by treatment of the N-acyl oxazolidinone 182 with dibutylboron 
trifluoromethanesulfonate in the presence of Hunig’s base; a 53% yield of 183 was 
obtained with a >95:<5 diastereoselectivity. The sense of diasteroselectivity was 
assigned by comparison to literature111 and ratio of diastereoisomers determined by 
500 1H MHz NMR spectroscopy. Protection of the secondary alcohol of as a tert-
butyldimethylsilyl ether was possible using the silyl chloride in 87% yield. Subsequently 
the chiral auxiliary was removed in two ways. Treatment of the N-acyl oxazolidinone 
184 with LiBH4 gave the alcohol 185 in 65% yield (Scheme 21) and hydrolysis of 184 
yielded the acid 190 (Scheme 23) 
 
Scheme 21 Chiral auxiliary controlled aldol reaction and subsequent removal of the auxiliary 
2.3.2 Synthesis of 2-nitrobenzenesulfonyl amides 
Ethyl lactate 186 was allylated by treatment with silver(I) oxide and allyl bromide; 
subsequent hydrolysis with lithium hydroxide gave the carboxylic acid 188 in 86% 
yield.112 The acyl sulfonamide 189 was obtained in 71% yield by DCC-mediated 
coupling of 188 with 2-nitrobenzenesulfonamide (Scheme 22). Treatment of the imide 
184 with lithium hydroxide in the presence of hydrogen peroxide yielded the acid 190 
(Scheme 23).  The acyl sulfonamide 133 was formed in 60% yield by an EDC-mediated 
coupling of acid 190 with 2-nitrobenzenesulfonamide.  
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Scheme 22 Preparation of the acyl sulfonamide 189 from ethyl lactate 
 
Scheme 23 Hydrolysis of the imide 184 and subsequent acyl sulfonamide formation 
 
2.3.3 N-(2-nitrobenzenesulfonamide) isocyanate synthesis and subsequent 
synthesis of N-(2-nitrobenzenesulfonamide) carbamates 
The synthesis of N-(2-nitrobenzenesulfonyl) carbamates required an efficient synthesis 
of 2-nitrobenzenesulfonyl isocyanate, which has been prepared previously;113 however 
experimental detail and procedures are poor. Franz exploited thermal decomposition of 
the oxamic chloride114. Initial experiments were based on a procedure by Oh,115 who 
showed that forming the oxamic chloride of anilines in ethyl acetate suppressed the 
formation of the bisoxamide; a solvent swap into dichlorobenzenes and heating under 
reflux achieved the thermal decomposition to the isocyanate.  
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Scheme 24 Formation of isocyanate functionality by thermal decomposition of an oxamic chloride 
ReactIR® was used to determine if toluene would serve as a suitable alternative solvent 
to dichlorobenzenes for thermal decomposition of 192. This in situ monitoring 
technique is useful for accurately quantifying the generation reactive intermediates 
such as isocyanates. The practicability of using IR to monitor the reaction is facilitated 
by the diagnostic infrared stretch of isocyanates (ca. 2250 cm-1), a region of the IR 
spectrum that it is diagnostic to few other functional groups. The formation and reaction 
of the isocyanate was followed by ReactIR® (See Graphs 6 and 7); elevated 
temperature (>86 ˚C) was required for efficient conversion of the oxamic chloride 192 
to the isocyanate 194. Graph 8 shows the stages throughout the synthesis of the nosyl 
isocyanate. The blue line depicts the temperature of the vessel in which the reaction 
was being carried out and the black line is the absorption at 2250 cm-1 (specifically the 
isocyanate region). 
 
43 
 
 
Graph 7. Formation of the isocyanate began at c.a. 86 °C. The relatively low intensity of the isocyanate 
band at 2250 cm
-1 
is due to the high concentration of ethyl acetate present.  
 
Graph 8. IR and temperature profile of isocyanate formation followed by ReactIR
®
, monitoring absorption 
at 2250 cm
-1
; 1) start point, PhMe added; 2) temperature ramped to 95 °C with holds; 3) temperature held 
at 95 °C and PhMe added (system dilution); 4) temperature hold at 78 °C; 5) ramp 5 °C/5 min; 6) 
temperature hold at 110 °C; 7) PhMe added; 8) temperature ramp to 110 °C; 9) system cooled to 10 °C; 
10) benzyl alcohol addition. The reported temperature is the jacketed vessel temperature as the internal 
size of the vessel would not accommodate a temperature probe. 
1 
2 
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4 
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10 
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Table 5 Summary of the nucleophiles reacted with 2-nitrobenzenesulfonyl isocyanate 
nucleophile method additive
a
 product Yield (%) 
 
A - 
 
77 
 
A - 
 
77 
 
A - 
 
95 
 
A Et3N 
 
25 
 
A Et(
iPr)2N 
 
51 
Methods; A) NsNH2 (2.0 eq.), (COCl)2 (10 eq.), EtOAc, reflux; then PhMe distil EtOAc, reflux (110 °C); 
Nucleophile addition, rt. a) The base was added simultaneously with the nucleophile 
The reactions of the isocyanate 194 with a range of nucleophiles are summarised in 
Table 5. Excess oxalyl chloride was reacted with 2-nitrobenzenesulfonamide, after 
heating under reflux in ethyl acetate a solvent swap into toluene allowed for the 
temperature required for the thermal decomposition (Scheme 24). After heating under 
reflux in toluene, the crude isocyanate 194 was used.  The reaction of the isocyanate 
194 with alcohols (197, 131, and 132) resulted in yields between 77 and 95%; however 
the reaction of alcohol 185 with isocyanate 194 resulted in a relatively low yield (25%), 
compared to reactions with 195, 173 and 180. Base was added simultaneously with 
alcohol 185 due to the nucleophile having an acid labile silyl protecting group. The 
addition of the organic base with allylamine 196 was to ensure the amine was not 
protonated in the crude acidic conditions. Purification of all the 2-nitrobenzenesulfonyl 
carbamates and ureas involved column chromatography, which was assisted by the 
low pKa (~4-5) of the carbamate proton. Eluting with 50:8:1 CH2Cl2—EtOH—NH4OH 
allowed for long retention of the products compared to the impurities; subsequent 
elution with 50:8 CH2Cl2—EtOH eluted the desired carbamates and ureas.  
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2.3.4 Synthesis of N-(trifluoromethanesulfonamide) terminating building blocks 
In addition to N-(2-nitrobenzenesulfonyl) amides and carbamates, triflamides were also 
synthesised. The alcohol 185 was converted into the triflamide 202 in 3 steps (Scheme 
25). The alcohol 185 was converted into the azide 200 in 97% yield by treatment with 
diphenylphosphoryl azide (DPPA). The azide 200 was reduced with triphenylphosphine 
in aqueous THF to give the amine 201 in 95% yield, which was reacted with 
trifluoromethanesulfonic anhydride to give the triflamide 202 in 77% yield. The 
ditriflamide 203 was observed as a minor by-product in 13% yield; gratifyingly it was 
shown that the ditriflamide 203 could be converted quantitatively back into the 
triflamide 202 using methanolic ammonia (Scheme 25). 
 
 
Scheme 25 Synthesis of the terminating building block 202. The terminating building block 135 was 
synthesised by Francesco Marchetti 
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2.4 Summary of building blocks synthesised 
The range of building blocks prepared is summarised in Table 6. Building blocks 125, 
127, 126 and 135 were synthesised by Francesco Marchetti. 
Table 6 Building Blocks synthesised  
Initiator Propagator Terminator 
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3 Development of methods for the synthesis of a diverse library 
of macrocycles 
This Chapter describes the development of robust methods for the preparation of a 
diverse library of macrocycles. The specific methods involved Fukuyama—Mitsunobu 
reactions to iteratively combine the building blocks (Section 3.1); ring closing 
metathesis (Section 3.2); and reactions for diversification and the release of the final 
compounds from the fluorous tag (Section 3.4). The Fukuyama—Mitsunobu or 
Fukuyama amine synthesis relies on a nitrobenzene sulfonamide to increase the 
acidity of the NH whilst also preventing over alkylation of the nitrogen.116 
3.1 Examination of the Fukuyama—Mitsunobu reaction as a method to link 
building blocks  
This Section describes the investigation of the Fukuyama—Mitsunobu reaction to 
append building blocks onto a fluorous-tagged building block.  The results of the study 
are summarised in Table 7. 
Table 7 Examination of Fukuyama—Mitsunobu methods 
E
n
tr
y
 
 
Fluorous-tagged 
building block 
building block 
M
e
th
o
d
 
Product 
M
a
s
s
 
re
c
o
v
e
ry
 %
,a
 
[P
u
ri
ty
]c
 
1 
  
M1, 
D 
 
99, 
[>95] 
2 
  
M1 
 
18d 
3 
  
 
M1, 
D 
 
70b 
48 
 
4 
  
 
 
M2 
 
 
69 
[81] 
5 
  
 
M2 
 
62b 
6 
  
M3 
 
93 
[>95] 
7 
  
M3 
 
56 
[85] 
Methods; M1) PPh3 (2 eq.), DEAD (2 eq.), ROH (2 eq.), THF (0.1 M), 0 °C → RT; M2) PPh3 (4 eq.), 
DEAD (4 eq.), NucH (4 eq.), CH2Cl2 (0.1 M) 0 °C → RT; M3) PPh3 (1.05 eq.), DEAD (1.05 eq.), 
CH2Cl2 (0.1 M), 0 °C → RT; D) sat. MeOH/NH3; [a] Purified by F-SPE unless otherwise stated; [b] 
Purified by column chromatography; [c] Purity estimated by 
1
H 500 MHz NMR spectroscopy using the 
1’-CH2 of the fluorous tag as an internal standard; [d] Notably, loading of the hydroxy-acetate 130 to the 
sulfonamide 112 proceeded smoothly, with complete consumption of the sulfonamide (hydroxy-acetate 
130 in 4-fold excess); however analysis by chromatography and 
1
H NMR indicated that the thiophene 130 
had polymerized; purification by conventional flash chromatography was required to isolate 204  
 
The 2-nitrobenzenesulfonamides have been shown in the literature116 and previous 
work in our group85 to be excellent nucleophiles; however it was crucial to determine 
whether the proposed building blocks reacted to give good yields of the required 
products (see Table 7). The sulfonamide 112 was treated with diethyl azodicarboxylate 
in the presence of triphenylphosphine and the corresponding alcohols 126, 128 and 
130 (entries 1, 2 and 3 respectively). This method worked well with the benzylic and 
heterobenzylic alcohols 126 and 130; however use of the more hindered alkyl alcohol 
128 led to poor conversion. The products from the Fukuyama—Mitsunobu reactions 
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were purified by fluorous-solid phase extraction.  Subsequently, the acetate protecting 
groups were removed with saturated ammonia in methanol (entries 1 and 3), and the 
products from this step did not require purification. The second round of Fukuyama—
Mitsunobu reactions appended the terminating building blocks onto the fluorous-tagged 
substrates (entries 4, 5, 6 and 7). The 2-nitrobenzenesulfonyl amides 133 and 134, 
entries 4 and 7, proved to be effective nucleophiles; and the triflamide 135 was an 
excellent nucleophile, entry 6.  
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3.2 Optimisation of the metathesis reaction 
As discussed in Section 1.5, ruthenium-catalysed metathesis was chosen to form the 
macrocyclic ring system. This section describes the development of a generic 
procedure for ring closing metathesis of substrates such as those products shown in 
the Table 7. Our studies are summarised in Table 8 
Table 8 Investigation of the cyclisation of potential metathesis substrates 
e
n
tr
y
 
substrate method 
M
e
ta
th
e
s
is
 
ti
m
e
 
product 
Yield %,
a
 
(E/Z)
b 
1 
 
RCM1 16 
 
60 
(>98:<2 
E) 
2 
 
RCM1 
5 
days 
Complex mixture - 
3 
 
RCM3 
then 
N1 
24  
 
34c 
4 
 
RCM2 24 
 
40 
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Methods: RCM1) Hoveyda-Grubbs 2
nd
 gen cat. (1 mol%), MTBE (5 mM), 55 °C then (HOCH2)3P (0.8 eq.), 
Et3N (1 eq.), silica, rt; RCM2) Hoveyda—Grubbs 2
nd
 gen cat. (2 mol%), 1,4-benzoquinone (4 mol%), MTBE 
(5 mM), 55 °C then (HOCH2)3P (0.8 eq.), Et3N (1 eq.), silica, rt;  RCM3) Hoveyda—Grubbs 2
nd
 generation 
(5 mol%), 1,4-benzoquinone (10 mol%), MTBE (5 mM), 55 °C then (HOCH2)3P (0.8 eq.), Et3N (1 eq.), 
silica, rt; N1) PhSH (10 eq.), K2CO3 (2.5 eq.), DMF, rt; [a] Purified by column chromatography [b] 
Determined using 
1
H 500 MHz NMR [c] Mixture of starting material and product isolated, removal of the 2-
nitrobenzene sulfonamides allowed for better separation. 
Initially, ring-closing metathesis using Hoveyda—Grubbs 2nd generation catalyst in t-
butyl methyl ether as the solvent117 was found to be rather substrate-specific. The 
metathesis of substrate 208 resulted in complete consumption of starting material to 
give the desired macrocycle in <16 h (entry 1); however, the substrate 212 gave a 
complex mixture of isomers of the starting material. The complex mixture of products 
was analysed by 1H NMR and appeared to be a mixture of internal alkenes of the linear 
substrates, that is, the products of double-bond migration (e.g. 215-217). The reaction 
was carried out in the presence of 1,4-benzoquinone, a known suppressor of this 
alkene migration,118 and, gratifyingly, under these conditions, 212 cyclised effectively 
(entry 3); after removal of the 2-nitrobenzenesulfonamide groups, the amine was 
obtained in 33% overall yield. Under these conditions the metathesis substrate 210 
was ring-closed in 40% yield (entry 4).  
. 
 
Figure 13 Proposed isomerised products of 212 
Double bond migration appears to be a common side reaction of ring closing 
metathesis; Grubbs et al., have tried to suppress this isomerisation by using 
additives.118 The isomerisation is proposed to stem from the formation of the ruthenium 
hydride species 218. The mechanism for the formation of the Ru-H species is 
unknown; however it is hypothesised that it could be formed from a π-allyl species. 
Presumably the 1,4-benzoquinone is reduced rapidly in the presence of the proposed 
ruthenium hydride species. 
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Figure 14 Grubbs proposed Ruthenium hydride species 
The application of N-(2-nitrobenzenesulfonyl) amides for the synthesis of macrocycles 
was reconsidered in the light of the result described in Scheme 26. Ring-closing 
metathesis of 210 to give 214 proceeded smoothly; however removal of the 2-
nitrobenzenesulfonyl) group using thiophenol highlighted a problem. After removal of 
the 2-nitrobenzenesulfonyl group and F-SPE purification, the methyl ester 221 was 
isolated; presumably, thiophenolate attacked the amide to give the thioester 
intermediate 220, (relief of ring-strain being the driving force) which was subsequently 
quenched with methanol during isolation. With this knowledge, 2-nitrobenzenesulfonyl 
amides were not used subsequently as terminating building blocks. 
 
Scheme 26 Proposed thiophenol activation of 2-nitrobenzenesulfonyl amides and subsequent methanol 
ring opening 
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3.3 Diversification of the free amine cyclic and acyclic scaffolds 
As discussed in Table 2 in Section 1.5, the acyclic and cyclic scaffolds were to be 
diversified with various electrophiles. As the diversifying groups 136, 137, 138 and 139 
have already been examined for their molecular properties, the reactivity had to be 
confirmed; the results are outlined in Table 9. 
Table 9 Diversification and removal of the fluorous tag 
entry 
Amine 
[purity]
a
 
Method, 
mass 
recovery 
[purity]
a
, 
amine 
methods final compound 
yield over 2 
steps 
1a 
208 
 
N1, 86 
[>95] 
222 
A1, S2 
 
80 
1b A4, S2 
 
71 
1c A3, S2 
 
47 
54 
 
1d S2 
 
27 
2a 
211 
N1, 84 
[>95], 
223 
A1, S2 
 
71 
2b A4, S2 
 
59e 
2c A3, S2 
 
69 
2d S2 
 
96 
Methods: N1 PhSH (10 eq.), K2CO3 (2.5 eq.), DMF, rt; N2 PhSH (5 eq.), K2CO3 (1.2 eq.), DMF, rt; 
A1) 136 (2 eq.), CH2Cl2 (0.1 M), rt; A2) 139 (5 eq.), Et3N (10 eq.), CH2Cl2 (0.1 M), 0 °C → rt; A3) 
138 (5 eq.), Et3N (10 eq.), CH2Cl2 (0.1 M), 0 °C → rt; A4) 137 (5 eq.), Et3N (10 eq.), CH2Cl2 (0.1 M), 
0 °C → rt; S1) HF (10 eq., aq 50%), CH2Cl2/MeCN (50/50, 0.05 M), rt, TMSOMe (50 eq.); S2) TBAF 
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(5 eq., 1 M), CH2Cl2 (1 M), rt; [a] Purified by F-SPE unless otherwise indicated; [b] Purity estimated 
by 
1
H 500 MHz NMR spectroscopy using the 1’-CH2 of the fluorous tag as an internal standard; [c] 
Purified by column chromatography; [d] Ratio of double bond isomers was determined using 
1
H 500 
MHz NMR spectroscopy; [e] The 2-oxazolidinone 232 was also isolated in a 34% 
The diversifications described in Table 9 proceeded as planned with one exception: the 
conversion of the amine 223 into final compound 229 (entry 2b).  In this case, the 
morpholine moiety of 229 was displaced by the alcohol to give 232 in 34% yield (along 
with the expected product 229 in 59% yield).  This result is not surprising due to the 
proximity of the alcohol. In the light of this finding we did not subsequently use the 
derivatization agent 139. 
 
Figure 15 Unexpected 2-oxazolidinone from the displacement of the morpholine moiety in 229 
The fluorous tagging group was removed from the final compounds in two ways. We 
found that whilst tetra-n-butylammonium fluoride (TBAF) removed the fluorous-tag 
efficiently, it made the purification of the final compounds difficult. We therefore tried 
aqueous 48-51% hydrofluoric acid, which removed the fluorous tagging group just as 
efficiently as TBAF; however the purification was straighter forward. The reactions were 
quenched with methoxytrimethylsilane to remove the excess reagent. 
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3.4 Summary 
This Chapter has outlined how the building blocks designed in section 1.5 and 
synthesised in Section 2.0 have been examined for their reactivity and stability towards 
the synthesis of a library of macrocycles. Section 3.1 described how the 2-
nitrobenzenesulfonamides performed in Fukuyama—Mitsunobu reactions with the 
hydroxyl acetate building blocks.  This study allowed the judicious selection of building 
blocks for the final library synthesis. Section 3.2 described the investigation of ring-
closing metathesis using a small range of substrates.  However this study allowed the 
most suitable conditions to be identified: specifically, the use of 1,4-benzoquinone as 
an additive with tert-butyl methyl ether as solvent. Section 3.3 described the 
investigation of the deprotection and derivatization of the final scaffolds.  The study 
allowed the identification of a suitable set of derivatization reagents, and appropriate 
conditions for the preparation of the final compounds. 
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4 Synthesis of library intermediates and natural product-like 
macrocycles 
This Section describes the synthesis of a library of natural product-like macrocycles. 
The building blocks described in Section 2.0 were combined in a ‘branching’ fashion 
using the robust methods that were described in Section 3.0.  
4.0.1 Revised library design 
This library of macrocycles was refined in view of the studies described in Chapter 3. 
Specifically, it was decided to focus on four benzylic and heterobenzylic alcohols as 
propagating building blocks; and two N-(2-nitrobenzenesulfonyl) carbamates and two 
triflamides as terminating building blocks. This revised library design was preferred as; 
the benzylic alcohols 129, 130, 127 and 126 completely consumed the fluorous tagged 
starting material c.f. the non-benzylic alcohol 128, a key objective otherwise making the 
F-SPE obsolete; this complete consumption of fluorous tagged intermediate was not as 
much a problem with the terminating building blocks, however the stability of the final 
bonds formed was (Scheme 26) 
Table 10 Revised building blocks  
Initiating building block 
Propagating building 
block 
Terminating building block Diversifier 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a] Building block prepared by Francesco Marchetti 
4.0.2 Molecular property distributions of the proposed library 
The revised building block selection led to reconsideration of the molecular properties 
of the proposed library. Changing of the building blocks that will compose the final 
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library will ultimately change the molecular properties of the final library. The molecular 
weights now ranged from 378.4 to 720.8 with an average molecular weight of 537.6 (an 
increase of 44.1 Da); the AlogP now ranged from 1.54 to 5.57 with a mean of 3.4 (an 
increase of 0.91); and the TPSA now ranges from 78.0 to 187.3 with an average of 
123.3. The most common ring size remained the same at 18. In section 1.5.4 it was 
discussed that a library of macrocycles may not fall within the ‘Lipinski Rule of 5’ and 
this was expected due to the general size of macrocyclic molecules. However it was 
gratifying to see that the averages were within the Rule of 5 for oral bioavailability; 
more importantly the compounds have a reasonable spread across the molecular 
property scales, important for a study where chemical space is being probed. 
 
Graph 9 Distribution of the TPSA vs. the molecular weights across the revised final compound library (See 
Table 10)  
 
 
 Graph 10 The distribution of the predicted atom contribution partition coefficient of the molecules versus 
the molecular weights of the revised final compound library (See Table 10) 
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Graph 11 Distribution of ring sizes across the revised library (See Table 10)
 
4.1 Attachment of propagating building blocks to the fluorous-tagged initiating 
building block  
The fluorous-tagged sulfonamide 112 was combined with four hydroxy acetates 
building blocks using Fukuyama—Mitsunobu reactions (Table 11). The sulfonamide 
112, triphenylphosphine and alcohols (126, 130, 127 and 129) were treated with 
diethylazodicarboxylate to yield 2-nitrobenzenesulfonyl secondary amines (→ 205, 204, 
113 and 233). The products were purified where possible by fluorous-solid phase 
extraction with generally high mass recoveries (>90%); however, in some cases, 
subsequent purification by flash chromatography was also required (entries 2 and 4). 
Following, the compounds were treated with saturated methanolic ammonia to give the 
corresponding benzylic alcohols. 
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Table 11 Linking the fluorous-tagged initiating building block to the hydroxyl acetates 
entry propagator method product 
mass 
recovery
a, 
[purity]
b,c 
1 
 
M1, D 
 
99 [>95] 
2 
 
M2, D 
 
70c 
3 
 
M1, D 
 
90 [>95] 
4 
 
M2, D 
 
82c  
Methods; M1: PPh3 (2 eq.), DEAD (2 eq.), ROH (2 eq.), THF (0.1 M), 0 °C → rt, F-SPE eluting with 
MeOH—H2O (80:20) → MeOH; M2: PPh3 (4 eq.), DEAD (4 eq.), ROH (4 eq.), THF (0.1 M), 0 °C → rt, F-
SPE eluting with MeOH—H2O (80:20) → MeOH; D: saturated methanolic ammonia (100 rel vols); [a] 
Purified by F-SPE unless otherwise indicated; [b] Purity estimated by 500 MHz 
1
H NMR spectroscopy 
using the 1’-CH2 of the fluorous tag as an internal standard; [c] Purified by column chromatography  
 
4.2 Attachment of terminating building blocks to yield metathesis substrates  
This Section outlines the preparation of substrates for ring closing metathesis. 
Terminating building blocks - two N-(2-nitrobenzenesulfonyl) carbamates and two 
triflamides - were appended using Fukuyama—Mitsunobu reactions (Table 12). The 
alcohol (204, 205, 113 and 233), triphenylphosphine and terminating building blocks 
(131, 132, 135 and 205) were treated with diethylazodicarboxylate to yield metathesis 
substrates. The products were initially purified by F-SPE; however if F-SPE purification 
was not sufficient, then conventional flash chromatography was used. Mass recoveries 
ranged from 56-115% with purities consistently >80%. 
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Scheme 27 Fukuyama—Mitsunobu reaction linking the fluorous tagged intermediate 205 to the terminator 
131 
 
Table 12 Linking of the terminating building blocks to the fluorous tagged alcohols prepared in Table 11 
e
n
tr
y
 substrate 
[purity]
b
 
n
u
c
le
o
p
h
ile
 
m
e
th
o
d
  
product 
mass 
recovery
a 
%, 
[purity]
b,c
 
1a 
 
131 L2 
 
62c 
1b 132 L2 
 
90 [93] 
2a 
 
[>95%] 
131 L2 
 
77 [93] 
62 
 
2b 132 L1 
 
66 [95] 
2c 135 L1 
 
93 
[>95] 
2d 205 L1 
 
57c 
3a 
 
[>95%] 
131 L3 
 
76    
[94] 
3b 132 L3 
 
112  
[59] 
63 
 
3c 135 L3 
 
115  
[83] 
3d 202 L1 
 
93 [95] 
4a 
 
131 L2 
 
93 [85] 
4b 132 L2 
 
81 [83] 
4c 135 L2 
 
96 [82] 
4d 205 L1 
 
97 [93] 
64 
 
Methods: L1) NucH (1.1 eq.), DEAD (1.1 eq.), PPh3 (1.1 eq.), CH2Cl2 (0. 25 M), 0 °C → rt; L2) NucH (4 
eq.), DEAD (4 eq.), PPh3 (4 eq.), CH2Cl2 (0.25 M), 0 °C → rt; L3) NucH (2.0 eq.), DEAD (2.0 eq.), PPh3 
(2.0 eq.), CH2Cl2 (0.25 M), 0 °C → rt; [a] Purified by F-SPE unless otherwise indicated; [b] Purity estimated 
by 500 MHz 
1
H NMR spectroscopy using the 1ʹ-CH2 of the fluorous tag as an internal standard; [c] Purified 
by column chromatography 
4.3 Ring-closing metathesis reactions   
Ruthenium-catalysed ring-closing metathesis was used to cyclise the linear oligomeric 
substrates (Table 13). Accordingly, the linear substrates were treated with 1-5 mol% 
Hoveyda—Grubbs 2nd generation catalyst with 2-10 mol% 1,4-benzoquinone in MTBE 
at 55 °C. Subsequently, the catalyst was inactivated by the addition of 
tris(hydroxymethyl)phosphine and triethylamine; purification by flash chromatography 
gave the macrocycles as mixtures of geometrical isomers or in some cases as single 
geometrical isomers; mixtures of geometrical isomers were not separated at this point. 
Deprotection of the secondary amines and carbamates was facilitated by treatment of 
the macrocycle with thiophenol and potassium carbonate and the products were 
purified by fluorous-solid phase extraction. Subsequently, if possible, chromatography 
was used to separate mixtures of geometrical isomers; however if separation was not 
easily possible then the macrocycle was carried through as a mixture of geometrical 
isomers. 
 
Scheme 28 Ring closing metathesis and subsequent denosylation of 209 to give the cyclic free-amine 
246
D
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Table 13  Metathesis and thiophenol mediated removal of the 2-nitrobenzenesulfonyl group to obtain the 
cyclic free amines. 
e
n
tr
y
 
s
u
b
s
tr
a
te
 
[p
u
ri
ty
] 
m
e
th
o
d
s
 
ti
m
e
 
(h
) product 
metathesis yield 
% 
a,b
 
(E/Z) 
deprotection 
mass 
recovery % 
(E/Z) 
1 211 
RCM1, 
N1 
16 
 
60c,  
(>98:<2) 
223 
84 [95] 
(>98:<2) 
223D  
2 
234 
[93] 
RCM2, 
N1 
24 
 
59c 
(>70:<30) 
244 
8% Z, 
44% E 
244D 
3 
235 
[95] 
RCM2, 
N1 
24 
 
56c, e 
Undetermined 
245 
64 [79] 
(70:30) 
245D 
4 
209 
[>95] 
RCM2, 
N2 
6 
 
75c 
(>98:<2) 
246 
82 [89] 
(>98:<2) 
246D 
5 236 
RCM2, 
N2 
24 
 
83c, e 
undetermined 
247 
88 [81] 
(90:10) 
247D 
66 
 
6 
114 
[94] 
RCM2, 
N1 
48 
 
88c, e 
Undetermined 
115 
15% Z 
26% Ec 
115D 
7 
237 
[59] 
RCM2, 
N1 
24 
 
56c, 
(55:45)  
255 
91 [95] 
(60:40) 
248 
8 
238 
[83] 
RCM2, 
N2 
16 
 
47c, e 
Undetermined 
249 
28% Z 
47% E 
249D 
9 
239 
[78] 
RCM2, 
N2 
4 
 
78c 
(<12:>88) 
250 
87 [93] 
(<5:>95) 
250D 
10 
240 
[83] 
RCM2, 
N1 
5 
 
- 
undetermined 
250 
16e  
(85:15) 
251D 
11 
241 
[82] 
RCM2, 
N2 
3 
Days 
 
38 
(<2:>98) 
252 
76 [93] 
(<2:> 98) 
252D 
67 
 
12 
242 
[93] 
RCM2, 
N2  
16 
 
naf - 
13 
243 
[85] 
RCM2 16 
 
naf - 
Methods: RCM1) Hoveyda—Grubbs 2
nd
 gen cat. (2 mol%), MTBE (2.5 mM), 55 °C; RCM2) Hoveyda—
Grubbs 2
nd
 gen cat. (2 mol%), 1,4-benzoquinone (4 mol%), MTBE (2.5 mM), 55 °C; N1 PhSH (10 eq.), 
K2CO3 (2.5 eq.), DMF, rt; N2 PhSH (5 eq.), K2CO3 (1.2 eq.), DMF, rt; [a] Purified by F-SPE unless 
otherwise indicated; [b] Purity estimated by 
1
H 500 MHz NMR spectroscopy using the 1ʹ-CH2 of the 
fluorous tag as an internal standard; [c] Purified by column chromatography; [d] Ratio of double bond 
isomers was determined using 500 MHz 
1
H NMR spectroscopy; [e] compound carried though to removal of 
the 2-nitrobenzenesulfonamides due to isolation of a complex mixture containing starting material and 
geometric isomers [f] Complex mixture isolated 
The reason that geometrical isomers became separable in some cases after removal of 
the 2-nitrobenzenesulfonyl group may have stemmed from significant intramolecular 
hydrogen bonding. It was observed that removal of the 2-nitrobenzenesulfonyl group 
often resulted in molecules with unexpected polarities; in some cases, the free amines 
were sometimes less polar than the 2-nitrobenzenesulfonyl-protected amines (Figure 
17) 
 
Figure 16 Comparisons of the relative polarity of macrocycles 248 and 255. 
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Figure 17 Proposed intramolecular bonding, resulting in less-polar molecules 
4.3.1 Dynamic behaviour of selected macrocyclic products  
Macrocycles are known to have pre-organised architectures;16 many of the 
macrocycles synthesised in this project were observed to slowly interconvert between 
alternative conformations on the NMR timescale, giving rise to broad peaks. This slow 
interconversion, could often be studied using variable temperature NMR. In this project, 
many spectra were recorded at elevated temperatures (to increase the rate of 
interconversion) or at low temperature (to decrease the rate of interconversion) to allow 
sharp spectra to be acquired.  
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4.3.2 Characterisation of the geometrical isomers of the 13-membered 
macrocycle 249 
The macrocycles Z-249D and E-249D were separated by column chromatography after 
removal of the 2-nitrobenzenesulfonyl protecting group; however initially it was 
impossible to determine the geometry of the double bonds because the signals 
corresponding to the alkene protons were extremely broad (Figure 19 and 20). 
However, recording the 500 MHz 1H NMR spectra of E-249D and Z-249D at 70 °C 
greatly improved the spectra and allowed assignment of the alkene geometries. 
 
Figure 18 Two stereoisomers isolated after removal of 2-nitrobenzenesulfonyl protecting groups 
 
 
Figure 19 500 MHz 
1
H NMR spectra of macrocycle Z-249
D
: top spectrum 343K in C6D6; bottom spectrum 
300K in C6D6   
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Figure 20 500 MHz 
1
H NMR spectrum of macrocycle E-249
D
; top spectrum 300K in C6D6; bottom 
spectrum 343K in C6D6 
Analysis of the fragmentation patterns of macrocycles Z-249D and E-249D was used to 
complement the variable temperature NMR studies. The initial NMR spectrum of the 
macrocycle E-249D at 300K in CDCl3 had extremely broad signals for the alkene 
protons at anomalously low chemical shift. However, careful analysis of the 
fragmentation patterns of E-249D and Z-249D suggested that they were indeed 
geometric isomers. Specifically, the molecular ions (m/z = 939, Panel A1 and A2) for 
both compounds fragmented to give ions with m/z = 361, tentatively assigned to the 
arizidinium ions of E-249D and Z-249D (Panel B1 and B2). Accordingly, further 
fragmentation of the assigned arizidinium ions E-249D and Z-249D resulted in very 
similar fingerprint spectra (Panels C1 and C2). 
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Figure 21 Mass fragmentation patterns of E-249
D
 and Z-249
D
; Panel A1 and A2, molecular ions (MS
1
); 
Panel B1 and B2, arizidinium ions MS
2
 (m/z = 939 → E-249
D
 and E-249
D
); Panel C1 and C2, fingerprint 
(MS
2
) (m/z = 361→ fragments) 
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4.4 Derivatization of the scaffolds  
To increase the diversity of the library, each scaffold was appended with a diversifying 
group. Thus, the free amines were reacted with the carbonyl chloride 139 and sulfonyl 
chloride 138 (used in excess in the presence of triethylamine); and the isocyanate 136 
(in the absence of any other reagents). The products were purified using F-SPE, 
concentrated and the fluorous-tag was removed using either tetra-n-butylammonium 
fluoride or hydrofluoric acid. Column chromatography or mass-directed HPLC yielded 
the final compounds on a ca. 10 mg scale.  
 
Figure 22 The suffices of the compound numbers denote the derivatization group; compounds diversified 
with 136 will be denoted as ‘XXa’. Furthermore, diversification with 139, 137 and 138 → ‘XXb’, ‘XXe and 
‘XXc’, respectively. Compounds that do not undergo any diversification will be denoted as ‘XXd’  
4.4.1 Derivatization of the macrocyclic scaffolds 
The derivatization reactions of the metathesis substrates are summarised in Table 14. 
Where the geometric isomers of macrocycles had been separated, both stereoisomers 
were derivatized if sufficient material was available; however, if it was not feasible to 
derivatize the minor isomer, then only the free amine of the minor isomer was prepared 
(see entry 2e). 
 
Scheme 29 Derivatisation and subsequest deprotection of the macrocyclic scaffold 246
D
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Table 14 Derivatization of the cyclic variants 
entry substrate methods scaffold 
Yield % 
(2 steps)a 
ratio 
(E/Z) 
1a 
223 [95] 
A1, S2 
 
73 
228 
>95/<5 
22 A4, S2 
59 
229 
>95/<5 
1c A3, S2 
42 
230 
>95/<5 
1d S2 
96 
231 
>95/<5 
2a 
E-244D 
A1, S2 
 
99 
256a 
>95/<5 
2b A2, S2 
78 
256b 
>95/<5 
2c A3, S2 
88 
256c 
>95/<5 
2d S2 
83 
256d 
>95/<5 
2e Z-244
D S1 
 
54 
257 
<5/>95 
3a 
245D [79] 
A1, S1 
 
62 
258a 
>75/<25 
3b A2, S1 
63 
258b 
>90/<10 
3c A3, S1 
43 
258c 
>80/<20 
3d S1 
99 
258d 
>80/<20 
4a 
246D [89] 
A1, S1 
 
77 
159a 
>95/<5 
4b A2, S1 
66 
159b 
>95/<5 
4c A3, S1 
72 
159c 
>95/<5 
4d S1 
46 
159d 
>95/<5 
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5a 
247D [81] 
A1, S1 
 
12d 
259a 
n.d. 
5b A2, S1 
42d 
259b 
>70/<30 
5c A3, S1 
12d 
259c 
n.d. 
5d S1 
22d 
259d 
n.d. 
6a 
E-115D  
A1, S1 
 
79 
E-117a 
>95/<5 
6b A2, S1 
60 
E-117b 
>95/<5 
6c A3, S1 
87 
E-117c 
>95/<5 
6d S1 
96 
E-117d 
>95/<5 
7a 
Z-115D 
A1, S1 
 
70 
Z-117a 
<5/>95 
7b A2, S1 
69 
Z-117b 
<5/>95 
7c A3, S1 
62 
Z-117c 
<5/>95 
7d S1 
72 
Z-117d 
<5/>95 
8a 
248D [95] 
A1, S1 
 
24 
260a 
n.d 
8b A2, S1 
20 
260b 
50/50 
8c A3, S1 
57 
260c 
50/50 
8d S1 
45 
260d 
n.d 
9a 
Z-249D 
A1, S1 
 
89 
Z-261a 
<5/>95 
9b A2, S1 
67 
Z-261b 
<5/>95 
9c A3, S1 
86 
Z-261c 
<5/>95 
9d S1 
69 
Z-261d 
<5/>95 
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10a 
E-249D 
A1, S1 
 
69 
E-261a 
>95/<5 
10b A2, S1 
70 
E-261b 
>95/<5 
10c A3, S1 
79 
E-261c 
>95/<5 
10d S1 
72 
E-261d 
>95/<5 
11a 
250D [93] 
A1, S1 
 
21 
262a 
<10/>90 
11b A2, S1 
34 
262b 
<5/>95 
11c A3, S1 
61 
262c 
<5/>95 
11d S1 
21 
262d 
<10/>90 
12a 
251D  
A1, S1 
 
85 
263a 
n.d 
12b A2, S1 
83 
263b 
>85/<15 
12c A3, S1 
76 
263c 
n.d 
12d S1 
69d 
263d 
>80/<20 
13a 
252D [93] 
A1, S1 
 
95d 
264a 
<5/>95 
13b A2, S1 
78 
264b 
<5/>95 
13c A3, S1 
50 
264c 
<5/>95 
13d S1 
85d 
264d 
<5/>95 
    
Methods: A1) 136 (2 eq.), CH2Cl2 (0.1 M), rt then F-SPE (80:20 MeOH/H2O → MeOH); A2) 139 (5 eq.), 
Et3N (10 eq.), CH2Cl2 (0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); A3) 138 (5 eq.), Et3N 
(10 eq.), CH2Cl2 (0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); A4) 137 (5 eq.), Et3N (10 
eq.), CH2Cl2 (0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); S1) HF (10 eq., aq 50%), 
CH2Cl2/MeCN (50/50, 0.05 M), rt, TMSOMe (50 eq.); S2) TBAF (5 eq., 1 M), CH2Cl2 (1 M), rt; [a] Purified 
by F-SPE after the derivatization step, then by column chromatography after desilylation unless otherwise 
stated; [b] Purity estimated by 500 MHz 
1
H NMR spectroscopy using the 1ʹ-CH2 of the fluorous tag as an 
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internal standard; [c] Purified by column chromatography; [d] Purified by mass-directed high performance 
liquid chromatography; [e] Ratio of double bond isomers was determined using 500 MHz 
1
H NMR 
spectroscopy;  
4.4.2 Derivatization of the linear scaffolds 
The acyclic variants were only derivatized upon successful completion of both the ring 
closing metathesis and removal of the 2-nitrobenzenesulfonamide of the corresponding 
macrocycle. Table 15 outlines removal of the 2-nitrobenzenesulfonamide from the 
linear substrates, followed by diversification and, ultimately, removal of the fluorous tag. 
Table 15 Derivatization of the acyclic variants  
entry 
substrate 
[purity] 
denosylation 
mass 
recovery 
[purity] 
methods scaffold 
Yield % 
a,b
  
1a 
211 N1 
86 
[>95], 
211D 
A1, S2 
 
80 
224 
1b A4, S2 
71 
225 
1c A3, S2 
47 
226 
1d S2 
27 
227 
2a 
234 [93] N1 
81 
[84], 
234D 
A1, S2 
 
58 
265a 
2b A2, S2 
72 
265b 
2c A3, S2 
64 
265c 
2d S2 
99 
265d 
3a 
235 [95] N1 
53 
[82], 
235D 
A1, S1 
 
99 
266a 
3b A2, S1 
56 
266b 
3c A3, S1 
72 
266c 
3d S1 
63 
266d 
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4a 
209 
[>95] 
N1 
100 
[89], 
209D 
A1, S1 
 
76 
267a 
4b A2, S1 
70 
267b 
4c A3, S1 
53 
267c 
4d S1 
92 
267d 
5a 
236 N1 
48 [88], 
236D 
A1, S1 
 
88 
268a 
5b A2, S1 
76 
268b 
5c A3, S1 
49 
268c 
5d S1 
77 
268d 
6a 
114 [94] N1 
87 [85], 
114D 
A1, S1 
 
41 
118a 
6b A2, S1 
27 
118b 
6c A3, S1 
73 
118c 
6d S1 
42 
118d 
7a 
237 [70] N1 
72 [89], 
237D 
A1, S1 
 
46 
269a 
7b A2, S1 
56 
269b 
7c A3, S1 
73 
269c 
7d S1 
34 
269d 
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8a 
238 
[>83] 
N1 
96 [99], 
238D 
A1, S1 
 
40 
270a 
8b A2, S1 
33 
270b 
8c A3, S1 
52 
270c 
8d S1 
47 
270d 
9a 
239 
[>85] 
N1 
96 
[>95], 
239D 
A1, S1 
 
87 
271a 
9b A2, S1 
22 
271b 
9c A3, S1 
41 
271c 
9d S1 
67 
271d 
10a 
240 
[>83] 
N1 
98 
[>92], 
240D 
A1, S1 
 
39 
272a 
10b A2, S1 
45 
272b 
10c A3, S1 
22 
272c 
10d S1 
50 
272d 
11a 
241 
[>82] 
N1 
93 
[>83], 
241D 
A1, S1 
 
72 
273a 
11b A2, S1 
88 
273b 
11c A3, S1 
73 
273c 
11d S1 
75 
273d 
  
81 
 
12a 
242 [93] N1 
111 
[89] 
242D 
A1, S1 
 
63 
274a 
12b A2, S1 
66 
274b 
12c A3, S1 
69 
274c 
12d S1 
40d 
274d 
    
Methods: N1 PhSH (10 eq.), K2CO3 (2.5 eq.), DMF, rt, then F-SPE (80:20 MeOH/H2O → MeOH); N2 
PhSH (5 eq.), K2CO3 (1.2 eq.), DMF, rt, then F-SPE (80:20 MeOH/H2O → MeOH); A1) 136 (2 eq.), 
CH2Cl2 (0.1 M), rt, then F-SPE (80:20 MeOH/H2O → MeOH); A2) 139 (5 eq.), Et3N (10 eq.), CH2Cl2 
(0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); A3) 138 (5 eq.), Et3N (10 eq.), CH2Cl2 
(0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); A4) 137 (5 eq.), Et3N (10 eq.), CH2Cl2 
(0.1 M), 0 °C → rt, then F-SPE (80:20 MeOH/H2O → MeOH); S1) HF (10 eq., aq 50%), 
CH2Cl2/MeCN (50/50, 0.05 M), rt, TMSOMe (50 eq.); S2) TBAF (5 eq., 1 M), CH2Cl2 (1 M), rt; [a] 
Purified by F-SPE unless otherwise indicated; [b] Purity estimated by 500 MHz 
1
H NMR 
spectroscopy using the 1ʹ-CH2 of the fluorous tag as an internal standard; [c] Purified by column 
chromatography; [d] Purified by mass-directed high performance liquid chromatography;  
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4.5 Review of molecular properties of the final library 
The molecular properties of the compounds that were ultimately prepared were 
determined.  The distribution of properties had been affected by the derivatization of 
the individual geometric isomers and by reactions that had not been successful. The 
TPSA and AlogP distributions of the final compounds that were prepared from the 
sulfonamide 112 are shown in Graphs 11 and 12 respectively. The molecular weights 
of the final library ranged from 378.4 to 718.8 with an average of 516.8; the topological 
surface area ranged from 78.0 to 159.6 with an average of 110.9; and the AlogP 
ranges from 1.99 to 6.06 with an average of 3.69. The most common ring size across 
the library was 18, shown in Graph 14 (the proportion of 18-membered macrocycles in 
the library had been increased by derivatization of the separated geometric isomers of 
117 and 257). The molecules synthesised in this diversity-oriented synthesis has 
produced compounds with physical properties that will lend themselves well to testing 
in vitro; the molecular weights of the compounds synthesised are higher than would be 
desired in a library of compounds to be tested in vitro,10-12 but this was expected. The 
compounds synthesised are at the top end of lipophilic range, but possess an average 
(3.69) well within the accepted boundaries (<5.00). 
Graph 12 Distribution of the topological polar surface area versus the molecular weights for the final 
compounds prepared 
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Graph 13 Distribution of the atom based partition coefficient versus the molecular weights for the final 
compounds prepared 
 
Graph 14 Distribution of ring sizes of the macrocycles prepared 
 
 
  
1
2
3
4
5
6
7
350 400 450 500 550 600 650 700 750
A
Lo
gP
 
Molecular weight (Da) 
0
5
10
15
20
25
30
35
12 13 14 15 16 17 18 19
D
is
tr
ib
u
ti
o
n
 a
cr
o
ss
 t
h
e 
lib
ra
ry
 (
%
) 
Ring size 
84 
 
Summary 
 
A building block-based approach to a library of diverse natural product-like molecules 
has been developed. The strategy relied upon a minimal number of robust chemistries 
(ca. 6) and followed a ‘build-couple-couple-pair’ approach. Through an iterative 
combination of bespoke building blocks, ring closing metathesis and subsequent 
deprotection and amine diversification this approach has gleaned over 100 diverse 
natural product-like molecules, all with varying scaffolds and molecular properties. This 
efficient synthetic approach was aided considerably by the expedient purification 
facilitated by the fluorous tag. The development of robust syntheses of diverse 
macrocycles may enable the discovery of valuable chemical probes of biological 
mechanisms.  
In this library synthesis many lessons were learnt that would improve future library 
design and synthesis. The fluorous tagged was critical to provide rapid and efficient 
purification of the intermediates; more standard purifications such as flash 
chromatography would have been more time consuming and costly in materials. The 
connective reactions used such as the Fukuyama—Mitsunobu were clean and 
provided bonds that would not be susceptible to cleavage in biological systems. Ring 
closing metathesis using the Hoveyda—Grubb’s 2nd generation catalyst was an 
extremely reliable method and provided a natural product-like feature within the 
molecule, the major downside to the ring-closing metathesis was that the selectivity 
between geometric isomers could not be predicted nor controlled. However there is 
constant development in the field of metathesis design and more controllable ligands 
are being discovered.  
The final products have all been prepared on milligram scales and the biological activity 
will be determined in a range of assays. This will allow for the direct comparison of the 
biological relevance of macrocycles and acycles. 
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5 Experimental 
All reactions were carried out in oven-dried glassware under an atmosphere of N2 from 
a Schlenk line fitted with a nitrogen bubbler, using dry techniques. Tetrahydrofuran, 
dichloromethane, toluene, acetonitrile were dried and purified by means of a Pure Solv 
MD solvent Purification System (Innovative Technology Inc.) or obtained from Oxford 
sure/seal™ bottles from Sigma-Aldrich. All other solvents used were chromatography 
or analytical grade. Chemicals used were supplied by Sigma-Aldrich, Alfa-Aesar, and 
Fluka. 
Thin layer chromatography was carried out on aluminium backed silica (Merck silica gel 
60 F254) plates supplied by Merck. Visualisation of the plates was achieved using an 
ultraviolet lamp (λmax = 254 nm), phosphomolybdic acid, KMnO4 and anisaldehyde.  
Flash chromatography was carried out using silica gel 60 (35-70 μm particles).   
Optical rotation measurements were carried out on a Perkin-Elmer AA-1000 and 
Polartronic H532 with a path length of 0.5 dm; concentrations are g/100mL and the 
optical rotations are given in 10-1 deg cm2g-1. Infrared spectra were recorded on a 
Perkin-Elmer one FT-IR spectrometer.  
Proton and carbon NMR data were collected on an Avance 500, DPX500 and Bruker 
DPX 300. All shifts were recorded against an internal standard of tetramethylsilane 
(TMS). Solvents (CDCl3, C6D6, DMSO-d6 and MeOD) used for NMR experiments were 
obtained from Sigma-Aldrich. Splitting patterns in this report have been recorded in an 
abbreviated manner, s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). 
NMR data was recorded in the following format, PPM (number of protons, splitting 
pattern, coupling constant (Hz), proton ID). Signal assignments were made by the aid 
of COSY, DEPT 90 and 135, HMQC and HMBC. 
Low resolution mass spectra data were recorded on a Agilent 1200 series LC system 
compromising a Bruker HCT Ultra ion trap mass spectrometer, a high vacuum 
degasser, a binary pump, a high performance autosampler, an autosampler 
thermostat, a thermostated column compartment a diode array detector. The system 
used two solvent systems: MeCN/H2O + 0.1% formic acid with a Phenomenex Luna 
C18 50 × 2mm 5 micron column or MeCN/H2O with a Phenomenex Luna C18 50 × 
2mm 5 micron column  
Nominal and high resolution mass spectrometry using electrospray ionization were 
recorded by Mrs Tanya Marinko-Covell on a Micromass LCT-KA11 or a Bruker 
Daltronics micrOTOF spectrometer.  Field Desorption Ionisation mass spectra were 
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acquired on a Water-Micromass GCT premier spectrometer equipped with a Linden 
LIFDI probe. 
Crystal structure measurements were carried out at 150 K on a Bruker-Nonius Apex X8 
diffractometer equipped with an Apex II CCD detector and using graphite 
monochromated Mo-Kα radiation from a FR591 rotating anode generator by Colin 
Kilner. The structure was solved by direct methods and refined using SHELXL-97. 
Compound 159a crystallises in the tetragonal space group P41 with one molecule in 
the asymmetric unit.  
All non-hydrogen atoms were refined anisotropically.  
All hydrogen atoms could be located in a difference Fourier map but, in the final stages 
of the refinement, they were placed in calculated positions and refined using a riding 
model. 
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4.1 General procedures 
F-SPE purification. When F-SPE (Fluorous solid phase extraction) was utilised the 
compounds were loaded onto the column with the minimal amount of CH2Cl2, MeOH or 
DMF allowed for the size of column. The non-fluorous compounds were eluted with a 
MeOH—Water (80:20) mix until deemed complete by TLC; then the fluorous 
compounds were eluted using 100% MeOH. 
A. Fukuyama—Mitsunobu of a Fluorous protected sulfonamide;  
M1: The fluorous sulfonamide (2 eq.), triphenylphosphine (2 eq.) and the alcohol (2 
eq.) were dissolved in anhydrous THF (ca. 0.01M) and cooled to 0 °C with an ice bath. 
Diethyl azodicarboxylate (4 eq.) was added dropwise and the reaction was stirred at 
room temperature until the endpoint was determined by TLC. 
M2: procedure as M1; However, equivalents are fluorous sulfonamide (1 eq.), 
triphenylphosphine (4.0 eq.), alcohol (4.0 eq.) and diethyl azodicarboxylate (4 eq.) 
B. Fukuyama—Mitsunobu of a Fluorous protected alcohol; 
L1: The fluorous alcohol (1 eq.), triphenylphosphine (2.0 eq.) and the nucleophile (2.0 
eq.) were dissolved in anhydrous CH2Cl2 (ca. 0.01M) and cooled to 0 °C with an ice 
bath. Diethyl azodicarboxylate (2 eq.) was added dropwise and the reaction was stirred 
at room temperature until the endpoint was determined by TLC. Upon completion the 
product was isolated using F-SPE 
L2: procedure as L1; However, equivalents are fluorous alcohol (1 eq.), 
triphenylphosphine (4.0 eq.), nucleophile (4.0 eq.) and diethyl azodicarboxylate (4 eq.) 
L3 procedure as L1; However, equivalents are fluorous alcohol (1 eq.), 
triphenylphosphine (1.1 eq.), nucleophile (1.1 eq.) and diethyl azodicarboxylate (1.1 
eq.) 
De-acetylation using saturated ammonia in methanol,  
D: The acetate ester (1 eq.) was dissolved in NH3 sat. MeOH (100 rel vols), stirred at 
room temperature until the endpoint is determined by TLC and the solvent, excess NH3 
and acetamide were removed in vacuo. 
Ring-closing metathesis  
RCM1: HG-II was added in one portion to the substrate dissolved in MTBE (ca. 2 mM) 
at room temperature and then heated to 55 °C. The reaction was then followed by TLC 
or LCMS. When the end point was determined the reaction was cooled to room 
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temperature, tris(hydroymethyl) phosphine (80 eq. WRT to HG-II), triethylamine (100 
eq. WRT to HG-II) and silica (5 × amount of phosphine) were added and stirred for a 
minimum of 10 min.  The reaction mixture was then passed through a pad of celite, 
washing with EtOAc, concentrated in vacuo to give the crude product. 
RCM2 procedure as RCM1; However, 1,4-benzoquinone (4 mol%) was added   
Denosylation 
N1: The sulfonamide (1 eq.) and potassium carbonate (2.4 eq.) were dissolved in DMF 
(ca. >0.1 M), cooled to 0 °C and thiophenol (10 eq.) was added dropwise. The reaction 
was allowed to warm to room temperature and stirred until completion was determined 
by TLC. The crude product was loaded directly onto a F-SPE cartridge (in portions if 
necessary not to exceed the maximum loading capacity of the cartridge) 
N2 procedure was as N1; however, the equivalents of thiophenol and K2CO3 were 
reduced to (5 eq.) and (1.2 eq.), respectively. 
Diversification 
A1: 3-pyridine isocyanate 136 (2 eq.) was added in one portion to the fluorous-tagged 
amine in anhydrous CH2Cl2 (0.1M) at room temperature. Completion of the reaction 
was determined by TLC (<1 h), the reaction was then concentrated in vacuo and 
purified using the generic F-SPE method. 
A2: cyclopropane carbonyl chloride 139 (5 eq.) was added to a stirred solution of the 
fluorous-tagged amine and triethylamine (10 eq.) in anhydrous CH2Cl2. Completion of 
the reaction was determined by TLC. The reaction was then concentrated in vacuo and 
purified using the generic F-SPE method. 
A3: 1-methyl-1H-imidazole-4-sulfonyl chloride 138 (5 eq.) was added to a stirred 
solution of the fluorous tagged amine and triethylamine (10 eq.) in anhydrous CH2Cl2. 
Completion of the reaction was determined by TLC. The reaction was then 
concentrated in vacuo and purified using the generic F-SPE method.  
A4: morpholine-4-carbonyl chloride (5 eq.) 137 was added to a stirred solution of the 
fluorous tagged amine and triethylamine (10 eq.) in anhydrous CH2Cl2. Completion of 
the reaction was determined by TLC. The reaction was then concentrated in vacuo and 
purified using the generic F-SPE method. 
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Desilylation 
S1: Aqueous hydrofluoric acid (0.2 mL, ca. 45%) was added in one portion to the silyl 
ether dissolved in CH2Cl2/MeCN (50:50, ca. 100 rel vols). Upon completion of the 
reaction determined by TLC, methoxytrimethylsilane (0.5 mL) was added and stirred for 
16 h. The solution was concentrated onto silica-gel in vacuo and purified by column 
chromatography 
S2: Tetra-n-butylammonium fluoride (0.5 mL, 1.0 M, ca. 100 rel vols) was added to the 
silyl ether, upon completion determined by TLC the reaction was concentrated in vacuo 
onto silica-gel and purified by column chromatography. 
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1,4-Di[tert-butyldimethylsilyl)oxy]but-2-ene 146119 
 
Imidazole (8.84 g, 130 mmol) and tert-butyldimethylsilyl chloride (20.0 g, 130 mmol) 
were dissolved in CH2Cl2 (50 mL); after 10 min, (Z)-but-2-ene-1,4-diol (5.6 g, 63 mmol) 
in CH2Cl2 (50 mL) was added at room temperature. After 16 h the reaction was filtered 
through a plug of silica and concentrated in vacuo to give the silyl ether 146 (19.5 g, 
61.7 mmol, 98%) as a colourless oil, which was not purified; Rf 0.95 (90:10, petrol—
EtOAc); H (500 MHz; CDCl3) 5.19 (2H, t, J 4.5, 2-H), 3.59 (4H, d, J 5.5, 1-H), 0.81 
(18H, s, SiC(CH3)3), 0.00 (12H, s, Si(CH3)2); νmax/cm
-1 (film) 3024, 1220, 1069 and 769 
 
2-[(Tert-butyldimethylsilyl)oxy]acetaldehyde 147120 
 
To a solution of 146 (10.0 g, 31.6 mmol) in CH2Cl2 (200 mL) at −78 °C, ozone was 
bubbled thorough the reaction until a pale blue colour persisted. Oxygen was then 
bubbled through the reaction until it became clear and colourless. Triphenylphosphine 
(8.44 g, 32.2 mmol) was added in one portion at −78 °C. The reaction was allowed to 
reach room 0 °C over a 16 h period; then concentrated in vacuo. Petrol (200 mL) was  
added and the slurry was filtered through a silica/Celite® plug, the filtrate was 
concentrate in vacuo to give the aldehyde 147 (10.1 g, 58.3 mmol, 92%) as a 
colourless volatile oil; Rf 0.87 (80:20, petrol—EtOAc); H (500 MHz; CDCl3) 9.60 (1H, s, 
C(O)H), 4.11 (2H, s, CH2), 0.82 (9H, s, SiC(CH3)3); δC (75 MHz; CDCl3) 202.4 (C(O)H), 
69.6 (CH2), 25.9 (SiC(CH3)3), 18.3 (SiC(CH3)3), -5.3 (Si(CH3)2); νmax/cm
-1 (film): 2929, 
1739, 1253, 1123, 832 and 775; m/z (ES+) 175.2 (100%, MH+) 
 
(S)-N-[(1E)-2-[(Tert-butyldimethylsilyl)oxy]ethylidene]-2-methylpropane-2-
sulfinamide 14898 
 
To a slurry of anhydrous copper(II) sulfate (23.9 g, 150 mmol) in CH2Cl2 (100 mL), 
aldehyde 147 (10.0g, 57 mmol) and (SS)-2-methylpropane-2-sulfinamide (10.0 g, 86 
mmol) were added. After 16 h at room temperature the reaction was filtered through a 
silica/Celite® plug and concentrated in vacuo to give the sulfinimine 148 (14.1 g, 51.2 
mmol, 89%) as a pale yellow oil, which was not purified. For analytical purposes, a 500 
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mg batch of the sulfinimine 148 was purified by column chromatography; hexanes—
EtOAc (80:20); Rf 0.74 (80:20, hexanes—EtOAc);    
    185 (c 1.00, CHCl3); H (500 
MHz; CDCl3) 7.96 (1H, t, J 3, 1-H), 4.44 (2H, d, J 3, 2-H), 1.07 (9H, s, 
tBu), 0.81 (9H, s, 
SiC(CH3)3), 0.00 (6H, s, Si(CH3)2); δC (75 MHz; CDCl3) 168.9 (1-C), 65.5 (2-C), 56.8 
(StBu), 25.8 (SiC(CH3)3), 22.4 (SiC(CH3)3) and −5.4 (Si(CH3)2); νmax/cm
-1 (film) 3236, 
2962, 1666, 1472, 1465, 1402, 1364, 1298; m/z (ES+) 300.1 (20%, [M+Na]+) 
 
N-[(2S)-1-[(Tert-butyldimethylsilyl)oxy]pent-4-en-2-yl}-2-methylpropane-2-
sulfinamide 15098 
 
To a solution of sulfinimine 148 (0.9 g, 3.6 mmol) in CH2Cl2 (30 mL) at −78 °C, allyl 
magnesium bromide 1M solution in ether (7.5 mL, 7.5 mmol) was added dropwise. 
After 1 h the reaction was stirred at 0 °C for 4 h and then allowed to reach room 
temperature. After 16 h the reaction was cooled with an ice-bath and sat. aqueous 
NH4Cl was added dropwise; after 2 h the reaction was concentrated in vacuo to half 
volume and extracted into ethyl acetate (3 × 50 mL). The organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo. Column chromatography, eluting with 
petrol—EtOAc (80:20) gave the amine (SsRc) 150 (810 mg, 2.54 mmol, 70%) as a 
colourless oil and a single diastereomer; Rf 0.31 (petrol—EtOAc, 80:20);    
      +57.6 
(c 1.01, CHCl3); H (500 MHz; CDCl3) 5.75 (1H, ddt, J 7.2, 10.3 and 17.5, 4-H), 5.11 
(1H, d, J 7.2, 5-H), 5.07 (1H, s, 5-H), 3.61 (1H, dd, J 4.3 and 10.3, 3-Ha), 3.47 (1H, dd, 
J 5.3 and 10.3), 3.46-3.43 (1H, m, N-H), 3.33-3.24 (1H, m, 2-H), 2.51-2.29 (2H, m, 1-
H), 1.14 (9H, s, tBu), 0.84 (9H, s, SiC(CH3)3), 0.00 (6H, s, Si(CH3)2); δC (75 MHz; 
CDCl3) 134.8 (4-C), 118.9 (5-C), 65.6 (1-C), 56.8 (2-C), 56.3 (SC(CH3)3), 37.5 (3-C), 
26.3 (tBu), 22.9 (SiC(CH3)3), 18.6 (SiC(CH3)3), 0.41 (Si(CH3)2); νmax/cm
-1 (film): 2954, 
2928, 2857, 1252, 1099, 1051, 855 and 775; m/z (ES+) 320.2 (100%, [M+H]+) 
 
 
 
 
N-[(2S)-1-[(Tert-butyldimethylsilyl)oxy]pent-4-en-2-yl]-2-methylpropane-2-
sulfinamide 14998 
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Also obtained was the diasteromer 149 (196 mg, 0.61 mmol, 17%);    
      +26.9 (c 1.0, 
CHCl3); Rf 0.48 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 5.77 (1H, dddd, J 17.0, 
10.4, 7.5 and 6.7, 4-H), 5.07 (1H, d , J 17, 5-H), 5.06 (1H, d, J 10.4, 5-H), 3.78 (1H, d, J 
6.7, NH), 3.74 (1H, dd , J 9.9 and 4.6, 1-H), 3.60 (1H, dd , J 9.9 and 5.1, 1-H), 3.38 
(1H, qt, J 6.4 and 4.8, 2-H), 2.40-2.21 (2H, m, 3-H); 1.21 (9H, s, tBu), 0.90 (9H, s, 
SiC(CH3)3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); δC (75 MHz; CDCl3) 134.5 (4-C), 
117.6 (5-C), 65.4 (1-C), 56.4 (2-C), 55.7 (SOtBu), 36.8 (3-C), 25.8 (SOtBu), 22.7 
(SiC(CH3)3), 18.2 (SiC(CH3)3), -5.2 (SiCH3), -5.3 (SiCH3); νmax/cm
-1 (film) 3312, 2956, 
2930, 2858, 1642, 1472, 1390, 1364 and 1324; m/z (ES+) 320.1 (20%, [M+H]
+) 
(2R)-2-Aminopent-4-enol hydrochloride 15198 
 
Sulfinamine 150 (4.0 g, 10 mmol) was dissolved in MeOH (40 mL) and 4N HCl in 1,4-
dioxane (20 mL) was added dropwise at 0 °C for 1 h and then the reaction was stirred 
at room temperature for 4 h. The reaction was concentrated in vacuo to give a pale 
yellow solid. The solid was slurried in Et2O (20 mL) and filtered to give the amine 
hydrochloride 151 (1.30 g, 9.5 mmol, 95%) as a white crystalline solid;    
      −10.3 (c. 
0.7, MeOH); H (500 MHz; MeOD) 5.84 (1H, ddt, J 7.1, 10.2 and 17.2), 5.31-5.20 (2H, 
m, 5-Htrans and 5-Hcis), 3.78 (1H, dd, J 3.8 and 11.6, 3-Ha), 3.58 (1H, dd, J 7.1 and 11.6, 
3-Hb), 3.31-3.24 (1H, m, 2-H), 2.5-2.34 (2H, m, 1-Hab); δC (75 MHz; MeOD) 131.9 (4-C), 
118.8 (5-C), 60.5 (1-C), 52.5 (2-C) , 33.5 (3-C); νmax/cm
-1 (solid): 2472, 2071, 1121 and 
972 
(2R)-1-Hydroxy-S-(2-nitrophenyl)pent-4-ene-2-sulfonamide 152 
 
The amine hydrochloride 151 (1.6 g, 11.6 mmol) was dissolved in CH2Cl2 (50 mL), 
triethylamine (2.93 g, 29 mmol) was added and the reaction cooled to 0 °C. 2-
Nitrobenzene sulfonyl chloride (2.58 g, 11.6 mmol) was added in one portion; after 1 h 
the ice bath was removed and the reaction was stirred at room temperature. After 16 h 
the reaction was poured into water (50 mL), separated and washed with HCl (0.5M, 50 
mL), 10% NaHCO3 (50 mL) and brine (100 mL). The organic layers were dried over 
MgSO4, filtered and concentrated in vacuo to give the sulfonamide 152 (3.15 g, 11.1 
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mmol, 95%) as a pale yellow viscous oil, which was not purified; Rf 0.71 (80:20, 
EtOAc—petrol);    
      −5.1 (c. 0.3, CHCl3); H (500 MHz; CDCl3) 8.17-8.13 (1H, m, 
nosyl 3-H), 7.90-7.85 (1H, m, nosyl 6-H), 7.79-7.72 (2H, m, nosyl 4 and 5-H), 5.54 (1H, 
ddt, J 7.2, 10.0 and 17.2, 4-H), 5.01 (1H, J 17.0, 5-Htrans), 4.92 (1H, J 10.0, 5-Hcis), 
3.66-3.53 (3H, m, 1-Hab and 2-H), 2.35-2.22 (2H, m, 3-Hab); δC (75 MHz; CDCl3) 147.7 
(nosyl 2-C), 134.5 (4-C), 133.6 (nosyl 1-C), 132.9 (nosyl 4 and 5-C), 130.7 (nosyl 6-C)), 
125.4 (nosyl 3-C), 118.9 (5-C), 64.4 (1-C), 56.2 (2-C), 36.2 (3-C); νmax/cm
-1 (film) 3334, 
1537, 1163 and 593; m/z (ES+) 309.1 (100%, [M+Na]+); found 309.0515, C11H14N2O5S 
requires MNa, 309.0516 
 
N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}pent-4-en-2-yl]-2-nitrobenzene-1-sulfonamide 112 
 
A solution of (1H, 1H, 2H, 2H-heptadecafluorodecyl)diisopropylsilane (6.6 g, 11.7 
mmol) in CH2Cl2 (40.0 mL) was added slowly to a solution of N-bromosuccinimide (2.2 
g, 12.2 mmol) in CH2Cl2 (50 mL) at 0 °C. After 5 min at 0 °C the reaction was then 
stirred for 20 min at room temperature. A solution of sulfonamide 152 (3.15 g, 11.1 
mmol) and imidazole (1.0 g, 14.6 mmol) dissolved in CH2Cl2 (50 mL) was added 
dropwise at 0 °C. After 16 h at room temperature the reaction was concentrated in 
vacuo, dissolved in the petrol—EtOAc (50:50) and filtered through a silica/Celite® plug. 
The resulting filtrate was concentrated in vacuo, to give the sulfonamide 112 (9.3 g, 
11.1 mmol, 99 %) as a pale yellow viscous oil which was not purified further. Rf 0.95 
(80:20 EtOAc—petrol);    
      −2.4 (c. 1.5, CHCl3); H (500 MHz; CDCl3) 8.14-8.12 (1H, 
m, Ns), 7.87-7.84 (1H, m, Ns), 7.73-7.69 (1H, m, Ns), 5.65 (1H, d, J 10, N-H), 5.61 (1H, 
ddt, J 9.5, 13 and 18, 4-H), 5.03 (1H, d, J 18, 5-H), 4.97 (1H, d, J 13, 5-H), 3.72-3.69 
(1H, m, 3-Ha), 3.61-3.52 (2H, m, 3-Hb and 2-H), 2.35-2.26 (2H, m, 1-H), 2.15-1.94 (2H, 
m, 2ʹ-H), 0.98 (14H, s, iPr), 0.86-0.75 (2H, m, 1ʹ-H); δC (75 MHz; CDCl3) 135.1 (4-C), 
133.4 (nosyl 1-C), 133.0 (nosyl 6-C), 132.9 (nosyl 4 or 5-C), 130.6 (nosyl 6-C), 125.4 
(nosyl 3-C), 118.8 (5-C), 64.6 (1-C), 55.8 (2-C), 36.2 (3-C), 24.5 (iPr), 17.4 (iPr), 12.2 
(iPr), -0.3 (1ʹ-C), nosyl 2-C missing; νmax/cm
-1 (film): 2949, 2870, 1643, 1543, 1275 and 
1259; m/z (ES+) 864.2 (100%, [M+NH4]
+); found 864.1787, C27H35F17N3O5SSi requires 
MNH4, 864.1790 
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2-Aminopent-4-enol 156 
 
To a solution of MeOH (40 mL) was added acetyl chloride (4.0 g, 52 mmol); to this, 2-
amino-4-petenoic acid (2.00 g, 17.4 mmol) in MeOH (60 mL) was added. The reaction 
was heated at reflux for 4 h, concentrated in vacuo to give the crude methyl ester 
hydrochloride. THF (100 mL) was added and the solution cooled to 0 °C, LiAlH4 (1.97 
g, 52 mmol) was added portionwise (ca. 0.5 g). After 16 h, aqueous sat. NH4Cl was 
added until effervescence ceased, the resulting solution was concentrated in vacuo 
onto silica gel. Column chromatography eluting with CH2Cl2—MeOH (85:15) gave the 
amino alcohol 156 (1.62 g, 16 mmol, 92%) as a pale yellow oil. RF 0.1 (90:10 CH2Cl2—
MeOH); δH (300 MHz; CDCl3) 5.58 (1H, ddt, J 17.1, 10.2 and 7.2, 4-H), 4.96-4.82 (2H, 
m, 5-HAB), 3.39 (1H, dd, J 10.9, 3.9, 1-HA), 3.16 (dd, J 10.9, 7.4, 1-HB), 2.74 (1H, dq, J 
9.7, 7.5 Hz, 2-H), 2.04 (1H, dt, J 12.5, 6.1, 3-HA), 1.96-1.80 (1H, m, 2-HB); δC (75 MHz; 
CDCl3) 134.4 (4-C), 177.8 (5-C), 65.1 (1-C), 52.1 (2-C), 37.7 (3-C); νmax/cm
-1 (film) 
3543, 3352, 2939, 2308, 1960, 1846, 1660, 1643, 1594, 1539, 1428, 1361 
(R) 2-Aminopent-4-enol (R)-156 
 
To a solution of MeOH (5 mL) was added acetyl chloride (3.4 g, 43 mmol); to this, (R)-
2-amino-4-petenoic acid (1.00 g, 8.7 mmol) in MeOH (10 mL) was added. The reaction 
was refluxed for 4 h, concentrated in vacuo to give the crude methyl ester 
hydrochloride. THF (100 mL) was added and the solution cooled to 0 °C, LiAlH4 (0.66 
g, 17.4 mmol) was added portionwise (ca. 0.2 g). After 16 h, aqueous sat. NH4Cl was 
added until effervescence ceased, the resulting solution was concentrated in vacuo 
onto silica gel. Column chromatography elution with CH2Cl2—EtOH—NH4OH 
(86:13.5:1.5) gave the amino alcohol (R)-156 (700 mg, 6.93 mmol, 80%) as a pale 
yellow oil;    
      −25.4 (c. 0.8, MeOH) 
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N-(1-Hydroxypent-4-en-2-yl)benzamide 157 
 
Benzoyl chloride (124 mg, 0.9 mmol) was added to a solution of 156 (100 mg, 0.99 
mmol) and Et3N (156 mg, 1.5 mmol) in CH2Cl2 (10 mL). After 24 h the reaction was 
concentrated in vacuo onto silica, column chromatography eluting with petrol—EtOAc 
(10:90 → 20:80) gave the amide 157 (104 mg, 0.51 mmol, 51% as an off white solid; 
RF 0.29 (90:10 petrol—EtOAc); δH (500 MHz; CDCl3) 7.76 (2H, dd, J 8.3 and 1.4, Ar 2 
and 6-H), 7.51 (1H, tt, J 7.5 and 1.4, Ar 4-H), 7.43 (2H, dd, J 8.3 and 7.5, Ar 3 and 5-
H), 6.38 (1H, br s, NH), 5.86 (1H, ddt, J 17.2, 10.1 and 7.1, 4-H), 5.20 (1H, ddd, J 17.2, 
1.7 and 1.6, 5-HA), 5.17 (1H, ddd, J 10.1, 1.3 and 1.7, 5-HB), 4.25-4.19 (1H, m, 2-H), 
3.81 (1H, dd, J 11.1 and 3.7, 1-HA), 3.75 (1H, dd, J 11.1 and 5.4, 1-HB), 2.88 (1H, br s, 
OH), 2.51-2.38 (2H, m, 3-HAB); δC (75 MHz; CDCl3) 168.2 (C=O), 134.3 (5-C), 134.2 (Ar 
1-C), 131.7 (Ar 4-C), 128.6 (Ar 2 and 6-C), 126.9 (Ar 3 and 5-C), 118.5 (4-C), 65.4 (1-
C), 51.6 (2-C), 35.8 (3-C); νmax/cm
-1 (film) 3302, 2952, 1955, 1894, 1637, 1603, 1578, 
1536, 1490, 1442; m/z (ES+) 228.1 (100%, [M+Na]+); found 228.1002, C12H15NO2 
requires MNa, 228.0995 
(R) N-(1-Hydroxypent-4-en-2-yl)benzamide 
 
Benzoyl chloride (124 mg, 0.9 mmol) was added to a solution of (R)-156 (101 mg, 0.1 
mmol) and Et3N (150 mg, 1.5 mmol) in CH2Cl2 (10 mL). After 24 h the reaction was 
concentrated in vacuo onto silica, column chromatography eluting with petrol—EtOAc 
(10:90 → 20:80) gave the amide (R)-157 (120 mg, 0.58 mmol, 58%) as an off white 
solid. Data as 157,    
      11.3 (c. 0.5, MeOH) 
2,5-Di(hydroxylmethyl)thiophene 165121,122 
 
To a slurry of LiAlH4 (4.4 g, 116 mmol) in THF (800 mL) was added 2,5-
thiophenedicarboxylic acid 164 (10.0 g, 58 mmol) portionwise at 0 °C. After addition the 
slurry was stirred at room temperature for 30 min and then refluxed for 24 h. The 
reaction was cooled to 0 °C and water was added until there was no more gas 
evolution. The reaction was then extracted with EtOAc (5 × 200 mL), dried (MgSO4), 
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filtered and concentrated in vacuo to give 165 (6.8 g, 82 %) as a pale yellow oil, that 
was used without further purification; Rf 0.1 (60:40 petrol—EtOAc); δH (500 MHz; 
CDCl3) 6.93 (2H, s, 3-H), 4.84 (s, 4H, 1-H), 1.91 (s, 2H, OH); δC (75 MHz; CDCl3) 144.7 
(2-C), 125.7 (3-C), 60.6 (1-C); νmax/cm
-1 (film) 3350, 2870, 1731, 1653, 1359, 1205, 
1159, 1008 and 808; m/z (ES+) 167.2 (100%, MNa+) 
[5-(Hydroxymethyl)thiophen-2-yl]methyl acetate 130 
 
To a solution of 165 (10.0 g, 69 mmol), triethylamine (9.2 mL, 82 mmol) and DMAP (80 
mg, 0.6 mmol) in CH2Cl2 (500 mL) at 0 °C, was added a solution of acetyl chloride (5.4 
g, 69 mmol) in CH2Cl2 (20 mL). The reaction was then stirred for 16 h at room 
temperature and then concentrated in vacuo. Column chromatography, eluting with 
60:40 petrol—EtOAc gave 130 (6.42 g, 49 %) as a pale yellow oil; Rf 0.47 (60:40 
petrol—EtOAc); δH (500 MHz; CDCl3) 7.00 (1H, d, J  3.5, 6-H), 6.93 (1H, d, J 3.5 , 5-H), 
5.26 (2H, s, 1-H), 4.84 (2H, d, J 5.38, 1ʹ-H), 2.13 (s, 3H, Ac), 1.93 (1H, t, J 5.8, OH); δC 
(75 MHz; CDCl3) 173.6 (Ac), 146.1 (4-C), 137.5 (6-C), 128.5 (2-C), 125.5 (3-C), 61.1 
(1-C), 60.6 (1ʹ-C), 21.4 (Ac); νmax/cm
-1 (film) 3448, 2864, 2250, 1740, 1379, 1235, 1023; 
m/z (ES+) 169.0 (50%, [M-H2O]
+) and 498.1 (100%, [M3+NH4]
+) 
{2-[2-(Hydroxymethyl)phenyl]phenyl}methanol 167123 
 
LiAlH4 (2M in THF, 45 mL, 90 mmol) was added dropwise to diphenic anhydride 166 
(10.0 g, 44.6 mmol) in THF (350 mL) at 0 °C. After 24 h the reaction was quenched 
with aqueous sat. NH4Cl until no gas was evolved and then the pH was corrected to ca. 
7 with 4N HCl. The slurry was filtered through a Celite® plug and concentrated in 
vacuo; the solution was extracted with CH2Cl2 (5 × 100 mL). The combined organic 
layers were dried, filtered and concentrated in vacuo to give the crude product which 
was recrystallized from toluene to give the diol 167 (8.01 g, 37.4 mmol, 85 %) as off-
white needles; m.p 127-129 °C; Rf 0.63 (20:80 petrol—EtOAc); δH (500 MHz; CDCl3) 
7.54 (2H, dd, J 1.1 and 7.6), 7.45 (2H, td, J 1.4 and 7.6), 7.40 (2H, td, J 1.4 and 7.4), 
7.21 (2H, dd, J 1.1 and 7.4), 4.40 (4H, d, J 11.7, benzylic), 2.72 (2H, br s, OH); δC (75 
MHz; CDCl3) 140.4, 138.9, 130.1, 130.0, 128.5, 128.1, 63.3; νmax/cm
-1 (film) 3055, 2987, 
2305, 1477, 1422, 1340, 1266; m/z (ES+) 237.1 (100%, [M+Na]+); found 237.0884, 
C14H14O2 requires MNa 237.0886  
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{2-[2-(Hydroxymethyl)phenyl]phenyl}methyl acetate 129 
 
Acetyl chloride (182 mg, 2.3 mmol) was added dropwise to a stirring solution of diol 
167 (500 mg, 2.3 mmol), triethylamine (255 mg, 2.5 mmol) and DMAP (28 mg, 0.23 
mmol) in CH2Cl2 (10 mL) at 0 °C. After 2 h at room temperature the reaction was 
washed with water (5 mL), 1M HCl (5 mL) and brine (5 mL). The organic layers were 
dried (MgSO4), filtered and concentrated in vacuo. Column chromatography, eluting 
with petrol--EtOAc (40:60) gave the mono acetate 129 (256 mg, 1.05 mmol, 46%) as a 
colourless oil; H (300 MHz; CDCl3) 7.50 (1H, d, J 8.0, Ar), 7.40 (1H, d, J 7.3, Ar), 7.36-
7.23 (4H, m, Ar), 7.13 (1H, dd, J 1.6 and 7.2, Ar), 7.07 (1H, dd, J 1.2 and 7.6), 4.85-
4.76 (2H, m, CH2OAc), 4.39-4.28 (2H, m, CH2OH), 1.94 (3H, s, Ac), 1.75 (1H, br s, 
OH); δC (75 MHz; CDCl3) 171.1 (CO), 140.5, 139.2, 139.1, 134.5, 130.4, 130.1, 129.3, 
128.9, 128.7, 128.5, 128.4, 127.8, 65.7 63.4, 21.3; νmax/cm
-1 (film): 3406, 1732, 1379, 
1223, 1024, 1006 and 775; m/z (ES+) 279.1 (100%, [M+Na]+); found 279.0996, 
C16H16O3 requires MNa 279.0992 
(2S)-3-Hydroxy-2-methylpropyl acetate 128124 
 
Vinyl acetate (5.7 g, 66 mmol) was added to 2-methyl propane 1,3-diol 168 (2.0g, 22 
mmol) and chloroform (10 mL) at room temperature. Pseudomonas Fluorescens (100 
mg) was added and the reaction stirred for 24 h. Once all the diol had been consumed, 
the reaction was filtered through Celite® and concentrated in vacuo to give the crude 
product. Column chromatography, eluting with petrol—EtOAc (50:50) gave the 
monoacetate 128 (1.2 g, 9.0 mmol, 41%) as a colourless oil; Rf 0.36 (50:50 petrol—
EtOAc); H (500 MHz; CDCl3) 4.13 (1H, dd, J 5.1 and 11.1, CHaOAc), 4.05 (1H, dd, J 
6.6 and 11.1, CHbOAc) 3.56 (1H, dd, J 5.1 and 11.1, CHaOH), 3.50 (1H, dd, J 6.6 and 
11.1, CHbOH) 2.08 (3H, s, Ac), 2.02-1.96 (1H, m, CH), 1.91 (1H, br s, OH), 0.96 (3H, d, 
J 6.9, CH3); δC (75 MHz; CDCl3) 171.7 (CO), 66.2 (CH2OAc), 64.5 (CH2OH), 35.4 (CH), 
20.9 (Ac), 13.5 (CH3); νmax/cm
-1 (film): 2963, 1736, 1715, 1367, 1221, 1031 and 988; 
m/z (ES+) 155.1 (100%, [M+H]+); found 155.0702, C6H12O3 requires MNa 155.0679 
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(2R)-3-(Acetyloxy)-2-methylpropyl (2R)-2-methoxy-2-phenylacetate 169 
 
To a solution of (S)-(α)-Methoxyphenylacetic acid (100 mg, 0.6 mmol), hydroxyl acetate 
128 (87.6 mg, 0.6 mmol) and DMAP (7 mg, 0.06 mmol) in CH2Cl2 (5 mL) was added 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (102.3 mg, 0.66 mmol). After 16 h the 
crude mixture was concentrated in vacuo, column chromatography eluting with 80:20 
petrol—EtOAc gave the ester 169 (93 mg, 0.30 mmol, 45%) as a colourless oil; Rf 0.84 
(70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 7.53-7.33 (5H, m, Ar), 4.81 (1H, s, 
(MeO)CH), 4.12 (1H, dd, J 11.1 and 6.2, 1-HA), 4.08 (1H, dd, J 11.1 and 6.1, 1-HB), 
3.94 (1H, dd, J 11 and 5.6, 3-HA), 3.86 (1H, dd, J 11 and 6.4, 3-HB), 3.44 (3H, s, OMe), 
2.20-2.08 (1H, m, 2-H), 2.05 (3H, s, Ac), 0.92 (3H, d, J 6.9, Me), 0.88 (d, J 6.9, Memin); 
δC (75 MHz; CDCl3) 171.4, 171.1, 136.6, 129.2, 129.1, 127.5, 82.9, 66.7, 65.9, 57.8, 
32.7, 21.3, 14.1; νmax/cm
-1 (film) 3004, 2989, 1738, 1455, 1275, 1261; m/z (ES+) 303.1 
(100%, [M+H]+); found 303.1199, C15H20O5 requires MH 303.1209 
 
(2R)-3-(Acetyloxy)-2-methylpropyl (2S)-2-methoxy-2-phenylacetate 170 
 
Using the same procedure as 169 gave the ester 170 (96 mg, 0.31 mmol, 52%) as a 
colourless oil; Rf 0.84 (70:30, Petrol−EtOAc); δH (500 MHz; CDCl3) 7.48 (2H, 8.0 and 
1.7, Ar), 7.44-7.36 (3H, Ar), 4.82 (1H, s, (MeO)CH), 4.14 (1H, dd, J 11 and 6.1, 1-HA), 
4.10 (1H, dd, J 11 and 5.9, 1-HB), 3.94 (1H, dd, J 11.1 and 6.3, 3-HA), 3.93 (1H, dd, J 
11.1 and 5.8, 3-HB); 3.87 (dd, J 11.1 and 6.4, 3-HB
min), 3.46 (3H, s, OMe), 2.19-2.13 
(1H, m, 2-H), 2.06 (3H, s Ac), 0.93 (d, Me), 0.89 (3H, d, J 6.8, Me); δC (75 MHz; CDCl3) 
170.9, 170.6, 136.3, 128.8, 128.7, 127.1, 126.6, 82.5, 66.3, 65.5, 57.3, 32.3, 20.8, 13.6, 
13.5 (min); νmax/cm
-1 (film) 3001, 2988, 1738, 1274, 1260; m/z (ES+) 303.1 (100%, 
[M+H]+); found 303.1209, C15H20O5 requires MH 303.1209 
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[2-(Prop-2-en-1-yloxy)phenyl]methanol 173125 
 
To a solution of salicyladehyde (1.00 g, 8.19 mmol) and potassium carbonate (2.80 g, 
20.2 mmol) in acetone (100 mL); was added allyl bromide (1.18 g, 9.83 mmol). The 
reaction was heated at reflux for 16 h. The reaction was concentrated in vacuo and the 
residue was dissolved in CH2Cl2 (100 mL); washed with NaOH (1M, 20.0 mL), water (2 
× 20.0 mL) and brine (2 × 20.0 mL). The CH2Cl2 solution was dried, MgSO4, filtered 
and concentrated in vacuo to give a yellow oil. The oil obtained was dissolved into 
MeOH (200 mL) and NaBH4 (1.00 g, 26.4 mmol) was added portionwise to the solution 
which self-heating and was not controlled. Once all the NaBH4 was added the solution 
was refluxed for 1 h; the solution was poured into ice/water (50.0 mL and extracted with 
CHCl3 (50.0 mL); the organic layer was dried, MgSO4, filtered and concentrated in 
vacuo to give a colourless oil. Flash chromatography, eluting with 30:70 EtOAc—
hexanes gave the product 173 (0.94 g, 5.80 mmol, 71%) as a colourless oil. Rf 0.34 
(70:30, EtOAc—hexanes); H (500 MHz; CDCl3) 7.32-7.21 (2H, m, Ph 3-H and 6-H), 
6.95 (1H, t, J 7.2, Ph 5-H), 6.88 (1H, d, J 8.2, Ph 4-H), 6.07 (1H, m, propenyl 2-H), 5.42 
(1H, dd, J 1.5, 17, propenyl 3-HA), 5.30 (1H, dd, J 1.5, 10, propenyl 3-HB), 4.72 (2H, d, 
J 6.1, CH2OH), 4.60 (2H, dt, J 5.2 and 1.5, propenyl 1-H) 2.34 (1H, br s, OH); δC (75 
MHz; CDCl3) 156.5 (Ph 2-C), 133.0 (propenyl 2-C), 129.4 (Ph 1-C), 128.9 (Ph 4-C or 
2), 128.8 (Ph 4-C or 2), 120.9 (Ph 5-C), 117.7 (propenyl 3-C), 111.5 (propenyl 3-C), 
68.8 (propenyl 1-C), 62.2 (PhCH2OH); νmax/cm
-1 (film) 3368, 2921, 2871, 1602, 1491, 
1423, 1236, 998 and 753; m/z (EI+) 164.1 (75%, [M]+); found 164.0834, C10H12O2 
requires M 164.0837 
1-Iodo-2,4-dimethoxybenzene 175126 
 
Sulfuric acid (18M, 2.00 mL, 36.0 mmol) was added to a stirred solution of methanol 
(40.0 mL). 1,3-Dimethoxybenzene (1.00 g, 7.20 mmol) and Potassium iodide (1.33 g, 8 
mmol) were added, which resulted in a colour change from colourless to pale yellow. 
Hydrogen peroxide (30.0%, 2 mL, 16 mmol) was added, which caused a solution 
colour change to dark brown. After 2.5 h the reaction mixture was poured into CH2Cl2 
(100 mL) and washed with NaHSO4 (0.1 M, 60.0 mL) and water (60.0 mL). The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo to afford the crude product 
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as brown oil which was purified by flash chromatography, eluting with CH2Cl2 to give 
purple fractions which were washed with sodium metabisulphite (10% w/v, 50.0 mL) to 
remove elemental I2, dried, MgSO4, filtered and concentrated in vacuo to give the 
product 175 as a colourless oil (1.62 g, 6.10 mmol, 84%); Rf 0.83 (CH2Cl2); H (500 
MHz; CDCl3) 7.62 (1H, d, J 8.6, 6-H), 6.43 (1H, d, J 2.7, 2-H), 6.32 (1H, dd, J 8.6, 2.7 , 
6-H), 3.85 (3H, s, OMe), 3.80 (3H, s, OMe); δC (125 MHz; CDCl3) 160.2 (2-C), 157.6 (4-
C), 137.6 (6-C), 105.9 (5-C), 98.0 (3-C), 73.6 (1-C), 55.0 (OMe), 54.3 (OMe); νmax/cm
-1 
(solid) 1575 and 822; m/z (EI+) 264.0 (75%, [M]+); found 263.9647, C8H9IO2 requires M 
263.9647 
1,3-Diethyl 2-(2,4-dimethoxyphenyl)propanedioate 176127 
 
Caesium carbonate (3.68 g, 11.4 mmol) was added to a solution of 175 (1.00 g, 3.78 
mmol) in dioxane (8.00 mL). Copper iodide (35.0 mg, 5 mol%) and picolinic acid (46.0 
mg, 10 mol%) were added in one portion. The solution was stirred at room temperature 
for 5 min and diethyl malonate (1.20 g, 7.56 mmol) was added in one portion and the 
solution was heated at reflux for 48 h. On completion the reaction was filtered through 
a short silica pad, the silica was washed with CH2Cl2 (3 × 25.0 mL). The solution was 
dried, MgSO4, filtered and concentrated in vacuo to give a viscous oil. Column 
chromatography, eluting with 20:80 Et2O—hexanes gave 176 (0.79 g, 2.67 mmol, 71%) 
as a colourless needles; m.p. 53.5-54.1 °C (hexanes—Et2O); Rf 0.65 (CH2Cl2); H (500 
MHz; CDCl3) 7.25 (1H, br s, Ph 6-H), 6.50 (1H, dd, J 8.3 and 2.0, Ph 5-H), 6.46 (1H, 
dd, J 2.0, Ph 3-H), 5.02 (1H, s, propyl 2-H), 4.27-4.17 (4H, m, 2 x CH2), 3.80 (3H, s, 
OMe), 3.79 (3H, s, OMe), 1.26 (6H, t, J 7, CH3); δC (75 MHz; CDCl3) 169.2 (2 x C=O), 
161.1 (Ph 2-C), 158.4 (Ph 4-C), 130.5 (Aryl 6-C), 114.8 (Aryl 1-C), 105.0 (Aryl 5-C), 
99.0 (Aryl 3-C), 62.2 (CH2CH3), 56.0 (OCH3), 55.7 (OCH3), 51.0 (C(O)CHC(O)), 14.4 
(CH3CH2); νmax/cm
-1 (solid) 2970, 2442, 2159, 2029, 1738, 1366, 1217; m/z (EI+) 297.5 
(90%, [M+H]+) and 223.4 (100%, [M-C(O)OEt]+) 
  
101 
 
2-(2,4-Dimethoxyphenyl)propane-1,3-diol 177 
 
Lithium aluminium hydride (0.40 g, 10.6 mmol) was slurried in THF (10.0 mL) and 
cooled to 0 °C. A solution of the -aryl diethyl malonate 176 (0.7 g, 2.36 mmol) in THF 
(3.60 mL) was added dropwise. Once addition was complete the reaction was stirred 
for 5 min at 0 °C and then 24 h at room temperature. The reaction mixture was cooled 
to 0 °C and water (15.0 mL) was added. The reaction mixture was then filtered through 
a short silica pad; washing the silica with Et2O (5 × 10.0 mL). The filtrate was separated 
and the aqueous layer was extracted with Et2O (3 × 10.0 mL). The combined organic 
layers were dried, MgSO4, and concentrated in vacuo to give the crude diol as a 
viscous oil. Column chromatography, eluting with 50:50 EtOAc—hexanes gave the diol 
177 (0.27 g, 1.27 mmol, 53%) as colourless needles; m.p. 84.7-85.9 °C (from EtOAc—
hexanes); Rf 0.11 (50:50, EtOAc—hexanes); H (500 MHz; CDCl3) 7.07 (1H, d, J 9, Aryl 
6-H), 6.5-6.43 (2H, m, Aryl 5-H and 3-H), 4.05-3.85 (4H, m, propyl 1-H), 3.81 (3H, s, 
OMe), 3.79 (3H, s, OMe), 3.50-3.39 (1H, m, propyl 2-H), 2.01 (2H, t, J 7.5, OH); δC (75 
MHz; CDCl3) 160.3 (Aryl 4-C) 158.8 (Aryl 2-C), 129.2 (Aryl 6-C), 120.2 (Aryl 1-C), 99.4 
(Aryl 3-C), 104.8 (Aryl 5-C), 65.8 (propyl 1-C), 55.8 (OMe), 55.7 (OMe), 43.3 (propyl 2-
C); νmax/cm
-1 (solid) 3234, 2509, 2159, 2030, 1615, 1469, 1040; m/z (ES+) 235.1 
(100%, [M+H]+); found 235.0944, C11H16O4 requires MH 235.0941 
(2S)-2-(2,4-Dimethoxyphenyl)-3-hydroxypropyl acetate 178 
 
Candida Antarctica (10.0 mg) immobilised on acrylic resin beads (Novozyme 435®) was 
added to the 1,3-diol 177 (50.0 mg, 0.23 mmol) dissolved in ether (2.00 mL). Vinyl 
acetate (30.0 mg, 0.35 mmol) was added. The reaction mixture was stirred gently as 
not to break up the enzyme resin beads for 20 min; after which the reaction was filtered 
and concentrated in vacuo to give the crude product as a viscous oil. Column 
chromatography, eluting with 50:50 EtOAc—hexanes gave the hydroxy acetate 178 
(41.0 mg, 0.16 mmol, 70%) as a colourless film. Rf 0.27 (50:50, hexanes—EtOAc); 
    
   −16.4 (c 1.2, CHCl3); H (500 MHz; CDCl3): 7.10 (1H, dd, J 6.9 and 2.4, Ar 6-H), 
6.49-6.43 (2H, m, Ar 2 and 5-H), 4.38 (1H, dd, J 11.1 and 7.2, propyl 1-HA), 4.34 (1H, 
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dd, J 11.1 and 5.9, propyl 1-HB), 3.83 (2H, d, J 5.9, propyl 3-HAB), 3.80 (3H, s, OMe), 
3.79 (3H, s, OMe), 3.50 (1H, p, J 5.9, propyl 2-H), 2.05 (3H, s, C(O)CH3), 1.90 (1H, brs, 
CH2OH); δC (75 MHz; CDCl3) 171.7 (C(O)CH3), 160.4 (Ar 2-C or 4-C), 158.8 (Ar 2-C or 
4-C), 129.4 (Ar 6-C), 119.7 (Ar 1-C), 104.7 (Ar 5-C), 99.3 (Ar 3-C), 64.9 (propyl 1-C), 
63.4 (propyl 3-C), 55.8 (OMe), 55.7 (OMe), 40.7 (propyl 2-C), 21.3 (C(O)CH3; νmax/cm
-1 
(film) 3006, 1727, 1616, 1584, 1506, 1458; m/z (ES+) 277.1 (100%, [M+Na]+); found 
277.1042, C13H18O5 requires MNa 277.1046  
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl acetate 179 
 
Alcohol 178 (15.0 g, 60.0 mmol) and allyl ethyl carbonate (23.0 g, 177 mmol) were 
dissolved in THF (500 mL) at room temperature. Palladium (II) acetate (132 mg, 0.59 
mmol) and triphenylphosphine (1.54 g, 5.9 mmol) were added and the reaction was 
refluxed for 24 h. The reaction was concentrated in vacuo dissolved in EtOAc (200 mL) 
and passed through a short silica pad and concentrated in vacuo to give the crude 
product. Column chromatography, eluting with petrol—EtOAc (80:20) gave the allyl 
ether 179 (13 g, 58.1 mmol, 72%); Rf 0.91 (80:20 petrol—EtOAc,);    
      4 (c 0.5, 
CHCl3); H (500 MHz, CDCl3); 7.11 (1H, d, J 9.0, Ph 6-H), 6.47-6.43 (2H, m, Ph 3-H 
and 5-H), 5.87 (1H, ddt, J 17.2, 10.7 and 5.5, propenyl 2-H), 5.24 (1H, d, J 17.2, 
propenyl 3-HA), 5.15 (1H, d, J 10.7, propenyl 3-HA), 4.38 (1H, dd, J 5.9 and 10.8, 1-Ha), 
4.32 (1H, dd, J 6.2 and 10.8, propyl 1-HB), 4.01 (2H, m, propenyl 1-H), 3.79 (6H, s, 
OMe), 3.67-3.56 (3H, m, propyl 2-H and 3-Hab), 1.99 (3H, s, Ac); δC (75 MHz; CDCl3) 
171.2 (C=O), 159.6 (Ph 2 or 4-C), 158.3 (Ph 2 or 4-C), 134.9 (propenyl 2-C), 128.9 (Ph 
6-C), 119.9 (Ph 1-C), 116.7 (propenyl 3-C), 104.0 (Ph 5-C), 98.6 (Ph 3-C), 64.9 
(propenyl 1-C), 60.4 (propyl 1 and 3-C), 55.4 (OMe), 55.3 (OMe), 37.7 (propyl 2-C), 
21.1 (Me); νmax/cm
-1 (film): 1735, 1612, 1506, 1233, 1207, 1032 and 541; m/z (ES+) 
317.1 (100%, [M+Na]+); found 317.1360, C16H22O5 requires MNa 317.1359 
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(2R)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propan-1-ol 180 
 
By general procedure D, acetate 179 (10.6 g, 36 mmol) was dissolved in sat. 
MeOH/NH3 (500 mL), after 48 h the reaction was concentrated in vacuo to give 180 
(7.5 g, 75%) as a colourless oil; Rf 0.18 (80:20, petrol—EtOAc);     
   8.3 (c. 2.9 in 
CH2Cl2); δH (500 MHz; CDCl3) 7.11 (1H, d, J 8.1, Ar), 5.51-6.47 (2H, m, Ar), 5.96 (1H, 
ddt, J 17.1, 10.5 and 5.6 , propenyl 2-H), 5.32 (1H, d, J 17.1, propenyl 3-HA), 5.23 (1H, 
d, J 10.5, propenyl 3-HB), 4.11-3.97 (4H, m, propenyl 1-H and 3-HAB), 3.85 (3H, s, 
OMe), 3.84 (3H, s, OMe), 3.83-3.79 (1H, m, 1-HA), 3.76 (1H, dd, J 9.1 and 4.7, 1-HB), 
3.64-3.58 (1H, m, 2-H), 2.61 (1H, br s, OH); δC (75 MHz; CDCl3) 160.1 (Ar 2- or 4-C), 
158.6 (Ar 2- or 4-C), 134.9 (propenyl 2-C) , 128.8 (Ar 6-C), 120.4 (Ar 1-C), 117.5 
(propenyl 3-C), 104.5 (Ar 5-C), 99.2 (Ar 3-C), 73.8 (propyl 1-C), 72.6 (propenyl 1-C), 
66.6 (propyl 3-C), 55.8 (OMe), 55.7 (OMe), 40.5 (propyl 2-C); νmax/cm
-1 (film) 3407, 
2937, 1609, 1212 and 833; m/z (ES+) 151 (100%, [M-Propyl]+) and 275.0 (85%, 
[M+Na]+); found 275.1261, C14H20O4 requires MH 275.1254 
(4S)-4-Benzyl-3-propanoyl-1,3-oxazolidin-2-one 182128 
 
n-Butyl lithium (18.75 mL, 1.6M in hexanes, 30 mmol) was added dropwise to a stirred 
solution of (S)-4-Benzyl-2-oxazolidinone (5.00 g, 28 mmol) in THF (100 mL) at −78  C. 
Propionyl chloride (2.94 mL, 30.0 mmol) was added dropwise after 1 h at −78 °C, the 
reaction was allowed to warm to room temperature over 16 h. Water (10.0 mL) was 
added and the reaction mixture was concentrated in vacuo; EtOAc (100 mL) was 
added; the organic layer was washed with water (3 × 50 mL) and dried MgSO4, filtered 
and concentrated in vacuo to give the oxazolidinone 182 (6.29 g, 27.0 mmol, 96%) as a 
pale yellow solid; Rf 0.92, (50:50 EtOAc—petrol); m.p 44 °C (from EtOAc—hexanes) 
[Lit. 44-45];     
     59.2 (c. 1 in CHCl3); [Lit.       55 (c. 1.27 in CHCl3)
128]; δH (500 
MHz; CDCl3) 7.36-7.16 (5H, m, Ar), 4.65 (1H, dddd, J 10.4, 7.5, 3.3 and 3.0, 5-H), 4.22-
4.11 (2H, m, 4-H), 3.28 (1H, dd, J 13.4 and 3.3, Bn-Ha), 2.94 (2H, q, J 7, Pr), 2.77 (1H, 
dd, J 13.4 and 10.4, Bn-Hb), 1.19 (3H, t, J 7, Pr); δC (75 MHz; CDCl3) 6.8 (3ʹ-C), 28.1 
(2ʹ-C), 36.5 (Bn-C), 53.9 (5-C), 65.2 (4-C), 126.3 (Ar), 127.9 (Ar), 128.3 (Ar), 134.4 (Ar), 
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152.5 (2-C), 173.0 (1ʹ-C); νmax/cm
-1 (solid): 3029, 2981, 2940, 1782, 1698, 1454, 1372; 
m/z (ES+)  234.1 (100%, [M+H]+); found 234.1119, C13H16NO3 requires MH 234.1125 
 
(4S)-4-Benzyl-3-[(2ʹS,3ʹR)-3ʹ-hydroxy-2ʹ-methylhept-6ʹ-enoyl]-1,3-oxazolidin-2-one 
183 111 
 
n-Dibutylboryl triflate (2.60 mL, 1M in CH2Cl2, 2.58 mmol) and N,N-
diisopropylethylamine (0.5 mL, 3.00 mmol) were added to a stirred solution of 
oxazolidinone 182 (0.50 g, 2.15 mmol) in CH2Cl2 (20 mL) at 0 °C. The reaction, after 30 
min the reaction was cooled to −78 °C, following this 4-pentenal (0.90 g, 10.8 mmol) 
was added dropwise. The reaction was stirred at −78 °C for 3 h and then 0 °C for a 
further 30 min. Phosphate buffer (pH 7.2)/MeOH (10 mL, ½ v/v) and H2O2/MeOH (10 
mL, ½ v/v) were added to the reaction at 0 °C. After 1 h the reaction was concentrated 
in vacuo and the aqueous solution was extracted with EtOAc (3 × 50 mL), the 
combined organic layers were washed with sat. NaHCO3 (50 mL), brine (50 mL) and 
concentrated in vacuo to give the crude product. Column chromatography, eluting with 
70:30 petrol—EtOAc, gave the oxazolidinone 183 (365 mg, 1.15 mmol, 53%) as 
colourless needles; m.p. 81.7-83.9 °C (from EtOAc—hexanes); Rf 0.41 (90:10 
hexanes—EtOAc);     
     51.1 (c. 0.9, CHCl3); [Lit. 82 (c. 0.83 in CH2Cl2)
111]; δH (500 
MHz; CDCl3) 7.42-7.31 (3H, m, Ph), 7.27-7.21 (2H, m, Ph), 5.87 (1H, ddt, J 16.9, 10.3 
and 6.7, 7ʹ-H), 5.09 (1H, ddd, J 16.9, 3.4 and 1.6, 6ʹ-HA), 5.02 (1H, dd, J 10.3 and 1.6, 
6ʹ-HB), 4.75 (1H, ddt, J 9.4, 7.2 and 3.3, 5-H), 4.31-4.20 (2H, m, 4-HAB), 4.02 (1H, ddd, 
J 8.9, 4.1 and 2.8, 3ʹ-H), 3.82 (1H, qd, J 7.0 and 2.8, 2ʹ-H), 3.29 (1H, dd, J 13.4 and 
3.3, Bn-HA), 2.85 (1H, dd, J 13.4 and 9.4, Bn-HB) 2.38-2.10 (m, 2H, 3ʹ-HAB), 1.78-1.64 
(1H, m, 4ʹ-HA or 4ʹ-HB), 1.60-1.46 (1H, m, 4ʹ-HA or 4ʹ-HB), 1.31 (3H, d, J 7.0, Me); δC (75 
MHz; CDCl3) 177.87 (1ʹ-C), 153.4 (2-C), (Ar), 138.5 (6ʹ-C), (Ar), 135.4 (Ar), 129.8 (Ar), 
129.4 (Ar), 127.9 (Ar), 115.4 (7ʹ-C), 71.3 (3ʹ-C), 66.6 (4-C), 55.5 (5-C), 42.6 (2ʹ-C), 38.2 
(Bn), 33.4 (4ʹ-C), 30.6 (5ʹ-C), 10.9 (Me); νmax/cm
-1 (solid) 3497, 2940, 1771, 1675 and 
897; m/z (ES+) 318.2 (100%, [M+H]+) 
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(4S)-4-Benzyl-3-[(2ʹS,3ʹR)-3ʹ-[(tert-butyldimethylsilyl)oxy]-2ʹ-methylhept-6ʹ-enoyl]-
1,3-oxazolidin-2-one 184 
 
Imidazole (383 mg, 5.64 mmol), DMAP (10.0 mg, 0.08 mmol) and tert-butyldimethylsilyl 
chloride (423 mg, 2.82 mmol) were added to a stirred solution of alcohol 183 (300 mg, 
0.94 mmol) in CH2Cl2 (30 mL) and stirred at room temperature for 4 days. The reaction 
mixture was filtered through Celite and washed with CH2Cl2 (50 mL). The combined 
organic layers were washed with water (2 × 20 mL), 0.1M HCl (20 mL), saturated 
NaHCO3 (20 mL) and brine (20 mL); dried (MgSO4) and concentrated in vacuo to give 
silyl ether 184 (352 mg, 0.81 mmol, 87 %) as a colourless waxy solid; m.p. 41.2-43.9 
°C (from EtOAc—hexanes); Rf 0.73 (90:10, petrol—EtOAc);     
    : 52 (c. 0.7, CHCl3); 
δH NMR (500 MHz; CDCl3) 7.36-7.18 (5H, m, Ar), 5.80 (1H, ddt, J 17.1, 10.3 and 6.4, 
6ʹ-H), 5.00 (1H, ddd, J 17.1, 3.5 and 1.7, 7ʹ-HA), 4.93 (1H, dd, J 10.3 and 1.7, 7ʹ-HB), 
4.59 (1H, ddt, J 15.8, 9.5 and 3.3, 5-H), 4.19-4.10 (m, 2H, 4-H), 4.01 (1H, q, J 5.3, 3ʹ-
H), 3.86 (1H, ddd, J 13.7, 6.8 and 5.1, 2ʹ-H), 3.28 (1H, dd, J 13.3 and 3.1, Bn-HA), 2.75 
(1H, dd, J 13.3 and 9.7, Bn-HB), 2.17-1.99 (2H, m, 5ʹ-H), 1.69-1.57 (2H, m, 4ʹ-H), 1.20 
(3H, d, J 6.8, Me), 0.87 (9H, s, (SiC(CH3)3)), 0.01 (6H, s, 2 × SiCH3); δC (75 MHz; 
CDCl3) 175.6 (1ʹ-C), 153.5 (2-C), 138.9 (6ʹ-C), 135.8 (Ar), 129.9 (Ar), 129.4 (Ar), 127.8 
(Ar), 114.8 (7ʹ-C), 72.9 (3ʹ-C) , 66.4 (4-C), 56.2 (5-C), 43.2 (2ʹ-C), 38.0 (Bn), 35.0 (4ʹ-C), 
29.6 (5ʹ-C), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 12.2 (Me), -2.5 (SiCH3); νmax/cm
-1 
(solid): 2929, 1783, 1704, 1382, 1208, 1108 and 837; m/z (ES+) 432.3 (100%, [M+H]+); 
found 454.2403, C14H30O2Si requires MNa 454.2384 
 
(2R,3R)-2-Methylhept-6-ene-1,3-diol 185 
 
LiBH4 (2.2 g, 100 mmol) was added portion-wise to a stirred solution of 184 (18 g, 42.5 
mmol) in THF (100 mL) and ether (400 mL) at 0 °C over the period of 1 h. The reaction 
was allowed to warm to room temperature and stirred for 2 h. The reaction was poured 
over crushed ice (ca. 50 mL) and extracted with CH2Cl2 (3 × 50 mL). The organic layers 
were concentrated in vacuo to give the crude product. Column chromatography, eluting 
with CH2Cl2 gave the alcohol 185 (7.1g, 27.5 mmol, 65 %); Rf 0.46 (CH2Cl2);     
     2.8 
(c. 1.4, CHCl3); H (500 MHz; CDCl3) 5.72 (1H, ddt, J 6.6, 10.2 and 16.9, 6-H), 4.93 
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(1H, dd, J 3.5 and 16.9, 7-HA), 4.87 (1H, dd, J 3.5 and 10.2, 7-HB), 3.70-3.65 (1H, m, 1-
Ha), 3.64-3.57 (1H, m, 1-Hb), 3.46-3.39 (1H, m, 3-H), 2.50 (1H, br s, OH), 2.13-2.03 
(1H, m, 2-H), 1.95-1.83 (2H, m, 5-H), 1.55-1.41 (2H, m, 4-H), 0.80 (9H, s, (SiC(CH3)3), 
0.72 (3H, d, J 7.1, 2-CH3), -0.01 (6H, s, 2 × SiCH3); δC (75 MHz; CDCl3) 138.5 (6-C), 
114.7 (7-C), 75.4 (3-C), 65.9 (1-C), 39.5 (2-C), 31.5 (4 or 5-C), 30.4 (4 or 5-C), 25.8 
(TBS), 18.0 (TBS), 12.1 (CH3), -4.4 (TBS); νmax/cm
-1 (film): 2929, 1251, 1031, 833 and 
772; m/z (ES+) 259.2 (100%, MH+); found 281.1914, C14H30O2Si requires MNa 
281.1900 
(2S)-2-(Prop-2-enyloxy)propanoic acid 188 
 
Allyl bromide (7.60 g, 63.0 mmol) and (S)-ethyl lactate 186 (5.00 g, 42.0 mmol) were 
added to a suspension of silver oxide(I) (19.6 g, 85.0 mmol) in acetone (100 mL) at 
room temperature. The reaction was stirred at room temperature in the dark for 2 days. 
The reaction was filtered through Celite and concentrated in vacuo to give the crude 
ethyl lactate. The crude product was dissolved in THF (50 mL) and 1M LiOH (100 mL) 
was added dropwise at 0 °C. The reaction mixture was stirred for 3 h and then acidified 
with 1M HCl. The solution was then concentrated in vacuo to half volume and extracted 
with EtOAc (5 × 50 mL), the combined organic layers were dried (MgSO4) and 
concentrated in vacuo to give 188 (5.10 g, 36.1 mmol, 84%) as a pale yellow oil; Rf: 
0.53 (50:50 hexanes—EtOAc);     
     −65 (c. 1.10, CHCl3); [Lit. −69 (c. 1.05, CHCl3); 
δH (500 MHz; CDCl3) 5.92 (1H, ddd, J 17.2, 10.2 and 5.8, propenyl 2-H), 5.32 (1H, dd, J 
17.2 and 1.5, propenyl 3-HA), 5.24 (1H, dd, J 1.5 and 10.2, propenyl 3-HB), 4.16 (1H, 
dd, J 12.5 and 5.6, propenyl 1-HA), 4.08 (1H, q, J 6.9, H-2), 4.03 (1H, dd, J 12.5 and 
5.6, propenyl 1-HB), 1.48 (3H, d, J 6.9, 3-H); δC (75 MHz; CDCl3)  176.2 (1-C), 132.6 
(propenyl 2-C), 117.3 (propenyl 3-C), 72.5 (2-C), 70.2 (propenyl 1-C), 17.2 (3-C); 
νmax/cm
-1 (film): 3083, 298, 2940, 1725, 1213, 1117; m/z (ES+) 153.1 (100%, [M+Na]+); 
found 153.0526, C6H10O3 requires MNa 153.0522 
(2S)-N-[(2-Nitrobenzene)sulfonyl]-2-(prop-2-enyloxy)propanamide 189 
 
Acid 188 (2.0 g, 15.4 mmol) and 2-nitrobenzene sulfonamide (3.42 g, 16.9 mmol) in 
CH2Cl2 (50 mL) were added dropwise to a stirred solution of N,Nʹ-
dicyclohexylcarbodiimide (3.48 g, 16.9 mmol) and DMAP (187 mg, 1.54 mmol) at 0 °C. 
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After 5 min the reaction was allowed to warm to room temperature. After 24 h the 
reaction was poured into water (50 mL), separated and the organic layer was washed 
with 1M HCl (20 mL) and brine (50 mL), dried (MgSO4) and concentrated in vacuo to 
give a viscous oil. Column chromatography, eluting with 50:50 petrol—EtOAc and 1% 
AcOH gave the sulfonamide 189 (3.43 g, 10.9 mmol, 71%) as a yellow viscous oil that 
solidified on standing; Rf 0.35 (petrol—EtOAc, 50:50);     
     11.1 (c. 8.3, CHCl3); H 
(500 MHz; CDCl3) 9.32 (1H, s, NH), 8.38-8.34 (1H, m, nosyl 3-H), 7.80-7.72 (3H, m, 
nosyl 4, 5 and 6-H), 5.85 (1H, ddt, J 5.6, 10.3 and 17.1, propenyl 2-H), 5.26 (1H, dd, J 
1.5 and 17.1, propenyl 3-HA), 5.20 (1H, dd, J 1.5 and 10.3, propenyl 3-HB), 4.01 (2H, dt, 
J 1.3 and 5.9, propenyl 1-H2), 3.88 (1H, q, J 6.8, 2-H), 1.30 (3H, d, J 6.8, CH3); δC (75 
MHz; CDCl3) 171.4 (C=O), 148.2 (nosyl 2-C), 135.1 (nosyl 1-C), 133.6 (propenyl 2-C), 
132.9, 132.6, 131.5, 124.9, 118.8 (propenyl 3-C), 75.5 (propenyl 1-C), 71.2 (2-C), 17.6 
(Me); νmax/cm
-1 (film): 2932, 1729, 1540, 1404, 1358, 1100, 852 and 739; m/z (ES) 
337.1 (70%, [M+Na]+) and 315.1 (30%, [M+H]+); found 315.0639, C12H15N2O6S1 
requires MH 315.0645 
(2S,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methyl-N-[(2-
nitrobenzene)sulfonyl]hept-6-enamide 133 
 
Acid 190 (800 mg, 2.94 mmol) and 2-nitrobenzene sulfonamide (1.18 g, 5.88 mmol) in 
CH2Cl2 (15 mL) were added to a stirred solution of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) (0.55 g, 3.52 mmol) and DMAP (24 mg, 0.2 mmol) at 0 °C. After 16 h, the 
reaction was concentrated in vacuo, column chromatography eluting with petrol—
EtOAc (50:50) gave acyl sulfonamide 133 (800 mg, 60%) as a viscous yellow oil that 
solidified on standing; Rf 0.23 (50:50, petrol—EtOAc);     
     −16.1 (c. 0.9, CHCl3); δH 
(300 MHz; CDCl3) 10.24 (1H, br s, NH), 8.50-8.45 (1H, m, nosyl 6-H), 7.83-7.78 (3H, 
m, nosyl 3,4 and 5-H), 5.66 (1H, ddt, J 16.9, 10.6 and 6.5, 6-H), 4.90 (1H, dd , J 10.6 
and 1.7, 7-HA), 4.89 (1H, dd , J 16.9 and 1.7, 7-HB), 3.80 (1H, dt, J 9.6 and 3.4, 3-H), 
2.75 (1H, qd, J 7.1 and 3.6, 2-H), 2.33-2.19 (1H, m, 5-HA), 2.03-1.87 (1H, m, 5-HB), 
1.50-1.20 (2H, m, 4-H2), 1.08-1.03 (12H, m, (SiC(CH3)3) and Me), -0.1 (6H, s, 
(Si(CH3)2); δC (75 MHz; CDCl3) 170.9 (C=O), 147.2 (nosyl 2-C), 146.8 (nosyl 1-C)), 
136.6, 133.6 (6-C), 132.9, 131.3, 123.5, 113.9 (7-C); 73.2 (3-C), 45.9 (2-C), 29.6 (3 or 
4-C), 28.9 (3 or 4-C), 24.9 ((SiC(CH3)3)), 16.9 (SiC(CH3)3), 10.9 (Me), 0.02 (Si(CH3)2); 
νmax/cm
-1 (film) 2987, 1724, 1546, 1422, 1275, 1261; m/z (ES+) 457.2 (20%, [M+H]+) 
and 474.2 (100%, [M+NH4]
+); found 235.0944, C20H32N2O6SSi requires MH 457.1823 
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(2S,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-enoic acid 190 
 
Hydrogen peroxide 35% v/v (0.20 mL, 1.84 mmol) and LiOH (23.0 mg, 0.92 mmol) 
were added to a stirred solution of 184 (100 mg, 0.23 mmol) in THF/H2O (10 mL, 4:1) 
at room temperature. Saturated sodium sulphite (5 mL) was added to the reaction 
mixture at 0 °C after 5 h and stirred for a further 30 min. The pH was adjusted to 14 
using 1M NaOH, and the reaction was washed with ether (2 × 10 mL). The aqueous 
layer was then acidified to pH 3 with 1M H2SO4 and extracted with EtOAc (4 × 20 mL); 
the combined organic layers were washed with brine (20 mL), dried (MgSO4) and 
concentrated in vacuo to give the crude product. Column chromatography, eluting with 
90:10 petrol—EtOAc, gave the acid 190 (57 mg, 0.21 mmol, 91%) as a colourless oil; 
Rf 0.38, (50:50 EtOAc—petrol);     
     −18.0 (c. 0.6, CHCl3); δH (500 MHz; CDCl3) 5.69 
(1H, ddt, J 16.9, 10.3 and 6.5, 6-H), 4.93 (1H, ddd, J 16.9, 1.6 and 1.3, 7-HA), 4.88 (1H, 
dd, J 10.3 and 1.3, 7-HB), 3.90 (1H, dd, J 6.0 and 5.3, 3-H), 2.51 (1H, ddd, J 14.1, 7.0 
and 4.4, 2-H), 2.10-1.8 (2H, m, 5-HAB), 1.55-1.45 (2H, m, 4-HAB), 1.04 (3H, d, J 7.0, 
Me), 0.79 (9H, s, (SiC(CH3)3)), -0.02 (6H, s, (Si(CH3)2); δC (75 MHz; CDCl3) 178.2 (1-C), 
138.3 (6-C), 115.4 (7-C), 73.6 (3-C), 44.8 (2-C), 33.5 (4-C), 29.9 (5-C), 26.2 
(SiC(CH3)3), 18.4 (SiC(CH3)3), 11.7 (Me), -4.3 (Si(CH3)2); νmax/cm
-1 (film) 2983, 1737, 
1439, 1201 and 1048; m/z (ES+)  273.2 (100%, [M+H]+) 295.2 (50%, [M+Na]+); found 
273.1876, C14H29O3Si requires MH 273.1886 
Benzyl N-[(2-nitrobenzene)sulfonyl]carbamate 197129 
 
To a solution of oxalyl chloride (3.18 g, 25 mmol) in EtOAc (20 mL), 2-nitrobenzene 
sulfonamide (1.0 g, 4.9 mmol) dissolved in EtOAc (20 mL) was added dropwise and 
stirred at room temperature. After 1 h the reaction was concentrated to ½ volume using 
a standard distillation setup at atmospheric pressure. Toluene (20 mL) was added and 
the remaining EtOAc and oxalyl chloride were distilled out. The reaction was then 
heated to reflux, after 2 h the reaction was cooled to 0 °C and triethylamine (3.03 g, 30 
mmol) was added, followed by benzyl alcohol (534 mg, 5 mmol). The reaction was 
allowed to warm to room temperature, after 2 h the reaction was concentrated in vacuo 
to give the crude product. Column chromatography, eluting with EtOAc—AcOH (97:3) 
gave the carbamate 197 (1.23 g, 3.6 mmol, 77%) as colourless prisms; m.p 112-115 
(from EtOAc—hexanes); Rf 0.39 (99:1 EtOAc—AcOH); H (500 MHz; CDCl3) 8.24 (1H, 
109 
 
dd, J 1.4 and 7.9, nosyl 3-H), 7.84 (1H, br s, NsNH), 7.79 (1H, dd, J 1.3 and 7.9, nosyl 
4-H), 7.72 (1H, td, J 1.4 and 7.7, nosyl 6-H), 7.64 (1H, td, J 1.3 and 7.7, nosyl 5-H) 
7.31-7.26 (3H, m, Ar), 7.25-7.20 (2H, m, Ar), 5.07 (2H, s, PhCH2); δC (75 MHz; CDCl3) 
149.9 (nosyl 2-C), 134.9 (nosyl 1-C), 134.0, 133.4, 132.6, 131.5, 128.9, 128.7, 128.6, 
125.2, 69.1 (PhCH2), C=O missing; νmax/cm
-1 (solid) 3263, 1743, 1541, 1360, 1228, 
1156, 1126, 854, 582 and 564; m/z (ES) 335.1 (100%, MH) 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-[(2-nitrobenzene)sulfonyl]carbamate 131 
 
To a solution of 2-nitrobenzene sulfonamide (15.0 g, 72 mmol) in EtOAc (400 mL) at 0 
°C was added a solution of oxalyl chloride (45.0 g, 360 mmol) in EtOAc (100 mL). The 
reaction was stirred at room temperature for 1 h and a further 24 h at reflux. The 
reaction was then distilled to ½ volume using a standard distillation setup, toluene (500 
mL) was added and the reaction was distilled further until the vapour temperature was 
105 °C at atmospheric pressure. The reaction was heated under reflux for a further 16 
h and then cooled to 0 °C. A solution of alcohol 173 (6.1 g, 36 mmol) in THF (100 mL) 
was added and the reaction was stirred at room temperature for 16 h and then 
concentrated in vacuo. Column chromatography, eluting with 85:14:1 CH2Cl2—EtOH—
NH4OH gave 131 (10.9 g, 77%) as a pale yellow foam; Rf 0.19 (85:14:1, CH2Cl2—
EtOH—NH4OH); δH (500 MHz; MeOD) 8.05-7.95 (1H, m, nosyl 3-H), 7.54-7.44 (3H, m, 
nosyl 4,5 and 6-H), 7.20-7.05 (2H, m, Ar), 6.81-6.73 (2H, m, Ar), 5.94 (1H, ddt, J 17.3, 
10.6 and 5.0, propenyl 2-H), 5.27 (1H, d, J 17.3, propenyl 3-HA), 5.09 (1H, d, J 10.6, 
propenyl 3-HB), 4.92 (2H, s, PhCH2), 4.42 (2H, d, J 5, propenyl 1-H); δC (75 MHz; 
MeOD) 158.0 (C=O), 153.7 (Ph 1-C), 149.6 (nosyl 2-C), 135.7 (nosyl 1-C), 134.6 
(propenyl 2-C), 133.8 (nosyl 5-C), 133.4 (Ar), 132.8 (nosyl 4-C), 131.1 (Ar), 130.9 
(nosyl 3-C), 125.6 (Ph 2-C), 125.0 (nosyl 6-C), 121.6 (Ar), 117.4 (propenyl 3-C) , 113.0 
(Ph 3-C), 69.8 (PhCH2), 64.8 (propenyl 1-C); νmax/cm
-1 (solid) 3238, 3024, 2898, 1746, 
1496, 1365, 999, 851 and 739; m/z (ES+)  415.1 (100%, [M+Na]+); found 415.0559, 
C17H16N2NaO7S1 requires MNa 415.057 
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2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl-[(2-
nitrobenzene)sulfonyl]carbamate 132 
 
To a solution of 2-nitrobenzene sulfonamide (12.1 g, 60 mmol) in EtOAc (500 mL) at 0 
°C was added oxalyl chloride (45.0 g, 360 mmol). The reaction was stirred for 1 h at 
room temperature and a further 24 h at reflux. The reaction was then distilled to ½ 
volume using a standard distillation setup, toluene (500 mL) was added and the 
reaction was distilled further until the vapour temperature was 105 °C at atmospheric 
pressure. The reaction was further reflux for 16 h and then cooled room temperature. A 
solution of alcohol 180 (4.3 g, 17 mmol) in THF (50 mL) was added and the reaction 
was stirred at room temperature for 1 h and then concentrated in vacuo. Column 
chromatography, eluting with 85:14:1 CH2Cl2—EtOH—NH4OH gave 132 (7.8 g, 16.2 
mmol, 95%) as a yellow foam; Rf 0.2 (85:14:1 CH2Cl2—EtOH—NH4OH);     
   12.0 (c. 
1.5 in EtOH);  δH (500 MHz; CDCl3) 8.15 (1H, d, J 7.8, nosyl 3-H), 7.74 (1H, d, J 7.8, 
nosyl 4-H), 7.68 (1H, t, J 6.6, nosyl 5-H), 7.62 (1H, t, J 6.6, nosyl 6-H), 6.93 (1H, d, J 
8.2, DMB 6-H), 6.31-6.26 (2H, m, DMB 3 and 5-H), 5.74 (1H, ddt, J 17.1, 10.4 and 5.5, 
propenyl 2-H), 5.11 (1H, d, J 17.1, propenyl 3-HA), 5.03 (1H, d, J 10.4, propenyl 3-HB), 
4.39 (1H, dd, J 5.1 and 10.4, propyl 1-HA), 4.28 (1H, dd, J 6.6 and 10.6, propyl 1-HB), 
3.86-3.78 (m, 2H, propenyl 1-H), 3.69 (3H, s, OMe), 3.66 (3H, s, OMe), 3.52-3.46 (m, 
3H, 2-H and 3-HAB); δC (75 MHz; CDCl3) 160.2 (Ar 2- or 4-C), 158.6 (Ar 2- or 4-C), 
150.4 (C=O), 148.5 (nosyl 2-C), 135.2 (nosyl 1-C), 135.1 (propenyl 2-C), 133.8 (), 
132.9 (nosyl 4-C), 131.9 (nosyl 5-C), 129.3 (Ar 6-C), 125.5 (nosyl 6-C), 119.3 (DMB 1-
C) , 117.4 (propenyl 3-C), 104.5 (DMB 5-C), 98.9 (DMB 3-C), 72.4 (1-C), 70.4 (3-C), 
68.1 (propenyl 1-C), 55.7 (OMe), 55.7 (OMe), 38.7 (2-C); νmax/cm
-1 (solid) 3369, 3096, 
1748, 1525, 1366, 1345, 1164 and 743; m/z (ES+)  503.1 (100%, [M+Na]+); found 
503.1088, C21H24N2O9S requires MNa 503.1095 
(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl N-[(2-
nitrobenzene)sulfonyl]carbamate 198 
 
To a solution of 2-nitrobenzene sulfonamide (1.59 g, 7.9 mmol) in EtOAc (100 mL) at 0 
°C was added oxalyl chloride (4.95 g, 39 mmol). The reaction was stirred for 1 h at 
room temperature and a further 24 h at reflux. The reaction was then distilled to ½ 
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volume using a standard distillation setup, toluene (100 mL) was added and the 
reaction was distilled further until the vapour temperature was 105 °C at atmospheric 
pressure. The reaction was further reflux for 16 h and then cooled room temperature. A 
solution of alcohol 185 (1.0 g, 3.9 mmol) and triethylamine (8.0 g, 80 mmol) in CH2Cl2 
(50 mL) was added at 0 °C and the reaction was then stirred at room temperature for 1 
h and then concentrated in vacuo. Column chromatography, eluting with 85:14:1 
CH2Cl2—EtOH—NH4OH gave 198 as a pale yellow foam (1.86 g, 25%); Rf 0.11 
(85:14:1, CH2Cl2—EtOH—NH4OH);     
   15.7 (c. 2.3 in EtOH); δH (500 MHz; CDCl3) 
8.37-8.32 (1H, m, nosyl 3-H), 7.85-7.72 (3H, m, nosyl 4, 5 and 6-H), 5.74 (1H, ddt, J 
16.9, 10.2 and 6.6, 6-H), 4.97 (1H, d, J 16.9, 7-HA), 4.93 (1H, d, J 10.2, 7-HA), 4.07 (1H, 
dd, J 10.4 and 6.9, 1-HA), 3.95 (dd, J 10.4 and 7.1, 1H, 1-HB), 3.67-3.62 (1H, m, 3-H), 
2.02-1.90 (2H, m, 5-HAB), 1.93-1.82 (1H, m, 2-H), 1.55-1.40 (m, 2H, 4-HAB), 0.81 (12H, 
s, CH3 and (SiC(CH3)3), 0.00 (3H, s, SiCH3), 0.08 (3H, s, SiCH3); δC (75 MHz, CDCl3) 
138.5 (6-C), 135.2 (nosyl 2-C), 133.8 (nosyl 1-C), 133.7 (nosyl 3-C), 132.9 (nosyl 4-C), 
131.6 (nosyl 6-C), 125.5 (nosyl5-C), 115.2 (7-C), 71.7 (3-C), 70.2 (1-C), 37.0 (2-C), 
33.5 (4-C), 30.3 (5-C), 26.2 (SiC(CH3)3), 18.4 (SiC(CH3)3), 10.7 (Me), -3.8 (SiCH3), -4.4 
(SiCH3), C=O is missing ; νmax/cm
-1 (solid) 3260, 2929, 2857, 1747, 1546, 1462, 1229, 
1168 and 836; m/z (ES+)  509.2 (80%, [M+H]+); found 509.1752, C21H34N2O7SSi 
requires MH 509.1748  
 
1-[(2-Nitrobenzene)sulfonyl]-3-(prop-2-en-1-yl)urea 199 
 
To a solution of 2-nitrobenzene sulfonamide (200 mg, 0.99 mmol) in EtOAc (7.5 mL) at 
0 °C was added oxalyl chloride (625 mg, 4.95 mmol). The reaction was stirred for 1 h at 
room temperature and a further 24 h at reflux. The reaction was then distilled to ½ 
volume using a standard distillation setup, toluene (20 mL) was added and the reaction 
was distilled further until the vapour temperature was 105 °C at atmospheric pressure. 
The reaction was further reflux for 16 h and then cooled room temperature. A solution 
of allyl amine 196 (56 mg, 0.99 mmol) and diisopropylethylamine (645 mg, 5 mmol) 
was added at 0 °C and the reaction was then stirred at room temperature for 1 h and 
then concentrated in vacuo. Column chromatography, eluting with 85:14:1 CH2Cl2—
EtOH—NH4OH gave 199 as a pale yellow foam (143 mg, 51%); Rf 0.11 (50:8:1, 
CH2Cl2—EtOH—NH4OH); δH (300 MHz; CDCl3/MeOD) 8.14-8.04 (1H, m, nosyl 3-H), 
7.58-7.39 (3H, m, nosyl 4, 5 and 6-H), 5.62 (1H, ddt, J 17.2, 10.5 and 5.4, propenyl 2-
H), 5.07-4.96 (1H, m, propenyl 3-HA), 4.95-4.87 (1H, m, propenyl 3-HB), 3.67 (0.6H, J 
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14.4 and 5.4, propenyl 1-HrotB), 3.56 (1.4H, J 14.4 and 5.4, propenyl 1-H rotA); δC (75 
MHz; CDCl3) 164.9 (C=O
rotA), 163.5 (C=OrotB), 148.3 (nosyl 2-C), 135.7 (nosyl 1-C), 
134.3 (propenyl 2-CrotA), 134.0 (propenyl 2-CrotB), 133.2 (nosyl 1-C), 132.7 (nosyl 5-C), 
132.5 (nosyl 4-C), 132.4 (nosyl 4-C), 131.6 (nosyl 6-C), 131.2 (nosyl 6-C), 124.5 (nosyl 
3-C), 123.6 (nosyl 3-C), 116.7 (propenyl 3-CrotA), 115.9 (propenyl 3-CrotB), 42.8 
(propenyl 1-CrotA), 42.2 (propenyl 1-CrotB); νmax/cm
-1 (solid) 3360, 2342, 1671, 1537, 
1364, 1166; m/z (ES+)  308.0 (100%, [M+Na]+); found 308.0322, C10H11N3O5S requires 
MNa 308.0312 
{[(2R,3R)-1-Azido-2-methylhept-6-en-3-yl]oxy}(tert-butyl)dimethylsilane 200 
 
DPPA (2.09 g, 7.6 mmol) was added dropwise to a stirred solution of alcohol 185 (1.00 
g, 3.8 mmol), Triphenylphosphine (1.99 g, 7.6 mmol) and diethylazodicarboxylate (1.32 
g, 7.6 mmol) in THF (50 mL) at −18 ˚C. After 30 min the reaction was concentrated in 
vacuo. Column chromatography, eluting with petrol gave the azide 200 (1.05 g, 97%) 
as a colourless oil. Rf 0.66 (Petrol);     
   38.5 (c. 0.9, CHCl3); δH (500 MHz; CDCl3) 
5.84 (1H, ddt, J 16.9, 10.2 and 6.6, 6-H), 5.06 (1H, dd , J 16.9 and 1.4, 7-HA), 5.02 (1H, 
dd, J 10.2 and 1.4, 7-HB), 3.74 (1H, td, J 6.6 and 2.9, 3-H), 3.41 (1H, dd, J 11.9 and 
6.6, 1-HA), 3.15 (1H, dd, J 11.9 and 7.6, 1-HB), 2.18-1.96 (2H, m, 5-HAB), 1.86 (1H, qd, 
J 6.9 and 2.9, 2-H), 1.67-1.46 (2H, m, 4-HAB), 0.97-0.87 (12H, m, (SiC(CH3)3) and Me), 
0.1 (3H, s, SiCH3), 0.09 (3H, s, SiCH3); δC (75 MHz; CDCl3) 138.7 (6-C), 115.2 (7-C), 
72.6 (3-C), 54.9 (1-C); 38.1 (2-C), 33.4 (4-C), 30.5 (5-C), 26.3 ((SiC(CH3)3)), 18.5 
((SiC(CH3)3)), 12.3 (Me), -3.8 (SiCH3), -4.2 (SiCH3); νmax/cm
-1 (film) 2956, 2931, 2100, 
1472, 1463, 1275; m/z (ES+)  306.2 (100%, [M+Na]+) and 256.2 (100%, [MH-N2]
+; 
found 306.1964, C14H29N3OSi requires MNa 306.1972 
{[(2R,3R)-1-Amino-2-methylhept-6-en-3-yl]oxy}(tert-butyl)dimethylsilane 201 
 
Triphenylphosphine (3.66 g, 13.9 mmol) was added in one portion to a solution of azide 
200 (3.6 g, 12.7 mmol) in THF (130 mL) at room temperature. Water (0.5 mL) was 
added, after 24 h the reaction was concentrated in vacuo and column chromatography 
eluting with 50:8:1 CH2Cl2—EtOH—NH4OH gave the amine 201 (3.1 g, 95%) as a 
colourless oil; Rf 0.2 (EtOAc);      
   5.1 (c. 0.3 CHCl3); δH (500 MHz; MeOD) 5.74 (1H, 
ddt, J 16.9, 10.2 and 6.6, 6-H), 4.93 (1H, ddd , J 16.9, 3.7  and 1.7 , 7-HA), 4.86 (1H, 
ddd , J 10.2, 3.0 and 1.7, 7-HB), 3.63 (1H, ddd , J 6.7, 5.8 and 3.2, 3-H), 2.68 (1H, dd, J 
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12.6 and 5.7, 1-HA), 2.37 (1H, dd, J 12.6 and 8, 1-HB), 2.10-1.87 (2H, m, 5-HAB), 1.66-
1.54 (1H, m, 2-H), 1.54-1.35 (2H, m, 4-HAB), 0.83 (9H, s, (SiC(CH3)3), 0.81 (3H, d, J 7, 
Me), 0.01 (6H, s, 2 × SiCH3); δC (75 MHz; CDCl3) 140.0 (6-C), 115.3 (7-C), 75.5 (3-C), 
45.8 (1-C), 41.8 (4-C), 34.5 (5-C), 31.6 (2-C), 26.7 (SiC(CH3)3), 19.3 ((SiC(CH3)3)), 12.9 
(Me), -3.7 (SiCH3), -3.9 (SiCH3); νmax/cm
-1 (film) 2956, 2931, 1672, 1463, 1261, 837; 
m/z (ES+)  258.2 (100%, [M+H]+); found 258.2253, C14H32NOSi requires MH 258.2248 
 
N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl]-1,1,1-
trifluoromethanesulfonamide 202 
 
Trifluoromethanesulfonic anhydride (7.3 g, 26 mmol) was made up to 10 mL with 
CH2Cl2, this solution was added using a syringe pump at 0.5 mL/min to amine 201 
(3.33 g, 13 mmol) and Et3N (5.2 g, 52 mmol) in CH2Cl2 (52 mL). The reaction was 
concentrated in vacuo and column chromatography, eluting with 90:10 petrol—EtOAc  
gave the triflamide 202 (3.9 g, 77%) as a colourless oil; Rf 0.4 (70:30, petrol—EtOAc); 
    
   16.1 (c. 1, CHCl3); δH (500 MHz; CDCl3) 6.39 (1H, br s, NH), 5.76 (1H, ddt, J 16.9, 
10.2 and 6.5, 6-H), 5.01 (1H, dd , J 16.9 and 1.6, 7-HA), 4.96 (1H, dd , J 10.2 and 1.6, 
7-HB), 3.68 (1H, ddd, J 7.8, 4.3 and 2.9, 3-H), 3.29 (1H, d, J 12, 1-HA), 3.24 (1H, d, J 
12, 1-HB), 2.26-1.88 (3H, m, 5-HAB and 2-H), 1.57-1.42 (2H, m, 4-HAB), 0.89-0.84 (12H, 
m, (SiC(CH3)3) and Me), 0.08 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); δC (75 MHz; CDCl3) 
138.2 (6-C), 115.6 (7-C), 76.8 (3-C), 47.4 (1-C), 38.0 (5-C), 30.8 (2-C or 4-C), 30.7 (2-
C or 4-C), 26.2 (SiC(CH3)3), 18.3 (SiC(CH3)3), 14.5 (Me), -3.8 (SiCH3), -4.2 (SiCH3); 
νmax/cm
-1 (film) 3311, 3005, 2957, 2708, 2306, 1835, 1641, 1473, 1425, 1370; m/z 
(ES+) 412.2 (100%, [M+Na]+); found 412.1580, C15H30F3NO3SSi MNa requires 
412.1560;  
N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl]-1,1,1-trifluoro-
N-(trifluoromethane)sulfonylmethanesulfonamide 203 
 
Also obtained was the ditriflamide 203 (680 mg, 10%) Rf 0.70 (90:10, petrol—EtOAc); 
    
   15.7 (c. 2.3 in EtOH); δH (500 MHz; CDCl3) 5.71 (1H, ddt, J 16.9, 10.2 and 6.6, 6-
H), 4.96 (1H, dd , J 16.9 and 1.7, 7-HA), 4.92 (1H, dd, J 10.2 and 1.3, 7-HB), 4.00 (1H, 
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dd, J 14.5 and 3.5, 1-H), 3.79 (1H, dd, J 14.5 and 10.9, 1-H), 3.59 (1H, td, J 6.7 and 
2.7, 3-H), 2.09-1.84 (3H, m, 5-HAB and 2-H), 1.59-1.36 (2H, m, 4-HAB), 0.91 (3H, d, J 
6.9, Me), 0.82 (9H, s, (SiC(CH3)3), 0.00 (3H, s, SiCH3), -0.02 (3H, s, SiCH3); δC (75 
MHz; CDCl3) 137.6 (6-C), 118.9 (q J 325, CF3) , 115.2 (7-C), 72.9 (3-C), 57.9 (1-C), 
36.6 (5-C), 32.8 (2-C), 29.9 (4-C), 25.7 (SiC(CH3)3), 17.9 (SiC(CH3)3), 10.4 (Me), -4.1 
(SiCH3), -4.8 (SiCH3); νmax/cm
-1 (film) 3082, 2955, 2859, 2329, 1832, 1643, 1453, 1431; 
m/z (ES+) 522.1 (100%, [M+H]+); found 522.1233, C16H29F6NO5S2Si MH requires 
522.1233; 
[2-({N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4-en-2-yl](2-
nitrobenzene)sulfonamido}methyl)phenyl]methyl acetate 205ʹ 
 
Following general procedure M2, diethyl azodicarboxylate (288 mg, 1.65 mmol), 
sulfonamide 112 (350 mg, 0.41 mmol), hydroxyacetate 126 (297 mg, 1.65 mmol) and 
triphenylphosphine (435 mg, 1.65 mmol) were stirred for 3 h at room temperature. The 
reaction was concentrated in vacuo and purified by F-SPE. The acetate 205ʹ (410 mg, 
0.4 mmol, 99 %, >95% purity as estimated using 500 MHz 1H NMR spectroscopy) was 
obtained as a colourless viscous oil; Rf 0.61 (80:20, petrol—EtOAc); H (500 MHz; 
CDCl3) 7.72 (1H, d, J 7.8, nosyl 3-H), 7.63-7.77 (2H, m, Ar), 7.48-7.41 (2H, m, Ar), 
7.29-7.25 (1H, m, Ar), 7.20-7.11 (2H, m, Ar), 5.57 (1H, ddt, J 7.1, 10.1 and 17.1, 4-H), 
5.19 (2H, d, J  2.4, PhCH2OAc), 5.00 (1H, dd, J 1.4 and 17.1, 5-HA), 4.90 (1H, d, J 
10.1, 5-HB), 4.81 (1H, d, J 16.8, N(Ns)CHAPh), 4.64 (1H, d, 16.8, N(Ns)CHAPh), 4.10-
4.04 (1H, m, 2-H), 3.74 (1H, dd, J 5.6 and 10.5, 3-HA), 3.50 (1H, dd, J 5.6 and 10.5, 3-
HB), 2.43-2.38 (2H, m, 1-H2), 2.10 (3H, s, Ac), 2.08-1.97 (2H, m, C8F17CH2CH2), 0.96 
(14H, s, Si(CH(CH3)2)2), 0.78-0.73 (2H, m, C8F17CH2CH2); C (75 MHz; CDCl3) 171.8 
(C=O), 148.5 (nosyl 2-C), 136.8 (nosyl 1-C), 134.6 (4-C), 134.3, 133.6, 133.5, 131.9, 
131.7, 130.4, 129.3, 128.9, 127.9, 124.4, 118.4 (5-C), 65.0 (1-C), 64.4 (PhCH2OAc), 
60.4 (2-C), 45.5 N(Ns)CH2Ph), 34.6 (3-C), 21.3 (Ac), 17.8 (SiCH(CH3)2), 12.5 
(SiCH(CH3)2), 0.04 (C8F17CH2CH2), C8F17CH2CH2 missing; νmax/cm
-1 (film) 2948, 2869, 
1741, 1546, 1372; m/z (ES+) 1031.2 (100%, [M+Na]+); found 1026.2435, 
C37H45F17N3O7SSi MNa requires 1026.2471 
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N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}pent-4-en-2-yl]-N-{[2-(hydroxymethyl)phenyl]methyl}-2-
nitrobenzene-1-sulfonamide 205 
 
Following the general procedure D, acetate ester 205ʹ (100 mg, 0.1 mmol) was 
dissolved in NH3 sat. MeOH (4 mL) and stirred for 16 h, concentrated in vacuo to give 
the alcohol 205 (96 mg, 0.099 mmol, 99%, >95% purity as estimated using 500 MHz 1H 
NMR spectroscopy) as a colourless viscous oil. Rf 0.4 (80:20, petrol—EtOAc); H (500 
MHz; CDCl3) 7.52 (2H, m, nosyl 3 and 6-H), 7.49 (2H, m, nosyl 4 and 5-H), 7.36 (1H, d, 
J 7.5, Ph 3-H), 7.30 (1H, d, J 7.5, Ph 4-H), 7.18 (1H, t, J 7.3, Ph 6-H), 7.08 (1H, t, J 7.3, 
Ph 5-H), 5.61 (1H, ddt, J 7.0, 10.0 and 17.0, 4-H), 5.02 (1H, d, J 17.0, 5-HA), 4.91 (1H, 
d, J 10.0, 5-HB), 4.85 (1H, d, J 16.3, N(Ns)CHAPh), 4.78 (1H, d, J 12.6, PhCHAOH), 
4.74 (1H, d, J 12.6, PhCHBOH), 4.70 (1H, d, J 16.3, N(Ns)CHBPh), 4.14-4.05 (1H, m, 2-
H), 3.72 (1H, dd, J 5.9 and 10.5, 1-HA), 3.52 (1H, dd, J 5.9 and 10.5, 1-HB), 2.50-2.33 
(2H, m, 3-H), 2.13-1.96 (2H, m, C8F17CH2CH2), 0.96 (14H, s, Si(CH(CH3)2)2), 0.80-0.72 
(2H, m, C8F17CH2CH2); C (75 MHz; CDCl3) 148.1 (nosyl 2-C), 136.4 (nosyl 1-C), 134.1 
(4-C), 134.0, 133.8, 133.6, 132.1, 131.7, 130.2, 129.5, 128.9, 127.8, 124.6, 118.7 (5-
C), 65.2 (1-C), 63.1 (PhCH2OH), 60.4 (2-C), 44.3 (N(Ns)CH2Ph), 35.1 (3-C), 17.8 (2 × 
SiCH(CH3)2) , 12.4 (2 × SiCH(CH3)2), 0.04 (C8F17CH2CH2), C8F17CH2CH2 missing; 
νmax/cm
-1 (film) 3079, 2949, 2869, 2733, 1643, 1591, 1547; m/z (ES+) 989.2 (100%, 
[M+Na]+); found 989.1951, C35H39F17N2O6SSi MNa requires 989.1916; 
[5-({N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4-en-2-yl](2-
nitrobenzene)sulfonamido}methyl)thiophen-2-yl]methyl acetate 204ʹ 
 
Following general procedure M2, diethyl azodicarboxylate (4.22 g, 24 mmol), 
sulfonamide 112 (5.08 g, 6.5 mmol), hydroxyacetate 130 (4.45 g, 24 mmol) and 
triphenylphosphine (6.2 g, 24 mmol) were stirred for 2 h at room temperature. F-SPE, 
followed by column chromatography, eluting with 70:30 CHCl3—CH2Cl2 gave 204ʹ (4.8 
g, 73%) as a colourless oil. Rf 0.71 (50:50, petrol—EtOAc);     
   −1.8 (c. 3.4, CHCl3); 
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δH (500 MHz; CDCl3) 7.91-7.88 (1H, m, nosyl 3-C), 7.69-7.64 (2H, m, nosyl 6 and 4-C), 
7.58-7.54 (1H, m, nosyl 5-C), 6.91 (1H, d, J  3.4, Thio 3 or 4-H), 6.87 (1H, d, J 3.4 , 
Thio 3 or 4-H), 5.64 (1H, ddt, J 17.1, 10.1 and 6.9, 4-H), 5.15 (2H, s, ThioCH2OAc), 
5.07 (1H, d, J 17.1, 5-HA), 4.97 (1H, d, J 10.1, 5-HB), 4.88 (1H, d, J 16.5, N(Ns)CHA), 
4.71 (1H, d, J 16.5, N(Ns)CHA), 4.03 (1H, quin, J 6.6, 2-H), 3.85 (1H, dd, J 10.4 and 
5.5, 1-HA), 3.63 (1H, dd, J 10.4 and 6.0 1-HB), 2.48 (2H, t, J 7.2, 3-HAB), 2.19-2.05 (2H, 
m, C8F17CH2CH2), 2.11 (3H, s, Ac), 1.04 (14H, s, Si(CH(CH3)2)2), 0.86-0.83 (2H, m, 
C8F17CH2CH2); δC (75 MHz, CDCl3) 170.8 (C=O), 148.0 (nosyl 2-C), 142.8 (Thio 2- or 4-
C), 139.2 (Thio 2- or 4-C), 134.6 (nosyl 1-C), 134.3 (4-C), 133.5, 131.7, 131.5, 127.8, 
127.4 (5ʹ or 6ʹ-C), 124.5 (5ʹ or 6ʹ-C), 118.3 (5-C), 65.1 (1-C), 60.8 (ThioCH2OAc), 60.3 
(2-C), 43.9 (N(Ns)CH2Thio), 34.7 (3-C), 25.9 (t, J 25, C8F17CH2CH2), 21.2 (Ac), 17.8 
(SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 
(film) 2948, 2870, 2159, 1976, 1744, 1546, 1440, 1371, 1024 and 736; m/z (ES+) 
1032.2 (100%, [M+NH4]
+); found 1037.1620, C35H39F17N2O7S2Si requires MNa 
1037.1589 
N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}pent-4-en-2-yl]-N-{[5-(hydroxymethyl)thiophen-2-yl]methyl}-2-
nitrobenzene-1-sulfonamide 204 
 
Following the general procedure D, acetate ester 204ʹ (4.8 g, 4.73 mmol) was 
dissolved in NH3 sat. MeOH (500 mL) and gave the crude product after 16 h. The crude 
product was concentrated in vacuo to give the alcohol 204 (4.45 g, 4.58 mmol, 97%, 
>95% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil 
which was used without further purification; Rf 0.54 (50:50, petrol—EtOAc); δH (500 
MHz; CDCl3) 7.91 (1H, d, J 7.6, nosyl 3-H), 7.69-7.65 (2H, m, nosyl 6 and 4-H), 7.58-
7.55 (1H, m, nosyl 5-H), 6.92 (1H, d, J 3.5, Thio 3 or 4-H), 6.81 (1H, d, J 3.5, Thio 3 or 
4-H), 5.65 (1H, ddt, J 17.2, 10.2 and 6.8, 4-H), 5.07 (1H, d, J 17.2, 5-HA), 4.98 (1H, d, J 
10.2, 5-HB), 4.88 (1H, d, J 16.5, N(Ns)CHAThio), 4.72 (2H, s, ThioCH2OH), 4.72 (1H, d, 
J 16.5, N(Ns)CHBThio), 4.08-4.02 (1H, m, 2-H), 3.86 (1H, dd, J 10.5 and 5.6, 1-HA), 
3.64 (1H, dd, J 10.5 and 4.2, 1-HB), 2.49 (2H, t, J 7.1, 3-H2), 2.17-2.05 (2H, m, 
C8F17CH2CH2), 1.05 (14H, s, Si(CH(CH3)2)2), 0.88-0.82 (2H, m, C8F17CH2CH2); δC (75 
MHz, CDCl3) 148.0 (nosyl 2-C), 145.2 (Thio 2 or 5-C), 141.6(Thio 2 or 5-C), 134.7 
(nosyl 1-C), 134.4 (4-C), 133.5 (Ns), 131.7 (Ns), 131.5 (Ns), 127.5 (Thio 3 or 4-C), 
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125.3 (nosyl 3-C), 124.5 (Thio 3 or 4-C), 118.3 (5-C), 65.0 (1-C), 60.4 (2-C), 60.3 
(ThioCH2OH), 43.9 (N(Ns)CH2Thio), 34.8 (3-C), 25.6 (C8F17CH2CH2), 17.8 
(SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 
(film) 3393, 2947, 2869, 2159, 1976, 1546, 1371, 1207 and 1063; m/z (ES+) 990.2 
(100%, [M+NH4]
+); found 990.1965, C33H37F17N2O12S2Si requires MNH4 990.1929 
 
N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}pent-4-en-2-yl]-N-({2-[2-(hydroxymethyl)phenyl]phenyl}methyl)-2-
nitrobenzene-1-sulfonamide 233 
 
Following general procedure M2, diethyl azodicarboxylate (165 mg, 0.95 mmol), 
sulfonamide 112 (200 mg, 0.24 mmol), hydroxyacetate 129 (240 mg, 0.95 mmol) and 
triphenylphosphine (248 mg, 0.95 mmol) gave the crude product after 16 h at room 
temperature. The crude product was concentrated in vacuo and purified by F-SPE, to 
give the acetate ester (213 mg). Following the general procedure D, the acetate ester 
(100 mg, 0.1 mmol) was dissolved in NH3 sat. MeOH (4 mL) was stirred for 16 h and 
concentrated in vacuo to give the alcohol 233 (175 mg, 0.17 mmol, 99%, >95% purity 
as estimated using 500 MHz 1H NMR spectroscopy) as a colourless viscous oil. Rf 0.41 
(80:20, petrol—EtOAc); δH (500 MHz; CDCl3, minor atropisomer denoted where 
possible) 7.87 (1H, d, J 7.8, nosyl 3-H), 7.78 (1H, J 7.9, nosyl 3-Hmin), 7.65-7.09 (11H, 
m, Ar), 5.43 (1H, ddt, J 7.1, 10.1 and 17.1, 4-Hmin), 5.10 (1H, ddt, J 7.3, 10.1 and 17.0, 
4-H), 4.81 (1H, d, J 10.1, 5-HA
min), 4.70 (1H, J 17.1, 5-HB
min), 4.62 (1H, d, J 16.8, 
N(Ns)CHA), 4.57 (1H, d, J 10.1, 5-HA), 4.52-4.36 (5H, m, PhCH2OH, 5-HB, 
N(Ns)CH2Ph), 4.10 (1H, d, J 16.8, N(Ns)CHBPh
min), 3.98-3.90 (1H, m, 2-Hmin), 3.89-
3.81 (1H, m, 2-H), 3.59-3.50 (2H, m, 1-HA and 1-HB
min), 3.34 (1H, dd, J 5.9 and 10.5, 1-
HA
min), 3.14 (1H, dd, J 7.7 and 9.7, 1-HB), 2.20-1.81 (4H, m, 3-HAB and C8F17CH2CH2), 
0.91 (14H, s, Si(CH(CH3)2)2), 0.86 (14H, s, 2 × SiCH(CH3)2
min), 0.73-0.63 (2H, m, 
C8F17CH2CH2); δC (500 MHz; CDCl3) 148.2 (nosyl 2-C), 139.8 (nosyl 1-C), 139.2 (Ns
min), 
139.1 (5-C), 139.0 (5-Cmin), 136.1, 135.8min, 134.6, 134.0min, 133.7, 133.6min, 131.77, 
131.74min, 131.73, 131.68min, 130.3min, 130.2min, 130.1, 129.9, 129.1, 128.8, 128.8, 
128.7, 128.6, 128.6, 128.2, 128.1, 127.9, 127.8, 127.3, 124.4 124.3min, 118.2 (4-Cmin), 
118.1 (4-C), 65.5 (1-C), 64.6 (1-Cmin), 63.17 (PhCH2OH
min), 63.12 (PhCH2OH), 60.13 
(2-C), 60.11 (2-Cmin), 46.5 (N(Ns)CH2Ph
min), 45.9 (N(Ns)CH2Ph), 34.9 (3-C
min), 34.1 (3-
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C), 25.6 (C8F17CH2CH2), 23.0 (Ac), 17.78 (SiCH(CH3)2
 min), 17.71 (SiCH(CH3)2), 12.45 
(SiCH(CH3)2
min), 12.35 ( SiCH(CH3)2), -0.05 (C8F17CH2CH2 ); νmax/cm
-1 (film) 3325, 
2914, 2743, 1927, 1661, 1599, 1455, 1275 and 1260; m/z (ES+) 1060.3 (100%, 
[M+NH4]
+); found 1060.2702, C50H55F17N5O12S3Si requires MNH4 1060.2678 
 
N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}pent-4-en-2-yl]-N-{[3-(hydroxymethyl)phenyl]methyl}-2-
nitrobenzene-1-sulfonamide 113 
 
Following general procedure M1, diethyl azodicarboxylate (2.1 g, 12 mmol), 
sulfonamide 112 (5.00 g, 6 mmol), hydroxyacetate 127 (2.15 mg, 12 mmol) and 
triphenylphosphine (3.14 mg, 12 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE, to give the acetate ester 
(6.3 g). Following the general procedure D, the acetate ester (6.3 g) was dissolved in 
NH3 sat. MeOH (200 mL) was stirred for 16 h and concentrated in vacuo to give the 
alcohol 113 (5.2 g, 5.3 mmol, 90%, >95% purity as estimated using 500 MHz 1H NMR 
spectroscopy); Rf 0.33 (70:30, petrol—EtOAc); δH (300 MHz; CDCl3) 7.83 (1H, d, J 7.3, 
nosyl 3-H), 7.63-7.59 (2H, m, nosyl 6-H and Ph), 7.50 (1H, ddd, J 8.0, 5.6 and 3.2, Ph), 
7.30-7.21 (4H, m, Ph), 5.55 (1H, ddt, J 17.1, 10.1 and 7.1, 4-H), 4.99 (1H, dd, J 17.1 
and 1.5, 5-HB), 4.88 (1H, dd, J 10.1 and 1.5, 5-HB), 4.75 (1H, d, J 16, N(Ns)CHA), 4.88 
(2H, ap d, J 5.9, PhCH2OH), 4.75 (1H, d, J 16, N(Ns)CHB), 3.99 (1H, p, J 6.9, 2-H), 
3.68 (1H, dd, J 10.4 and 5.7, 1-HA), 3.38 (1H, dd, J 10.4 and 6.5, 1-HB), 2.35  (2H, ap t, 
J 7.3, 3-HAB), 2.14-1.93 (2H, m, C8F17CH2CH2), 1.06-0.93 (14H, m, Si(CH(CH3)2)2), 
0.78-0.70 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 148.1 (nosyl 2-C), 141.6 (nosyl 
1-C), 138.2, 134.7 (4-C), 134.4, 133.5, 131.8, 131.7, 129.1, 128.0, 127.1, 126.7, 124.4, 
118.2 (5-C), 65.4 (1-C), 65.1 (PhCH2OH), 60.5 (2-C), 48.9 (N(Ns)CH2Ph), 34.8 (3-C), 
25.6 (t, J 25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.4 (C8F17CH2CH2); 
νmax/cm
-1 (film) 2989, 1545, 1462, 1275, 1260 and 748; m/z (ES+) 989.2 (100%, 
[M+Na]+); found 989.1939, C35H39F17N2O6SSi requires MNa 989.1919 
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(2S)-N-{[5-({N-[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4-en-2-yl](2-
nitrobenzene)sulfonamido}methyl)thiophen-2-yl]methyl}-N-[(2-
nitrobenzene)sulfonyl]-2-(prop-2-en-1-yloxy)propanamide 207 
 
 
Following general procedure L1, alcohol 204 (103 mg, 0.1 mmol), acyl sulfonamide 134 
(99 mg, 0.32 mmol), triphenylphosphine (82 mg, 0.32 mmol) and diethyl 
azodicarboxylate (55 mg, 0.32 mmol) gave the crude product in 24 h. The crude 
product was concentrated in vacuo and purified by F-SPE, to give 207 (88 mg, 69%, 
>81% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil; Rf 
0.69 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) rotamers denoted where possible 
8.45 (1H, dd, J 8.5 and 1.9, nosyl 3-H), 8.11 (dd, J 8.5 and 1.9, nosyl 3-Hrot), 7.94-7.63 
(6H, m, Ns), 7.62-7.53 (1H, m, Ns), 6.90 (1H, d, J 2.9, Thio 3-H), 6.88 (1H, d, J 2.9, 
Thio 4-H), 6.82-6.71 (1H, m, Thio 3-Hrot and 4-Hrot), 5.92 (ddt, J 16.7, 10.1 and 5.2, 
propenyl 3-Hrot), 5.84 (1H, ddt, J 17.1, 10.5 and 5.2, propenyl 3-H), 5.67 (1H, ddt, J 
16.7, 11.4 and 7.2, 4-H), 5.61 (ddt, J 16.7, 10.7 and 7.2, 4-Hrot), 5.33 (d, J 16.7, 
propenyl 2-HA), 5.26 (d, J 10.1, propenyl 2-HB
rot), 5.23 (1H, d, J 17.1, propenyl 2-HA
rot), 
5.19 (1H, d, J 16.7, 5-HA), 5.16 (1H, d, J 10.5, 5-HB), 5.12-4.95 (4H, m, propenyl 1-H 
and ThioCH2N(CO)), 4.89-4.59 (2H, m, N(Ns)CH2Thio), 4.55-4.40 (1H, m, 
COCH(CH3)), 4.12-3.95 (1H, m, 2-H), 3.90-3.55 (2H, m, 1-H2), 2.48-2.46 (2H, m, 3-H2), 
2.43-2.39 (2H, m, 3-H2
rot), 2.20-2.03 (2H, m, C8F17CH2CH2), 1.44 (3H, d, J 6.8, CH3
rot), 
1.35 (3H, d, J 7.3, CH3), 1.06 (14H, s, Si(CH(CH3)2)2), 0.88-0.79 (2H, m, C8F17CH2CH2); 
δC (75 MHz; CDCl3) 173.4 (C=O
rot), 173.0 (C=O), 148.3 (nosyl 2-C), 148.0 (nosyl 2-Crot), 
142.1 (Thio 1-C), 139.7 (Thio 5-C), 135.4, 135.0, 134.5, 134.4, 134.3, 134.2, 133.8, 
133.8, 133.3, 132.8, 132.8, 131.9, 131.7, 131.5, 131.4, 131.2, 127.7, 127.2, 127.0, 
126.8, 125.9, 125.3, 124.4, 118.4 (propenyl 2-C or 4-Crot), 118.3 (propenyl 2-C or 4-C), 
118.3 (propenyl 2-C or 4-Crot), 76.1 (1ʹʹʹ-C rot), 74.5 (1ʹʹʹ-C), 71.2 (propenyl 1-Crot), 70.7 
(propenyl 1-C), 64.9 (1-C), 60.3 (2-C), 45.36 (ThioCH2N(CO)), 43.9 (ThioCH2N(CO)
rot), 
43.8 (N(Ns)CH2Thio), 43.0 (N(Ns)CH2Thio
rot); 35.0 (3-C), 34.8 (3-C rot), 25.6 
(C8F17CH2CH2), 17.9 (SiCH(CH3)2), 12.4 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 
(film) 2963, 2533, 1643, 1545, 1370, 1241, 1165 and 1063; m/z (ES+) 1291.2 (60%, 
[M+NH4]
+); found 1291.2009, C45H49F17N4O11S3Si requires MNH4 1291.1950 
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(2S,3R)-3-[(Tert-butyldimethylsilyl)oxy]-N-{[5-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)thiophen-2-
yl]methyl}-2ʹ-methyl-N-[(2-nitrobenzene)sulfonyl]hept-6ʹ-enamide 210 
 
Following general procedure L1, alcohol 204 (1.0 mg, 1.02 mmol), acyl sulfonamide 
133 (0.49 g, 1.08 mmol), triphenylphosphine (293 mg, 1.12 mmol) and diethyl 
azodicarboxylate (195 mg, 1.12 mmol) gave the crude product in 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE, to give 210 (800 mg, 0.57 
mmol, 56%, >82% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
colourless oil; Rf 0.78 (80:20 petrol—EtOAc); δH (500 MHz; CDCl3) 8.45-8.35 (2H, m, 
nosyl 3-H), 8.25-8.20 (3H, m, Ns), 7.85-7.44 (3H, m, Ns), 6.83-6.69 (2H, m, Thio), 5.77 
(1H, ddt, J 16.8, 10.3 and 6.4, 4-H), 5.67-5.43 (1H, m, 6ʹ-H), 5.17 (1H, d , J 12.9, 
(CO)N(Ns)CHAThio), 5.06-4.43 (5H, m, (CO)N(Ns)CHBThio, 5-HAB and 7ʹ-HAB), 4.05 
(1H, ap p, J 5.5, 3ʹ-H), 3.98-3.72 (2H, m, N(Ns)CH2Thio), 3.68 (1H, dd , J 10.5 and 5.7, 
1-HA), 3.60 (1H, ap p, J 6.3, 2-H), 3.47 (1H, dd, J 10.5 and 6.3, 1-HB), 2.45-2.27 (2H, 
m, 3-HAB), 2.19-1.90 (4H, m, C8F17CH2CH2 and 5ʹ-HAB), 1.59-1.52 (1H, m, 2ʹ-H), 1.23-
1.15 (3H, m, Me), 0.99-0.91 (14H, m, Si(CH(CH3)2)2), 0.83 (9H, SiC(CH3)3), 0.79 (9H, 
SiC(CH3)3
min), 0.8-0.67 (2H, C8F17CH2CH2), 0.02 (3H, s, SiCH3), 0.00 (3H, s, SiCH3), -
0.07 (s, SiCH3
min), -0.14 (s, SiCH3
min); δC (75 MHz; CDCl3) 176.3 (C=O), 173.6 (C=O), 
145.4, 144.5, 144.4, 140.1, 139.9, 138.5, 138.4, 135.4, 130.4, 129.1, 126.8, 126.4, 
126.0, 125.8, 124.5, 124.4, 118.1min, 117.6, 115.0, 114.9min, 74.7min, 74.5, 69.4, 65.4, 
65.3min, 57.8min, 57.8, 46.5, 45.9, 45.7, 38.6, 36.1, 36.0, 34.2, 32.1min, 31.9, 30.4, 
30.2min, 26.1, 25.9 (SiC(CH3)3), 25.6 (t, J 25, C8F17CH2CH2), 18.1 (SiC(CH3)3), 13.1 
(Me), 0.00 (C8F17CH2CH2), -4.26 (SiCH3), -4.30 (SiCH3); νmax/cm
-1 (film) 3323, 3077, 
2937, 1832, 1668, 1546; m/z (ES+) 1041.1 (100%, [M+H]+) 
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Methyl (2S,3R,6E,9R)-9-({[5-(aminomethyl)thiophen-2-yl]methyl}amino)-3-[(tert-
butyldimethylsilyl)oxy]-10-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}-2-methyldec-6-enoate 221 
 
Following general procedure N1, potassium carbonate (41 mg, 0.30 mmol), 
sulfonamide 214 (210 mg, 0.151 mmol) and thiophenol (167 mg, 1.5 mmol) gave the 
crude product after 16 h. The reaction was purified by F-SPE and column 
chromatography, eluting with 70:30 petrol—EtOAc gave the methyl ester 221 (125 mg, 
0.120 mmol, 80%) as a colourless oil; Rf 0.44 (70:30, petrol—EtOAC); δH (500 MHz; 
CDCl3) 6.72 (1H, d, J 3.4, Thio 3 or 4-H), 6.65 (1H, d, J 3.4, Thio 3 or 4-H), 6.31 (1H, br 
s, NH), 5.36 (1H, dt, J 15.3 and 6.2, 6-H), 5.29 (1H, dt, J 15.3 and 6.9, 7-H), 5.17 (1H, 
br s, NH), 4.45 (1H, d, J 12.9, NHCHAPh), 4.44 (1H, d, J 12.9, NHCHBPh), 3.88 (1H, d, 
J 14.3, NH2CHAPh), 3.85 (1H, d, J 14.3, NH2CHBPh), 3.70-3.64 (1H, m, 3-H), 3.52-3.46 
(2H, m, 10-HAB), 3.25 (3H, s, OMe), 2.62 (1H, p, J 6.1, 9-H), 2.42 (1H, qd, J 7.1 and 
3.9, 2-H), 2.13-1.94 (5H, C8F17CH2CH2, 5-H and 8-H), 1.90-1.80 (1H, 5-H), 1.48-1.37 
(2H, 4-H), 0.99 (3H, d, J 7.1, Me), 0.94 (14H, s, Si(CH(CH3)2)2), 0.82 (9H, s, 
SiC(CH3)3), 0.77-0.73 (2H, m, C8F17CH2CH2), 0.01 (6H, s, 2 × SiCH3); δC (125 MHz; 
CDCl3) 184.4 (C=O), 149.3 (Thio 2 or 5-C), 145.8 (Thio 2 or 5-C), 138.7 (4-C), 131.9 
(Thio 3 or 4-C), 137.7 (Thio 3 or 4-C); 130.4 (5-C), 79.2 (8-C), 74.3 (1-C), 70.7 (2-C); 
61.9 (9-C), 51.1 (CH2NH2), 40.2 (NHCH2Ph), 39.4 (6-C); 31.1 (3-C), 30.7 (7-C); 22.2 
(Me), 22.1 (C8F17CH2CH2), 18.0 (SiC(CH3)3), 17.9 (SiCH(CH3)2), 5.28 (C8F17CH2CH2), 
0.2 (SiCH3), 0.00 (SiCH3), SiCH(CH3)2 missing; νmax/cm
-1 (film) 3110, 2996, 1739 and 
1562; m/z (ES+) 1045.4 (100%, [M+H]+); found 1045.3713, C40H62F17N2O4SSi2 requires 
MH 1045.3692 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[5-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)thiophen-2-
yl]methyl}-N-[(2-nitrobenzene)sulfonyl]carbamate 212 
 
Following general procedure L2, alcohol 204 (164 mg, 0.17 mmol), acyl sulfonamide 
208 (323 mg, 0.67 mmol), triphenylphosphine (88 mg, 0.34 mmol) and 
diethylazodicarboxylate (59 mg, 0.34 mmol) gave the crude product after 24 h. The 
crude product was concentrated in vacuo and purified using F-SPE; to give 212 (218 
mg, 89 %, >93% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
colourless oil; Rf 0.27 (80:20 CH2Cl2—petrol); δH (500 MHz; CDCl3) 8.14 (1H, d, J 7.8, 
nosyl 3-H), 7.70-7.63 (3H, m, Ns), 7.61-7.56 (1H, m, Ns), 7.51-7.47 (2H, m, Ns), 7.41-
7.36 (1H, m, Ns), 6.90 (1H, d, J 8.3, DMB 6-H), 6.68 (1H, d, J 3.5, Thio 3-H), 6.61 (1H, 
d, J 3.5, Thio 4-H), 6.31 (1H, d, J 2.3, Ar, DMB 3-H), 6.28 (1H, dd, J 8.3 and 2.3, DMB 
5-H), 5.75 (1H, ddt, J 17.2, 10.4 and 5.6, propenyl 2-H), 5.62 (1H, ddt, J 17.1, 10.1 and 
7.2, 4-H), 5.12 (1H, d, J 17.2, propenyl 3-HA), 5.05 (1H, d, J 10.4, propenyl 3-HB), 5.00 
(1H, d, J 17.1, 5-HA), 4.92 (1H, d, J 10.1, 5-HB), 4.81-4.78 (2H, m, ThioCH2N(Ns)CO)), 
4.65 (2H, d, J 9.5, N(Ns)CH2Thio), 4.56-4.41 (1H, m, propyl 1-HA), 4.36-4.30 (1H, m, 
propyl 1-HB), 4.05-3.97 (1H, m, 2-H, 2-H), 3.86-3.80 (2H, m, propenyl 1-H), 3.76 (1H, 
dd, J 10.5 and 5.5, 1-HB), 3.70 (3H, s, OMe), 3.66 (3H, s, OMe), 3.63 (1H, dd, J 10.5 
and 5.5, 1-HA), 3.50-3.42 (3H, m, propyl 2- and 3-H2), 2.47-2.33 (2H, m, 3-H2), 2.10-
1.95 (2H, m, C8F17CH2CH2), 0.95 (14H, s, Si(CH(CH3)2)2), 0.79-0.72 (2H, m, 
C8F17CH2CH2); δC (75 MHz, CDCl3) 160.2 (DMB 2- or 4-C), 158.6 (DMB 2- or 4-C), 
151.8 (C=O), 148.1 (nosyl 2-C), 147.7 (nosyl 2-C), 141.4 (Thio 2-C), 139.8 (Thio 5-C), 
134.9 , 134.8, 134.8 (propenyl 3-C), 134.7, 134.5 (5-C), 133.6, 133.0, 132.2, 131.8, 
131.3, 129.2, 127.8 (Thio 3-C), 127.6 (Thio 4-C), 124.8, 124.3, 119.1, 118.4 (4-C), 
117.3 (propenyl 2-C), 104.5 (DMB 5-C), 98.9 (DMB 3-C), 72.3 (propenyl 1-C), 70.5 
(propyl 3-C), 68.6 (1-C), 65.0 (propyl 1-C) , 60.1 (2-C), 55.6 (2 × OMe), 45.8 
(ThioCH2N(CO)), 43.8 (N(Ns)CH2Thio), 38.4 (propyl 2-C), 35.0 (3-C), 25.6 (t, J 25, 
C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 12.4 
(SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 (film) 2947, 2869, 1737, 1545, 1440, 
123 
 
1370, 1163 and 779; m/z (ES+) 1457.3 (100%, [M+NH4]
+); found 1457.2730, 
C50H55F17N5O12S3Si  requires MNa 1457.2580 
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)thiophen-2-
yl]methyl}-N-[(2-nitrobenzene)sulfonyl]carbamate 211 
 
Following general procedure L2, alcohol 204 (195 mg, 0.2 mmol), acyl sulfonamide 131 
(314 mg, 0.8 mmol), triphenylphosphine (104 mg, 0.4 mmol) and diethyl 
azodicarboxylate (70 mg, 0.4 mmol gave the crude product after 36 h. The crude 
product was concentrated in vacuo, purified by F-SPE and column chromatography, 
eluting with CH2Cl2 to give 211 (190 mg, 70%) as a colourless oil. Rf 0.89 (CH2Cl2); 
    
   −2.0 (c. 2.0, CHCl3);  δH (500 MHz; CDCl3) 8.17 (1H, d, J 7.9, nosyl 3-H), 7.80-
7.68 (3H, m, Ns), 7.63-7.56 (2H, m, Ns), 7.49 (2H, t, J 8.1, nosyl 5-H), 7.36 (1H, t, J 
8.1, Ph 6-H), 7.24 (1H, d, J 7.5, Ph 4-H), 6.96 (1H, t, J 7.5, Ph 3-H), 6.89 (1H, d, J 3.5, 
Thio 4-H), 6.87 (1H, d, J 8.1, Ph 5-H), 6.83 (1H, d, J 3.5, Thio 3-H), 5.99 (1H, ddt, J 
17.2, 10.6 and 5.1, 4-H), 5.75 (1H, ddt, J 17.0, 9.9 and 7.0, propenyl 2-H), 5.37 (1H, d, 
J 17.2, 5-HA), 5.29 (1H, d, J 16.2, PhCHAO), 5.28 (1H, d, J 16.2, PhCHAO), 5.27 (1H, d, 
J 10.6, 5-HB), 5.13 (1H, d, J 17.0, propenyl 3-HA), 5.05 (d, J 9.9, propenyl 3-HB), 5.03 
(2H, s, ThioCH2N(CO)), 4.79 (1H, d, J 16.3, 1ʹʹ-Ha), 4.73 (1H, d, J 16.3, 1ʹʹ-Hb), 4.52-
4.49 (2H, m, propenyl 1-H2), 4.18-4.11 (1H, m, 2-H), 3.90 (1H, dd, J 10.5 and 5.5, 1-
HA), 3.77 (1H, dd, J 10.5 and 5.1, 1-HB), 2.57-2.47 (2H, m, 3-H2), 2.22-2.09 (2H, m, 
C8F17CH2CH2), 1.07 (14H, s, Si(CH(CH3)2)2), 0.90-0.86 (2H, m, C8F17CH2CH2); δC (75 
MHz, CDCl3) 157.2 (C=O), 151.7 (nosyl 2-C), 148.1 (Ph 2-C), 147.7 (nosyl 2-C), 141.5, 
139.8, 134.8 (4-C), 134.7 (Thio 3-C), 134.7 (Thio 4-C), 134.5, 133.6, 133.1, 133.0, 
131.8, 131.3, 131.1, 130.8, 128.2 (Thio 2-C), 127.6 (Thio 5-C), 124.7 (nosyl 3-C), 124.2 
(nosyl 3-C), 122.8, 120.9 (Ph 5-C), 117.8 (5-C), 117.4 (propenyl 3-C), 112.0 (Ph 3-C), 
69.1 (propenyl 1-C), 65.7 (PhCH2O), 65.1 (1-C), 60.1 (2-C), 45.8 (ThioCH2N(CO)), 43.9 
(N(Ns)CH2Thio), 35.0 (3-C), 25.6 (t, J 25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 
(SiCH(CH3)2), 12.5 (SiCH(CH3)2), 12.4 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 
(film) 3629, 2490, 2029, 1738, 1544, 1370, 1207, 736 and 586; m/z (ES+) 1364.3 
(100%, [M+NH4]
+); found 1364.2536, C50H51F17N4O12S3Si  requires MNH4 1364.2502 
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N-[(2-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-N-
[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 209 
 
Following general procedure L1, trifluoromethanesulfonamide 135 (1.17 g, 5.8 mmol), 
alcohol 205 (1.4 g, 1.45 mmol), triphenylphosphine (0.76 g, 2.9 mmol) and diethyl 
azodicarboxylate (0.5 g, 2.9 mmol) gave the crude product after 1 h. The crude product 
was concentrated in vacuo and purified with F-SPE; to give 209 (1.55 g, 1.35 mmol, 
93%, >95% purity as estimated using 500 MHz 1H NMR spectroscopy) as a pale yellow 
oil; Rf 0.88 (80:20, petrol—EtOAc); δH (300 MHz; CDCl3) 7.75 (1H, d, J 7.8, Ar), 7.7-
7.63 (2H, m, Ar), 7.57-7.49 (2H, m, Ar), 7.37-7.21 (3H, m, Ar), 5.6 (2H, ddt, J 17, 10.1 
and 6.8, 4ʹ-H and 3-H), 5.08-5.02 (2H, m, 4-HA and 5ʹ-HA), 4.99 (1H, dd, J 8.7 and 1.7, 
5ʹ-HB), 4.92 (1H, d, J 10.3, 4-HB), 4.97.4.57 (2H, br s, PhCH2NTf), 4.85 (1H, d, J 16.6, 
N(Ns)CHBPh), 4.67 (1H, d, J 16.6, N(Ns)CHAPh), 4.10 (1H, ap p, J 6.7, 2ʹ-H), 3.77-3.69 
(1H, dd, J 10.9 and 6.4, 1ʹ-HA), 3.55-3.33 (1H, m, 1ʹ-HB), 3.41 (2H, t, J 7.7, 1-H2), 2.39 
(2H, ap t, J 7.7, 3ʹ-H), 2.31-1.96 (4H, m, 2ʹ-H and C8F17CH2CH2), 0.99 (14H, s, 
Si(CH(CH3)2)2); δC (75 MHz; CDCl3) 148.2 (nosyl 2-C), 136.3 (nosyl 1-C), 134.3, 134.1 
(3-C), 133.8 (4ʹ-C), 133.5, 132.6 (nosyl 5-C), 132.4, 131.9, 131.7 (nosyl 4-C), 130.1, 
129.3, 129.1, 128.9 (nosyl 6-C), 128.5, 124.5 (nosyl 3-C), 118.6 (4-C and 5ʹ-C), 64.8 
(1ʹ-C), 60.5 (2ʹ-C), 50.6 (N(Ns)CH2Ph), 48.8 (1-C), 46.0 (PhCH2Tf); 34.5 (3ʹ-C), 33.2 (2-
C), 25.6 (t, J 24, C8F17CH2CH2), 17.7 ((SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2), CF3 missing; νmax/cm
-1 (film) 2948, 2870, 2357, 1643, 1574, 1390; m/z 
(ES+) 1169.2 (100%, [M+NH4]
+); found 1169.2490, C40H45F20N3O7S2Si  requires MNH4 
1169.2487 
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[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[2-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)phenyl]methyl}-
N-[(2-nitrobenzene)sulfonyl]carbamate 235 
 
Following general procedure L2, sulfonamide 131 (2.2 g, 5.8 mmol), alcohol 205 (1.4 g, 
1.45 mmol), triphenylphosphine (1.5 g, 5.8 mmol) and diethyl azodicarboxylate (1.0 g, 
5.8 mmol) gave the crude product after 16 h. The crude product was concentrated in 
vacuo and purified by F-SPE to give the sulfonamide 235 (1.5 g, 1.12 mmol, 77%, 
>93% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil; Rf 
0.71 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 8.16 (1H, d, J 7.9, nosyl 3-C), 7.73 
(1H, dd, J 8.1 and 1, nosyl 3-C), 7.66 (1H, td, J 7.5 and 1, nosyl 6-C), 7.58 (1H, dd, J 
8.4 and 1, nosyl 6-C), 7.54-7.50 (2H, m, Ar), 7.47-7.43 (1H, m, Ar), 7.36 (1H, d, J 7.9, 
Ar), 7.34 (1H, d, J 7.9, Ar), 7.30-7.25 (2H, m, Ar), 7.20-7.17 (1H, m, Ar), 7.07-7.03 (2H, 
m, Ar), 6.88-6.84 (1H, m, Ph 3-H), 6.76 (1H, d, J 8.3, Ph 4-H), 5.89 (1H, ddt, J 17.2, 
10.3 and 5, propenyl 2-H), 5.67 (1H, ddt, J 17.1, 10.1 and 7.0, 4-H), 5.29 (1H, dd, J 
17.2 and 1.7, propenyl 3-HA), 5.21 (1H, dd, J 10.3 and 1.4, propenyl 3-HB); 5.18 (2H, s, 
PhCH2O), 5.13 (1H, d, J 17, PhCH2N(CO)), 5.09 (1H, d, J 17.1, 5-HA), 5.0 (1H, d, J 17, 
PhCH2N(CO)), 4.96 (1H, d, J 10.1, 5-HB), 4.68 (1H, d, J 16.1, N(Ns)CHAPh), 4.60 (1H, 
d, J 16.1, N(Ns)CHBPh), 4.40-4.32 (2H, m, propenyl 1-H2), 4.21-4.15 (1H, m, 2-H), 3.74 
(1H, dd, J 10.5 and 6.2, 1-HA), 3.57 (1H, dd, J 10.5 and 5.9, 1-HB), 2.53 (1H, dt, J 13.5 
and 6.6, 3-HA), 2.41 (1H, dt, J 13.5 and 7.7, 3-HB), 2.16-2.02 (2H, m, C8F17CH2CH2), 
0.99 (14H, s, Si(CH(CH3)2)2), 0.83-0.78 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 
157.1 (Ph 2-C), 152.1 (C=O), 148.3 (nosyl 2-C), 147.9 (nosyl 2-C), 135.4 (nosyl 1-C), 
135.0 (nosyl 1-C), 134.8 (Ph 1-C), 134.7 (4-C), 134.7, 134.1, 133.2 (propenyl 2-C), 
133.1, 133.0, 131.9, 131.7, 130.7, 130.1, 128.4, 127.5, 126.9, 124.7, 124.4, 122.9, 
120.9 (Ph 5-C), 118.2 (5-C), 117.7 (propenyl 3-C), 111.9 (Ph 3-C); 69.0 (propenyl 1-C), 
65.7 (PhCH2O), 64.5 (1-C), 60.3 (2-C), 48.5 (PhCH2N(CO)), 45.8 (N(Ns)CH2Ph), 34.7 
(3-C), 25.6 (t, J 23.4, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2); νmax/cm
-1 (film) 3075, 2946, 2869, 1734, 1544, 1369, 1243; m/z (ES+) 
1358.3 (100%, [M+NH4]
+); found 1358.2931, C52H53F17N4O12S2Si requires MNH4 
1358.2937 
126 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)phenyl]methyl}-
N-[(2-nitrobenzene)sulfonyl]carbamate 235 
 
Following general procedure L2, sulfonamide 132 (2.7 g, 5.8 mmol), alcohol 205 (1.4 g, 
1.45 mmol), triphenylphosphine (1.5 g, 5.8 mmol) and diethyl azodicarboxylate (1.0 g, 
5.8 mmol) gave the crude product after 16 h. The crude product was concentrated in 
vacuo and purified by F-SPE to give the sulfonamide 235 (1.3 g, 0.91 mmol, 63%, 
>95% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil; Rf 
0.67 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 8.31 (1H, d, J 7.8, nosyl 3-H), 7.81-
7.76 (2H, m, Ar), 7.74-7.70 (2H, m, Ar), 7.66 (1H, d, J 7.8, nosyl 4-H), 7.64-7.59 (1H, 
m, Ar), 7.47-7.42 (2H, m, Ar), 7.34-7.30 (1H, m, Ar), 7.26-7.22 (1H, m, Ar), 7.16-7.11 
(1H, m, Ar), 6.92 (1H, d, J 8.2, DMB 6-H), 6.39-6.34 (2H, m, DMB 3 and 5-H), 5.84 (1H, 
ddt, J 16.9, 10.6 and 5.5, 4-H), 5.68 (1H, ddt, J 16.9, 10.0 and 6.9, propenyl 2-H), 5.22 
(1H, ddt, J 16.9 and 1.7, propenyl 3-HA), 5.17-5.11 (3H, m, PhCHAN(CO), 5-HA and 3-
HB), 5.09-5.03 (1H, m, PhCHBN(CO)), 4.99 (1H, d, J 10.1, 5-HB), 4.79 (1H, d, J 16, 
N(Ns)CHAPh), 4.67 (1H, d, J 16, N(Ns)CHAPh), 4.52 (1H, dd, J 10.7 and 5.6, propyl 1-
HA), 4.42 (1H, dd, J 10.7  and 6.6, propyl 1-HB), 4.23-4.16 (1H, m, 2-H), 3.89 (2H, dd, J 
5.6 and 1.7, propenyl 1-H2), 3.84-3.79 (4H, m, 1-HA and OMe), 3.75 (3H, s, OMe), 
3.58-3.47 (4H, m, 1-HB, propyl 2-H and propyl 3-HAB), 2.56 (1H, dt, J 13.9 and 6.9, 3-
HA), 2.48 (1H, dt, J 13.9 and 7.6, 3-HB), 2.20.2.08 (2H, m, C8F17CH2CH2), 1.04-1.02 
(14H, m, Si(CH(CH3)2)2), 0.87-0.82 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3)  160.1 
(DMB 4-C), 158.5 (DMB 2-C), 152.2 (C=O), 148.3 (nosyl 2-C), 147.9 (nosyl 2-C), 135.2 
(propenyl 2-C), 135.1 (4-C), 134.9, 134.8, 134.7, 134.6, 134.1, 133.4, 133.0, 132.2, 
131.9, 131.8, 129.9, 129.1, 128.5,  127.4, 126.5, 124.9, 124.5, 119.1, 118.3 (propenyl 
3-C), 117.1 (5-C), 104.4 (DMB 5-C), 98.9 (DMB 3-C), 72.2 (propyl 3-), 70.1 (propenyl 
1-C), 68.4 (1-C), 64.6 (propyl 1-C), 60.5 (2-C), 55.6 (2 × OMe), 48.7 (N(Ns)CH2Ph), 
45.8 (PhCH2N(CO)), 38.1 (propyl 2-C) , 34.7 (3-C), 25.6 (t, J 23.4, C8F17CH2CH2) 17.8 
(SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.01 (C8F17CH2CH2); νmax/cm
-1 (film) 3300, 2946, 
127 
 
1869, 1740, 1548, 1371; m/z (ES+) 1451.3 (100%, [M+Na]+); found 1451.3013, 
C56H61F17N4O14S2Si requires MNa 1451.3016 
 
N-{[2-({N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 236 
 
 
Following general procedure L3, sulfonamide 202 (220 mg, 0.57 mmol), alcohol 205 
(519 mg, 0.54 mmol), triphenylphosphine (148 mg, 0.57 mmol) and diethyl 
azodicarboxylate (98 mg, 0.57 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo, column chromatography eluting with 80:20 
petrol−EtOAc gave the sulfonamide 236 (430 mg, 0.32 mmol, 57%) as a colourless oil; 
Rf 0.89 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 7.76 (1H, d, J 7.9, nosyl 3-H), 
7.71-7.62 (2H, m, Ar), 7.57-7.43 (2H, m, Ar), 7.34 (1H, d, J 7.1, Ar), 7.28 (1H, d, J 7.8, 
Ar), 7.23-7.19 (1H, m, Ar), 5.78 (0.5H, br s, 4ʹ-Hrot), 5.68 (1H, ddt, J 18.2, 9.5 and 16.5, 
6-H), 5.57-5.46 (0.5H, m, 4ʹ-H), 4.99-4.96 (2H, m, 5ʹ-HAB), 4.94-4.79 (5H, m, 7-HAB, 
N(Ns)CHAPh and PhCHANTf), 4.6 (1H, d, J 16.8, N(Ns)CHBPh), 4.63-4.78 (1H, br s, 
PhCHBNTf), 4.03-3.98 (1H, m, 2ʹ-H), 3.68-3.60 (1H, m, 1ʹ-HA), 3.50-3.21 (4H, m, 1ʹ-HB 
and 1-HAB and 3-H), 2.39-2.30 (2H, m, 3ʹ-H2), 2.10-1.97 (2H, m, C8F17CH2CH2), 1.84-
1.69 (2H, m, 5-H2), 1.60-1.56 (1H, m, 2-H), 1.43-1.21 (2H, m, 4-H), 0.97-0.93 (14H, m, 
Si(CH(CH3)2)2), 0.82 (12H, s, Me and SiC(CH3)3), 0.77-0.72 (2H, m, C8F17CH2CH2), 
0.00 (3H, s, SiCH3), -0.07 (3H, s, SiCH3); δC (75 MHz; CDCl3) 148.2 (nosyl 2-C), 138.5 
(nosyl 1-C), 135.9 (6-C), 134.2 (4ʹ-C), 134.1, 133.8, 133.5, 131.9, 131.9, 130.4, 128.9, 
128.8, 128.6; 122.8, 118.4 (5ʹ-C), 115.1 (7-C), 73.7 (3-C), 64.7 (1ʹ-C), 60.6 (2ʹ-C), 52.3 
(PhCH2NTf), 46.5 (N(Ns)CH2Ph), 36.6 (1-C), 34.3 (3ʹ-C), 33.5 (5-C), 30.2 (2-C), 26.1 
(SiC(CH3)3), 25.6 (t, J 23, C8F17CH2CH2), 18.4 (SiC(CH3)3), 17.8 (SiCH(CH3)2), 12.5 
(SiCH(CH3)2), 11.3 (CH3), 0.00 (C8F17CH2CH2), -3.77 (SiCH3), -4.4 (SiCH3); νmax/cm
-1 
(film) 2951, 2867, 1642, 1547, 1372, 1227; m/z (ES+) 1355.4 (100%, [M+NH4]
+); found 
1355.3869, C50H67F20N3O8S2Si2 requires MNH4 1355.3927 
128 
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)phenyl]methyl}-
N-[(2-nitrobenzene)sulfonyl]carbamate 114 
  
Following general procedure L1, sulfonamide 131 (973 mg, 2.4 mmol), alcohol 113 (1.2 
g, 1.2 mmol), triphenylphosphine (628 mg, 2.4 mmol) and diethyl azodicarboxylate (417 
mg, 2.4 mmol) gave the crude product after 16 h. The crude product was concentrated 
in vacuo and purified by F-SPE to give the sulfonamide 114 (1.22 g, 0.91 mmol, 76%, 
>94% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil; Rf 
0.23 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 8.14 (1H, dd, J 8.1 and 1.3, nosyl 3-
H), 7.71 (1H, dd, J 7.8 and 1.3, nosyl 6-H), 7.70 (1H, dd, J 8.1 and 1.8, nosyl 3-H), 7.67 
(1H, dd, J 3.8 and 1.3, Ar), 7.65 (1H, dd, J 3.8 and 1.3, Ar); 7.58-7.51 (2H, m, Ar), 7.47-
7.39 (3H, m, Ar), 7.27-7.23 (2H, m, Ar), 7.13 (1H, apt, J 7.3, Ar), 7.08 (1H, dd, J 7.5 
and 1.7, Ar), 6.86 (1H, td, J 7.5 and 1, Ar), 6.78 (1H, dd, J 8.3 and 1.0, Ar), 5.91 (1H, 
ddt, J 17.2, 10.4 and 5.1, propenyl 2-C), 5.64 (1H, ddt, J 17.1, 10.1 and 7.0, 4-H), 5.29 
(1H, ddd, J 17.2, 3.3 and 1.6, propenyl 3-HA), 5.19 (1H, ddd, J 10.4, 2.9 and 1.6, 
propenyl 3-HB), 5.19 (2H, s, PhCH2O), 5.02 (1H, dd, J 17.1 and 1.6, 5-HA), 4.92 (1H, 
dd, J 10.1 and 1.6, 5-HB), 4.91 (2H, s, PhCH2N(CO)), 4.63 (1H, d, J 15.8, 
N(Ns)CHAPh), 4.48 (1H, d, J 15.8, N(Ns)CHBPh), 4.40 (2H, dt, J 5.1 and 1.7, propenyl 
1-C2), 4.08-4.03 (1H, m, 2-H), 3.76 (1H, dd, J 10.5 and 5.8, 1-HA), 3.53 (1H, dd, J 10.5 
and 5.9, 1-HB), 2.41 (1H, dt, J 13.9 and 6.9, 3-HA), 2.34 (1H, dt, J 13.9 and 7.5, 3-HB), 
2.16-2.02 (2H, m, C8F17CH2CH2), 1.06-0.96 (14H, m, Si(CH(CH3)2)2), 0.82-0.78 (2H, m, 
C8F17CH2CH2); δC (75 MHz; CDCl3) 156.7 (C=O), 151.7 (Ph 2-C), 147.8 (nosyl 2-C), 
147.6 (nosyl 2-C), 137.5 nosyl 1-C), 137.2 (nosyl 1-C), 134.6 (4-C), 134.5 (propenyl 2-
C), 134.3, 132.9, 132.8, 132.7, 132.2, 132.0, 131.94, 131.9, 131.6, 131.3, 131.3, 130.3, 
128.7, 128.6, 128.4, 127.9, 127.8, 127.1, 124.3, 124.0, 122.7, 120.5 (Ph 5-C)), 117.8 
(5-C), 117.4 (propenyl 3-C), 111.6 (Ph 3-C), 68.7 (propenyl 1-C), 65.2 (PhCH2O), 64.6 
(1-C), 60.0 (2-C), 50.8 (PhCH2N(CO)), 48.5 (N(Ns)CH2Ph), 34.7 (3-C), 25.3 (t, J 25, 
C8F17CH2CH2), 17.4 (SiCH(CH3)2), 17.4 (SiCH(CH3)2), 12.3 (SiCH(CH3)2), -0.03 
(C8F17CH2CH2); νmax/cm
-1 (film) 3521, 2957, 1737, 1651, 1538, 1372 and 1254; m/z 
(ES+) 1363.3 (100%, [M+Na]+); found 1363.2414, C52H53F17N4O12S2Si requires MNa 
1363.2491 
129 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-nitrobenzene)sulfonamido}methyl)phenyl]methyl}-
N-[(2-nitrobenzene)sulfonyl]carbamate 237 
  
Following general procedure L1, sulfonamide 132 (993 mg, 2.07 mmol), alcohol 113 
(1.00 g, 1.04 mmol), triphenylphosphine (542 mg, 2.07 mmol) and diethyl 
azodicarboxylate (360 mg, 2.07 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE to give the sulfonamide 237 
(1.65 g, 1.16 mmol, 112%, >59% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a colourless oil; Rf 0.39 (70:30, petrol—EtOAc); δH (500 MHz; MeOD; 
323K) 8.15 (1H, dd, J 7.6 and 1.1, nosyl 3-H), 7.90-7.82 (2H, m, Ar), 7.77-7.69 (3H, m, 
Ar), 7.65-7.58 (2H, m, Ar), 7.34-7.15 (4H, Ar), 6.91 (1H, dd, J 8.5, DMB 6-H), 6.43 (1H, 
d, J 2.4, DMB 3-H), 6.35 (1H, dd, J 8.4 and 2.5, DMB 5-H), 5.80 (1H, ddt, J 17.2, 10.4 
and 5.5, propenyl 2-H), 5.59 (1H, ddt, J 17.3, 10.2 and 7.1, 4-H), 5.16 (1H, ddd, J 17.2, 
1.7 and 1.7, propenyl 3-HA), 5.08 (1H, dd, J 10.4 and 1.7, propenyl 3-HB), 5.01 (1H, dd, 
J 17.3 and 1.6, 5-HA), 4.88 (1H, dd, J 10.2 and 1.8, 5-HB), 4.80 (2H, s, PhCH2N(CO)), 
4.56 (1H, d, J 16, N(Ns)CHAPh), 4.50 (1H, d, J 16, N(Ns)CHAPh), 4.44 (1H, dd, J 10.6 
and 5.3, propyl 1-HA), 4.36 (1H, dd, J 10.6 and 7.0, propyl 1-HB), 4.08-3.99 (2H, m, 1-
HAB), 3.87-3.84 (2H, m, propenyl 1-C), 3.76 (3H, s, OMe), 3.72 (3H, s, OMe); 3.50-3.40 
(4H, m, 2-H, propyl 2-H and 3-HAB propyl), 2.40-2.31 (2H, m, 3-HAB), 2.21-2.09 (2H, m, 
C8F17CH2CH2), 0.99 (14H, s, Si(CH(CH3)2)2), 0.85-0.77 (2H, m, C8F17CH2CH2); δC (75 
MHz; MeOD) 165.7 (C=O), 161.5 (DMB 4-C), 159.8 (DMB 2-C), 153.2 (nosyl 2-C), 
149.2 (nosyl 2-C), 143.4 (nosyl 1-C) , 139.5, 139.3, 138.9, 136.1, 136.7, 134.8, 133.1, 
132.8, 132.2, 130.1, 129.8, 129.5, 129.0, 128.8, 128.8 (DMB 6-C), 127.9, 125.8, 125.4, 
125.3, 120.0 (DMB 1-C), 118.1 (propenyl 3-C), 117.0 (5-C), 105.9 (DMB 5-C), 99.7 
(DMB 3-C), 72.9 (3-C propyl), 72.3 (propenyl 1-C), 69.2 (PhCH2N(CO)), 65.8 
(N(Ns)CH2Ph), 64.9 (2-C), 61.6 (1-C), 55.9 (OMe), 55.8 (OMe), 51.8 (1-H propyl), 39.5 
(2-C propyl), 35.7 (3-C); 26.7 (t, J 25, C8F17CH2CH2), 17.9 (SiCH(CH3)2), 13.4 
(SiCH(CH3)2), 0.8 (C8F17CH2CH2); νmax/cm
-1 (film) 3573, 3080, 2946, 2868, 1843, 1735, 
1643, 1658, 1543; m/z (ES+) 1446.3 (100%, [M+NH4]
+); found 1446.3394, 
C65H51F17N4O14S2Si requires MNH4 1446.3462 
130 
 
N-[(3-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-N-
[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 238 
  
Following general procedure L1, sulfonamide 135 (478 mg, 2.4 mmol), alcohol 113 
(1.21 g, 1.2 mmol), triphenylphosphine (628 mg, 2.4 mmol) and diethyl 
azodicarboxylate (417 mg, 2.4 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE to give the sulfonamide 238 
(1.6 g, 1.25 mmol,115%, >83% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a colourless oil; Rf 0.75 (50:50, petrol—EtOAc); δH (500 MHz; CDCl3) 
7.89 (1H, d, J 8.0 and 1.3, nosyl 3-H), 7.66-7.60 (2H, m, Ar), 7.54 (1H, ddd, J 8.7, 7 
and 1.8, Ar), 7.36 (1H, d, J 7.3, Ar), 7.32-7.28 (2H, m, Ar), 7.26-7.22 (1H, m, Ar), 5.62 
(1H, ddt, J 17.1, 10.3 and 6.9, 3-H), 5.52 (1H, ddt, J 17.5, 9.8 and 6.7, 4ʹ-H), 5.08-5.01 
(2H, m, 5ʹ-HAB), 4.96 (1H, dd, J 17.1 and 1.6, 4-HA), 4.87 (1H, d, J 10.3, 4-HB), 4.74 
(1H, d, J 16.2, N(Ns)CHAPh), 4.53 (1H, d, J 16.2, N(Ns)CHAPh), 4.45 (2H, br s, 
PhCH2NTf), 3.96 (1H, ap p, J 6.8, 2ʹ-H), 3.67 (1H, dd, J 10.4 and 5.8, 1ʹ-HA), 3.39 (1H, 
dd, J 10.4 and 6.3, 1ʹ-HB), 3.32 (2H, t, J 7.8, 1-H2), 2.32-2.19 (4H, m, 3ʹ-H and 2-H), 
2.09-1.96 (2H, m, C8F17CH2CH2), 0.95 (14H, s, Si(CH(CH3)2)2), 0.76-0.72 (2H, m, 
C8F17CH2CH2); δC (75 MHz; CDCl3) 147.8 (nosyl 2-C), 138.8 (nosyl 1-C), 134.8 (4ʹ-C), 
134.8 (3-C), 134.0, 133.8, 133.3, 133.2, 131.4, 131.3, 129.2, 128.5, 127.9, 127.6, 
124.2, 118.1 (4-C), 117.9 (5ʹ-C), 64.5 (1ʹ-C), 60.1 (2ʹ-C), 51.8 (N(Ns)CH2Ph), 48.4 (1-
C), 47.4 (PhCH2NTf), 34.5 (3ʹ-C), 32.5 (2-C), 17.4 (SiCH(CH3)2), 17.3 (SiCH(CH3)2), 
12.1 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 (film) 2948, 2870, 1574, 1390, 1372, 
1203; m/z (ES+) 1174.4 (100%, [M+Na]+); found 1174.2080, C40H45F20N3O7S2Si 
requires MNa 1174.2041 
 
  
131 
 
N-{[3-({N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 239 
  
Following general procedure L3, sulfonamide 202 (465 mg, 1.19 mmol), alcohol 113 
(1.0 g, 1.14 mmol), triphenylphosphine (311 mg, 1.19 mmol) and diethyl 
azodicarboxylate (207 mg, 1.19 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE to give the sulfonamide 239 
(1.41 g, 1.06 mmol, 93%, >95% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a colourless oil; Rf 0.89 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) 
7.88 (1H, dd, J 7.9 and 1.3, nosyl 3-H), 7.66-7.59 (2H, m, nosyl 6 and 4-H), 7.56-7.48 
(1H, m,), 7.37 (1H, d , J 7.5, Ar), 7.31-7.22 (3H, m, nosyl 5-H), 5.72 (1H, ddt, J 16.9, 
10.3 and 6.6, 6-H), 5.59-5.50 (1H, 4ʹ-H), 4.99-4.87 (4H, m, 5ʹ-HAB and 7-HAB), 4.75 (1H, 
d, J 16.5, N(Ns)CHAPh), 4.74 (1H, d, J 16.3, N(Ns)CHBPh), 4.68-4.20 (2H, br , 
PhCH2NTf), 4.51 (1H, d, J 16.5, N(Ns)CHAPh
rot), 4.49 (1H, d, J 16.3, N(Ns)CHBPh
rot), 
4.02-3.94 (1H, m, 1ʹ-HA
rot), 3.72-3.64 (1H, m, 1ʹ-HB
rot), 3.49 (1H, br s, 3-H), 3.41-3.24 
(2.5H, m, 1ʹ-HAB
rot and 1-HAB), 2.35 (1H, ap t, J 7.6, 2ʹ-H), 2.32-2.27 (2H, m, 3ʹ-H), 2.10-
1.97 (2H, m, C8F17CH2CH2), 1.93-1.79 (2H, m, 5-H), 1.72 (1H, br s, 2-H), 1.5-1.37 (2H, 
m, 4-H), 0.96 (14H, s, Si(CH(CH3)2)2), 0.83 (9H, SiC(CH3)3), 0.80 (3H, d, J 7, Me), 0.77-
0.72 (2H, m, C8F17CH2CH2), 0.00 (3H, SiCH3), -0.08 (3H, SiCH3); δC (75 MHz; CDCl3) 
148.2, 139.2, 139.4, 134.5, 134.3, 133.7, 133.5, 131.8, 131.7, 129.5, 129.1, 128.9, 
128.2, 128.1, 127.9, 124.5, 118.3 (4ʹ-C), 115.2 (7-C), 73.5 (3-C), 64.9 (1ʹ-C), 60.5 (2ʹ-
C), 48.8 (N(Ns)CH2Ph), 36.1 (1-C), 34.9 (2-C), 34.8 (3ʹ-C), 33.3 (5-C), 30.3 (4-C), 26.1 
(SiC(CH3)3), 25.9 (t, J 25, C8F17CH2CH2), 18.4 (SiC(CH3)3), 17.8 (SiCH(CH3)2), 12.5 
(SiCH(CH3)2), 12.4 (Me), 11.4  (TBS), 0.4 (C8F17CH2CH2), −3.8 (SiCH3), −4.3 (SiCH3); 
νmax/cm
-1 (film) 3080, 2851, 2868, 2736, 2391, 1836, 1720, 1642, 1592, 1547 ; m/z 
(ES+) 1355.4 (100%, [M+NH4]
+); found 1355.3877, C50H67F20N3O8S2Si2  requires MNH4 
1355.3927 
  
132 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-({2-[2-({N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl](2-
nitrobenzene)sulfonamido}methyl)phenyl]phenyl}methyl)-N-[(2-
nitrobenzene)sulfonyl]carbamate 241 
 
Following general procedure L2, sulfonamide 132 (2.7 g, 5.8 mmol), alcohol 233 (1.4 g, 
1.45 mmol), triphenylphosphine (1.5 g, 5.8 mmol) and diethyl azodicarboxylate (1.0 g, 
5.8 mmol) gave the crude product after 16 h. The crude product was concentrated in 
vacuo and purified by F-SPE to give the sulfonamide 241 (1.3 g, 0.91 mmol, 63%, 
>90% purity as estimated using 500 MHz 1H NMR spectroscopy) as a colourless oil; Rf 
0.6 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3) atropisomers denoted where possible 
8.24-8.20 (1H, m, Ar), 7.97-7.55 (m, Ar), 7.51-7.31 (m, Ar), 7.28-7.24 (m, Ar), 7.23-7.10 
(m, Ar), 6.89 (0.5H, d, J 8.4), 6.83 (0.5H, d, J 8.4), 6.46 (0.5H, d, J 2.4), 6.39 (0.5H, d, J 
2.4), 6.36 (0.5H, d, J 8.4 and 2.5), 6.33 (0.5H, d, J 8.4 and 2.4), 5.88-5.79 (m, propenyl 
2-H), 5.58-5.36 (0.5H, m, 4-Hatrop), 5.23-5.17 (0.5H, m, 4-Hatrop), 5.14-5.10 (2H, m, 
propenyl 3-HAB), 4.83-4.33 (7H, m, 5-HA and propyl 1-HAB and N(Ns)CH2Ph and 
PhCH2N(Ns)(CO)), 4.21 (1H, d, J 17, 5-HB), 4.15-4.06 (m, 2-H), 3.90-3.87 (2H, s, 
propenyl 1-H2), 3.80 (s, OMe), 3.79 (s, OMe), 3.75 (s, OMe), 3.71 (s, OMe), 3.69-3.39 
(m, 1-HA, propyl 2-H and 3-HAB), 3.31 (1H, dd, J 10.3 and 7.1, 1-HB), 3.26 (1H, dd, J 
10.3 and 7.3, 1-HB
atrop), 2.27-2.09 (3H, m, C8F17CH2CH2 and 3-HA), 2.06-1.97 (1H, m, 3-
HB), 1.03-0.90 (14H, m, Si(CH(CH3)2)2), 0.87-0.82 (C8F17CH2CH2
atrop), 0.80-0.76 (2H, 
C8F17CH2CH2); δC (75 MHz; CDCl3) 163.8, 159.7, 158.1, 151.7, 148.0, 147.9, 138.3, 
138.2, 135.7. 135.6, 135.5, 134.7, 134.6, 134.4, 134.2, 134.0, 132.9, 132.5, 132.4, 
132.2, 131.6, 131.5, 131.4, 131.3, 131.1, 129.9, 129.7, 129.2, 129.1, 128.6, 128.0, 
127.8, 127.6, 127.2, 127.1, 125.6, 124.4, 124.3, 123.6, 123.4, 122.5, 119.1, 118.7, 
118.6, 117.7, 117.6, 117.5, 116.7, 104.1, 103.9, 98.6, 98.4, , 71.9, 71.8, 69.8, 67.9, 
67.9, 64.6, 63.4, 60.4, 59.8, 59.5, 55.2, 55.1, 49.6, 49.5, 45.9, 45.8, 45.5, 38.3, 37.6, 
34.4, 33.9, 29.7, 25.3 (t, J 25, C8F17CH2CH2), 17.5, 17.4, 17.3, 12.1, 12.0, 0.01; 
νmax/cm
-1 (film) 3055, 2987, 2306, 1737, 1546, 1422, 1273; m/z (ES+) 1527.3 (100%, 
[M+Na]+); found 1527.3407, C62H65F17N4O14S2Si  requires MNa 1527.3329 
133 
 
full carbon assignment was not possible to mixture atropisomers 
N-{[2-(2-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)phenyl]methyl}-N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 242 
  
Following general procedure L2, sulfonamide 135 (689 mg, 3.4 mmol), alcohol 233 
(920 mg, 0.84 mmol), triphenylphosphine (890 mg, 3.4 mmol) and diethyl 
azodicarboxylate (591 mg, 3.4 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE to give the sulfonamide 242 
(1.02 g, 0.81 mmol, 96%, >95% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a colourless oil; Rf 0.83 (60:40, petrol—EtOAc); δH (500 MHz; CDCl3) 
minor atropisomer denoted where possible (ca. 43:57) 7.88 (1H, d, J 7.4, nosyl 3-H), 
7.80 (d, J 7.9, nosyl 3-Hmin), 7.74-7.29 (7H, m, Ar), 7.26-7.23 (1H, m, Ar), 7.18 (1H, dd, 
J 7.8 and 1.2, nosyl 5-H), 7.16 (1H, d, J 7.3, Ar), 7.12-7.09 (1H, m, Ar); 5.57-5.41 (2H, 
m, 4ʹ-H and 3-H), 5.02-4.76 (4H, m, 4-HAB and 5ʹ-HAB), 4.63 (1H, d, J 16, PhCHANTf), 
4.49 (d, J 9.8, 5-HB
min), 4.46 (1H, d, J 16.6, N(Ns)CHAPh), 4.27 (d, J 17, 
N(Ns)CHAPh
min), 4.19 (1H, d, J 16.6, N(Ns)CHBPh), 3.96 (1H, dq, J 8.2 and 6.0, 2ʹ-
Hmin), 3.88 (1H, d, J 16.9, PhCHBNTf), 3.82 (1H, br s, 2-H); 3.52 (1H, dd, J 9.9 and 5.1, 
1ʹ-HA), 3.59-3.40 (m, 1ʹ-HA 
min), 3.38-3.24 (1H, m, 1ʹ-HB), 3.13 (2H, dt, J 15 and 7.8, 1-
Hmin), 3.05 (2H, dt, J 15 and 7.8, 1-H2), 2.97 (1H, br s, 1-HB
min); 2.23-2.08 (2H, m, 3ʹ-
HAB), 2.08-1.96 (4H, m, 2-H and C8F17CH2CH2), 0.94-0.69 (16H, m, Si(CH(CH3)2)2 and 
C8F17CH2CH2), 0.64-0.58 (2H, m, C8F17CH2CH2
min); δC (75 MHz; CDCl3) minor 
atropisomer denoted where possible 148.4 (nosyl 3-Cmin), 148.3 (nosyl 3-C), 140.00 
(nosyl 1-C), 139.9 (nosyl 1-Cmin), 138.3, 138.2 (min), 136.5, 136.2 (min), 134.5 (3-C), 
134.2, 134.0 (4ʹ-C), 133.9, 133.8, 133.7, 133.6, 133.5, 133.3, 131.7, 131.6, 130.3 (min), 
130.2, 129.9, 129.8 (min), 129.2 (min), 129.1, 129.0, 128.8, 128.7 (min), 128.6 (min), 128.2, 
127.8 (min), 124.3, 124.31 (min), 120.1 (q, J 320, CF3), 118.2 (5ʹ-C), 118.1 (4-C), 118.0 
(4-Cmin), 66.7 (1ʹ-C), 63.8 (1ʹ-Cmin), 60.3 (2-C), 60.1 (2-Cmin), 48.5 (N(Ns)CH2Ph
min), 48.4 
(N(Ns)CH2Ph), 46.3 (PhCH2NTf
min), 45.2 (PhCH2NTf), 35.4 (1-C), 33.7 (3-C), 32.7 (3ʹ-
Cmin), 32.6 (2-C), 30.1 (2-Cmin), 25.6 (t, J 25, C8F17CH2CH2), 17.7 (SiCH(CH3)2), 17.6 
(SiCH(CH3)2), 12.5-12.2 (m, (SiCH(CH3)2), 0.12 (C8F17CH2CH2); νmax/cm
-1 (film) 3005, 
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2947, 2868, 1723, 1642, 1462, 1388; m/z (ES+) 1245.3 (100%, [M+NH4]
+); found 
1245.2756, C26H49F20N3O7S2Si  requires MNH4 1245.2800 
N-({2-[2-({N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]phenyl}methyl)-N-[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]-2-nitrobenzene-1-sulfonamide 243 
  
Following general procedure L2, sulfonamide 202 (540 mg, 1.39 mmol), alcohol 233 
(1.37 g, 1.26 mmol), triphenylphosphine (364 mg, 1.39 mmol) and diethyl 
azodicarboxylate (241 mg, 1.39 mmol) gave the crude product after 16 h. The crude 
product was concentrated in vacuo and purified by F-SPE to give the sulfonamide 243 
(1.78 g, 1.22 mmol, 97%, >80% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a colourless oil; Rf 0.81 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 
50:50 atropisomers denoted where possible 7.91 (0.5H, dd, J 7.9 and 1.3, nosyl 3-
Hatrop), 7.86 (0.5H, dd, J 8.0 and 1.3, nosyl 3-Hatrop), 7.82-7.75 (1H, m, Ar), 7.72-7.56 
(3H, m, Ar), 7.58-7.43 (2H, m, Ar), 7.40-7.34 (2H, m, Ar), 7.28 (0.5H, dd, J 7.5 and 1.3, 
Aratrop), 7.23 (0.5H, dd, J 7.5 and 1.3, Aratrop), 7.21-7.17 (1H, m, Ar), 7.17-7.13 (1H, Ar), 
5.74 (1H, ddt, J 17.1, 10.4 and 6.6, 4ʹ-H), 5.54 (0.5H, ddt, J 17.1, 10.3 and 7.0, 6-
Hatrop), 5.15 (0.5H, ddt, J 16.9, 10.3 and 6.4, 6-Hatrop), 4.99-4.99 (2H, m, 5-HAB), 4.86 
(0.5H, dd , J 10.3 and 1.6, 7-HA
atrop), 4.80 (0.5H, dd, J 17.1 and 1.4, 7-HB
atrop), 4.76 
(0.5H, d, J 15.2, PhCHANTf), 4.67 (0.5H, d, J 15.2, PhCHBNTf), 4.65 (0.5H, d, J 16.7, 
N(Ns)CHAPh
atrop), 4.57 (0.5H, dd, J 10.4 and 1.5, 7-HA
atrop), 4.43 (0.5H, dd, J 16.9 and 
1.4, 7-HB
atrop), 4.41 (0.5H, d, J 17.3, N(Ns)CHAPh
atrop), 4.25 (0.5H, d, J 17.3, 
N(Ns)CHBPh
atrop), 4.12-4.06 (1H, m, Ph(CH2NTf
atrop), 4.01 (1H, p, J 7, 2ʹ-H), 3.96 (0.5H, 
d, J 16.7, N(Ns)CHBPh
atrop), 3.97-3.92 (1H, m, 3-H), 3.55 (1H, dd, J 10.2 and 5.9, 1ʹ-
HA), 3.5 (1H, 1-H2
atrop), 3.30-3.21 (1H, m, 1-H2), 3.19 (1H, dd, J 10.2 and 7.4, 1ʹ-HB), 
2.21-2.02 (4H, m, 3ʹ-HAB and C8F17CH2CH2), 1.93-1.73 (3H, m, 2-H and 5-HAB), 1.68-
1.53 (1H, m, 4-HA), 1.49-1.38 (1H, m, 4-HB), 0.99-0.96 (14H, m, Si(CH(CH3)2)2), 0.94-
0.90 (12H, m, SiC(CH3)3 and Me), 0.08-0.71 (2H, m, C8F17CH2CH2), 0.05 (3H, s, 
SiCH3), 0.00 (s, SiCH3
atrop), -0.02 (3H, s, SiCH3); δC (75 MHz; CDCl3) 149.6 (nosyl 2-C), 
141.0, 139.7, 139.4, 139.2, 137.6, 135.4, 135.3, 134.9, 134.6, 133.1, 132.8, 132.3, 
131.6, 130.9, 130.8, 130.0, 129.9, 129.8, 129.7, 129.6, 124.5, 129.3, 128.9, 128.6, 
135 
 
125.4, 118.2, 118.1, 115.3, 115.1, 74.6, 74.4, 66.4, 64.9, 61.6, 61.4, 55.1, 53.1, 51.3, 
47.3, 46.4, 37.7, 36.9, 36.0, 35.3, 35.1, 34.8, 30.9, 30.8, 26.4, 18.9, 17.9, 17.8, 13.5, 
13.4, 11.2, 11.1, 0.99 (C8F17CH2CH2), -3.8 (SiCH3), -3.82 (SiCH3), -4.3 (SiCH3), -4.4 
(TBS); νmax/cm
-1 (film) 3311, 3010, 2956, 2707, 2305, 1834, 1641, 1473, 1429 and 
1350; m/z (ES+) 1436.4 (100%, [M+Na]+); found 1436.3791, C56H71F20N3O8S2Si2 
requires MNa 1436.3794 
full carbon assignment was not possible to mixture atropisomers 
(5S,6R,9E)-6-[(Tert-butyldimethylsilyl)oxy]-12-
({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-5-methyl-3,13-bis[(2-nitrobenzene)sulfonyl]-18-thia-3,13-
diazabicyclo[13.2.1]octadeca-1(17),9,15-trien-4-one 214 
  
Following general procedure L2, HG-II (5 mg, 2 mol%), 1,4-benzoquinone (1.7 mg, 4 
mol%) and acyl sulfonamide 210 (550 mg, 0.39 mmol) were stirred in MTBE (195 mL) 
at 55 ˚C for 16 h. After the workup procedure the crude product was concentrated in 
vacuo; column chromatography, eluting with 80:20 petrol—EtOAc gave the macrocycle 
214 (220 mg, 0.16 mmol, 40%, E/Z >61:<29); Rf 0.55 (CH2Cl2);     
     −17.1 (c. 0.7, 
CHCl3); δH (300 MHz; CDCl3) 8.28 (1H, dt, J 7.7 and 1, nosyl 3-H), 8.12-8.07 (1H, m, 
nosyl 3-H), 7.82-7.56 (6H, m, nosyl 4-, 5-, and 6-H), 6.90-6.83 (1, m, ArZ), 6.81 (1H, d , 
J 3.5, Thio 3-H), 6.66 (1H, d , J 3.5, Thio 4-H), 5.71 (1H, d, J 12.5, ThioCH2N(CO)), 
5.60 (d, J 12.4, ThioCH2N(CO)
Z), 5.41-5.31 (1H, m, 10-HZ), 5.25 (1H, dt, J 15.3 and 
6.1, 10-H), 5.19-5.10 (1H, m, 9-HZ), 5.04 (1H, dt, J 15.3 and 6.8, 9-H), 4.91 (d, J 12.4, 
ThioCH2N(CO)
Z), 4.88 (1H, d, J 12.5, ThioCH2N(CO)), 4.81 (1H, d, J 15.9, 14-HA), 4.45 
(1H, d, J 15.9, 14-HB), 3.86 (1H, dd, J 10.2 and 6.6, SiOCHA), 3.77-3.66 (2H, m, 8-HA 
and 6-H), 3.60 (1H, dd, J 10.2 and 5.8, SiOCHB), 3.54-3.37 (2H, m, 5-H and 8-HB), 
2.67-2.53 (1H, m, 12-H), 2.20-1.77 (4H, m, C8F17CH2CH2 and 11-HAB), 1.34 (3H, d, J 
6.8, Me), 1.27-1.09 (2H, m, 7-HAB), 0.97 (14H, s, Si(CH(CH3)2)2), 0.84 (9H, s, 
SiC(CH3)3), 0.81-0.72 (2H, m, C8F17CH2CH2), 0.04 (3H, s, SiCH3), 0.00 (3H, s, SiCH3); 
δC (75 MHz; CDCl3) 177.1 (C=O), 148.7 (nosyl 2-C), 148.2 (nosyl 2-C), 144.3 (nosyl 1-
C), 143.7 (nosyl 1-C), 137.7 (nosyl 4-C), 134.9 (nosyl 4-C), 134.8 (Thio 2 or 5-C), 134.1 
(Thio 2 or 5-C), 134.0, 133.9 (Thio 3 or 4-C), 133.7 (9-C), 132.9, 132.3, 131.9 (Thio 3 
or 4-C); 130.6 (Ns), 129.9, 127.7, 125.4 (10-C), 124.6, 74.2 (6-C); 65.7 (2-C), 64.4 (2-
136 
 
CZ), 64.1 (SiOCH2), 63.5 (12-C), 46.2 (14-C), 35.7 (5-C), 34.8 (11-C), 33.4 (8-C), 32.5 
(7-C), 26.2 SiC(CH3)3, 25.6 (t, J 25, C8F17CH2CH2), 18.4 (SiC(CH3)3), 17.9 
(SiCH(CH3)2), 17.8 (SiCH(CH3)2), 16.8 (Me), 12.5 (SiCH(CH3)2), 0.01 (C8F17CH2CH2), -
3.7 (SiCH3), -4.0 (SiCH3); νmax/cm
-1 (film) 2953, 2867, 1601, 1545, 1367, 1207; m/z 
(ES+) 1400.4 (100%, [M+NH4]
+); found 1405.3144, C51H63F17N4O11S3Si2  requires MNa 
1405.2815 
(15E,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-3,19-bis[(2-
nitrobenzene)sulfonyl]-5,13-dioxa-24-thia-3,19-diazatricyclo[19.2.1.07,12]tetracosa-
1(23),7,9,11,15,21-hexaen-4-one 211 
 
Following general procedure RCM1, HG-II (0.8 mg, 1 mol%) and sulfonamide 211 (180 
mg, 0.13 mmol) were stirred in MTBE (60 mL) at 55 ˚C for 16 h. After the workup 
procedure the crude product was concentrated in vacuo; column chromatography, 
eluting with 70:30 CH2Cl2−petrol gave the macrocycle 223 (103 mg, 0.78 mmol, 60%, 
E/Z >99<1) as a colourless oil; Rf 0.15 (70:30, CH2Cl2—petrol);     
     −0.9 (c. 2.2 in 
CDCl3); δH (500 MHz; CDCl3) 7.98 (1H, s, nosyl 3-H), 7.73-7.61 (3H, m, Ar), 7.59-7.48 
(2H, m, Ar) 7.44, (2H, t, J 7.2, Ar), 7.31 (1H, td, J 7.9 and 1.7, 8-H), 7.11 (1H, dd, J 7.6 
and 1.7, 11-H), 6.88-6.80 (4H, m, Ar), 5.74 (1H, dt, J, 15.9 and 5.8, 16-H), 5.38 (1H, dt, 
J, 15.9 and 6.9, 15-H), 5.33 (1H, d, J 10.8, 2-HA), 4.91 (2H, s, 6-H2), 4.83 (1H, d, 10.8, 
2-HB), 4.77 (1H, d, J 15.8, 20-HA), 4.46 (1H, d, J 15.8, 20-HB), 4.42 (1H, dd, J 12.4 and 
4.3, 14-HA), 4.35 (1H, dd, J 12.4 and 6.4, 14-HB), 4.13 (1H, dq, J 9.9 and 5.0, 18-H), 
3.80 (1H, dd, J 10.6 and 5.5, SiOCHA), 3.76 (1H, dd, J 10.5 and 5.5, SiOCHB), 2.49-
2.30 (2H, m, 17-HAB), 2.09-1.96 (2H, m, C8F17CH2CH2), 0.97 (14H, s, Si(CH(CH3)2)2), 
0.78-0.73 (2H, M C8F17CH2CH2); δC (75 MHz, CDCl3) 158.3 (4-C), 151.8 (12-C), 148.3 
(nosyl 2-C), 148.1 (nosyl 2-C), 140.4 (7-C), 135.1 (1-C), 134.9 (21-C), 134.5 (nosyl 1-
C), 133.1, 132.2, 132.1, 132.0, 131.8, 131.2, 129.6 (16-C), 128.8, 128.6 (15-C), 128.4, 
124.8, 124.1, 122.8, 120.5 (9-C), 112.7 (11-C), 68.9 (14-C), 66.0 (1ʹ-C), 65.8 (6-C), 
60.5 (18-C), 45.7 (2-C), 44.1 (20-C), 33.5 (17-C), 25.6 (t, J 25, C8F17CH2CH2), 17.8 
(SiCH(CH3)2), 12.5 ((SiCH(CH3)2), 1.4 (C8F17CH2CH2); νmax/cm
-1 (film) 2948, 2869, 
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2159, 2029, 1736, 1545, 1371, 1208 and 1166; m/z (ES+) 1336.2 (100%, [M+NH4]
+); 
found 1336.2221, C48H47F17N4O12S3Si requires MNH4 1336.2189 
(15E,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,13-dioxa-24-thia-3,19-
diazatricyclo[19.2.1.07,12]tetracosa-1(23),7,9,11,15,21-hexaen-4-one 223D 
 
Following general procedure N1; thiophenol (264 mg, 2.4 mmol), sulfonamide 223 (320 
mg, 0.24 mmol) and potassium carbonate (80 mg, 0.58 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 223D (190 mg, 
0.20 mmol, 84%, >95% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow foam; δH (500 MHz; CDCl3) 7.4-7.28 (2H, m, Ar), 6.94 (1H, ap t, J 7.4, Ar), 
6.88 (1H, d, J 8.2, Ar), 6.70 (1H, d, J 3.9, Thio 3 or 4-H), 6.64 (1H, d, J 3.9, Thio 3 or 4-
H), 5.74 (2H, s, 15-H and 16-H), 5.32 (1H, d, J 10.7, 6-HA), 5.09 (1H, NH); 4.98 (1H, d, 
J 10.7, 6-HB), 4.62-4.46 (3H, m, 2-HAB and 14-HA), 4.38 (1H, dd, J 15.8 and 5.4, 14-HB), 
4.04 (1H, d, J 14.7, 20-HB), 3.96 (1H, d, J 14.7, 20-HB), 3.60 (2H, d, J 5.1, SiOCH2), 
2.83-2.63 (1H, m, 18-H), 2.28-2.00 (4H, m, C8F17CH2CH2 and 17-HAB), 1.05 (14H, s, 
Si(CH(CH3)2)2), 0.9-0.83 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 158.2 (12-C), 
156.9 (C=O), 144.6 (Thio 2 or 5-C), 143.1 (Thio 2 or 5-C), 132.3 (14-C), 130.8, 130.1 
(15-C), 129.9, 127.9, 124.6 ,120.8 (9-C), 112.6 (11-C), 69.1 (SiOCH2), 65.4 (14-C), 
64.1 (2-C), 55.9 (18-C), 45.6 (2-C), 40.7 (20-C), 34.9 (17-C), 25.7 (t, J 25, 
C8F17CH2CH2), 17.8 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.01 (C8F17CH2CH2); νmax/cm
-1 
(film) 2945, 2159, 2029, 1716, 1206; m/z (ES+) 949.2 (100%, [M+H]+); found 949.2372, 
C36H41F17N2O4SSi requires MH 949.2358 
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(7S,11E,14R)-7-(2,4-Dimethoxyphenyl)-14-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-3,15-bis[(2-
nitrobenzene)sulfonyl]-5,9-dioxa-20-thia-3,15-diazabicyclo[15.2.1]icosa-
1(19),11,17-trien-4-one 213 
  
Following general procedure RCM2, HG-II (7 mg, 5 mol%), 1,4-benzoquinone (2 mg, 
10 mol%) and sulfonamide 212 (300 mg, 0.2 mmol) were stirred in MTBE (100 mL) at 
55 ˚C for 24 h. After the workup procedure the crude product was concentrated in 
vacuo. Following general procedure N1, thiophenol (116 mg, 1.06 mmol), crude 
product (150 mg) and potassium carbonate (10 mg, 0.25 mmol) gave the amine crude 
product after 16 h. The crude product was purified by F-SPE and column 
chromatography, eluting with 80:20 petrol—EtOAc to give the amine 213 (71 mg, 0.068 
mmol, 34%; 63/37 E/Z) as a pale yellow oil; Rf 0.31 (70:30, petrol—EtOAc); δH (500 
MHz; CDCl3) 7.13 (1H, m, DMB 6-H), 6.74 (d, J 3.4, Thio 3 or 4-H), 6.70 (1H, d, J 3.5, 
Thio 3 or 4-H), 6.66 (1H, d, J 3.5, Thio 3 or 4-H), 6.45-6.40 (2H, m, DMB 3 and 5-H), 
5.66 (1H, dt, J 15.4 and 8.1, 12-H), 5.56 (1H, dt, J 15.4 and 5.6, 11-H), 5.52-5.45 (m, E 
isomer 11-H and 12-H), 5.04 (1H, br s, NH), 4.54-4.19 (4H, m, 2-H and 6-H), 4.11 (1H, 
d, J 14.1, 16-H), 3.91 (1H, d, J 14.1, 16-H), 4.02-3.87 (2H, m, 10-H), 3.79 (3H, s, OMe), 
3.78 (3H, s, OMe), 3.74-3.50 (5H, 7-H, 8-H and SiOCH2), 2.76 (1H, br s, 14-H), 2.28-
2.07 (3H, m, C8F17CH2CH2 and 13-H), 2.00 (1H, dt, J 15.3 and 8.1, 13-H), 1.06 (14H, 
Si(CH(CH3)2)2), 0.90-0.86 (2H, C8F17CH2CH2); δC (75 MHz; CDCl3) 168.4 (C=O), 159.8 
(DMB 4-C), 158.2 (DMB 2-C), 129.6 (11-C), 129.1 (DMB 6-C), 2 x124.2 (Thia), 104.4 
(DMB 5-C), 98.8 (DMB 3-C), 71.9 (10-C), 65.6 (6-C), 65.5 (7-C), 57.2 (14-C), 55.4 
(OMe), 55.2 (OMe), 46.1 (16-C), 38.1 (7-C), 34.7 (13-C), 25.6 (C8F17CH2CH2), 17.5 
(SiCH(CH3)2), 17.4 (SiCH(CH3)2), 12.4 (SiCH(CH3)2), -0.02 (C8F17CH2CH2); Thio 1 and 
4 missing; νmax/cm
-1 (film) 2952, 2857, 1715 and 1165; m/z (ES+) 1037.3 (100%, 
[M+H]+); found 1037.2894, C40H49F17N2O6SSi requires MH 1037.2882 
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(15E,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-3,19-bis[(2-
nitrobenzene)sulfonyl]-5,13-dioxa-3,19-diazatricyclo[19.4.0.07,12]pentacosa-
1(25),7,9,11,15,21,23-heptaen-4-one 244 
 
Following general procedure L2, HG-II (9.4 mg, 2 mol%), 1,4-benzoquinone (3.2 mg, 4 
mol%) and sulfonamide 234 (1.0 g, 0.75 mmol) were stirred in MTBE (360 mL) at 55 ˚C 
for 24 h. After the workup procedure the crude product was concentrated in vacuo; 
column chromatography, eluting with 90:10 CH2−petrol gave the macrocycle 244 (550 
mg, 0.42 mmol, 56%; >65/<35 E/Z); Rf 0.85 (90:10, CH2Cl2—petrol);     
     32 (c. 1, 
CH2Cl2); δH (500 MHz; CDCl3) minor isomer denoted where possible 8.41-8.38 (1H, m, 
nosyl 3-HZ), 8.17 (1H, d, J 8, nosyl 3-H), 7.72-6.91 (13H, m, nosyl 3-H. 2 × nosyl 4, 5 
and 6 H, 8-H, 9-H and Ar ); 6.79 (t, J 7.4, 11-HZ), 6.67-6.63 (1H, m, 10-H and 11-H); 
6.54 (1H, d, J 8.2, 10-HZ), 5.87 (1H, dt, J 14.9 and 7.2, 15-H), 5.60 (1H, dt, J 14.9 and 
5.2, 16-H), 5.58-5.51 (2H, m, 15 and 16-HZ), 5.19-5.12 (1H, m, 6-H), 4.96-4.88 (3H, 2-
H and 6-HAB), 4.83 (d, J 11, 2-H
Z), 4.55 (1H, d, J 15.5, 20-HA), 4.47 (1H, d, J 15.5, 20-
HB), 4.36-4.14 (3H, m, 18-H and 14-H), 3.85-3.76 (2H, m, SiOCH2), 3.57 (dd, J 11.1 
and 5.4, SiOCHA
Z), 3.37 (1H, ap t, J 9.9, SiOCHB
Z), 2.64 (2H, ap t, J 6.7, 17-H), 2.39 
(2H, ap dt, J 16.9 and 8.9, 17-HZ), 2.10-1.95 (2H, m, C8F17CH2CH2), 0.94 (14H, s, 
Si(CH(CH3)2)2), 0.89 (14H, s, Si(CH(CH3)2)2
Z), 0.80-0.75 (2H, m, C8F17CH2CH2), 0.75-
0.68 (2H, m, C8F17CH2CH2
Z); δC (75 MHz; CDCl3) 157.5 (12-C), 152.3 (nosyl  2-C
Z), 
151.9 (nosyl 2-C), 148.0 (nosyl 2-CZ), 147.9 (nosyl 2-C), 134.9 (nosyl 1-C), 134.7 
(nosyl 1-Cmin), 134.6 (nosyl 1-C), 133.7, 133.5, 133.3, 132.7, 132.0, 131.9, 131.8, 
131.4, 131.2, 130.9, 129.6 (17-C), 128.5 (16-C), 128.3, 127.3, 127.2, 124.9 (17-CZ), 
124.8 (17-CZ), 124.6, 124.4, 123.3 (nosyl 3-C), 122.8 (nosyl 3-C), 120.4 (9-C), 112.1 
(11-CZ), 111.5 (11-C), 67.6 (6-C), 66.4 (14-C), 65.2 (SiOCH2), 64.3 (SiOCH2
Z), 62.7 
(18-CZ), 60.3 (18-C), 48.8, 48.2, 46.1, 34.0 (17-C), 29.6 (17-CZ), 25.6 (t, J 25, 
C8F17CH2CH2), 17.8 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 12.4 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2); νmax/cm
-1 (film) 3597, 3006, 1712, 1423, 1367, 1223; m/z (ES+) 1330.3 
(100%, [M+NH4]
+); found 1330.2669, C50H49F17N4O12S2Si requires MNH4 1330.2624 
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(15E,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one E-244D 
 
Following general procedure N1; thiophenol (443 mg, 4.03 mmol), sulfonamide 244 
(530 mg, 0.40 mmol) and potassium carbonate (140 mg, 1.00 mmol) gave the crude 
product after 4 h. The crude product was purified by F-SPE and column 
chromatography to give the amine E-244D (152 mg, 0.16 mmol, 40%) as a colourless 
oil; Rf 0.58 (70:30, petrol—EtOAc);     
     −1.6 (c. 1.2, CH2Cl2); δH (500 MHz; CDCl3) 
7.44 (1H, br s, NH), 7.27-7.10 (6H, m, 11-H, 8-H and Ar), 6.80 (1H, ap t, J 7.4, 9-H), 
6.75 (1H, d, J 8.3, 10-H), 6.10 (1H, dt, J 15.2 and 7.0, 16-H), 5.54 (1H, d, J 15.2, 15-H), 
5.21 (1H, d, J 11.2, 6-HA), 4.88 (1H, d, J 11.2, 6-HB), 4.57 (1H, d, J 14.1, 2-HA), 4.52 
(1H, d, J 14.1, 2-HB), 4.34 (1H, dd, J 13.5 and 6.3, 14-HA), 4.29 (1H, d, J 13.5, 14-HB), 
3.74-3.63 (3H, m, 20-HAB and SiOCHA), 3.48 (1H, dd, J 10.1 and 5.2, SiOCHB), 2.77 
(1H, br s, 18-H), 2.27-2.21 (1H, m, 17-HA), 2.18-1.96 (3H, m, C8F17CH2CH2 and 17-HB), 
0.96 (14H, s, Si(CH(CH3)2)2), 0.82-0.76 (2H, m, 1ʹ-H); δC (75 MHz; CDCl3) 138.6, 131.7, 
130.8, 130.7, 130.6, 130.2, 128.6, 128.5, 128.1, 126.7, 120.4 (9-C), 111.4 (11-C), 65.8 
(6 or 14-C), 64.3 (6 or 14-C), 60.1 (18-C), 50.6 (20-C), 44.9 (2-C), 35.5 (17-C), 25.7 (t, 
J 25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.01 
(C8F17CH2CH2); 12-C and C=O missing; νmax/cm
-1 (film) 2964, 2867, 1714, 1275 and 
1260; m/z (ES+) 943.3 (100%, [M+H]+); found 943.2815, C38H43F17N2O4Si requires MH 
943.2793 
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(15Z,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(21),7,9,11,15,22,24-heptaen-4-one Z-244D 
 
Also obtained was the geometric isomer Z-244D (51 mg, 0.054 mmol; 13%) as a 
colourless oil; Rf 0.75 (70:30, petrol—EtOAc);     
     −16.5 (c. 2.2, CH2Cl2); δH (500 
MHz; CDCl3) 8.23 (1H, s, NH), 7.28-7.23 (2H, m, Ar), 7.22-7.14 (3H, m, Ar), 7.11-7.07 
(1H, m, Ar), 6.85-6.82 (1H, m, Ar), 6.74 (1H, d, J 8.2, Ar), 5.72 (1H, dt, J 11 and 5.9, 
15-H), 5.51 (1H, dt, J 11 and 7.5, 16-H), 5.21 (1H, d, J 10.8, 6-HA), 4.78 (1H, d, J 10.8, 
6-HB), 4.57 (1H, dd, J 13.3 and 5.1, 14-HA), 4.47 (1H, dd, J 13.3 and 5.3, 14-HB), 4.35 
(1H, d, J 13.4, 2-HA), 4.23 (1H, dd, J 13.4 and 6.2, 2-HB), 3.73 (1H, d, J 11.2, 19-HA), 
3.64-3.58 (2H, m, 19-H and SiOCHA), 3.25 (1H, ap t, J 6.9, SiOCHB), 2.73-2.67 (1H, m, 
18-H), 2.49-2.38 (2H, m, 17-HAB), 2.05-1.91 (2H, m, C8F17CH2CH2), 0.91 (14H, s, 
Si(CH(CH3)2)2), 0.76-0.72 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 157.6 (4-C), 
157.0 (12-C), 138.9 (Ar), 137.6 (Ar), 132.9 , 132.5, 131.1, 130.7, 130.3, 128.6 (16-C), 
125.8 (15-C), 125.6, 120.9, 112.8 (11-C), 65.2 (14-C), 64.3 (6-C), 63.7 (SiOCH2), 59.9 
(18-C), 50.4 (2-C), 46.1 (20-C), 30.2 (17-C), 25.7 (t, J 25, C8F17CH2CH2), 17.9 
(SiCH(CH3)2), 17.8 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.01 (C8F17CH2CH2); νmax/cm
-1 
(film): 2947, 2868, 1713, 1495, 1457, 1275 and 1260; m/z (ES+) 943.3 (100%, [M+H]+); 
found 943.3005, C38H43F17N2O4Si requires MH 943.2793 
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(10E,6S,13R)-6-(2,4-Dimethoxyphenyl)-13-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-2,3,5,6,7,9,12,13,14,15-
decahydro-1H-4,8,2,14-benzodioxadiazacycloheptadecin-3-one 245D 
  
Following general procedure RCM2, HG-II (6.5 mg, 2 mol%), 1,4-benzoquinone (2.5 
mg, 4 mol%) and sulfonamide 235 (750 mg, 0.52 mmol) were stirred in MTBE (260 mL) 
at 55 ˚C for 24 h. After the workup procedure the crude product was concentrated in 
vacuo. Following general procedure N1, thiophenol (297 mg, 2.7 mmol), crude product 
(400 mg) and potassium carbonate (94 mg, 0.68 mmol) gave the amine crude product 
after 16 h. The crude product was purified by F-SPE and column chromatography, 
eluting with 80:20 petrol—EtOAc to give the amine 245D (180 mg, 0.17 mmol, 33%; 
>60<40 E/Z) as a pale yellow oil; Rf 0.50 (80:20, petrol—EtOAc);     
     9.5 (c. 1.2, 
CH2Cl2); δH (500 MHz; C6D6) 7.21 (1H, dd, J 7.5 and 1.5, Ar), 7.16-6.96 (4H, m, Ar), 
6.35 (1H, ap t, J 2.6, DMB 3-H), 6.32 (1H, dt, J 8.4 and 2.6, DMB 5-H), 6.06 (1H, dt, J 
15.9 and 5.9, 10-HE), 5.63 (1H, ddd, J 11, 7,2 and 5.5, 10-HZ), 5.49-5.42 (2H, m, 11-
HZE), 4.74-4.64 (2H, m, ), 4.55-4.36 (6H, m, 15-HAB, 5-HAB and 1-HAB), 4.09 (1H, dd, J 
12.4 and 7.4, 5 or 7HE), 3.94-3.52 (7H, m, 7-HAB, 6-H, SiOCHAB and 9-HAB), 3.39 (3H, s, 
OMeE or Z), 3.38 (3H, s, OMeE or Z), 3.27 (3H, s, OMeE or Z), 3.26 (3H, s, OMeE or Z), 2.76 
(1H, qd, J 5.9 and 3.5, 13-HE), 2.70 (1H, m, 13-HZ), 2.60-2.53 (1H, m, 12-HZ), 2.38-2.31 
(1H, m, 12-HZ), 2.26-2.16 (3H, m, C8F17CH2CH2 and 12-HA
E), 2.14-2.06 (1H, m, 12-
HB
E), 0.98-0.93 (16H, m, Si(CH(CH3)2)2 and C8F17CH2CH2); δC (75 MHz; CDCl3) 160.3 
(DMB 2 or 4-C), 158.4 (DMB 2 or 4-C), 156.4 (C=O), 130.2, 129.4, 129.2, 121.4 (DMB 
1-C), 105.0 (DMB 5-C), 99.4 (DMB 3-C), 99.3 (DMB 3-C), 72.2 (7-C), 66.6 (9-C), 66.4 
(SiOCH2), 65.3 , 60.0 (13-C), 54.9 (OMe), 54.8 (OMe), 54.7 (OMe), 50.8 (1-C), 44.3 (5-
C), 38.4 (15-CZ), 38.1 (15-C) , 34.6 (12-C), 29.9 (6-C), 26.2 (t, J 25, C8F17CH2CH2), 
17.4 (SiCH(CH3)2), 17.3 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), -0.4 (C8F17CH2CH2); νmax/cm
-
1 (film) 2946, 2869, 1718, 1508, 1465, 1243, 1208; m/z (ES+) 1031.3 (100%, [M+H]+); 
found 1031.3294, C42H51F17N2O6Si  requires MH 1031.3318  
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(8E,4R,5R,11R)-5-[(Tert-butyldimethylsilyl)oxy]-11-
({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-4-methyl-2-(trifluoromethane)sulfonyl-2,3,4,5,6,7,10,11,12,13-
decahydro-1H-2,12-benzodiazacyclopentadecine 247D 
 
Following general procedure RCM1, HG-II (4 mg, 2 mol%), 1,4-benzoquinone (1.38 
mg, 4 mol%) and sulfonamide 236 (430 mg, 0.32 mmol) were stirred in MTBE (160 mL) 
at 55 ˚C for 24 h. After the workup procedure the crude product was concentrated in 
vacuo, column chromatography eluting with 90:10 petrol−EtOAc gave the sulfonamide 
as a complex mixture which was used directly in the next step. Following general 
procedure N1, thiophenol (330 mg, 3.0 mmol), sulfonamide 247 (399 mg, 0.3 mmol) 
and potassium carbonate (126 mg, 0.9 mmol) gave the crude product after 16 h. The 
crude product was purified by F-SPE, to give the amine 247D (300 mg, 0.27 mmol, 
84%; >99% purity as estimated using 500 MHz 1H NMR spectroscopy, <32/>68 E/Z) as 
a pale yellow oil; Rf 0.53 (80:20, petrol—EtOAc);     
     −4.3 (c. 1.1, CH2Cl2);δH (500 
MHz; CDCl3) 7.41-7.21 (4H, m, Ar), 5.44 (1H, dt, J 14.9 and 7.4, 8-H
E), 5.38-5.27 (3H, 
m, 8-HZ, 9-HE and Z), 5.15-4.57 (2H, m, 1-HAB), 3.93 (0.5H, d , J 12.8, 13-HA
Z), 3.87 
(0.5H, d , J 12.5, 13-HA
E), 3.79 (0.5H, d, J 12.8, 13-HB
Z), 3.78-3.68 (2H, m, SiOCH2), 
3.66 (0.5H, d, J 12.5, 13-HB
E), 3.64-3.20 (2H, 3-HAB), 3.06 (1H, dd, J 14.3 and 3.8, 5-
H), 2.78-2.68 (1H, m, 11-H), 2.32-1.98 (5H, m, C8F17CH2CH2 and 10-HA and 7-HAB), 
1.95-1.85 (1H, m, 10-HB), 1.80-1.35 (3H, m, 6-HAB and 4-H), 1.09 (14H, s, Si(CH(CH3)2-
)2), 0.95-0.89 (2H, C8F17CH2CH2), 0.88-0.8 (12H, SiC(CH3)3 and Me), 0.00 (3H, SiCH3), 
-0.06 (3H, SiCH3); δC (75 MHz; CDCl3) 138.4, 138.1, 134.0, 133.9, 133.7, 133.4, 132.0, 
131.8, 131.6, 130.2, 130.0, 128.1, 128.0, 127.9, 127.7, 126.7, 124.7, 120.2 q J 325, 
73.7, 71.8, 65.7, 65.1, 60.8, 59.6, 59.1, 52.8, 50.6, 49.9, 48.7, 47.5, 39.0, 35.9, 34.8, 
34.3, 33.9, 33.8, 33.5, 32.8, 30.9, 29.9, 29.3, 29.2, 25.9, 25.7, 25.4, νmax/cm
-1 (film) 
2950, 2867, 1734, 1547, 1463, 1389; m/z (ES+) 1125.4 (100%, [M+H]+); found 
1125.3605, C42H60F20N2O4SSi2  requires MH 1125.3566 
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(3R,5E)-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-2-[(2-nitrobenzene)sulfonyl]-9-(trifluoromethane)sulfonyl-
1,2,3,4,7,8,9,10-octahydro-2,9-benzodiazacyclododecine 246 
 
Following general procedure RCM2, HG-II (30 mg, 5 mol%), 1,4-benzoquinone (11 mg, 
10 mol%) and sulfonamide 209 (1.1 g, 0.95 mmol) were stirred in MTBE (477 mL) at 55 
˚C for 6 h. After the workup procedure the crude product was concentrated in vacuo; 
column chromatography, eluting with 70:30 petrol−EtOAc gave the macrocycle 246 
(805 mg, 0.72 mmol, 76%) as a colourless oil; Rf 0.61 (70:30, petrol—EtOAc);     
     
6.5 (c. 0.9, CH2Cl2); δH (500 MHz; CDCl3) 8.06 (1H, d, J 7.7, nosyl 3-H), 7.67-7.55 (3H, 
m, nosyl 4,5 and 6-H and Ar), 7.32 (1H, t, J 7.5, Ar), 7.21 (1H, br s, Ar), 7.09 (1H, br s, 
Ar), 7.46 (1H, br s, Ar), 5.47 (2H, br s, 5 and 6-H), 4.83 (1H, d, J 14, 1-H or 10-H), 4.73 
(3H, br s, 1-H or 10-H), 4.17 (1H, br s, SiOCHA), 3.84 (1H, br s, 3-H), 3.52 (1H, br s, 
SiOCHA), 3.33-3.02 (2H, m, 8-HAB) 2.52 (1H, br s, 7-HA), 2.39-2.27 (1H, br s, 4-HA), 
2.17 (1H, br s, 7-HB), 2.02-1.88 (2H, m, C8F17CH2CH2), 1.81 (1H, br s, 4-HB), 0.86 
(14H, s, Si(CH(CH3)2)2), 0.66-0.61 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) broad 
peaks 148.5 (nosyl 2-C), 134.8 (nosyl 1-C), 134.4 (6-C), 134.2 (nosyl 4-C), 132.3 
(nosyl 3-C), 131.9, 130.0 (5-C), 128.8, 127.6, 124.8, 123.2, 121.0 (q, J 325, CF3), 
118.9, 115.7; 60.4 (3-C), 53.5 (2-C), 49.9 (10-C), 47.5 (8-C), 33.8 (4-C), 32.2 (7-C); 
25.7 (t, J 25, C8F17CH2CH2), 17.9 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.01 
(C8F17CH2CH2); νmax/cm
-1 (film) 2949, 1546, 1388, 1145; m/z (ES+) 1141.2 (100%, 
[M+NH4]
+); found 1141.2204, C38H41F20N3O7S2Si  requires MNH4 1141.2174 
(5E,8R)-8-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}methyl)-2-(trifluoromethane)sulfonyl-1,2,3,4,7,8,9,10-octahydro-2,9-
benzodiazacyclododecine 246D 
 
Following general procedure N1; thiophenol (616 mg, 5.6 mmol), sulfonamide 246 (630 
mg, 0.56 mmol) and potassium carbonate (232 mg, 1.68 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 246D (430 mg, 
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0.20 mmol, 82%, >89% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.84 (80:20, petrol—EtOAc); δH (500 MHz; MeOD) 7.34-7.25 (4H, m, 
Ar), 5.31 (1H, ddd, J 15.7, 8.8 and 4.4, 6-H), 5.24 (1H, dd, J 15.7 and 6.4, 5-H), 5.10 
(1H, d, J 16, 1-HA), 4.85 (1H, d, J 16, 1-HB), 4.10 (1H, d, J 13.7, 10-HA), 3.75 (1H, dd, J 
9.7 and 6.0, SiOCHA); 3.73 (1H, d, J 13.7, 10-HB), 3.67 (1H, dd, J 9.7 and 5.8, 
SiOCHB), 3.66-3.62 (1H, m, 3-HA), 3.49-3.42 (1H, m, 3-HB), 2.68 (1H, dtd, J 10.4, 5.9 
and 2.6, 8-H), 2.33-2.20 (5H, m, 7-HA, 4-HAB and C8F17CH2CH2), 1.76 (1H, ddd, J 13.7, 
10.5 and 8.8, 7-HB), 1.13-1.10 (14H, m, Si(CH(CH3)2)2), 0.97-0.92 (2H, m, 
C8F17CH2CH2); δC (75 MHz; CDCl3) 139.1 (5-C), 133.2 (6-C), 130.9, 130.5, 128.4, 
127.8, 127.7, 119.5, 67.1 (SiOCH2), 58.4 (8-C), 50.2 (1-C), 49.7 (10-C), 35.3 (7-C), 
32.7 (4-C), 25.9 (t, J 25, C8F17CH2CH2), 16.9 (SiCH(CH3)2), 16.99 (SiCH(CH3)2), 12.7 
(SiCH(CH3)2), 0.01 (C8F17CH2CH2); νmax/cm
-1 (film) 3005, 2948, 2868, 1547, 1463, 
1387; m/z (ES+) 939.2 (100%, [M+H]+); found 939.2137, C32H38F20N2O3SSi requires 
MNH4 939.2126 
(15E,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one E-115D 
 
Following general procedure RCM1, HG-II (5.5 mg, 2 mol%) and sulfonamide 114 (600 
mg, 0.45 mmol) were stirred in MTBE (250 mL) at 55 ˚C for 24 h. After the workup 
procedure the crude product was concentrated in vacuo as a complex mixture of 
geometric isomers and starting material 114. Following general procedure N1, 
thiophenol (407 mg, 3.7 mmol), sulfonamide 115 (490 mg, 0.37 mmol) and potassium 
carbonate (128 mg, 0.93 mmol) gave the crude product after 16 h. The crude product 
was purified by F-SPE and column chromatography, eluting with 70:30 petrol—EtOAc 
to give the amine E-115D (107 mg, 0.114 mmol, 25%) as a pale yellow oil; Rf 0.31 
(70:30, petrol—EtOAc);     
     6 (c. 0.9, CH2Cl2); δH (500 MHz; CDCl3) 7.35-7.10 (4H, 
m, Ar), 7.10-6.99 (2H, m, Ar), 6.97-6.88 (2H, m, Ar), 5.95-5.86 (1H, m, 17-H), 5.61-5.54 
(1H, m, 16-H), 5.43 (1H, d, 6-HA), 4.99-4.91 (2H, m, 6-HB and 2-HA); 4.76-4.63 (1H, m, 
14-HA), 4.58-4.48 (2H, m, 14-HB and 2-HB), 4.28 (1H, dd, J 15.6 and 5.6, 20-HA), 3.83 
(1H, d, J 12.9, 20-HB), 3.78-3.71 (2H, m, SiOCHA), 3.61-3.57 (1H, m, SiOCHB), 2.80-
2.69 (1H, m, 18-H), 2.40-2.23 (2H, m, 17-HAB), 2.20-2.07 (2H, m, C8F17CH2CH2), 1.06 
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(14H, s, Si(CH(CH3)2)2), 0.91-0.84 (2H, C8F17CH2CH2); δC (75 MHz; CDCl3) 157.9 (12-
C), 157.1 (C=O) 139.7, 131.9, 131.1, 130.6, 130.2, 129.0, 128.5, 127.9, 127.2, 126.2, 
125.6, 120.9, 112.5, 68.4 (14-C), 66.0 (6-C), 64.9 (SiOCH2), 58.8 (18-C), 51.9 (1-C), 
44.7 (20-C), 30.6 (17-C), 25.6 (t, J 25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 
(SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 (film) 3109, 2868, 
2756, 1617, 1471 and 1345; m/z (ES+) 943.3 (100%, [M+H]+); found 943.2803, 
C38H43F17N2O4Si  requires MH 943.2793  
(15Z,18R)-18-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one Z-115D 
 
Also obtained was the geometric isomer Z-115D (66 mg, 0.07 mmol; 16%) as a 
colourless oil; Rf 0.85 (70:30, petrol—EtOAc);     
     1.8 (c. 2, CH2Cl2); δH (500 MHz; 
CDCl3) 7.35-7.30 (3H, m, Ar), 7.21 (1H, ap t, J 7.5, Ar), 7.10 (1H, d, J 7.7, Ar), 7.05 
(1H, d, J 7.6, Ar), 6.94 (1H, ap t, J 7.4, Ar), 6.88 (1H, d, J 8, Ar), 5.88 (1H, dt, J 14.5 
and 7, 16-H), 5.79 (1H, dt, J 14.5 and 4.7, 15-H), 5.18 (1H, d, J 10.4, 6-HA), 5.10 (2H, 
d, J 10.4, 6-HB and NH), 4.51 (2H, d, J 4.6, 14-HAB), 4.47 (1H, dd, J 15.6 and 6.7, 2-
HA), 4.36 (1H, dd, J 15.6 and 6 , 2-HB), 3.81 (2H, s, 20-HAB), 3.64 (1H, dd, J 9.8 and 
6.0, SiOCHA), 3.58 (1H, dd, J 9.8 and 5.7, SiOCHB), 2.77-2.71 (1H, m, 18-H), 2.35-2.21 
(2H, m, 17-HAB), 2.17-2.04 (2H, m, C8F17CH2CH2), 1.02 (14H, s, Si(CH(CH3)2)2), 0.87-
0.82 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 157.9 (12-C), 157.2 (C=O), 139.6, 
132.3, 130.8, 128.8, 127.9, 127.6, 126.3, 124.3, 120.9 (9-C), 112.1 (11-C), 68.4 (14-C), 
65.4 (SiOCH2), 64.5 (6-C), 57.3 (18-C), 51.3 (1-C), 44.6 (20-C), 34.5 (17-C), 25.6 (t, J 
25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.6 SiCH(CH3)2, 0.3 
(C8F17CH2CH2); νmax/cm
-1 (film) ; m/z (ES+) 943.3 (100%, [M+H]+); found 943.2820, 
C38H43F17N2O4Si  requires MH 943.2793 
  
147 
 
(6Z,9R)-9-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}methyl)-3-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(16),6,12,14-tetraene Z-249D 
 
Following general procedure RCM2, HG-II (10 mg, 2 mol%), 1,4-benzoquinone (3.6 
mg, 4 mol%) and sulfonamide 238 (998 mg, 0.86 mmol) were stirred in MTBE (400 mL) 
at 55 ˚C for 16 h. After the workup procedure the crude product was concentrated in 
vacuo and column chromatography gave the sulfonamide (460 mg) as a mixture of 
geometric isomers. Following general procedure N1, thiophenol (429 mg, 3.9 mmol), 
sulfonamide 249 (440 mg, 0.39 mmol) and potassium carbonate (162 mg, 1.17 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and  
column chromatography, eluting with 95:5 petrol—EtOAc to give the amine Z-249D 
(100 mg, 0.106 mmol, 12%) as a pale yellow oil; Rf 0.1 (90:10, petrol—EtOAc);     
     
14.1 (c. 1.2, CH2Cl2); δH (500 MHz; C6D6) Exists as atropisomers 7.53 (1H, s, Ar
major), 
7.34 (1H, s, Arminor), 6.99-6.86 (2H, m, Ar), 6.76-6.71 (1H, m, Ar), 4.71 (1H, dt, J 13.9 
and 6.5, 7-Hmajor), 4.59 (1H, dt, J 13.9 and 6.4, 6-Hmajor and 7-Hminor), 4.33 (1H, dt, J 
14.8 and 6.9, minor), 4.22 (1H, br s, 2-HA), 3.90 (1H, br s, 2-HB), 3.79 (1H, d, J 14.5, 11-
Hmajor), 3.68 (1H, d, J 14.5, 11-Hminor), 3.50 (1H, dd, J 9.7 and 5.7, SiOCHA
major), 3.37 
(1H, dd, J 9.7 and 6.2, SiOCHB
major), 3.34 (1H, d, J 14.5, 11-Hmajor), 3.28 (1H, dd, J 10.4 
and 4.8, SiOCHA
minor), 3.21 (1H, br s, 4-HA), 3.15 (1H, d, J 14.5, 11-H
minor), 3.10 (1H, 
dd, J 10.4 and 6.1, SiOCHB
minor), 2.85 (1H, br s, 4-HB), 2.45-2.38 (1H, m, 9-H
minor); 2.33-
2.14 (2H, m, 9-Hmajor and C8F17CH2CH2), 2.02-1.95 (1H, m, 8-HA), 1.95-1.87 (1H, m, 5-
HA), 1.87-1.79 (1H, m, 5-HA), 1.78-1.63 (1H, m, 5-HB), 1.61-1.46 (1H, m, 8-HB and 5-
HB), 1.02-0.81 (14H, m, Si(CH(CH3)2)2); δC (126 MHz; C6D6) 142.8,  135.8, 135.6, 
131.6,  131.1, 130.9, 130.7,  128.3; 127.7, 127.6, 126.3,  122.5,  119.9, 105.2, 92.2, 
92.1, 67.5, 65.4, 59.9, 59.5, 54.5, 52.6, 52.5, 50.7, 50.6, 38.5, 35.8, 35.7, 32.6, 32.5,  
31.4, 25.9; 17.4, 12.6,  12.4, 0.3; νmax/cm
-1 (film) 2945, 2869, 1463, 1391, 1226, 1147; 
m/z (ES+) 939.2 (100%, [M+H]+); found 939.2103, C32H38F20N2O3SSi  requires MH 
939.2126 
Full 13C assignment was not possible due to atropisomers 
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(6E,9R)-9-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-
2-yl)silyl]oxy}methyl)-3-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(16),6,12,14-tetraene E-249D 
 
Also obtained was the geometric isomer E-249D (173 mg, 0.184 mmol; 21%) as a 
colourless oil; Rf 0.25 (90:10, petrol—EtOAc);     
     3.2 (c. 1.1, CH2Cl2); δH (500 MHz; 
C6D6; 343 K) 7.14-7.09 (1H, m, Ar), 7.06-6.99 (3H, m, Ar), 5.24 (1H, ddd, J 17.3, 9.3 
and 6.7, 7-H), 5.06 (1H, ddd, J 17.3, 10.8 and 8.6, 6-H), 4.16 (2H, br s, 2-H), 3.86 (1H, 
d , J 14.1, 11-HA), 3.54 (1H, d, J 14.1, 11-HB), 3.53 (1H, dd , J 9.7 and 4.4, SiOCHA), 
3.43 (1H, dd, J 9.7 and 6.3, SiOCHB), 3.22 (1H, br s, 4-HA), 2.59 (1H, br s, 4-HB), 2.32-
2.19 (3H, m, C8F17CH2CH2 and 9-H), 1.84-1.72 (2H, m, 8-HA and 5-HA), 1.66-1.56 (1H, 
m, 5-HB), 1.56-1.44 (1H, m, 8-HB), 0.97-0.84 (16H, m, C8F17CH2CH2 and Si(CH(CH3)2-
)2); δC (126 MHz; C6D6; 343 K) 134.8 (7-C), 130.2, 129.7 (6-C), 128.9, 128.4, 126.8, 
65.7 (SiOCH2), 59.7 (9-C), 53.8 (2-C), 52.7 (4-C), 48.9 (11-C), 38.5 (5-C), 31.4 (8-C), 
29.8 (7-C), 27.4, 26.0 (t, J 24.4, C8F17CH2CH2), 17.4 (SiCH(CH3)2), 17.3 (SiCH(CH3)2), 
12.6 (SiCH(CH3)2), 0.4 (C8F17CH2CH2); νmax/cm
-1 (film) 2949, 2868, 1462, 1388, 1275, 
1260, 760; m/z (ES+) 939.2 (100%, [M+H]+); found 939.2121, C32H38F20N2O3SSi  
requires MH 939.2126 
(11E)-7-(2,4-Dimethoxyphenyl)-14-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-3,15-bis[(2-
nitrobenzene)sulfonyl]-5,9-dioxa-3,15-diazabicyclo[15.3.1]henicosa-
1(20),11,17(21),18-tetraen-4-one 248 
 
Following general procedure RCM2, HG-II (0.8 mg, 2 mol%), 1,4-benzoquinone (1.6 
mg, 4 mol%) and sulfonamide 237 (540 mg, 0.37 mmol) were stirred in MTBE (185 mL) 
at 55 ˚C for 24 h. After the workup procedure the crude product was concentrated in 
vacuo; column chromatography, eluting with 70:30 petrol—EtOAc gave the macrocycle 
248 (295 mg, 0.21 mmol, 56%; 60/40 E/Z) as a colourless oil; Rf 0.17 (70:30, petrol—
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EtOAc);     
     22.8 (c. 0.9, CH2Cl2); δH (500 MHz; C6D6; 343 K) 8.19 (0.5H, dd, J 8.0 
and 1.4, nosyl 3-HZ), 8.11 (0.5H, dd, J 8.0 and 1.4, nosyl 3-HE), 7.7-6.60 (11H, m, 2 × 
nosyl 4-H, 5-H and 6-H, and Ar), 6.39-6.21 (3H, m, DMB 3-, 5- and 6-H), 5.68 (1H, dt, J 
14.6 and 7.0, 12-HE), 5.55-5.46 (1H, m, 11-HE, 12-HZ and 11-HZ), 5.10-4.96 (2H, m, 16-
HAB), 4.75-4.57 (2H, m, 2-HAB), 4.55-4.45 (1H, 6-HA), 4.37-4.24 (2H, 14-H and 6-HB), 
3.90-3.75 (3H, 10-H2 and 7-H), 3.60-3.39 (4H, SiOCH2 and 8-HAB), 3.36 (3H, OMe), 
3.19 (3H, OMe), 2.71-2.38 (2H, 13-HAB), 2.35-2.22 (2H, C8F17CH2CH2), 1.07-0.78 (16H, 
Si(CH(CH3)2)2 and C8F17CH2CH2); δC (125 MHz; C6D6; 343 K) 160.1, 160.0, 157.9, 
157.8, 151.5, 151.5, 148.0, 147.8, 137.9, 137.5, 137.2, 134.4, 134.1, 134.0, 133.3, 
133.2, 132.8, 132.7, 132.3, 132.3, 130.5, 130.4, 128.8, 128.7, 128.4, 128.1, 123.5, 
123.4, 119.8 (DMB 1-C), 119.4 (DMB 1-C), 104.5 (DMB 5-C), 104.4 (DMB 5-C), 98.8 
(DMB 3-C), 70.9 (10-C), 69.4 (10-C), 69.1 (8-C), 67.8 (8-C), 67.0 (6-C), 66.4 (6-C), 
64.6 (SiOCH2), 64.3 (SiOCH2), 60.1 (13-C), 59.9 (13-C), 54.4 (2 × OMe), 50.8 (2-C), 
50.7 (2-C), 49.8 (16-C), 48.7 (16-C), 37.9 (7-C), 37.6 (7-C), 33.7 (13-C), 29.6 (13-C), 
25.6 (C8F17CH2CH2), 17.1 (SiCH(CH3)2), 12.1 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); 
νmax/cm
-1 (film) 3006, 2990, 2318, 1737, 1588, 1545, 1463, 1370; m/z (ES+) 1418.3 
(100%, [M+NH4]
+); found 1418.3110, C54H53F17N4O14S2Si  requires MNH4 1418.3149 
(7S,11E,14R)-7-(2,4-Dimethoxyphenyl)-14-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-5,9-dioxa-3,15-
diazabicyclo[15.3.1]henicosa-1(21),11,17,19-tetraen-4-one 248 
 
Following general procedure N1; thiophenol (231 mg, 2.1 mmol), sulfonamide 255 (298 
mg, 0.212 mmol) and potassium carbonate (58 mg, 0.42 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 248 (198 mg, 
0.19 mmol, 91%, >95% purity as estimated using 500 MHz 1H NMR spectroscopy; 
60/40 E/Z) as a pale yellow foam; Rf 0.37 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 
7.60-5.56 (1H, s, Ar), 7.35-7.14 (3H, m, Ar), 6.90-6.83 (1H, m, Ar), 6.48-6.43 (2H, m, 
Ar), 5.86-5.77 (1H, m, 12-HZ and 11-HE), 5.69 (0.5H, dt, J 15.6 and 4.7, 11-HZ), 5.53 
(0.5H, dd, J 17.5 and 8.3, 12-HE); 4.80-3.73 (11H, m, 2-HAB, 6-HAB, 8-HAB, 10-HAB and 
16-HAB), 3.7-3.64 (1H, m, SiOCHA), 3.64-3.57 (1H, m, SiOCHB), 3.48 (3H, s, OMe), 
3.47 (3H, s, OMe), 2.83-2.73 (1H, m, 14-H), 2.4-2.15 (4H, 13-HAB, C8F17CH2CH2), 1.06-
0.93 (16H, m, C8F17CH2CH2 and Si(CH(CH3)2)2); δC (75 MHz; CDCl3) 160.6, 158.8, 
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140.7, 140.5, 130.5 (11 or 12-C), 130.4 (11 or 12-C), 129.8 (11 or 12-C), 129.7 (11 or 
12-C), 127.5, 127.1, 127.0, 126.7, 121.8, 121.6, 105.3, 105.2, 99.6 (DMB 3-C), 71.9 
(10-C), 67.5 (8-C), 66.5 (6-C), 65.6 (SiOCH2), 59.1 (14-C
E), 58.5 (14-C), 55.2 (OMe), 
55.1 (OMe), 52.1 , 52.0 , 45.1 (16-C), 38.9 (7-C), 34.9 (13-C), 26.3 (t, J 24.8, 
C8F17CH2CH2), 17.6 (SiCH(CH3)2), 17.6 (SiCH(CH3)2), 12.8 (SiCH(CH3)2), 0.7 
(C8F17CH2CH2); νmax/cm
-1 (film) 3331, 2943, 2868, 1712, 1614, 1546, 1464; m/z (ES+) 
1031.3 (100%, [M+H]+); found 1031.3302, C42H51F17N2O6Si  requires MH 1031.3318 
Full 13C assignment was not possible due to a mixture of stereoisomers 
(4R,6E,10R,11R)-10-[(Tert-butyldimethylsilyl)oxy]-4-
({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-11-methyl-3-[(2-nitrobenzene)sulfonyl]-13-
(trifluoromethane)sulfonyl-3,13-diazabicyclo[13.3.1]nonadeca-1(19),6,15,17-
tetraene 250 
 
Following general procedure RCM2, HG-II (7.5 mg, 2 mol%), 1,4-benzoquinone (2.7 
mg, 4 mol%) and sulfonamide 239 (860 mg, 0.64 mmol) were stirred in MTBE (320 mL) 
at 55 ˚C for 4 h. After the workup procedure the crude product was concentrated in 
vacuo; column chromatography, eluting with 90:10 petrol—EtOAc gave the macrocycle 
250 (650 mg, 0.50 mmol, 78%, <12/>88 E/Z) as a colourless oil; Rf 0.24 (90:10, 
petrol—EtOAc);     
     16 (c. 0.5, CH2Cl2); δH (500 MHz; C6D6; 343 K) 7.77 (1H, dd, J 
7.9 and 1.4, nosyl 3-H), 7.68 (dd, J 8.1 and 1.4, nosyl 3-HE), 7.37 (1H, d , J 7.9, Ar), 
7.20-7.09 (1H, m, Ar), 6.99 (1H, d , J 7.7, Ar), 6.93 (1H, dd, J 7.9 and 1.3, Ar), 6.87 (dd, 
J 7.8 and 1.4, ArE), 6.81 (1H, td, J 7.7 and 1.4, Ns), 6.78 (1H, m, ArE), 6.74 (1H, td, J 
7.4 and 1.4, Ns), 5.33 (1H, td, J 10.1 and 5.2, 6-H), 5.20 (1H, td, J 10.1 and 5.7, 7-H), 
5.17-5.15 (m, 7-HE), 5.00 (1H, d, J 16.3, 1-H), 4.45 (1H, br s, 14-H), 4.35 (1H, d, J 16.4, 
1-H), 4.20 (1H, ddt, J 11.4, 8.2 and 4.2, 4-H), 3.82 (1H, br s, 14-H), 3.77-3.60 (3H, 
SiOCHAB and 11-H), 3.27-3.22 (1H, m, 10-H), 2.84 (1H, d, J 14.1, 12-H), 2.28-2.08 (3H, 
m, 5-H and C8F17CH2CH2), 1.97 (1H, m, J 14.5 and 10.0, 5-H), 1.61-1.50 (1H, m, 11-
H), 1.44-1.22 (4H, m, 8-H and 9-H), 0.98-0.80 (28H, SiC(CH3)3, Si(CH(CH3)2)2, 
C8F17CH2CH2 and Me); δC (125 MHz; C6D6; 343 K) 148.3 (nosyl 2-C), 138.1 (nosyl 1-
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C), 134.2 (nosyl 4-C), 132.5 (nosyl 5-C), 131.5 (Ar), 131.0 (7-C), 130.7 (nosyl 6-C), 
130.5 (Ar), 126.4 (6-C), 123.7 (nosyl 3-C); 71.4 (10-C), 62.7 (CH2OSi), 60.1 (4-C), 53.8 
(12-C), 48.6 (2-C), 34.1 (8-C), 33.5 (5-C), 31.2 (9-C), 25.4 (SiC(CH3)3), 22.5 (11-H), 
17.7 (SiCH(CH3)2), 16.9 (SiCH(CH3)2), 12.0 (SiCH(CH3)2), 9.3 (Me), 0.00 
(C8F17CH2CH2), -4.5 (SiCH3), -5.3 (SiCH3); CF3 missing; νmax/cm
-1 (film) 2952, 2867, 
1547, 1463, 1440, 1388 and 1373; m/z (ES+) 1327.4 (100%, [M+NH4]
+); found 
1327.3558, C48H63F20N3O8S2Si2 requires MNH4 1327.3614 
(5R,6R,9E,12R)-6-[(Tert-butyldimethylsilyl)oxy]-12-
({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-5-methyl-3-(trifluoromethane)sulfonyl-3,13-
diazabicyclo[13.3.1]nonadeca-1(19),9,15,17-tetraene 250D 
 
Following general procedure N1; thiophenol (251 mg, 2.29 mmol), sulfonamide 250 
(600 mg, 0.46 mmol) and potassium carbonate (126 mg, 0.91 mmol) gave the crude 
product after 2 h. The crude product was purified by F-SPE to give the amine 250D 
(450 mg, 0.40 mmol, 87%, >93% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow foam; Rf: 0.81 (60:40, petrol—EtOAc); δH (500 MHZ; 
C6D6) 7.23-7.09 (4H, m, Ar), 5.52 (dt, J 15.6 and 6.8, 10-H
trans >7%), 5.38 (1H, dt, J 
11.1 and 8.4, 10-Hcis), 5.31 (1H, dt, J 11.1 and 6.1, 9-Hcis), 5.25 (dt, J 15.6 and 6.1, 9-
Htrans, >7%), 4.47 (1H, br s, 2-HA), 4.11 (1H, br s, 2-HB), 3.85 (1H, d , J 14, 14-HA), 
3.63-3.58 (3H, m, CHABOSi and 4-HA), 3.58 (1H, d , J 14, 14-HB), 3.36 (1H, br s, 6-H), 
3.02 (1H, br d, J 11.2, 4-HB), 2.62 (1H, ap p, J 5.9, 12-H), 2.35-2.15 (3H, m, 
C8F17CH2CH2 and 11-HA), 2.01 (1H, dt, J 13.9 and 6.8, 11-HB), 1.76-1.70 (2H, m, 8-
HAB), 1.59 (1H, br s, 5-H), 1.35-1.48 (2H, m, 7-HAB), 1.06 (14H, s, Si(CH(CH3)2)2), 0.9-
0.83 (9H, m, SiC(CH3)3), 0.79 (3H, d, J 6.8, Me), 0.08-0.11 (6H, m, 2 × SiCH3); δC (126 
MHz; C6D6) 135.3 (10-C), 132.1, 129.2, 128.5 (9-C), 127.2, 126.5, 72.9 (6-C), 65.9 
(SiOCH2), 59.3 (12-C), 53.7 (2-C), 53.2 (4-C), 51.6 (14-C), 34.9 (8-C), 34.7 (11-C), 30.2 
(5-C), 29.9 (7-C), 25.8 (t, J 25, C8F17CH2CH2), 23.1 (SiC(CH3)3), 19.9 (SiC(CH3)3), 18.1 
(SiCH(CH3)2), 12.6 (Me), -4.2 (SiCH3), -4.8 (SiCH3); νmax/cm
-1 (film) 3055, 2988, 2306, 
1603, 1550, 1422, 1388, 1264 and 1152; m/z (ES+) 1225.4 (100%, [M+H]+); found 
1125.3563, C42H60F20N2O4SSi2 requires MH 1125.3566 
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(13S,17E,20R)-13-(2,4-Dimethoxyphenyl)-20-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-11,15-dioxa-9,21-
diazatricyclo[21.4.0.02,7]heptacosa-1(27),2,4,6,17,23,25-heptaen-10-one 251D 
 
Following general procedure RCM1, HG-II (6.56 mg, 2 mol%), 1,4-benzoquinone (2.2 
mg, 4 mol%) and sulfonamide 240 (810 mg, 0.52 mmol) were stirred in MTBE (208 mL) 
at 55 ˚C for 5 h. After the workup procedure the crude product was concentrated in 
vacuo and column chromatography eluting with 80:20 → 70:30 petrol—EtOAc gave the 
sulfonamide (475 mg) as a complex mixture. Following general procedure N1, 
thiophenol (286 mg, 7.6 mmol), sulfonamide 251 (400 mg, 0.26 mmol) and potassium 
carbonate (91 mg, 0.66 mmol) gave the crude product after 16 h. The crude product 
was purified by column chromatography, eluting with 80:20 petrol—EtOAc to give the 
amine 251D (93 mg, 0.084 mmol, 16%) as a pale yellow oil; Rf 0.11 (80:20, petrol—
EtOAc);     
     3.2 (c. 1.1, CH2Cl2); δH (500 MHz; CDCl3) 7.42-7.38 (1H, m, BiPh), 7.37-
7.28 (4H, m, BiPh), 7.20-7.10 (3H, m, BiPh), 6.95 (1H, d , J 8.3, DMB 6-H), 6.52-6.41 
(1H, m, DMB 3-H), 6.40 (1H, dd, J 8.3 and 2.5, DMB 5-H), 5.67 (1H, dt, J 15.4 and 6.6, 
17-H), 5.58 (1H, dt, J 15.4 and 6.8, 18-H), 5.55-5.44 (m, 17 and 18-Hcis), 4.36 (1H, dd, 
J 13.7 and 3.7, 12-HA), 4.06 (1H, dd, J 13.7 and 4.4, 12-HB), 4.03-3.98 (1H, m, 16-HA), 
3.92 (1H, dd, J 13.8 and 5.3, 16-HB), 3.88-3.84 (2H, m, 14-HAB), 3.79 (3H, s, OMe), 
3.77 (3H, s, OMe), 3.68-3.52 (4H, m, 22-HAB and 8-HAB), 3.48-3.39 (1H, m, 13-H), 3.14 
(2H, br s, CHABOSi), 2.57 (1H, br s, 20-H), 2.38 (1H, br s, 19-HA), 2.20 (1H, brs, 19-HB), 
2.14-2.03 (2H, m, C8F17CH2CH2), 1.00 (14H, s, Si(CH(CH3)2)2), 0.88-0.83 (2H, m, 
C8F17CH2CH2); δC (75 MHz; CDCl3) 160.0 (DMB 4-C
trans), 159.9 (DMB 4-Ccis), 158.6 
(DMB 2-Ctrans), 158.5 (DMB 2-Ccis), 156.6 (CO), 141.2, 140.8, 136.8, 136.2, 131.4, 
130.6, 130.1, 130.0, 129.8, 129.7, 129.3, 129.2, 128.9, 128.2, 128.2, 128.1, 127.9, 
127.7, 127.4, 120.5, 120.2, 104.6, 104.5, 98.9, 98.8, 69.5 , 67.2 , 64.4, 64.3 , 59.3 (20-
C), 55.6 (OMe), 55.5 (OMe), 50.7, 45.0, 37.1, 33.1, 32.3, 30.0, 29.9, 29.7, 25.7 (t, J 25, 
C8F17CH2CH2) 24.2, 23.0, 17.8 (SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 
12.5 (SiCH(CH3)2), 0.00 (C8F17CH2CH2); νmax/cm
-1 (film) 3005, 2946, 2868, 1712, 1614, 
1587, 1543, 1508, 1465, 1274 and 1260; m/z (ES+) 1107.4 (100%, [M+H]+); found 
1107.3655, C48H56F17N2O6Si  requires MH 1107.3631  
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Full 13C assignment was not possible due to a mix of rotamers and geometric isomers 
(12Z)-10-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}methyl)-9-[(2-nitrobenzene)sulfonyl]-16-(trifluoromethane)sulfonyl-
9,16-diazatricyclo[16.4.0.02,7]docosa-1(18),2,4,6,12,19,21-heptaene 252D 
 
Following general procedure RCM2, HG-II (6.0 mg, 2 mol%), 1,4-benzoquinone (2.1 
mg, 4 mol%) and sulfonamide 241 (611 mg, 0.48 mmol) were stirred in MTBE (192 mL) 
at 55 ˚C for 4 h. After the workup procedure the crude product was concentrated in 
vacuo; column chromatography, eluting with 90:10→80:20 petrol−EtOAc gave the 
macrocycle 252D (220 mg, 0.18 mmol, 38%) as a colourless oil; Rf 0.11 (80:20, petrol—
EtOAc);     
     6.9 (c. 1, CH2Cl2); δH (500 MHz; DMSO-d6; 343 K) 8.03 (1H, dd, J 7.9 
and 1.3, nosyl 3-H), 7.94 (1H, d , J 8.4, nosyl 6-H), 7.92-7.85 (2H, m, nosyl 5-H), 7.82-
7.79 (1H, m, Ar), 7.58-7.52 (2H, m, nosyl 4-H and Ar), 7.46-7.40 (2H, m, Ar), 7.36 (1H, 
td, J 7.5 and 1.4, Ar), 7.29 (1H, dd, J 7.7 and 1.4, Ar), 7.27-7.25 (1H, m, Ar), 5.34 (1H, 
dd, J 10.3 and 5.1, 12-H), 5.32-5.25 (1H, m, 13-H), 5.11 (1H, d, J 16.7, 8-HA), 4.91 (1H, 
d, J 16.5, 17-HA), 4.21 (1H, d, J 16.7, 8-HB), 4.10 (1H, d, J 16.5, 17-HB), 4.02-3.95 (1H, 
m, 10-H), 3.25 (1H, dd, J 10.4 and 6.0, CHAOSi), 3.18 (1H, dd, J 10.4 and 7.6, 
CHBOSi), 3.18-3.13 (1H, m, 15-HA), 3.05-2.98 (1H, m, 15-HB), 2.22-2.06 (2H, m, 
C8F17CH2CH2), 2.06-1.89 (2H, m, 14-HAB), 1.79-1.64 (2H, m, 11-HAB), 0.96 (14H, s, 
Si(CH(CH3)2)2), 0.77-0.72 (2H, m, C8F17CH2CH2); δC (125 MHz; DMSO-d6; 343 K) 
147.2 (nosyl 2-C), 137.2 (nosyl 1-C), 136.2 (nosyl 5-C), 134.3 (nosyl 4-C), 134.1, 
131.8, 131.7, 131.4, 131.3, 131.1, 130.6, 129.8 (nosyl 6-C), 129.2 (12-C), 128.5, 128.0, 
127.7, 127.2, 126.9, 126.5, 126.4 (13-C), 124.8 (nosyl 3-C), 123.9, 64.2 (CH2OSi), 58.1 
(10-C), 49.5 (8-C), 47.8 (15-C), 43.6 (17-C), 27.3 (14-C), 24.7 (C8F17CH2CH2), 16.5 
(SiCH(CH3)2), 11.3 (SiCH(CH3)2), -1.01 (C8F17CH2CH2); CF3 missing; νmax/cm
-1 (film) 
2926, 2870, 1547, 1390, 1202; m/z (ES+) 1222.2 (100%, [M+Na]+); found 1222.2096, 
C44H45F20N3O7S2Si requires MNa 1222.2041 
(12Z,15R)-15-({[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}methyl)-9-
(trifluoromethane)sulfonyl-9,16-diazatricyclo[16.4.0.02,7]docosa-
1(22),2,4,6,12,18,20-heptaene 252 
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Following general procedure N2; thiophenol (93 mg, 0.85 mmol), sulfonamide 252D 
(210 mg, 0.169 mmol) and potassium carbonate (46 mg, 0.34 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE to give the amine 252 
(123 mg, 0.12 mmol, 76%, >93% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.41 (90:10, petrol—EtOAc); δH (500 MHz; CDCl3; 
323 K) 7.71 (1H, d, J 7.8, Ar), 7.57 (1H, dd, J 7.7 and 1.2, Ar), 7.44 (1H, td, J 7.6 and 
1.4, Ar), 7.37 (1H, td, J 7.6 and 1.5, Ar), 7.33 (1H, td, J 7.5 and 1.3, Ar), 7.28 (1H, td, J 
7.5 and 1.3, Ar), 7.15 (1H, dd, J 7.7 and 1.3, Ar), 7.02 (1H, dd, J 7.5 and 1.3, Ar), 5.28 
(1H, dd, J 10.9 and 7.7, 13-H), 5.23 (1H, dd, J 10.9 and 6.3, 12-H), 4.75 (1H, d, J 16.1, 
8-HA), 4.05 (1H, d, J 16.1, 8-HB), 3.70 (1H, d, J 13.2, 17-HA), 3.62 (1H, d, J 13.2, 17-
HB), 3.59 (1H, dd, J 10.0 and 5.9, CHAOSi), 3.56 (1H, dd, J 10.0 and 7.4, CHBOSi), 
3.37 (1H, ddd, J 15.3, 11.6 and 4.9, 10-HA), 2.93 (1H, ddd, J 15.3, 10.9, and 6.2, 10-
HB), 2.65-2.61 (1H, m, 15-H), 2.20-1.99 (4H, m, C8F17CH2CH2 and 11-H), 1.98-1.86 
(2H, m, 14-H), 1.06 (14H, s, Si(CH(CH3)2)2); δC (125 MHz; CDCl3; 323 K) Exists as 
atropisomers 139.7, 138.4, 138.2, 133.4, 130.5, 130.1, 129.5, 129.2, 128.6, 128.2, 
128.0, 127.7 (12 or 13-C), 127.4 (12 or 13-C), 127.2, 126.6, 120.4 (q, J 325, CF3), 65.3 
(CH2OSi), 61.2 (15-C), 51.2 (8-C), 51.0 (10-C), 50.9 (17-C); 28.2 (11-C), 28.1 (14-C), 
25.6 (t, J 25, C8F17CH2CH2), 17.4 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 12.4 (SiCH(CH3)2), 
0.00 (C8F17CH2CH2); νmax/cm
-1 (film) 3058, 3009, 2946, 2868, 1461, 1441, 1387, 1274, 
1265 and 1227; m/z (ES+) 1015.2 (100%, [M+H]+); found 1015.2460, C38H42F20N2O3SSi  
requires MH 1015.2439 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[5-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)thiophen-2-yl]methyl}carbamate 275 
 
Following general procedure N1; thiophenol (68 mg, 0.62 mmol), sulfonamide 212 (90 
mg, 0.062 mmol) and potassium carbonate (20 mg, 0.15 mmol) gave the crude product 
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after 2 h. The crude product was purified by F-SPE to give the amine 275 (58 mg, 
0.054 mmol, 87%, >95% purity as estimated using 500 MHz 1H NMR spectroscopy) as 
a pale yellow foam; Rf 0.46 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 7.10 (1H, d, J 
8.4, DMB), 6.77-6.68 (2H, m, Thio 3 and 4-H), 6.44 (1H, s, DMB), 6.43 (1H, s, DMB), 
5.86 (1H, ddt, J 16.4, 10.9 and 5.4, propenyl 2-H), 5.76 (1H, ddt, J 17.5, 10.6, and 7.8, 
4-H), 5.22 (1H, dd , J 17.5 and 1.8, propenyl 3-HA), 5.13 (1H, dd , J 10.6 and 1.7, 
propenyl 3-HB), 5.07 (1H, d, J 16.4, 5-HA), 5.06 (1H, d, J 10.9, 5-HB), 4.46-4.31 (4H, m, 
PhCH2N(CO) and propyl 1-HAB), 3.98-3.92 (4H, m, propenyl 1-H2 and NHCH2Ph), 3.78 
(6H, s, 2 x OMe), 3.66-3.58 (5H, 1-H, propyl 3-HAB and 2-H), 2.75 (1H, p, J 5.9, 2-H), 
2.28-2.18 (2H, 3-HAB), 2.17-2.05 (2H, C8F17CH2CH2), 1.04 (14H, s, Si(CH(CH3)2)2), 
0.88-0.83 (2H, C8F17CH2CH2); δC (75 MHz; CDCl3) 159.8 (DMB 4-C), 158.5 (DMB 2-C), 
144.5 (Thio 2-C), 140.3 (Thio 5-C), 135.3 (propenyl 2-C), 135.1 (DMB 6-C), 129.1 (4-
C); 125.3 (DMB 1-C), 124.4 (Thio 4-C), 120.3 (Thio 3-C), 117.4 (propenyl 3-C), 116.6 
(5-C), 104.3 (DMB 5-C), 98.8 (DMB 3-C), 77.3 (propenyl 1-C), 72.0 (1-C), 70.6 (propyl 
3-C), 2 × 65.3 (NHCH2Ph and PhCH2N(CO)), 57.9 (2-C), 55.5 (OMe), 55.4 (OMe), 46.4 
(propyl 1-C), 38.4 (propyl 2-C), 35.9 (3-C), 25.6 (t, J 25, C8F17CH2CH2), 17.6 
(SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.06 (C8F17CH2CH2); νmax/cm
-1 (film) 3325, 2914, 
2746, 1927, 1720, 1661, 1455, 1275; m/z (ES+) 1065.3 (100%, [M+H]+); found 
1065.3109, C42H53F17N2O6SSi  requires MH 1065.3122 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)thiophen-2-yl]methyl}carbamate 211D 
 
Following general procedure N1; thiophenol (286 mg, 2.6 mmol), sulfonamide 211 (350 
mg, 0.26 mmol) and potassium carbonate (90 mg, 0.52 mmol) gave the crude product 
after 4 h. The crude product was purified by F-SPE to give the amine 211D (220 mg, 
0.22 mmol, 86%, >95% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.37 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 7.34 (1H, dd, J 7.5 
and 1.8, Ar), 7.29-7.24 (1H, m, Ar), 6.94 (1H, td, J 7.5 and 1.8, Ar), 6.87 (1H, dd, J 8.4, 
Ar), 6.79-6.77 (1H, br s, Ar), 6.72 (1H, dd, J 3.3, Ar), 6.04 (1H, ddt, J 17.4, 10.4 and 5, 
propenyl 2-H), 5.77 (1H, ddt, J 17.3, 10.3 and 7.1, 4-H), 5.41 (1H, dd, J 17.3 and 1.7, 
propenyl 3-HA), 5.26 (1H, dd, J 10.4 and 1.7, propenyl 3-HB), 5.23 (2H, s, PhCH2O), 
5.08 (1H, d, J 10.3, 5-HA), 5.05-5.01 (2H, m, NH and 5-HB), 4.56 (2H, dt, J 5.1 and 1.7, 
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propenyl 1-H2), 4.49 (2H, d, J 5.8, PhCH2N(CO)), 3.95 (2H, d, J 4.4, NHCH2Thio), 3.63 
(1H, dd, J 9.9 and 5.1, 1-HA), 3.59 (1H, dd, J 9.9 and 5.9, 1-HB), 2.76 (1H, p, J 5.9, 2-
H), 2.27-2.18 (2H, m, 3-HAB), 2.17-2.05 (2H, m, C8F17CH2CH2); 1.04-1.00 (14H, m, 
Si(CH(CH3)2)2), 0.86-0.79 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 156.7 (phenyl 1-
C), 144.7, 144.6, 140.4, 135.4 (4-C), 133.4 (propenyl 2-C), 129.8, 129.6, 129.3, 125.6, 
125.3, 124.6, 120.9, 117.7 (5-C), 117.5 (propenyl 3-C), 111.9, 69.1 (propenyl 1-C), 
65.3 (1-C), 62.7 (PhCH2O), 57.9 (2-C), 46.5 (ThioCH2NCO), 40.5 (NHCH2Thio), 36.1 
(3-C), 25.7 (t, J 25, C8F17CH2CH2), 17.8 (SiCH(CH3)2), 17.7 (SiCH(CH3)2), 12.6 
(SiCH(CH3)2), 12.4 (SiCH(CH3)2); νmax/cm
-1 (film) 3326, 2945, 2159, 2029, 1719, 1494, 
1458; m/z (ES+) 977.3 (100%, [M+H]+); found 977.2703, C38H46F17N2O4SSi  requires 
MH 977.2671 
N-(But-3-en-1-yl)-1,1,1-trifluoro-N-{[2-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]methyl}methanesulfonamide 
209D 
 
Following general procedure N1; thiophenol (429 mg, 3.9 mmol), sulfonamide 209 (450 
mg, 0.39 mmol) and potassium carbonate (161 mg, 1.17 mmol) gave the crude product 
after 4 h. The crude product was purified by F-SPE to give the amine 209D (385 mg, 
0.39 mmol, 100%, >89% purity as estimated using 500 MHz 1H NMR spectroscopy) as 
a pale yellow oil; Rf: 0.79 (80:20, petrol—EtOAc); δH (300 MHz; CDCl3) 7.46-7.29 (4H, 
m, Ar), 5.84 (1H, ddt, J 17.4, 10.4 and 7.1, 4-H), 5.59 (1H, ddt, J 17.1, 10.3 and 6.8, 3-
H), 5.12 (1H, d, J 17.4, 5ʹ-HA), 5.11 (1H, d, J 10.4, 5ʹ-HB), 5.02 (1H, d, J 10.3, 4-HA), 
4.97 (1H, dd, J 17.1 and 1.7, 4-HB), 4.81 (2H, br s, PhCH2NTf), 3.90 (1H, d, J 12.5, 
NHCHAPh), 3.83 (1H, d, J 12.5, NHCHBPh), 3.71 (1H, dd, J 9.9 and 5.1, 1ʹ-HA), 3.64 
(1H, dd, J 9.9 and 5.7, 1ʹ-HB), 3.42 (2H, t, J 7.9, 1-H2), 2.79 (1H, ap p, J 5.8, 2ʹ-H), 
2.39-2.23 (2H, m, 3-HAB), 2.23-2.03 (4H, m, 2-H2 and C8F17CH2CH2), 1.08 (14H, s, 
Si(CH(CH3)2)2), 0.94-0.86 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 138.9, 135.6, 
133.8, 133.6, 130.1, 129.0, 128.7, 128.2, 120.5 (q, J 324.1, CF3), 117.9 (5ʹ-C), 115.5 
(4-C), 65.2 (1ʹ-C), 59.2 (2-C), 49.9 (NHCH2Ph), 49.7 (PhCH2NTf), 48.4 (1-C), 36.2 (3ʹ-
C), 33.2 (2-C), 25.7 (t, J 23.7, C8F17CH2CH2), 17.7 (SiCH(CH3)2), 12.6 (SiCH(CH3)2); 
νmax/cm
-1 (film) 2870, 1642, 1461, 1389, 1275 and 1261;m/z (ES+) 967.2 (100%, 
[M+H]+); found 967.2465, C34H42F20N2O3SSi requires MH 967.2439 
157 
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[2-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 234D 
 
Following general procedure N1; thiophenol (572 mg, 5.2 mmol), sulfonamide 234 (700 
mg, 0.52 mmol) and potassium carbonate (180 mg, 1.3 mmol) gave the crude product 
after 4 h. The crude product was purified by F-SPE to give the amine 234D (410 mg, 
0.42 mmol, 81%, >84% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.24 (60:40, petrol—EtOAc); δH (300 MHz; CDCl3) 7.71-7.20 (6H, m, 
Ar), 7.01-6.84 (2H, m, Ar), 6.05 (1H, ddt, J 17.1, 10.3 and 4.8, 4-H), 5.79 (1H, ddt, J 
17.7, 10.3 and 7.3, propenyl 2-H), 5.43 (1H, ddt, J 17.1 and 1.8, 4-HA), 5.31-5.21 (3H, 
m, PhCH2O and 4-HB), 5.07 (1H, d , J 17.7, propenyl 3-HA), 5.06 (1H, d , J 10.3, 
propenyl 3-HB), 4.57 (2H, d, J 4.7), 4.54-4.39 (2H, m, ), 3.89 (1H, d, J 11.7, NHCHAPh), 
3.80 (1H, d, J 11.7, NHCHBPh), 3.75 (1H, dd , J 10 and 4.7, 1-HA), 3.61 (1H, dd, J 10 
and 5.5, 1-HB), 2.81 (1H, ap p, J 5.6, 2-H), 2.35-2.25 (2H, m, 3-HAB), 2.23-2.02 (2H, m, 
C8F17CH2CH2), 1.04 (14H, s, Si(CH(CH3)2)2), 0.91-0.84 (2H, m, C8F17CH2CH2); δC (75 
MHz; CDCl3) 138.5, 133.6, 130.5, 129.4, 129.2, 128.3, 120.9, 118.0 (propenyl 3-C), 
117.4 (5-C), 111.9 (Ar 3-C), 69.1 (propenyl 1-C), 64.6 (1-C), 62.1 (PhOCH2), 59.2 (2-
C), 50.6 (PhCH2N(CO)), 44.4 (NHCH2Ph), 36.2 (3-C), 17.9 (SiCH(CH3)2), 17.8 
(SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.14 (C8F17CH2CH2), CO missing; νmax/cm
-1 (film) 
3054, 2987, 2305, 1713, 1455, 1275  and 1262; m/z (ES+) 971.3 (100%, [M+H]+); found 
971.3153, C40H48F17N2O4Si requires MH 971.3106 
  
158 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 235D 
 
Following general procedure N1; thiophenol (246 mg, 2.2 mmol), sulfonamide 235 (320 
mg, 0.22 mmol) and potassium carbonate (76 mg, 0.55 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 235D (123 mg, 
0.116 mmol, 57%, >82% purity as estimated using 500 MHz 1H NMR spectroscopy) as 
a pale yellow oil; Rf 0.49 (70:30, petrol—EtOAc); δH (300 MHZ; CDCl3) very broad 7.42-
7.00 (5H, m, Ar), 6.46-6.34 (2H, m, Ar), 5.91-5.68 (2H, m, 4-H and propenyl 2-H), 5.24-
5.01 (4H, m, 5-HABand propenyl 3-HAB), 4.42-4.23 (4H, m, PhCH2N(CO) and propyl 1-
HAB, 3.92 (2H, d, J 5.9, propenyl 1-H2), 3.83-3.67 (11H, 2 × OMe, 1-HA, propyl 2-H, 
propyl 3-HAB, NHCHAPh), 3.66-3.51 (2H, m, 1-HB and NHCHBPh), 2.74 (1H, p, J 5.8, 2-
H), 2.25-2.00 (4H, m, C8F17CH2CH2 and 3-HAB), 1.04 (14H, s, Si(CH(CH3)2)2), 0.9-0.83 
(2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 159.7, 158.6, 138.4, 135.3, 130.2, 129.2, 
128.3, 128.0, 120.5, 117.8, 116.7, 104.2, 98.8, 72.1 (propyl 3-C), 70.7 (propyl 1-C), 
64.5 (1-C), 59.2 (2-C), 55.5 (OMe), 55.4 (OMe), 50.5 (NHCH2Ph), 38.5 (propyl 2-C), 
36.2 (3-C), 17.7 (SiCH(CH3)2), 17.6 (SiCH(CH3)2), 12.5 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2), PhCH2N(CO) missing; νmax/cm
-1 (film) 2947, 2868, 1719, 1546, 1275, 
1260, 1153; m/z (ES+) 1059.4 (100%, [M+H]+); found 1059.3661, C44H56F17N2O6Si  
requires MH 1059.3631 
  
159 
 
N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl]-1,1,1-trifluoro-
N-{[2-({[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4-en-2-
yl]amino}methyl)phenyl]methyl}methanesulfonamide 236D 
 
Following general procedure N1; thiophenol (246 mg, 2.2 mmol), sulfonamide 236 (600 
mg, 0.45 mmol) and potassium carbonate (123 mg, 0.89 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 236D (250 mg, 
0.22 mmol, 48%, >88% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.33 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3) 7.41 (1H, d, J 7.6, 
Ar), 7.33 (1H, dt, J 7.5 and 4.3, Ar), 7.30-7.26 (2H, m, Ar), 5.82 (1H, ddt, J 17.3, 10.2 
and 7, 4ʹ-H), 5.68 (1H, ddt, J 16.9, 10.4 and 6.5, 6-H), 5.12 (2H, br s, PhCH2NTf), 5.10 
(1H, d, J 17.3, 5ʹ-HA), 5.09 (1H, d, J 10.2, 5ʹ-HB), 4.91 (1H, d, J 10.4, 7--HA), 4.90 (1H, 
d, J 16.9, 7-HB), 3.86 (1H, d, J 12.6, NHCHAPh), 3.81 (1H, d, J 12.6, NHCHBPh), 3.70-
3.63 (2H, m, 1ʹ-HAB), 3.44 (1H, br s, 1-HA), 3.37 (2H, br s, 1-HB and 3-H), 2.76 (1H, p, J 
5.9, 2-H), 2.31 (1H, dt, J 13.5 and 6.3, 3-HA), 2.22 (1H, dt, J 13.5 and 6.5, 3ʹ-HB), 2.20-
2.08 (2H, m, C8F17CH2CH2), 1.80-1.68 (2H, m, 5-HAB), 1.50-1.34 (3H, m, 4-HAB and 2-
H), 1.09-1.04 (14H, m, Si(CH(CH3)2)2), 0.93-0.86 (2H, C8F17CH2CH2); 0.81 (12H, 
SiC(CH3)3 and Me), 0.00 (3H, SiCH3), -0.08 (3H, SiCH3); δC (75 MHz; CDCl3) 138.35, 
138.24, 135.6, 133.9, 130.3, 130.0, 129.1, 128.7, 128.4, 128.1; 120.5 (q, J 325, CF3), 
117.6 (5ʹ-C), 114.9 (7-C), 73.3 (3-C), 65.2 (1ʹ-C), 59.1 (2ʹ-C), 53.9 (1-C), 50.0 
(NHCH2Ph), 36.2 (3ʹ-C), 35.9 (2-C), 33.5 (4-C), 30.0 (5-C), 26.0 (C8F17CH2CH2), 18.2 
(SiCH3), 17.7 (C8F17CH2CH2), 12.6 (SiCH(CH3)2), 11.0 (Me), 0.25 (C8F17CH2CH2), -3.9 
(SiCH3), -4.6 (SiCH3); νmax/cm
-1 (film) 2950, 2867, 1642, 1464, 1391, 1227; m/z (ES+) 
1153.4 (100%, [M+H]+); found 1153.3828, C44H64F20N2O4SSi2 requires MH 1153.3879 
 
  
160 
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 116 
 
Following general procedure N1; thiophenol (517 mg, 4.7 mmol), sulfonamide 114 (630 
mg, 0.47 mmol) and potassium carbonate (194 mg, 1.4 mmol) gave the crude product 
after 16 h. The crude product was purified by F-SPE to give the amine 116 (397 mg, 
0.41 mmol, 87%, >85% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.41 (50:50, petrol—EtOAc); δH (500 MHz; CDCl3) 7.40-7.15 (6H, m, 
Ar), 6.94 (1H, ap t, J 7.5, Ar), 6.87 (1H, d, J 8.5, Ar), 6.04 (1H, ddt, J 17, 10.2 and 5, 
propenyl 2-H), 5.78 (1H, ddt, J 16.3, 10.6 and 7.1, 4-H), 5.41 (1H, dd , J 17 and 1.7, 
propenyl 3-HA), 5.28-5.23 (3H, m, propenyl 3-HB and PhCH2O), 5.11-5.04 (2H, m, 5-
HAB), 4.57 (2H, d, J 4.8, propenyl 1-H2), 4.38 (2H, d, J 5.9, PhCH2N(CO)), 3.83 (1H, d, 
J 13.3, NHCHAPh), 3.77 (1H, d, J 13.3, NHCHAPh), 3.65-3.59 (2H, m, 1-HAB), 2.72 (1H, 
p, J 6, 2-H), 2.28-2.16 (2H, m, 3-HAB), 2.17-2.00 (2H, m, C8F17CH2CH2), 1.03 (14H, s, 
Si(CH(CH3)2)2), 0.89-0.82 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 156.6 (CO), 
141.3 (Ar), 138.9 (Ar), 135.5 (4-C), 133.4 (propenyl 2-C), 129.9, 129.6, 129.1, 127.5, 
127.4, 126.4, 125.4, 120.9, 117.6 (5-C), 117.4 (propenyl 3-C), 111.9, 69.1 (propenyl 1-
C), 65.4 (1-C), 62.6 (PhOCH2), 58.5 (2-C), 45.4 (PhCH2N(CO)), 36.1 (3-C), 25.7 
(C8F17CH2CH2), 17.8 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.27 (C8F17CH2CH2); νmax/cm
-1 
(film) 2945, 2869, 1710, 1456, 1242, 1207; m/z (ES+) 971.3 (100%, [M+H]+); found 
971.3098, C40H48F17N2O4Si  requires MH 970.3028 
 
  
161 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 237D 
 
Following general procedure N1; thiophenol (378 mg, 3.43 mmol), sulfonamide 237 
(491 mg, 0.34 mmol) and potassium carbonate (94 mg, 0.69 mmol) gave the crude 
product after 3 h. The crude product was purified by F-SPE to give the amine 237D 
(260 mg, 0.25 mmol, 72%, >89% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.52 (50:50, petrol—EtOAc); δH (500 MHz; CDCl3) 
7.34-7.16 (4H, m, Ar), 7.15-7.10 (1H, m, Ar), 6.45-6.42 (2H, m, DMB 3 or 5), 5.86 (1H, 
ddt, J 16.2, 10.7 and 5.5, propenyl 2-H), 5.78 (1H, ddt, J 17.5, 10.4 and 3.6, 4-H), 5.22 
(1H, dd , J 17.5 and 1.8, 5-HA), 5.13 (1H, dd, J 10.4 and 1.8, 5-HB), 5.08 (1H, d, J 16.2, 
propenyl  3-HA), 5.07 (1H, d, J 10.7, propenyl 3-HB), 4.88 (1H, br s, NH), 4.42 (1H, dd, J 
10.5 and 5.3, propyl 1-HA), 4.36 (1H, dd, J 10.5 and 5.7, propyl 1-HB), 4.32 (2H, d, J 
5.8, PhCH2N(CO)), 3.98-3.91 (2H, br s, propenyl 1-H2), 3.84-3.74 (8H, m, 2 × OMe, 1-
HAB and NHCHABPh), 3.65-3.59 (3H, m, propyl 3-HAB and propyl 2-H), 2.76-2.69 (1H, 
m, 2-H), 2.30-2.19 (2H, m, 3-HAB), 2.17-2.05 (2H, m, C8F17CH2CH2), 1.04 (14H, s, 
Si(CH(CH3)2)2), 0.88-0.84 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 159.9, 158.6, 
156.9, 141.4, 141.3, 141.2, 138.9, 135.5, 135.2, 129.2, 129.0, 128.9, 127.6, 127.4, 
126.9, 126.4, 125.9, 120.3 (Ar), 117.6 (5-C), 116.9 (propenyl 3-C), 104.3 (DMB 3 or 5), 
98.9 (DMB 3 or 5), 80.2, 72.2 (propenyl 1-C), 70.7 (1-C), 65.6 (propyl 3-C), 65.4 (propyl 
1-C), 58.5 (2-C), 55.6 (OMe), 51.7 (NHCH2Ph), 45.3 (PhCH2C(O)N), 38.4 (propyl 2-C), 
36.1 (3-C), 25.6 (C8F17CH2CH2), 17.7 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2); νmax/cm
-1 (film) 2946, 2868, 1718, 1508, 1243, 1208; m/z (ES+) 1059.3 
(100%, [M+H]+); found 1059.3588, C44H55F17N2O6Si  requires MH 1059.3631 
 
  
162 
 
N-(But-3-en-1-yl)-1,1,1-trifluoro-N-{[3-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-yl]amino}methyl)phenyl]methyl}methanesulfonamide 
238D 
 
Following general procedure N1; thiophenol (248 mg, 2.25 mmol), sulfonamide 238 
(520 mg, 0.45 mmol) and potassium carbonate (124 mg, 0.9 mmol) gave the crude 
product after 3 h. The crude product was purified by F-SPE to give the amine 238D 
(420 mg, 0.43 mmol, 96%, >99% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.55 (70:30, petrol—EtOAc); δH (500 MHz; 
CDCl3) 7.35-7.21 (4H, m, Ar), 5.78 (1H, ddt, J 17.4, 10.4 and 7.1, 4ʹ-H), 5.60 (1H, ddt, J 
17.1, 10.3 and 6.8, 3-H), 5.11-4.97 (4H, m, 4-HAB and 5ʹ-HAB), 4.52 (2H, br s, 
PhCH2NTf), 3.85 (1H, d , J 13.4, NHCHAPh), 3.81 (1H, d, J 13.4, NHCHBPh), 3.63 (2H, 
qd, J 9.9 and 5.5, 1ʹ-HA), 3.32 (2H, t, J 7.8, 1-HB), 2.75-2.69 (1H, m, 2ʹ-H), 2.31-2.17 
(4H, m, 2-H2 and 3ʹ-H2), 2.17-2.06 (2H, m, C8F17CH2CH2); 1.04 (14H, s, Si(CH(CH3)2)2), 
0.88-0.84 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 135.2 (Ar), 134.4 (Ar), 133.4 (Ar), 
129.1 (Ar), 128.3 (Ar), 128.0 (4-C), 127.0 (3-C), 117.9 (4-C or 5ʹ-C), 117.4 (4-C or 5ʹ-
C), 65.1 (1ʹ-C), 58.1 (2ʹ-C), 52.1 (PhCH2NTf), 51.3 (NHCH2Ph), 47.4 (1-C), 35.8 (2-C), 
32.5 (3ʹ-C), 17.5 (SiCH(CH3)2), 17.4 (SiCH(CH3)2), 12.3 (SiCH(CH3)2), 0.29 
(C8F17CH2CH2); νmax/cm
-1 (film) 2946, 2869, 1642, 1463, 1391, 1226; m/z (ES+) 967.2 
(100%, [M+H]+); found 967.2485, C34H43F20N2O3SSi  requires MH 967.2439 
 
  
163 
 
N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl]-1,1,1-trifluoro-
N-{[3-({[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4ʹ-en-2ʹ-
yl]amino}methyl)phenyl]methyl}methanesulfonamide 239D 
 
Following general procedure N1; thiophenol (163 mg, 1.49 mmol), sulfonamide 239 
(400 mg, 0.30 mmol) and potassium carbonate (82 mg, 0.59 mmol) gave the crude 
product after 2 h. The crude product was purified by F-SPE to give the amine 239D 
(330 mg, 0.29 mmol, 96%, >95% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.45 (60:40, petrol—EtOAc); δH (500 MHz; 
CDCl3) 7.33-7.28 (3H, m, Ar), 7.25-7.19 (1H, m, Ar), 5.80 (1H, ddt, J 17.2, 10.1 and 
7.1, 4ʹ-H), 5.71 (1H, ddt, J 16.9, 10.3 and 6.6, 6-H), 5.08 (1H, d, J 17.2, 5ʹ-HA), 5.07 
(1H, d, J 10.1, 5ʹ-HB), 4.94 (1H, d, J 16.9, 7-HA), 4.93 (1H, d, J 10.3, 7-HB), 4.65-4.41 
(2H, br m, PhCH2NTf), 3.84-3.81 (2H, m, NHCH2Ph), 3.65 (2H, dd, J 7.8 and 5.5, 1ʹ-
H2), 3.46 (1H, td, J 6.5 and 2.7, 3-H), 3.38-3.31 (1H, m, 1-HA), 3.27 (1H, dd, J 14.1 and 
4.2, 1-HB), 2.77-2.71 (1H, m, 2ʹ-H), 2.32-2.18 (2H, m, 3ʹ-HAB), 2.19-2.07 (2H, m, 
C8F17CH2CH2), 1.88-1.83 (2H, m, 5-HAB), 1.77 (1H, br s, 2-H), 1.50-1.37 (2H, m, 4-HAB), 
1.05 (14H, s, Si(CH(CH3)2)2), 0.9-0.86 (2H, m, C8F17CH2CH2), 0.84 (9H, s, TBS), 0.81 
(3H, d, J 6.7, CH3), -0.01 (3H, s, TBS), -0.08 (3H, s, TBS); δC (75 MHz; CDCl3) 141.8 , 
137.9, 135.3 (6-C), 134.9 (4ʹ-C), 128.9, 128.0, 127.9, 126.8, 117.1 (5ʹ-C), 114.7 (7-C), 
75.3 (3-C), 65.4 (1ʹ-C), 58.4 (2ʹ-C), 51.4 (NHCH2Ph), 35.9 (3ʹ-C), 35.7 (5-C), 33.3 (4-C), 
29.8 (2-C), 25.8 (C8F17CH2CH2), 17.9 (SiCH(CH3)2), 17.5 (SiCH(CH3)2), 12.4 
(SiCH(CH3)2), 10.9 (CH3), -4.22 (TBS), -4.76 (TBS), PhCH2Tf and 1-C missing; νmax/cm
-
1 (film) 2948, 2868, 1642, 1548, 1464, 1204; m/z (ES+) 1153.4 (100%, [M+H]+); found 
1153.3903, C44H64F20N2O3SSi requires MH 1153.3879 
 
  
164 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-({2-[2-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4-en-2-yl]amino}methyl)phenyl]phenyl}methyl)carbamate 240D 
 
Following general procedure N1; thiophenol (319 mg, 2.9 mmol), sulfonamide 240 (450 
mg, 0.29 mmol) and potassium carbonate (120 mg, 0.87 mmol) gave the crude product 
after 4 h. The crude product was purified by F-SPE to give the amine 240D (335 mg, 
0.28 mmol, 98%, >92% purity as estimated using 500 MHz 1H NMR spectroscopy) as a 
pale yellow oil; Rf 0.33 (60:40, petrol—EtOAc); δH (500 MHz; CDCl3) Atropisomers 
denoted in italics where possible 7.57-7.23 (7H, m, Ar), 7.21-7.03 (4H, m, Ar), 6.44-
6.39 (2H, m, Ar), 6.21 (1H, br s, NH), 5.83 (1H, ddt, J 17.3, 10.2 and 5.5, propenyl 2-
H), 5.64 (0.5H, ddt, J 17.1, 10.1 and 7, 4-Hmin), 5.52 (0.5H, ddt, J 17.3, 10.1 and 7.2, 4-
H), 5.18 (1H, dd, J 17.3 and 1.9, propenyl 3-HA), 5.08 (1H, dd , J 10.5 and 1.5, 
propenyl 3-HB), 5.02-4.84 (2H, m, 5-HAB), 4.42-4.26 (1H, m, propyl 3-HA), 4.26-4.08 
(1H, m, propyl 3-HB), 3.90 (2H, d, J 5.9, propenyl 1-H2), 3.77 (3H, s, OMe), 3.75 (3H, s, 
OMe), 3.73 (3H, s, OMemin), 3.65-3.38 (8H, 1-HA, propyl 1-HAB and 2-H, NHCH2Ph, 
N(CO)CH2Ph), 3.30-3.18 (1H, m, 1-HB), 2.67-2.62 (2-H
min), 2.57-2.47 (1H, m, 2-H), 
2.22-1.98 (4H, m, C8F17CH2CH2 and 3-HAB), 1.01 (14H, s, Si(CH(CH3)2)2), 0.98 (s, 
SiCH(CH3)2
min), 0.97-0.67 (2H, m, C8F17CH2CH2); δC (75 MHz; CDCl3) 159.8 (DMB 4-
C), 158.7, 158.6 (DMB 2-C), 156.9 (CO), 141.4, 140.7, 140.4, 140.3, 140.2, 137.7, 
137.2 (4-C or propenyl 2-C), 135.4, 135.2, 134.0 (4-C or propenyl 2-C), 130.9, 130.8, 
130.2, 129.9, 129.8, 129.7, 129.6, 129.5, 129.2, 129.1, 128.9, 128.4, 128.4, 128.2, 
127.8, 127.7, 127.5, 127.4, 127.3, 127.2, 120.5, 117.8 (propenyl 3-C or 5-C), 117.3 
(propenyl 3-C or 5-C), 116.7 (propenyl 3-C or 5-C), 104.3 (DMB 5-C), 98.8 (DMB 3-C), 
98.79 (DMB 3-C), 72.1 (propenyl 1-C), 70.8 (1-C), 64.8 (propyl 3-C); 60.1, 60.0 (Propyl 
1-C), 59.4, 59.24 (2-C), 55.5 (2 x OMe), 49.5 (CN(CO)Ph), 49.4 (CN(CO)Ph), 43.2, 
42.7 (NHCPh), 38.5 (propyl 2-C), 35.9 (3-C), 35.3 (3-C); 25.7 (C8F17CH2CH2), 17.7 
(SiCH(CH3)2), 12.4 (SiCH(CH3)2), -0.01 (C8F17CH2CH2); νmax/cm
-1 (film) 2944, 2867, 
1697, 1508, 1464, 1275, 1260; m/z (ES+) 1135.4 (100%, [M+H]+); found 1135.3972, 
C50H59F17N2O6Si requires MH 1135.3944  
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N-(But-3-en-1-yl)-1,1,1-trifluoro-N-({2-[2-({[(2R)-1-
{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bis(propan-2-
yl)silyl]oxy}pent-4ʹ-en-2ʹ-
yl]amino}methyl)phenyl]phenyl}methyl)methanesulfonamide 241D 
 
Following general procedure N1; thiophenol (177 mg, 1.61 mmol), sulfonamide 241 
(409 mg, 0.32 mmol) and potassium carbonate (89 mg, 0.64 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE to give the amine 241D 
(324 mg, 0.30 mmol, 93%, >83% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.37 (70:30, petrol—EtOAc); δH (500 MHz; CDCl3; 
323 K) 7.57 (1H, d, J 7.8, Ar), 7.49 (1H, d, J 8.5, Ar), 7.47 (1H, d, J 7.6, Ar), 7.42 (1H, 
td, J 7.6 and 1.3, Ar), 7.39-7.34 (1H, m, Ar); 7.30 (1H, t, J 7.5, Ar), 7.19 (1H, td, J 7.4 
and 1.2, Ar), 7.10 (1H, d, J 7.5, Ar), 5.63 (1H, ddt, J 17.3, 11.6 and 7.1, 4ʹ-H), 5.50 (1H, 
ddt, J 17.1, 10.3 and 6.8, 3-H), 5.0-4.92 (3H, m, 4ʹ-HA and 5-HAB), 4.88 (1H, d, J 17.1, 
4ʹ-HB), 4.53 (1H, d, J 15.8, PhCHANTf), 4.13 (1H, d, J 15.8, PhCHBNTf), 3.53-3.47 (1H, 
m, 1ʹ-HA), 3.45-3.38 (3H, m, 1ʹ-HB and NHCH2Ph), 3.26 (1H, dt, J 14.8 and 7.9, 1-HA), 
3.15 (1H, dtd, J 14.8, 7.8 and 3.6, 1-HB), 2.52 (1H, dp, J 8.7 and 5.9, 2ʹ-H), 2.20-1.93 
(6H, m, C8F17CH2CH2, 3ʹ-H2 and 2-H2), 1.01 (14H, s, Si(CH(CH3)2)2), 0.86-0.79 (2H, m, 
C8F17CH2CH2); δC (125 MHz; CDCl3; 323 K) 50:50 atropisomers 140.67, 140.65, 139.4, 
139.3, 139.0, 138.9, 135.3 (4ʹ-C), 135.2 (4ʹ-C), 133.4 (3-C), 132.96, 132.93, 130.12, 
130.08, 129.50, 129.47, 129.2, 129.1, 128.3, 128.2, 128.12, 128.06, 127.8, 127.1, 
127.0, 120.2 (q, J 325, CF3), 117.6 (4-C), 117.1 (4-C), 116.9 (5ʹ-C), 65.4 (1ʹ-C), 65.2 
(1ʹ-C), 58.89 (2ʹ-C), 58.87 (2ʹ-C), 49.5 (PhCNTf), 49.3 (PhCNH), 49.1 (PhCNH), 47.9 
(1-C), 36.0 (2-C), 35.7 (2-C), 32.4 (3ʹ-C), 25.7 (t, J 25, C8F17CH2CH2), 17.5 
(SiCH(CH3)2), 17.4 (SiCH(CH3)2), 12.45 (SiCH(CH3)2), 12.43 (SiCH(CH3)2), 0.00 
(C8F17CH2CH2); νmax/cm
-1 (film) 3065, 3005, 2947, 2868, 1642, 1462, 1388; m/z (ES+) 
1043.3 (100%, [M+H]+); found 1043.2794, C40H47F20N2O2SSi requires MH 1043.2752 
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N-[(2R,3R)-3-[(Tert-butyldimethylsilyl)oxy]-2-methylhept-6-en-1-yl]-1,1,1-trifluoro-
N-({2-[2-({[(2R)-1-{[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluorodecyl)bis(propan-2-yl)silyl]oxy}pent-4ʹ-en-2ʹ-
yl]amino}methyl)phenyl]phenyl}methyl)methanesulfonamide 243D 
 
Following general procedure N1; thiophenol (169 mg, 1.54 mmol), sulfonamide 243 
(450 mg, 0.31 mmol) and potassium carbonate (85 mg, 0.62 mmol) gave the crude 
product after 3 h. The crude product was purified by F-SPE to give the amine 243D 
(437 mg, 0.34 mmol, 111%, >89% purity as estimated using 500 MHz 1H NMR 
spectroscopy) as a pale yellow oil; Rf 0.36 (80:20, petrol—EtOAc); δH (500 MHz; CDCl3; 
323 K) Atropisomers denoted where possible 7.59 (1H, d, J 7.9, Ar), 7.50-7.47 (1H, m, 
Ar), 7.45 (1H, dd, J 7.7 and 1.3, Ar), 7.41 (1H, tt, J 7.7 and 1.8, Ar), 7.36 (1H, tdd, J 
7.6, 2.4 and 1.4, Ar), 7.33-7.26 (1H, m, Ar), 7.19-7.13 (1H, m, Ar), 7.08 (1H, dd, J 7.5 
and 1.4, Ar), 5.75-5.57 (2H, m, 4ʹ-H and 6-H), 4.99-4.89 (4H, m, 7-HAB and 5ʹ-HAB), 4.69 
(0.5H, d, J 16.1, NTfCH2Ph), 4.62 (0.5H, d, J 16.7, NTfCH2Ph), 4.09-3.93 (1H, m, 
NTfCH2Ph), 3.53-3.29 (5H, m, 1-H2, 3-H and NHCH2Ph), 3.23-3.07 (2H, m, 1ʹ-H), 2.50 
(1H, ddd, J 7.7, 6.5 and 4.9, 2ʹ-H), 1.47-1.35 (6H, m, C8F17CH2CH2, 5ʹ-H and 3ʹ-H), 
1.65-1.55 (1H, m, 2-H), 1.46-1.35 (2H, m, 4-H2), 1.00 (14H, s, Si(CH(CH3)2)2), 0.86-
0.79 (11H, TBS and C8F17CH2CH2), 0.70 (3H, d, J 6.8, Me), -0.04 (3H, TBS), -0.08 (3H, 
TBS); δC (125 MHz; CDCl3; 323 K) 50:50 atropisomers 140.4 (Ar), 140.3 (Ar), 139.7 
(Ar), 139.6 (Ar), 139.5 (Ar), 139.2 (Ar), 138.2 (4ʹ or 6-C), 138.1 (4ʹ or 6-C), 135.5 (4ʹ or 
6-C), 135.4 (4ʹ or 6-C), 133.7 (Ar), 133.2 (Ar), 130.4 (Ar), 130.1 (Ar), 129.5 (Ar), 129.4 
(Ar), 129.3 (Ar), 129.2 (Ar), 128.4 (Ar), 128.3 (Ar), 128.2 (Ar), 128.0 (Ar), 127.9 (Ar), 
127.8 (Ar), 127.7 (Ar), 127.5 (Ar), 127.4 (Ar), 127.2 (Ar), 127.1 (Ar), (120.5, q, J 325), 
117.2 (5- or 7ʹ-C), 117.0 (5ʹ- or 7-C), 114.9 (5ʹ- or 7-C), 114.8 (5ʹ- or 7-C), 73.6 (3-C), 
73.3 (3-C), 65.5 (1ʹ-C), 65.3 (1ʹ-C), 59.0 (2ʹ-C), 58.9 (2ʹ-C), 54.9 (NTfCH2Ph), 53.0 
(NTfCH2Ph), 52.2 (1-H), 50.4 (1-H), 49.5 (NHCH2Ph) , 49.1 (NHCH2Ph), 36.6 (2-C) , 
36.2 (2-C) , 35.9 (3ʹ-C), 35.8 (3ʹ-C), 29.9 (5-C), 29.8 (5-C), 26.0 (4-C), 25.8 (SiC(CH3)3), 
25.6 (t, J 25, C8F17CH2CH2), 18.2 (SiC(CH3)3), 17.6 (SiCH(CH3)2), 12.6 (SiCH(CH3)2), 
11.3 (Me), 10.7 (Me), 0.15 (C8F17CH2CH2), -3.99 (SiCH3), -4.01 (SiCH3); νmax/cm
-1 (film) 
2950, 2867, 1738, 1641, 1548, 1464, 1390; m/z (ES+) 1229.4 (100%, [M+H]+); found 
1229.4240, C50H68F20N2O4SSi2 requires MH 1229.4192 
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[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({[(2R)-1-hydroxypent-4-en-2-
yl]amino}methyl)thiophen-2-yl]methyl}carbamate 227 
 
Following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the amine 211D (52 mg, 0.053 mmol); on completion of the reaction the crude 
product was purified by column chromatography, eluting with EtOAc gave the amine 
227 (6 mg, 0.014 mmol, 27%) as a yellow oil; Rf 0.1 (EtOAc);   
   4.8 (c. 0.5, CHCl3); δH 
(500 MHz; CDCl3) 7.41-7.37 (1H, m, Ph 3-H), 7.34-7.29 (1H, m, Ph 5-H), 7.00 (1H, ap 
t, J 7.41, Ph 6-H), 6.92 (1H, d, J 8.22, Ph 4-H), 6.84 (1H, s, Thio 3 or 4-H), 6.79 (1H, s, 
Thio 3 or 4-H), 6.09 (1H, ddt, J 17.6, 10.2 and 5.5, propenyl 2-H), 5.80 (1H, ddt, J 16.6, 
11.0 and 7.2, 3-H), 5.46 (1H, dd, J 17.6 and 1.7, propenyl 3-HA), 5.32 (1H, dd, J 10.2 
and 1.1, propenyl 3-HB), 5.29 (2H, s, PhCH2O), 5.17 (1H, d, J 16.6, 5-HA), 5.15 (1H, d, 
J 11, 5-HB), 4.62 (2H, ap d, J 5.5, propenyl 1-H2), 4.54 (2H, ap d, J 7.2, ThioCH2NCO), 
4.03 (1H, d, J 14, NHCH2Ph), 3.96 (1H, d, J 14, NHCH2Ph), 3.69 (1H, dd, J 10.7 and 
4.2, 1-HA), 3.39 (1H, dd, J 10.7 and 5.9, 1-HB), 2.87-2.81 (1H, m, 2-H), 2.35-2.24 (2H, 
m, 3-HAB), 1.88 (1H, br s, OH); δC (75 MHz; CDCl3) 156.8 (Ph 1-C), 156.6 (C=O), 144.3 
(Thio 3 or 4-C), 140.9 (Thio 3 or 4-C), 135.0 (propenyl 2-C), 133.6 (4-C), 130.0, 129.8, 
125.7, 125.4, 124.9, 121.0 (Ph 4-C), 118.5 (5-C), 117.6 (propenyl 3-C), 112.1 (Ph 6-C), 
69.2 propenyl (1-C), 63.4 (1-C), 62.8 (PhCH2NCO), 57.5 (2-C), 46.3 (NHCH2Ph), 40.6 , 
36.5 (3-C); νmax/cm
-1 (film) 3316, 3073, 2925, 1704, 1494, 1245;m/z (ES+) 417.2 (100%, 
[M+H]+); found 417.1853, C22H28N2O4S3 requires MH 417.1843 
(15E,18R)-18-(Hydroxymethyl)-5,13-dioxa-24-thia-3,19-
diazatricyclo[19.2.1.07,12]tetracosa-1(23),7,9,11,15,21-hexaen-4-one 231 
 
Following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the amine 223D (38 mg, 0.04 mmol); on completion of the reaction, the crude 
product was purified by column chromatography, eluting with EtOAc gave the amine 
231 (15 mg, 0.038 mmol, 96%) as a pale yellow glass; Rf 0.1 (EtOAc);    
  4 (c. 0.9, 
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CDCl3); δH (300 MHz; MeOD) 7.29-7.15 (2H, m, Ar), 6.88-6.76 (2H, m, Ar), 6.69 (2H, s, 
Ar), 5.68 (1H, dd, J 16.1 and 3.8, 15-H), 5.62 (1H, dd, J 16.1 and 4.1, 16-H), 5.03 (1H, 
d, J 10.4, 6-HA), 4.85 (1H, d, J 10.4, 6-HB), 4.41 (1H, d, J 12.1, 2-HA), 4.36 (1H, d, J 
12.1, 2-HB), 4.32 (1H, d, J 15.5, 14-HA), 4.23 (1H, d, J 15.5, 14-HB), 3.92 (2H, s, 20-H), 
3.43 (1H, dd, J 11 and 5, , CHAOH), 3.39 (1H, dd, J 11 and 5.7, , CHBOH), 2.58-2.48 
(1H, m, 18-H), 2.05 (2H, br s, 17-H); δC (75 MHz; CDCl3) 159.5 (12-C), 145.4 (Thio 2 or 
5-C), 143.2 (Thio 2 or 5-C), 133.3 (8 or 9-C), 131.8 (8 or 9-C), 130.3 (7-C), 129.8 (15 or 
16-C), 127.1 (15 or 16-C), 126.1 (Thio 3 or 4-C), 125.7 (Thio 3 or 4-C), 121.7 (10-C), 
113.4 (11-C), 69.9 (14-C), 64.9 (CH2OH), 64.6 (PhCH2O), 56.9 (18-C), 45.8 (2-C), 41.1 
(20-C), 34.9 (17-C), C=O missing; νmax/cm
-1 (film) 3336, 2935, 2480, 1677, 1438; m/z 
(ES+) 389.2 (100%, [M+H]+); found 389.1541, C20H24N2O4S requires MH 389.1530  
(15E,18R)-18-(Hydroxymethyl)-19-(1-methyl-1H-imidazole-4-sulfonyl)-5,13-dioxa-
24-thia-3,19-diazatricyclo[19.2.1.07,12]tetracosa-1(23),7,9,11,15,21-hexaen-4-one; 
ethane 230 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (28 mg, 
0.16 mmol), triethylamine (32 mg, 0.32 mmol) and amine 223D (38 mg, 0.04 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the crude product; on completion of the reaction, the crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
sulfonamide 230 (9 mg, 0.017 mmol, 42%) as a colourless oil; Rf 0.09 (60:40 petrol—
EtOAc);     
     1.3 (c. 0.9, CH2Cl2); δH (500 MHz; CDCl3) 7.52 (2H, s, Ar), 7.32 (1H, d, J 
8, Ar), 7.28 (1H, d, J 8, Ar), 6.98-6.79 (4H, m, Ar), 5.92 (1H, br s, NH), 5.65 (1H, dt, J 
15.0 and 7.5, 15-H), 5.36 (1H, dt, J 15 and 5.3, 16-H), 5.23 (1H, d, J 12.3, 6-HA), 5.22 
(1H, br s, ), 5.02 (1H, d, J 12.3, 6-HB), 4.52 (1H, d, J 15, 2-HA), 4.43 (4H, ap s, 14-H2 
and 20-H2), 4.17 (1H, m, 18-H), 4.16 (1H, d, J 15, 2-HA), 3.92-3.80 (1H, m, CH2OH), 
3.77 (3H, s, NCH3), 3.75-3.66 (1H, m, CH2OH), 2.41-2.20 (1H, m, 17-HA), 2.18-2.02 
(1H, m, 17-HB); δC (75 MHz; CDCl3) 156.4 (12-C), 143.4 (Thio 2 or 5-C), 141.4 (Thio 2 
or 5-C), 138.5 (Imid 4-C), 131.6 (Thio 3 or 4-C), 130.5 (Thio 3 or 4-C), 129.3 , 127.9 , 
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127.3 , 125.9 , 124.2 , 120.5 , 112.5 (11-C), 68.5 (6-C), 64.3 (CH2OH), 61.9 (18-C), 
34.2 (17-C), 29.7 (NMe); νmax/cm
-1 (film) 2919, 1701, 1531, 1330, 1255, 1157, 1120; 
m/z (ES+) 533.2 (100%, [M+H]+) and 555.1 (10%, [M+Na]+); found 533.1530, 
C24H28N4O6S2 requires MH 533.1523  
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({[(2R)-1-hydroxypent-4-en-2-
yl][(morpholin-4-yl)carbonyl]amino}methyl)thiophen-2-yl]methyl}carbamate 225 
 
Following general procedure A2, 4-morpholinecarbonyl chloride (15.6 mg, 0.1 mmol), 
triethylamine (20 mg, 0.2 mmol) and amine 211D (51 mg, 0.052 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with EtOAc gave the urea 225 (20 mg, 0.037 mmol, 71%) as a 
pale yellow oil; Rf 0.5 (EtOAc);     
     2.8 (c. 2, CH2Cl2); δH (500 MHz; CDCl3) 7.34 (1H, 
dd, J 7.6 and 1.6, Ph 3-H), 7.31 (1H, dt, J 8.3 and 1.6, Ph 6-H), 6.99 (1H, ap t, J 7.6, 
Ph 4-H), 6.95 (1H, d, J 8.3, Ph 5-H), 6.83 (2H, ap s, Thio 3 and 4-H), 6.08 (1H, ddt, J 
17.3, 10.5 and 4.9, propenyl 2-H), 5.79 (1H, ddt, J 17.6, 10.5 and 7.5, 4-H); 5.45 (1H, 
ddd, J 17.6, 3.6 and 1.5, 5-HA), 5.30 (1H, ddd, J 10.5 3.6 and 1.5, 5-HB); 5.22 (2H, s, 
PhCH2O); 5.15 (1H, ddd, J 17.3, 2.9 and 1.4, propenyl 3-HA), 5.12-5.07 (1H, m, 
propenyl 3-HB), 4.59-4.57 (2H, m, propenyl 1-H2), 4.54-4.49 (2H, m, , PhCH2N(CO)), 
4.51 (1H, d, J 16, N(CO)NCH2Ph), 4.45 (1H, d, J 16, N(CO)NCH2Ph), 3.98 (1H, br s, 2-
H), 3.77-3.63 (5H, m, O(CH2)2 and 1-HA); 3.63-3.52 (1H, m, 1-HB), 3.37 (4H, dd, J 4.4 
and 5.7, N(CH2)2), 2.58-2.34 (2H, m, 3-HAB), 1.29 (1H, OH); δC (75 MHz; CDCl3) 164.9 
(C=O), 141.7 (Thio 2 or 5-C) ,141.4 (Thio 2 or 5-C), 135.3 (propenyl 2-C), 133.5 (4-C), 
130.1, 129.8 , 126.1, 125.9 (Thio 3 or 4-C), 125.3 (Thio 3 or 4-C), 121.0, 118.1 (5-C), 
117.6 (propenyl 3-C), 112.1 (Ph 6-C), 69.2 (propenyl 1-C), 67.0 (O(CH2)2), 63.6 
(PhCH2O), 62.8 (1-C), 61.1 (2-C), 47.7 (N(CH2)2), 46.5 PhCH2(CO), 40.5 N(CO)CH2Ph, 
34.0 (3-C); νmax/cm
-1 (film) 3323, 3077, 2925, 1669, 1581, 1549, 1453 ; m/z (ES+) 530.2 
(100%, [M+H]+); found 530.2332, C27H35N3O6S1 requires MH 530.2319 
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[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({N-[(2R)-1-hydroxypent-4-en-2-yl]1-
methyl-1H-imidazole-4-sulfonamido}methyl)thiophen-2-yl]methyl}carbamate 226 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (38 mg, 
0.21 mmol), triethylamine (42 mg, 0.42 mmol) and amine 211D (52 mg, 0.053 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the crude product; on completion of the reaction, the crude product was 
purified by column chromatography, eluting with EtOAc gave the sulfonamide 226 (14 
mg, 0.025 mmol, 60%) as a colourless glass; Rf 0.1 (EtOAc);     
     2.9 (c. 1.4, 
CH2Cl2); δH (500 MHZ; CDCl3) 7.44 (1H, ap d, J 4.3, Imid), 7.34 (1H, d, J 7.8, Ph 3-H), 
7.31-7.23 (1H, m, Ph 6-H), 6.95 (1H, td, J 7.4 and 2.5, Ph 4-H), 6.90-6.71 (4H, m, Thio 
3 and 4-H, Imid, Ph 5-H), 6.04 (1H, ddt, J 16.3, 10.8 and 5.1, propenyl 2-H), 5.74 (1H, 
br ddt, J 17.3, 9.9 and 7.1, 4-H), 5.41 (1H, d, J 17.3, propenyl 3-HA), 5.26 (1H, d, J 9.9, 
propenyl 3-HB), 5.23 (2H, s, PhCH2O), 5.11 (1H, d, J 16.3, 5-HA
rotA), 5.10 (1H, d, J 10.8, 
5-HB
rotA), 4.97 (1H, d, J 16.3, 5-HA
rotB), 4.96 (1H, d, J 10.8, 5-HB
rotB), 4.57 (2H, ap dt, J 
4.8 and 1.8, propenyl 1-H2), 4.41 (1H, d, J 14.3, PhCH2N(CO)
rotA), 4.33 (1H, d, J 15.8, 
PhCH2N(CO)
rotB), 4.05-3.86 (2H, m, PhCH2N(CO)
rotA,B), 3.72 (2H, s, N(SO2Imid)CH2), 
3.64 (1H, dd, J 10.8 and 4.1, 1-HA), 3.49 (3H, s, NMe), 3.34 (1H, dd, J 10.8 and 6.0, 1-
HB), 2.79 (1H, m, 2-H), 2.42-2.18 (2H, m, 3-H); δC (75 MHz; CDCl3) 156.8 (Ph 1-C), 
144.3 (Imid 1-C), 142.6 (Thio 2 or 5-C), 141.8 (Thio 2 or 5-C), 140.9, 139.9, 138.9, 
135.0, 133.5, 130.0 (Ph 5-C), 129.8 (Ph 3-C), 127.8, 125.7, 125.5, 124.9, 124.6, 121.1, 
121.0, 118.5 (5-C or propenyl 3-CrotB), 117.9 (5-C or propenyl 3-CrotB), 117.7 (5-C or 
propenyl 3-CrotB), 117.6 (5-C or propenyl 3-CrotB), 112.1 (Ph 6-C), 69.2 (propenyl 1-C), 
64.6 (1-C), 63.4 (PhCH2O
rotA), 62.8 (PhCH2O
rotB), 57.5 (2-C), 46.5 
(NSO2ImidCH2Ph
rotA), 46.3 (NSO2ImidCH2Ph
rotB), 40.6 (PhCH2N(CO)), 37.3 (3-C
rotA), 
36.5 (3-C), 34.6 (NMe); νmax/cm
-1 (film) 3317, 2926, 1713, 1604, 1531, 1494, 1455, 
1334, 1275, 1260, 1158 and 1119; m/z (ES+) 561.0 (100%, [M+H]+); found 561.1829, 
C26H32N4O6S2 requires MH 561.1836  
Full carbon assignment was not possible due to rotamers 
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[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[5-({[(2R)-1-hydroxypent-4-en-2-
yl][(pyridin-3-yl)carbamoyl]amino}methyl)thiophen-2-yl]methyl}carbamate 224 
 
Following general procedure A1, 3-pyridyl isocyanate (15.5 mg, 0.129 mmol) and 
amine 211D (63 mg, 0.065 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S2, tetra-n-butylammonium 
fluoride (1M, 0.1 mL) was added to the crude product; on completion of the reaction, 
the crude product was purified by column chromatography, eluting with EtOAc gave the 
urea 224 (27 mg, 0.05 mmol, 77%) as a pale yellow oil; Rf 0.1 (EtOAc);   
    : 3 º (c. 
0.4, CHCl3); δH (500 MHz; CDCl3) 9.24 (1H, br s, NH), 8.22 (1H, d, J 2.8, Py 2-H), 8.11 
(1H, d, J 4.4, Py 4-H), 8.04 (1H, d, J 8.1, Py 6-H), 7.3 (1H, d, J 7.1, Ph 5-H), 7.25 (1H, 
ddd, J 8,8 and 1.5, Ph 3-H), 7.18 (1H, ddd, J 8.1 and 4.4, Py 5-H), 6.95-6.79 (3H, m, 
Ph 6-H and 4-H , Thio 3 or 4-H), 6.75 (1H, d, J 3.2, Thio 3 or 4-H), 6.02 (1H, ddt, J 
17.2, 10.4 and 4.8, propenyl 2-H), 5.67 (1H, ddt, J 17.2, 9.9 and 6.8, 4-H), 5.45 (1H, br 
s, NH), 5.39 (1H, dd, J 17.2 and 1.9, propenyl 3-HA), 5.25 (1H, dd, J 10.4 and 1.9, 
propenyl 3-HB), 5.19 (2H, s, PhCH2O), 5.05 (1H, d, J 17.2, 5-HA), 5.04 (1H, d, J 9.9, 5-
HB), 4.64-4.60 (2H, m, ), 4.54 (2H, d, J 4.8, propenyl 1-H), 4.46-4.43 (2H, m, 
PhCH2N(CO)), 3.85 (3H, m, 1-H2 and 2-H); 2.47 (2H, br s, 3-HAB), 1.19 (1H, br s, OH); 
δC (75 MHz; CDCl3) 157.1 (Ph 1-C), 156.8 (C=O), 143.1 (Py 2-C), 142.3 (Py 6-C), 
141.7 (Thio 2 or 5-C), 140.5 (Thio 2 or 5-C), 137.4 (Py 3-C), 134.6 (propenyl 2-C), 
133.5 (4-C), 129.9 (Ar), 129.8 (Py 5-C), 127.4 (Ar), 126.4 (Ar), 125.6 (Thio 3 or 4-C), 
125.4 (Thio 3 or 4-C), 124.3 (Py 4-C), 121.0 (Ph 4-C), 118.6 (5-C), 117.6 (propenyl 3-
C), 112.1 (Ph 5-C), 69.2 (propenyl 1-C), 64.4 (1-C), 62.8 (PhCH2O), 60.4 (2-C), 46.2, 
40.5 (PhCH2N(CO)), 34.1 (3-C); νmax/cm
-1 (film) 3301, 2929, 1700, 1660, 1532, 1242; 
m/z (ES+) 537.2 (100%, [M+H]+); found 537.2178, C28H32N4O5S requires MH 537.2166 
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(15E,18R)-18-(Hydroxymethyl)-4-oxo-N-(pyridin-3-yl)-5,13-dioxa-24-thia-3,19-
diazatricyclo[19.2.1.07,12]tetracosa-1(23),7,9,11,15,21-hexaene-19-carboxamide 
228 
  
Following general procedure A1, 3-pyridyl isocyanate (10 mg, 0.082 mmol) and amine 
223D (39 mg, 0.041 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S2, tetra-n-butylammonium fluoride 
(1M, 0.1 mL) was added to the crude product; on completion of the reaction, the crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the urea 228 (15 mg, 0.03 mmol, 73%) as a brown oil; Rf 0.05 (EtOAc);   
     −16 
(c. 0.5, MeOH); δH (500 MHz; CDCl3) 8.77 (1H, br s, Py 2-H), 8.26  (1H, s, Py 6-H), 
8.21 (1H, d, J 4.6, Py 5-H), 8.14 (1H, d, J 7.9, Py 4-H), 7.31 (2H, d, J 5.7, 8 or 9-H), 
7.25 (1H, dd, J 8.5 and 4.4, 8 or 9-H), 7.03 (1H, br s, Thio 3 or 4-H), 6.95 (1H, ap t, J 
7.5, 11-H), 6.88-6.84 (2H, m, Thio 3 or 4-H and 10-H), 5.72 (1H, d, J 15.2, 16-H), 5.62 
(1H, d, J 15.2, 15-H), 5.29-5.02 (4H, m, 6-H2 and 2-H2), 4.61-3.81 (7H, m, 18-H, 
CH2OH, N(CO)PyCH2 and 14-H2), 2.60 (1H, br s, 17-HA ), 2.07 (1H, br s, 17-HB); δC (75 
MHz; CDCl3) 157.8, 156.6, 143.9, 143.0, 140.3, 140.0, 131.8, 130.5, 128.8, 128.4, 
126.8, 126.6, 125.3, 124.4, 123.9, 120.8, 112.6, 68.5, 64.3, 63.0, 59.1, 45.7, 40.1, 32.3, 
29.7; νmax/cm
-1 (film) 3303, 2925, 1695, 1661, 1532, 1254; m/z (ES+) 509.2 (100%, 
[M+H]+); found 509.1848, C26H28N4O5S requires MH 509.1853 
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(15E,18R)-18-(Hydroxymethyl)-19-[(morpholin-4-yl)carbonyl]-5,13-dioxa-24-thia-
3,19-diazatricyclo[19.2.1.07,12]tetracosa-1(23),7,9,11,15,21-hexaen-4-one 229 
 
Following general procedure A2, cyclopropane carbonyl chloride (13 mg, 0.086 mmol), 
triethylamine (13 mg, 0.129 mmol) and amine 223D (41 mg, 0.043 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the 
crude product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the urea 229 (11 mg, 0.022 
mmol, 51%) as a colourless glass; Rf 0.27 (90:10, CHCl3—MeOH);   
     18.7 (c. 0.2, 
MeOH); δH (500 MHz; CDCl3) 7.37-7.28 (2H, m, 8 and 11-H), 6.95 (1H, t, J 7.3, 9-H), 
6.88 (1H, d, J 8.3, 10-H), 6.75 (1H, s, Thio 3 or 4-H), 6.72 (1H, s, Thio 3 or 4-H), 5.81 
(1H, dt, J 15.8 and 7.7, 16-H), 5.70 (1H, d , J 15.8, 15-H), 5.35 (1H, d, J 10.6, 6-HA), 
5.29-4.98 (1H, m, NH), 4.95 (1H, d, J 10.6, 6-HB), 4.66-4.32 (6H, m, O(CH2)2 and 2-
HAB), 3.93 (1H, d, J 12.2, 20-HA), 3.75-3.57 (5H, m, CH2OH, 14-HAB and 20-HB), 3.49 
(2H, ddd, J 13.3, 6.5 and 3.1, N(CHA)2), 3.39-3.26 (2H, m, N(CHB)2), 3.23 (1H, br s, 18-
H), 2.61 (1H, dt, J 14.7 and 6.7, 17-HA), 2.55 (1H, dt, J 14.7 and 7.5, 17-HB); δC (75 
MHz; CDCl3) 164.5 (C=O), 157.7 (12-C), 156.4 (C=O), 143.6 (Thio 2-C), 139.9 (Thio 5-
C), 131.9 (15-C), 130.6, 129.2, 127.1 (16-C), 126.0 (Thio 3-C), 124.9 (Thio 4-C), 124.1, 
120.7 (9-C), 112.4 (11-C), 68.3 (CH2OH), 66.7 (O(CH2)2), 61.2 (14-C), 59.0 (18-C), 
49.5 (20-C), 47.4 (N(CH2)2), 40.1 (2-C), 31.9 (17-C); νmax/cm
-1 (film) 3321, 2856, 1703, 
1606, 1455, 1252, 1115; m/z (ES+) 502.2 (100%, [M+H]+) and 524.2 (60%, [M+Na]+); 
found 502.2006, C25H31N3O5S requires MH 502.2006. 
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(7R,9E)-5,12,20-Trioxa-27-thia-3,22-diazatetracyclo[22.2.1.03,7.013,18]heptacosa-
1(26),9,13,15,17,24-hexaene-4,21-dione 232 
 
Also obtained was the 2-oxazolidinone 232 (4 mg, 9.6 µM, 23%) as a colourless glass; 
Rf 0.24 (90:10, CHCl3—MeOH) δH (500 MHz; C6D6; 343 K) 7.13-7.04 (2H, m, 16-H and 
17-H), 6.72-6.78 (1H, 14-H), 6.67 (1H, d, J 3.5, Thio 3 or 4-H), 6.53 (1H, d, J 8.3, 15-
H), 6.36 (1H, s, Thio 3 or 4-H), 5.33-5.26 (2H, m, 9 and 10-H), 5.23 (1H, d, J 10.8, 18-
HA), 5.11 (1H, s, NH), 4.58 (1H, d, J 15.4, 2 or 22-H), 4.30 (1H, s, 15-H), 4.08-3.98 (4H, 
m, 11-HAB and 2 or 22-H), 3.83 (1H, br s, 2 or 22-H), 3.55 (1H, ap t, J 8.4, 6-HA), 3.27 
(1H, ap t, J 7.6, 6-HB), 3.13-3.04 (1H, m, 7-H), 2.11-1.87 (2H, 8-HAB); νmax/cm
-1 (film) 
3307, 3008, 2920, 1713, 1619, 1533, 1490, 1275, 1260; m/z (ES+) 437.1 (100%, 
[M+Na]+); found 437.1157, C24H30N2O4 requires MH 437.1142 
Unable to obtain a 13C NMR due to insufficient material 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[2-({[(2R)-1-hydroxypent-4-en-2-
yl][(pyridin-3-yl)carbamoyl]amino}methyl)phenylʹ]methyl}carbamate 265a 
 
Following general procedure A1, 3-pyridyl isocyanate (15 mg, 0.13 mmol) and amine 
234D (70 mg, 0.068 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S2, tetra-n-butylammonium fluoride 
(1M, 0.1 mL) was added to the crude product; on completion of the reaction, the crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the urea 265a (21 mg, 0.04 mmol, 58%) as a pale yellow oil; Rf 0.19 (70:30 
petrol−EtOAc);     
     12.1 (c. 1, CH2Cl2); δH (500 MHz; MeOD) 8.38 (1H, br s, Py 2-H), 
8.03 (1H, d, J 4.3, Py 6-H), 7.72 (1H, d, J 8.5, Py 4-H), 7.29-7.01 (7H, m, Py 5-H and 
Ph and Phʹ), 6.83 (1H, d, J 8.4, Ph 6-H), 6.80 (1H, ap t, J 7.4, Ph 5-H), 5.93 (1H, ddt, J 
17.4, 10.2 and 4.9, propenyl 2-H), 5.76-5.66 (1H, m, 4-H), 5.28 (1H, dd, J 17.4 and 1.8, 
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propenyl 3-HA), 5.11 (1H, dd, J 10.2 and 1.8, propenyl 3-HB), 5.05 (2H, s, PhCH2O), 
4.99 (1H, d, J 17.3, 5-HA), 4.94 (1H, d, J 10.3, 5-HB), 4.70 (1H, d, J 17.7, 
N(CO)PyCH2Ph), 4.59 (1H, d, J 17.7, N(CO)PyCH2Ph), 4.45 (2H, d, J 4.6, propenyl 1-
H2), 4.26 (2H, s, PhCH2N(CO)O), 4.14 (1H, br s, 2-H), 3.59-3.48 (2H, m, CH2OH), 2.41-
2.25 (2H, m, 3-H2); δC (75 MHz; CDCl3) 159.3 (C=O), 158.9 (Ph 1-C), 157.9 (C=O), 
144.2 (Py 6-C), 142.8 (Py 2-C), 138.8 (Py 3-C), 137.8 , 137.4, 136.5, 135.1, 130.7, 
130.4, 130.0, 128.8, 128.7, 128.2, 126.8, 125.3, 121.9 (Ph 4-C), 118.4 (5-C), 117.6 
(propenyl 3-C), 113.2 (Ph 6-C), 70.1 (propenyl 1-C), 64.2 , 63.5, 60.3 (2-C), 46.6, 42.9, 
35.3 (3-C); νmax/cm
-1 (film) 3439, 3292, 3054, 2987, 2305, 1714, 1665, 1605, 1589, 
1520, 1485, 1455, 1422, 1336 and 1273; m/z (ES+) 531.3 (100%, [M+H]+); found 
531.2615, C30H34N4O5 requires MH 531.2602  
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[2-({N-[(2R)-1-hydroxypent-4-en-2-yl]1-
methyl-1H-imidazole-4-sulfonamido}methyl)phenylʹ]methyl}carbamate 265c 
  
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (62 mg, 
0.34 mmol), pyridine (1 mL) and amine 234D (72 mg, 0.069 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the sulfonamide 265c (20.9 
mg, 0.038 mmol, 55%) as a colourless glass; Rf 0.1 (90:10, CHCl3—MeOH);     
     2 
(c. 1, CH2Cl2); δH (500 MHz; CDCl3) 7.43-7.38 (2H, m, ), 7.32-7.22 (2H, m, ), 7.22-7.13 
(4H, m, ), 6.86 (1H, ap t, J 6.5), 6.78 (1H, d, J 7.9), 5.95 (1H, ddt, J 15.9, 10.2 and 4.9, 
propenyl 2-H), 5.58 (1H, br s, NH), 5.49-5.36 (1H, m, 4-H), 5.32 (1H, dd, J 17.3 and 
1.7, propenyl 3-HA), 5.18 (1H, dd, J 10.2 and 1.7, propenyl 3-HB), 5.12 (2H, s, benzyl 
o(o)), 4.89-4.84 (2H, m, 5-HA and 5-HB ), 4.48 (2H, d, J 5, propenyl 1-H), 4.42 (1H, d, J 
15, N(SO2Imid)CHA), 4.34 (2H, d, J 6.1, PhCH2N(CO)), 4.24 (1H, d, J 15, 
N(SO2Imid)CHB), 4.04-3.97 (1H, m, 2-H), 3.74-3.66 (1H, m, CH2OH), 3.62 (3H, s, 
NMe), 3.55 (1H, dd, J 12.5 and 3.7, CH2OH), 2.29 (1H, dt, J 14.1 and 6.7, 3-H), 2.10 
(1H, dt, J 14.1 and 7.6, 3-H); δC (75 MHz; CDCl3) 156.3 (Ph 1-C), 155.7 (C=O), 139.7 
(Imid 1-C), 138.9, 136.3, 136.1, 135.5, 133.6, 129.2 (Imid 5-C), 128.9, 128.2, 127.1, 
126.6, 126.5, 125.1, 125.0, 120.3 (Ph 4-C), 116.9 (5-C), 116.5 (propenyl 3-C), 111.9 
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(Ph 6-C), 68.1 (propenyl 1-C), 61.8 (PhCH2O), 60.9 (1-C), 60.4 (2-C), 45.0 
N(SO2Imid)CH2Ph, 41.0 (PhCH2N(CO)), 33.9 (3-C), 33.5 (NMe); νmax/cm
-1 (film) 3285, 
1713, 1531, 1455, 1336, 1275; m/z (ES+) 577.2 (100%, [M+Na]+); found 555.2280, 
C28H34N4O6S requires MNa 555.2272 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[2-({[(2R)-1-hydroxypent-4-en-2-
yl]amino}methyl)phenylʹ]methyl}carbamate 265d 
 
Following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the amine 234D (70 mg, 0.07 mmol); on completion of the reaction, the crude 
product was purified by column chromatography, eluting with 90:10 CHCl3−MeOH gave 
the amine 265d (29 mg, 0.070 mmol, 99%) as a pale yellow oil; Rf 0.45 (90:10 CHCl3—
MeOH);    
 
    
 5.6 (c. 1.5, CH2Cl2); δH (500 MHZ; CDCl3) 7.24-7.09 (6H, m, Ar), 6.83 
(1H, d, J 8.2, Ph 5-H), 6.80 (1H, t, J 7.5, Ph 6-H), 5.94 (1H, ddt, J 16, 10.3 and 5, 
propenyl 2-H), 5.71 (1H, ddt, J 17.3, 10.1 and 7, 4-H), 5.29 (1H, dd, J 16 and 1.9, 
propenyl 3-HA), 5.11 (1H, dd, J 1.3 and 10.3, propenyl 3-HB), 5.05 (2H, s, PhCH2O), 
4.97 (1H, dd, J 17.3 and 1.9, 5-HA), 4.93 (1H, dd, J 10.1 and 2.0, 5-HB), 4.45 (2H, d, J 
5, propenyl 1-H2), 4.29 (2H, s, PhCH2N(CO)), 3.78 (1H, d, J 12.5, NHCHAPh), 3.73 (1H, 
d, J 12.5, NHCHBPh), 3.50 (1H, d, J 11.2 and 4.8, 1-HA), 3.37 (1H, d, J 11.2 and 6.4, 1-
HB), 2.67-2.61 (1H, m, 2-H), 2.20-2.09 (2H, m, 3-H2); δC (75 MHz; CDCl3) 159.2 (Ph 1-
C), 157.9 (C=O), 139.2 (Phʹ), 139.1 (Phʹ), 136.8 (propenyl 2-C), 135.1 (4-C); 131.3 
(Phʹ), 130.3 (Phʹ), 130.6 (Phʹ), 130.4 (Ph), 129.1 (Phʹ), 129.9 (Ph); 121.8 (Ph 4-C), 
118.2 (5-C), 117.6 (propenyl 3-C), 113.1 (Ph 6-C), 70.1 (propenyl 1-C), 64.4 (1-C), 63.4 
(PhCH2O), 60.2 (2-C), 50.0, 43.8 , 36.9 (3-C); νmax/cm
-1  (film) 3260, 2925, 2858, 1698, 
1540, 1494, 1454, 1361; m/z (ES+) 411.2 (100%, [M+H]+); found 411.2286, C24H30N2O4 
requires MH 411.2278 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-[(2-{[1-cyclopropyl-N-(1-hydroxypent-4-en-
2-yl)formamido]methyl}phenyl)methyl]carbamate 265b 
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Following general procedure A2, cyclopropane carbonyl chloride (37 mg, 0.36 mmol), 
triethylamine (73 mg, 0.72 mmol) and amine 234D (75 mg, 0.072 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with CHCl3 gave the amide 265b (15 mg, 0.031 mmol, 44%) 
as a colourless glass; Rf 0.41 (CHCl3);     
    
 8 (c. 1.5, CH2Cl2); δH (500 MHz; CDCl3) 
7.47-7.22 (6H, m, Ar), 6.94 (1H, t, J 7.4, Ar 3-C), 6.88 (1H, d, J 8.3, Ar 4-C), 6.04 (1H, 
ddt, J 17.3, 10.4 and 5, propenyl 2-H), 5.75 (1H, ddt, J 17.1,  and 6.9, 4-H), 5.41 (1H, 
dd , J 17.3 and 1.5, propenyl 3-HA), 5.30-5.22 (3H, m, PhCH2O and propenyl 3-HB), 
5.13-5.03 (3H, m, NH and 5-HAB), 4.87 (1H, d, J 17.5, N(CO)CHAPh), 4.67 (1H, d, J 
17.5, N(CO)CHBPh), 4.57 (2H, d, J 4.9, PhCH2NH(CO)), 4.42 (2H, d, J 5.8, propenyl 1-
H2), 4.12-4.00 (1H, m, 2-H), 3.76 (1H, d, J 10.3, 1-HA), 3.64 (1H, br s, 1-HB), 3.47 (1H, 
br s, OH), 2.42 (2H, ap t, J 6.9, 3-HAB), 1.49 (1H, br s, 
CPr), 1.08-0.95 (2H, CPr), 0.77-
0.69 (2H, CPr); δC (75 MHz; CDCl3) 134.8, 133.1, 129.6, 128.9, 128.3, 127.6, 126.5, 
124.9, 120.6 (Ar 3-C), 117.7 (propenyl 3-C), 117.2 (5-C), 111.8 (Ar 4-C); 77.2 (propenyl 
1-C), 68.8 (PhCH2O), 64.1 (1-C), 60.0 (2-C), 47.8 (N(CO)CH2Ph), 43.4 
(PhCH2NH(CO)); 33.1 (3-C), 12.4 (
CPr), 8.4 (CPr); missing Ar 2-C and C=O; νmax/cm
-1 
(film) 3307, 2920, 2352, 2319, 1713, 1619, 1532, 1493, 1455; m/z (ES+) 479.3 (20%, 
[M+H]+) and 552.3 (100%, [M+MeCN+MeOH]+); found 479.2562, C28H34N2O5 requires 
MH 479.2540 
(15E,18R)-18-(Hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one 256d 
 
Following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the amine E-244D (33 mg, 0.035 mmol); on completion of the reaction, the 
crude product was purified by column chromatography, eluting with 90:10 CHCl3—
MeOH gave the amine 256d (11.1 mg, 0.029 mmol, 83%) as a pale yellow film;     
     
14.4 (c. 0.6, MeOH); δH (500 MHz; MeOD/DMSO-d6) 7.33-7.21 (5H, m, 8-H, 22-H, 23-
H, 24-H and 25-H), 7.18 (1H, d, J 7.2, 9-H), 6.83 (1H, d, J 8.4, 11-H), 6.78 (1H, d, J 
7.2, 10-H), 6.09 (1H, br s, 16-H), 5.68 (1H, d, J 15.8, 15-H), 5.08 (1H, d, J 11.6, 6-H), 
5.02 (1H, d, J 11.6, 6-H), 4.42 (2H, s, 14-H), 4.24 (1H, d, J 14.4, 2-H), 4.15 (1H, d, J 
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14.4, 2-H), 4.02 (1H, s, 18-H), 3.71-3.52 (2H, m, 20-H), 3.25-2.92 (2H, m, CHABOH), 
2.37 (2H, br s, 17-H); δC (125 MHz; MeOD/DMSO-d6) 159.7 (12-C), 159.4 (CO), 133.2 
, 132.1, 130.3, 129.8, 122.4 , 113.9 (9-C), 106.4 (11-C), 68.6 (14-C), 64.9 (6-C), 62.3 
(CH2OH), 44.7 (20-C), 31.4 (17-C), 2-C and aromatic carbons missing; νmax/cm
-1 (film) 
3006, 2989, 2409, 1715, 1459; m/z (ES+) 383.2 (100%, [M+H]+); found 383.1955, 
C24H30N2O4 requires MH 383.1965 
(15E,18R)-18-(Hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one 257 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine Z-244D (50 mg, 0.05 mmol); on completion of the reaction it was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 90:10 CH2Cl2-MeOH gave the 
amine 159d (10.4 mg, 0.027 mmol, 54%) as a pale yellow film; Rf 0.51 (CH2Cl2—
EtOH—NH4OH 50:8:1);     
    
 0.3 (c. 1, MeOH); δH (500 MHz; MeOD/DMSO-d6) 7.38-
7.20 (6H, m, Ar), 7.05-6.94 (1H, m, 11-H), 6.90 (1H, t, J 7.4, 9-H), 5.83 (1H, dt, J 11.6 
and 6.0, 15-H), 5.7 (1H, dt, J 11.6 and 7.1, 16-H), 5.19 (1H, d , J 10.9, 6-HA), 4.91 (1H, 
d, J 10.9, 6-HB), 4.62 (1H, dd, J 12.1 and 6.3, 14-HA), 4.57 (1H, dd, J 12.1 and 5.8, 14-
HB), 4.37 (1H, d, J 13.8, 2-HA), 4.29 (1H, d, J 13.8, 2-HB), 3.88 (1H, d, J 12.1, 20-HA), 
3.78 (1H, d, J 12.1, 20-HB), 3.66 (1H, dd, J 11.2 and 4.1, CHAOH), 3.41 (1H, dd, J 11.2 
and 6.6, CHBOH), 2.84-2.78 (1H, m, 18-H), 2.47 (1H, dt, J 15.3 and 6.7, 17-HA), 2.37 
(1H, dt, J 15.3 and 7.6, 17-HB); δC (125 MHz; MeOD/DMSO-d6) 158.7 (12-C), 138.1, 
133.6, 132.9 (16-C), 131.5, 131.3, 128.9, 126.9 (15-C), 121.8 (9-C), 114.4 (11-C), 66.1 
(2-C), 64.6 (6-C), 64.1 (CH2OH), 60.8 (18-C), 50.1 (20-C), 31.0 (17-C), C=O missing; 
νmax/cm
-1 (film) 3055, 2988, 2305, 1669, 1605, 1522, 1421, 1262; m/z (ES+) 383.2 
(100%, [M+H]+); found 383.1965, C24H30N2O4 requires MH 383.1965 
  
179 
 
(15E,18R)-18-(Hydroxymethyl)-4-oxo-N-(pyridin-3-yl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaene-19-
carboxamide 256a  
 
Following general procedure A1, 3-pyridyl isocyanate (10 mg, 0.06 mmol) and amine 
E-244D (31 mg, 0.033 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S2, tetra-n-butylammonium fluoride 
(1M, 0.1 mL) was added to the crude product; on completion of the reaction, the crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the urea 256a (18 mg, 0.033 mmol, 99%) as a pale yellow film; Rf 0.41 (90:10, 
CHCl3—MeOH);     
    
 12 (c. 0.8, CH2Cl2); δH (500 MHZ; MeOD; 333 K) 8.38 (1H, s, 
Ar), 8.09 (1H, s, Ar), 7.69 (1H, s, Ar), 7.50 (1H, s, J 7.7, Ar), 7.32-7.11 (6H, m, Ar), 
6.91-6.86 (2H, m, 10 and 11-H), 5.87 (1H, dd, J 15.1 and 6.6, 15 or 16-H), 5.85-5.81 
(1H, m, 15 or 16-H), 4.96-4.05 (9H, m, 2-H, 6-H, 14-H, 18-H and 20-H); 3.81-3.74 (2H, 
m, CHABOH), 2.63 (1H, br s, 17-H), 2.49 (1H, d, J 12.6, 17-H); δC (75 MHz; MeOD; 333 
K) 159.0 (12-C), 158.8 (C=O), 158.6 (C=O), 144.2 (Py), 142.7 (Py), 132.6, 131.4, 
130.5, 129.8 (15 or 16-C), 129.4 (15 or 16-C), 128.3 (Py), 124.9, 121.5, 113.2 (11-C), 
69.1 (14-C), 64.8 (6-C), 54.7 (20-C), 39.6 (2-C), 30.7 (17-C) ; νmax/cm
-1 (film) 3281, 
3053, 2926, 2127, 1707, 1661, 1531, 1456, 1421, 1262; m/z (ES+) 503.2 (100%, 
[M+H]+); found 503.2311, C28H30N4O5 requires MH 503.2289 
full carbon assignment was not possible due to rotamers 
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(15E,18R)-19-Cyclopropanecarbonyl-18-(hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one 256b 
 
Following general procedure A2, cyclopropane carbonyl chloride (19.3 mg, 0.2 mmol), 
triethylamine (100 mg, 1 mmol) and amine E-244D (35 mg, 0.037 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with CHCl3 gave the amide 256b (8.1 mg, 0.018 mmol, 47%); 
as a pale yellow oil; Rf 0.23 (CHCl3);     
     5.5 (c. 0.4, MeOH); δH (500 MHz; MeOD; 
233 K) 7.71 (1H, d, J 7.7, Ar), 7.45-7.16 (5H, m, Ar), 7.01 (1H, d, J 8.4, Ar); 6.89 (1H, t, 
J 7.3, 9-H), 6.13 (1H, d, J 10.9, 6-HA), 5.93 (1H, dd, J 15.5 and 9.1, 15-H), 5.64 (1H, d, 
J 15.5, 16-H), 5.24-5.19 (1H, m, 18-H), 4.94 (1H, d, J 18.3, 2-HA), 4.84 (1H, d, J 13.6, 
20-HA), 4.58 (1H, ap t, J 9.1, 14-HA), 4.49 (1H, d, J 18.3, 2-HB), 4.38-4.32 (2H, m, 14-
HB and 6-HB), 4.01 (1H, d, J 13.6, 20-HB), 3.62-3.56 (2H, m, CHABOH), 2.5-2.29 (2H, m, 
17-HAB), 1.29 (1H, s, 
CPr), 0.85-0.80 (1H, m, CPr), 0.36 (1H, d, J 7, CPr), 0.25 (1H, d, J 
7, CPr), 0.15 (1H, br s, CPr); δC (75 MHz; CDCl3) 180.2 (C=O), 159.2 (12-C), 158.5 (7-
C), 140.2, 134.6 (15-C), 132.7, 132.1, 131.9, 131.8, 130.1, 129.9 (16-C), 128.2, 127.6, 
125.8, 121.2 (9-C), 112.0 (11-C), 69.7 (14-C), 64.2 (CH2OH), 62.7 (6-C), 57.0 (18-C), 
45.4 (20-C), 43.6 (2-C), 34.5 (17-C), 14.2 (CPr), 10.5 (CPr); νmax/cm
-1 (film) 3307, 1688, 
1623, 1530, 1495, 1456; m/z (ES+) 451.2 (100%, [M+H]+); found 451.2241, 
C26H30N4O6S1 requires MH 451.2227 
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(15E,18R)-18-(Hydroxymethyl)-19-(1-methyl-1H-imidazole-4-sulfonyl)-5,13-dioxa-
3,19-diazatricyclo[19.4.0.07,12]pentacosa-1(25),7,9,11,15,21,23-heptaen-4-one 256c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (23 mg, 
0.13 mmol), pyridine (1 mL) and amine E-244D (30 mg, 0.03 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction, the crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the sulfonamide 256c (14.4 
mg, 0.29 mmol, 88%) as a colourless film; Rf 0.24 (90:10, CHCl3—MeOH);     
    
 10 (c. 
0.7, CH2Cl2); δH (500 MHz; MeOD; 333 K) 7.65 (1H, br s, Ar), 7.50 (2H, br s, Ar), 7.35-
7.09 (5H, m, Ar), 6.94-6.87 (3H, m, 9, 10 and 11-H); 5.60 (2H, br s, 15 and 16-H), 5.21 
(1H, br s, 6-H), 5.04 (1H, br s, 6-H), 4.53-4.28 (4H, 14-H and 20-H), 3.92 (1H, dd, J 
11.2 and 6.7, CHAOH), 3.86-3.65 (3H, m, 18-H and 2-H), 3.59 (1H, dd, J 11.2 and 6.5, 
CHBOH), 3.35 (3H, s, Me), 2.52-2.36 (2H, m, 17-H); δC (75 MHz; CDCl3) 159.1 (12-C), 
158.5 (C=O), 141.7 (Imid 4-C), 140.7 (Imid 2-C), 132.5, 131.4, 130.5, 128.9, 128.4, 
126.3, 121.3 (9-C), 112.9 (11-C), 68.7 (14-C), 65.0 (CH2OH), 64.8 (6-C), 44.7 (20-C), 
40.7 (2-C), 34.9 (17-C), 34.2 (NMe); νmax/cm
-1 (film) 3308, 2822, 1942, 1708, 1604, 
1530, 1495, 1455, 1331; m/z (ES+) 527.2 (100%, [M+Na]+); found 527.1948, 
C26H30N4O6S1 requires MNa 527.1959 
Full carbon assignment was not possible due to rotamers 
[(5E,3R)-9-(Trifluoromethane)sulfonyl-1,2,3,4,7,8,9,10-octahydro-2,9-
benzodiazacyclododecin-3-yl]methanol 159d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 246D (66 mg, 0.07 mmol); on completion of the reaction it was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
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was purified by column chromatography, eluting with CH2Cl2:EtOH:NH4OH 50−8−1 
gave the amine 159d (12.2 mg, 0.032 mmol, 46%) as a pale yellow film; Rf 0.71 
(CH2Cl2—EtOH—NH4OH, 50:8:1);     
    
 3.8 (c. 0.6, MeOH); δH (500 MHz; MeOD; 333 
K) 7.40-7.27 (4H, m, Ar), 5.34 (1H, ddd, J 15.8, 8.4 and 3.9, 5 or 6-H), 5.25 (1H, ddd, J 
15.8, 10. and 5.6, 5 or 6-H), 5.09 (1H, d, J 15.9, 10-HA), 4.85 (1H, d, J 15.9, 10-HB), 
4.02 (1H, d, J 13.6, 1-HA), 3.73 (1H, d, J 13.6, 1-HB), 3.66 (1H, ddd, J 15, 6.8 and 4.3, 
CHAOH), 3.55 (1H, dd, J 10.7 and 5.9, 8-HA), 3.54 (1H, dd, J 10.7 and 3.6, 8-HB), 3.45 
(1H, ddd, J 15 and 7.7, 3.6, CHBOH), 2.68 (1H, dtd, J 11.4, 5.8 and 2.6, 3-H), 2.35-2.28 
(2H, m, 4-HA and 7-HA), 2.27-2.18 (1H, m, 7-HB), 1.84-1.72 (1H, m, 4-HB); δC (125 MHz; 
MeOD) 140.1 (Ar), 134.3 (Ar); 132.3 (5 or 6 C), 132.1 (5 or 6 C), 130.7 (Ar), 129.9 (Ar), 
129.3 (Ar), 129.1 (Ar); 121.6 (q, J 318, (CF3), 79.8 (10-C), 66.4 (CH2OH), 59.4 (3-C), 
51.7 (1-C), 49.2 (8-C), 36.5 (4-C), 34.1 (7-C); νmax/cm
-1 (film) 3348, 2928, 2353, 2256, 
2128, 1723, 1644, 1455, 1384; m/z (ES+) 379.1 (100%, [M+H]+); found 379.1309, 
C16H21F3N2O3S1 requires MH 379.1298 
(5E,3R)-3-(Hydroxymethyl)-N-(pyridin-3-yl)-9-(trifluoromethane)sulfonyl-
1,2,3,4,7,8,9,10-octahydro-2,9-benzodiazacyclododecine-2-carboxamide 159a 
 
Following general procedure A1, 3-pyridyl isocyanate (18 mg, 0.15 mmol) and amine 
246D (70 mg, 0.075 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product; on completion of the reaction it was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 50:8:1 CH2Cl2—EtOH—
NH4OH gave the urea 159a (28.8 mg, 0.058 mmol, 77%) as a colourless solid; m.p. 
78.9-81.2 ˚C (DMSO); Rf 0.89 (50:8:1, CH2Cl2—EtOH—NH4OH);     
     1.6 (c. 1.4, 
MeOH); δH (300 MHz; DMSO-d6; 343 K) 8.60 (1H, d, J 2.6, Py 2-H), 8.56 (1H, s, NH), 
8.16 (1H, dd, J 4.6 and 1.6, Py 6-H), 7.84 (1H, ddd, J 8.3, 2.6 and 1.6, Py 4-H), 7.48-
7.23 (5H, m, Ar and Py 5-H), 5.22 (1H, br s, 5- or 6-H), 4.97 (1H, br s, 5- or 6-H), 4.85 
(1H, d, J 14.4, 1-HA or 10-HA), 4.80 (1H, d, J 16.6, 1-HA or 10-HA), 4.63 (1H, d, J 16.6, 
1-HB or 10-HB), 4.39 (1H, d, J 14.4, 1-HB or 10-HB), 4.31 (1H, s, 3-H), 3.72 (2H, s, 
CHABOH), 3.54 (1H, d, 8-HA), 3.45-3.31 (1H, m, 8-HB), 2.60-2.46 (1H, m, 4-HA), 2.38-
2.21 (1H, m, 4-HB), 2.07-1.93 (2H, m, 7-HAB); δC (75 MHz; DMSO-d6/MeOD; 333 K) 
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158.5 (C=O), 144.3 (Py 2-C), 142.9 (Py 4-C), 129.9, 129.6, 128.4, 125.0, 120.8, 62.9 
(CH2OH), 53.6 (8-C), 33.9 (7-C), 33.7 (4-C), 10-C, 3-C and CF3 missing; νmax/cm
-1 (film) 
3006, 2989, 1638, 1588, 1532, 1478, 1424, 1388; m/z (ES+) 499.2 (100%, [M+H]+); 
found 499.1610, C22H25F3N4O4S requires MH 499.1621 
Full carbon assignment was not possible due to rotamers 
[(5E,3R)-2-Cyclopropanecarbonyl-9-(trifluoromethane)sulfonyl-1,2,3,4,7,8,9,10-
octahydro-2,9-benzodiazacyclododecin-3-yl]methanol 159b 
 
Following general procedure A2, cyclopropane carbonyl chloride (35 mg, 0.34 mmol), 
triethylamine (69 mg, 0.68 mmol) and amine 246D (64 mg, 0.068 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product; 
on completion of the reaction it was quenched with methoxytrimethylsilane (0.5 mL) 
and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 70:30 petrol—EtOAc gave the amide 159b (20 mg, 0.045 
mmol, 66%) as a pale yellow oil; Rf 0.41 (70:30, petrol—EtOAc);     
     3 (c. 1.3, 
CH2Cl2); δC (500 MHz; DMSO-d6; 343 K) 7.30-6.75 (4H, m, Ar), 5.37-2.80 (10H, m, 5-
H, 6-H, 1-H2, 8-H2, 10-H2 and CH2OH), 2.35-2.23 (1H, m, 3-H), 2.18-1.81 (2H, m, 4-HA 
and 7-HA), 1.80-1.53 (2H, m, 4-HB and 7-HB), 0.74-0.32 (5H, m, 
CPr); δC (125 MHz; 
DMSO-d6; 343 K) 173.5, 128.9, 128.5, 127.0, 124.1, 121.5, 118.9, 59.6, 54.7, 51.5, 
47.3, 32.3, 30.8, 30.5, 28.9, 11.0, 7.9, 7.8, 7.3, CF3 missing; νmax/cm
-1 (film) 3388, 3007, 
2989, 2949, 1726, 1625, 1455, 1428, 1387, ; m/z (ES+) 447.2 (100%, [M+H]+); found 
447.1567, C20H25F3N2O4S  requires MH 447.1560 
Full proton and carbon assignment was not possible due to severely broad peaks 
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[(5E,3R)-2-(1-Methyl-1H-imidazole-4-sulfonyl)-9-(trifluoromethane)sulfonyl-
1,2,3,4,7,8,9,10-octahydro-2,9-benzodiazacyclododecin-3-yl]methanol 159c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (68 mg, 
0.33 mmol), triethylamine (73 mg, 0.72 mmol) and amine 246D (68 mg, 0.072 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product; on completion of the reaction it was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with EtOAc → 50:8:1 CH2Cl2—EtOH—
NH4OH gave the sulfonamide 159c (27 mg, 0.051 mmol, 72%) as a colourless glass; 
Rf 0.31 (EtOAc);     
    
 28.1 (c. 1.4, MeOH); δH (500 MHz; DMSO-d6; 343 K) 7.87 (1H, 
s, Imid), 7.85 (1H, s, Imid), 7.50-7.38 (4H, m, Ar), 4.99 (1H, d, J 17, 10-HA), 4.96-4.85 
(2H, m, 5- and 6-H), 4.51 (1H, d, J 16, 1-HA), 4.45 (1H, d, J 17, 10-HB), 4.20 (1H, d, J 
16, 1-HB), 3.76 (4H, s, NMe and 3-H), 3.69-3.50 (4H, CH2OH and 8-HAB), 2.46-2.38 
(1H, m, 4-HA), 2.33-2.26 (1H, m, 7-HA), 2.10-2.03 (1H, m, 4-HB), 2.02-1.95 (1H, m, 7-
HB); δC (125 MHz; DMSO-d6; 343 K) 139.7 (Imid 4-C), 139.3 (Imid 2-C), 128.2, 127.6, 
125.5, 122.2 (q, J 325, CF3), 59.6 (CH2OH), 50.3 (1-C), 47.7 (8-C), 33.6 (NMe), 32.8 
(4-C), 31.6 (7-C), 10-C missing; νmax/cm
-1 (film) 3286, 3056, 2947, 2306, 1712, 1532, 
1455, 1438, 1423, 1382, 1327; m/z (ES+) 523.1 (100%, [M+H]+); found 523.1295, 
C20H25F3N4O5S2 requires MH 523.1291 
(2R)-N-[(2-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-1-hydroxy-S-(1-methyl-
1H-imidazol-4-yl)pent-4ʹ-ene-2ʹ-sulfonamido 267c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (89.5 mg, 
0.49 mmol), triethylamine (100 mg, 0.99 mmol) and amine 209D (96 mg, 0.1 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
185 
 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with EtOAc gave the sulfonamide 267c (29 
mg, 0.052 mmol, 53%); Rf 0.23 (EtOAc);     
    
 3.1 (c. 1.4, CH2Cl2); δH (500 MHz; 
CDCl3) 7.62 (1H, d, J 5.8, Ar), 7.52 (1H, d, J 1.4, Imid), 7.37 (1H, d, J 1.4, Imid), 7.36-
7.31 (3H, m, Ar), 5.61-5.48 (1H, m, 4ʹ-H or 3-H), 5.52 (1H, ddt, J 16.9, 10.3 and 6.1, 3-
H or 4ʹ-H), 5.01-4.95 (3H, m, 4-HA or 5ʹ-HA , 5ʹ-HB and 4-HB), 4.92 (1H, dd, J 17.1 and 
1.6, 4-HB or 5ʹ-HB), 4.68 (2H, br s, PhCH2NTf), 4.45 (1H, d, J 15.9, N(SO2Imid)CH2Ph), 
4.35 (1H, d, J 15.9, N(SO2Imid)CH2Ph), 4.08 (1H, m, 2ʹ-H), 3.76 (4H, m, NMe and 
CHAOH), 3.67 (1H, dd, J 12.6 and 3.6, CHBOH), 3.30 (2H, t, J 8, 1-H), 2.47-2.18 (2H, 
m, 3ʹ-H), 2.10 (2H, br s, 2-H), 1.66 (1H, br s, OH); δC (75 MHz; CDCl3) 138.6 (Imid 4-C), 
136.9 (Imid 2-C), 133.3, 132.8, 131.3, 130.5, 128.5, 126.9, 126.7, 126.2, 122.8, 120.3, 
115.9 (5ʹ-C or 4-C), 115.7 (5ʹ-C or 4-C), 62.1 (1ʹ-C), 60.6 (2ʹ-C), 48.2 (PhCH2NTf), 46.3 
(N(SO2Imid)CH2Ph), 34.9 (3ʹ-C), 32.2 (NMe), 30.8 (2-C), CF3 missing; νmax/cm
-1 (film) 
3006, 2988, 2318, 1642, 1532, 1456, 1386, 1337; m/z (ES+) 551.2 (100%, [M+H]+); 
found 551.1613, C22H29F3N4O5S2 requires MH 551.1604 
 
N-[(2-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-N-
[(2R)-1-hydroxypent-4ʹ-en-2ʹ-yl]cyclopropanecarboxamide 267b 
 
Following general procedure A2, cyclopropane carbonyl chloride (55.4 mg, 0.53 mmol), 
triethylamine (107 mg, 1.06 mmol) and amine 209D (103 mg, 0.106 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 50:8:1 CH2Cl2—EtOH—NH4OH gave the amide 267b (35 
mg, 0.073 mmol, 70%) as a colourless oil; Rf 0.93 (EtOAc);     
    
 4.8 (c. 1.7, CH2Cl2);  
δH (500 MHz; CDCl3) 7.55-7.26 (4H, m, Ar), 5.79 (1H, ddt, J 17.1, 9.7 and 7.4, 4ʹ-H), 
5.52 (1H, ddt, J 17, 10.2 and 6.8, 3-H), 5.15-5.06 (2H, m, 5ʹ-H2), 4.99 (1H, d, J 10.2, 4-
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HA), 4.90 (1H, d, J 17, 4-HB), 4.91 (1H, d, J 18.4, N(C=O)CH2Ph), 4.71 (1H, d, J 18.4, 
N(C=O)CH2Ph), 4.51 (2H, br s, PhCH2NTf), 4.16-4.06 (1H, m, 2ʹ-H), 3.80 (1H, dt, J 
11.8 and 3.8, 1ʹ-HA), 3.67 (1H, dt, J 11.8 and 6.9, 1ʹ-HB), 3.40-3.26 (2H, 1-H2), 2.45 
(2H, ap t, J 7.4, 2-H2), 2.17-2.09 (2H, br s, 3ʹ-HAB), 1.46-1.36 (1H, m, 
CPr), 1.21-1.01 
(2H, m, CPr), 0.81-0.69 (2H, m, CPr); δC (75 MHz; CDCl3) 176.6 (C=O), 134.5 (4ʹ-C), 
133.0 (3-C), 130.1, 129.5, 127.8, 127.0, 118.1 (5ʹ-C), 117.9 (4-C), 64.1 (1ʹ-C), 60.1 (2ʹ-
C), 50.7 (N(C=O)CH2Ph), 48.2 (PhCH2NTf), 47.8 (1-C), 33.2 (3ʹ-C), 33.0 (2-C), 12.5 
(CPr), 8.6 (CPr), 8.5 (CPr); CF3 missing; νmax/cm
-1 (film) 3284, 3079, 3006, 2984, 1727, 
1664, 1587, 1536, 1484; m/z (ES+) 475.2 (20%, [M+H]+) and 548.3 (100%, 
[M+MeOH,MeCN,H]+); found 475.1884 , C22H29F3N2O4S1 requires MH 475.1873 
3-[(2-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-3-
[(2R)-1-hydroxypent-4ʹ-en-2ʹ-yl]-1-(pyridin-3-yl)urea 267a 
 
Following general procedure A1, 3-pyridyl isocyanate and amine 209D (99 mg, 0.1 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:8:1 CH2Cl2—EtOH—NH4OH gave 
the urea 267a (40 mg, 0.076 mmol, 76%) as a colourless glass; Rf 0.77 (50:8:1 
CH2Cl2—EtOH—NH4OH);     
     1.96 (c. 2, MeOH); δH (500 MHz; CDCl3) 9.27 (1H, br 
s, NH), 8.29 (1H, s, Py), 8.22-8.05 (2H, m, Py), 7.46-7.30 (4H, m, Ar), 7.30-7.18 (1H, 
m, Ar), 5.73 (1H, ddt, J 15.9, 11.2 and 7, 4ʹ-H), 5.55 (1H, ddt, J 17.1, 10.4 and 6.8, 3-
H), 5.09 (1H, d , J 11.2, 5ʹ-HA), 5.08 (1H, d, J 15.9, 5-HB), 4.99 (1H, d, J 10.4, 4-HA), 
4.95 (1H, d, J 17.1, 4-HB), 4.67 (4H, br s, PhCH2NTf and N(C=O)CH2Ph), 3.80-3.58 
(3H, m, 1ʹ-H2 and 2ʹ-H), 3.39 (2H, t, J 8, 1-H2), 2.58 (1H, dt, J 14.8 and 7.6, 3ʹ-HA), 2.42 
(1H, dt, J 14.8 and 7.1, 3ʹ-HB), 2.22-2.10 (2H, m, 2-H); δC (75 MHz; CDCl3) 156.7 
(C=O), 142.6 (Py), 139.7 (Py), 137.2 (Py), 136.4, 134.0 (4ʹ-C), 133.1 (3-C), 132.8, 
129.2, 128.7, 128.6, 128.1, 126.9 (Py), 124.0; 118.5 (4-C), 118.1 (5ʹ-C), 64.1 (1ʹ-C), 
59.9 (2ʹ-C), 49.8 (1-C), 48.6 (N(C=O)CH2Ph), 47.8 (PhCH2NTf), 33.3 (3ʹ-C), 32.8 (2-C), 
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CF3 missing; νmax/cm
-1 (film) 3006, 2989, 1715, 1614, 1587, 1508, 1464; m/z (ES+) 
527.2 (100%, [M+H]+); found 527.1937, C24H29F3N4O4Si  requires MH 527.1934  
N-(But-3-en-1-yl)-1,1,1-trifluoro-N-{[2-({[(2R)-1-hydroxypent-4ʹ-en-2ʹ-
yl]amino}methyl)phenyl]methyl}methanesulfonamide 267d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 209D (104 mg, 0.107 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:8:1 CH2Cl2−EtOH−NH4OH gave the 
amine 267d (40 mg, 0.098 mmol, 92%) as a pale yellow oil; Rf 0.89 (50:8:1 CH2Cl2—
EtOH—NH4OH);     
     −2 (c. 2, CH2Cl2); δH (500 MHz; MeOD) 7.37-7.22 (4H, m, Ar), 
5.74 (1H, ddt, J 17.2, 10.1 and 7.1, 4ʹ-H), 5.47 (1H, ddt, J 17.1, 10.3 and 6.9, 3-H), 5.00 
(1H, ddd, J 17.2, 3.2 and 1.4, 5ʹ-HA), 4.96 (1H, dd, J 10.1 and 1.4, 5ʹ-HB), 4.86 (1H, d, J 
10.3, 4-HA), 4.83-4.76 (1H, m, 4-HB), 4.85-4.54 (2H, br s, PhCH2NTf), 3.85 (1H, d, J 13, 
NHCHAPh), 3.78 (1H, d, J 13, NHCHBPh), 3.51 (1H, dd, J 11 and 4.9, 1ʹ-HA), 3.38 (1H, 
dd, J 11 and 6.4, 1ʹ-HB), 3.31 (2H, t, J 7.8, 1-H2), 3.21 (1H, ap p, J 1.6, OH), 2.65 (1H, 
qd, J 6.3 and 4.7, 2ʹ-H), 2.20-2.13 (2H, m, 3ʹ-H2), 1.95 (2H, br s, 2-H2); δC (75 MHz; 
CDCl3) 140.2 (Ar), 136.9 (4ʹ-C), 135.4 (3-C), 134.9 (Ar), 131.5 (Ar), 130.8 (Ar), 130.0 
(Ar), 129.2 (Ar), 121.9 (d, J 323.9, CF3), 118.3 (4-H and 5ʹ-H), 118.1 (4-H and 5ʹ-H), 
64.5 (1ʹ-C), 60.2 (2ʹ-C), 51.5 (1-C), 50.0 (PhCH2NTf), 49.7 (NHCH2Ph), 37.0 (3ʹ-C), 
34.7 (2-C); νmax/cm
-1 (film) 3402, 3079, 2984, 2881, 1642, 1456, 1387; m/z (ES+) 407.2 
(100%, [M+H]+); found 407.1623, C18H25F3N2O3S  requires MH 407.1611 
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(6S,10E,13R)-6-(2,4-Dimethoxyphenyl)-13-(hydroxymethyl)-3-oxo-N-(pyridin-3-yl)-
2,3,5,6,7,9,12,13,14,15-decahydro-1H-4,8,2,14-benzodioxadiazacycloheptadecine-
14-carboxamide 258a 
 
Following general procedure A1, 3-pyridyl isocyanate (10 mg, 0.068 mmol) and amine 
245D (35 mg, 0.034 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S2, tetra-n-butylammonium fluoride 
(1M, 0.1 mL) was added to the crude product; on completion of the reaction the crude 
product was purified by column chromatography, eluting with EtOAc gave the amine 
258a (12.5 mg, 0.021 mmol, 62%) as a yellow glass;      
     0.6 (c. 0.6, CH2Cl2); Rf 
0.29 (EtOAc); δH (500 MHz; CDCl3; 323 K) E/Z >75/<25 8.24-8.17 (2H, m, Py 2 and 6-
H), 7.96 (1H, d, Py 4-Hmin), 7.91 (1H, d, J 7.4, Py 4-H), 7.57 (1H, d, J 7.7, Py 5-H), 7.49 
(1H, d, J 7.7, Py 5-Hmin), 7.36-7.05 (5H, m, Ar), 6.92 (1H, d, J 8.4, DMB 6-H), 6.42 (1H, 
dd, J 10.7 and 2.5, DMB 5-H), 6.38 (1H, dd, J 8.4 and 2.5, DMB 5-Hmin), 6.13 (1H, s, 
DMB 3-Hmin), 5.72 (1H, ddd, J 15.9, 6.9 and 3.7, 10-H), 5.71-5.65 (2H, m,11-H and 10-
Hmin), 5.62 (1H, dt, J 11.1 and 7.2, 11-Hmin), 5.21 (1H, br s, NH), 5.12 (1H, br s, NH), 
4.83-4.01 (6H, m, 1-H2, 20-H2 and 5-H2) 3.96-3.72 (7H, m, OMe, 9-HAB and CHABOH), 
3.71 (3H, s, OMe), 3.64 (1H, dd, J 9.7 and 4.8, 7-HA), 3.58 (1H, dd, J 9.7 and 6.7, 7-
HB), 3.56-3.46 (1H, m, 6-H), 3.40 (1H, br s, 13-H), 2.63-2.53 (1H, m, 12-HA), 2.49-2.37 
(1H, m, 12-HB); δC (75 MHz; MeOD; 333 K) 159.9, 159.6, 158.0, 157.9, 156.9, 156.8, 
156.3, 143.6, 141.2, 140.9, 136.9, 136.4, 134.6, 131.3, 130.6, 129.0, 128.9, 128.8, 
128.5, 127.7, 127.4, 127.3, 127.0, 123.6, 123.5, 120.4, 104.4, 104.1, 98.8, 71.2, 71.1, 
69.1, 66.7, 65.7, 64.6, 60.3, 55.4 (OMe), 55.3 (OMe), 55.3, 44.4, 38.1, 32.3, 27.8 ; 
νmax/cm
-1 (film) 3281, 3053, 2926, 2127, 1707, 1661, 1605, 1531, 1495, 1484, 1456; 
m/z (ES+) 591.3 (100%, [M+H]+); found 591.2827, C32H38N4O7 requires MH 591.2813 
Full carbon assignment was not possible due to geometric isomers and rotamers 
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(6S,10E,13R)-14-Cyclopropanecarbonyl-6-(2,4-dimethoxyphenyl)-13-
(hydroxymethyl)-2,3,5,6,7,9,12,13,14,15-decahydro-1H-4,8,2,14-
benzodioxadiazacycloheptadecin-3-one 258b 
 
Following general procedure A2, cyclopropane carbonyl chloride (14 mg, 0.14 mmol), 
triethylamine (28 mg, 0.28 mmol) and amine 245D (29 mg, 0.028 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was added to the crude 
product; on completion of the reaction; the crude product was purified by column 
chromatography, eluting with 50:50 EtOAc—petrol gave the amide 258b (11.9 mg, 
0.022 mmol, 79%); Rf 0.66 (50:50, petrol—EtOAc);     
     0.7 (c. 0.6, MeOH); δH (500 
MHz; CDCl3; 333 K) >90/<10 E/Z 7.51-7.01 (5H, m, Ar), 6.47-6.35 (2H, m, DMB), 5.73-
5.63 (2H, m, 10 and 11-H), 5.11-3.10 (20H, m, 1-HAB, 5-HAB, 6-H, 7-HAB, 9-HAB, 15-HAB, 
CHABOH and 2 x OMe), 2.71-2.25 (2H, 12-HAB), 1.55 (1H, 
CPr), 1.06 (2H, CPr), 0.73 
(2H, CPr); δC (125 MHz; CDCl3) 176.3 (C=O), 176.1 (C=O), 174.9 (C=O), 159.8, 159.6, 
159.3, 157.9, 157.8, 156.6, 156.0, 137.3, 136.9, 134.3, 131.8, 131.2, 130.9, 130.8, 
130.7, 129.8, 129.1, 128.9, 128.8, 128.5, 128.2, 127.7, 127.4, 127.2, 126.9, 126.7, 
126.4, 126.3, 120.3, 120.1, 103.8, 103.7, 103.6, 98.5, 98.5, 98.4, 98.3, 71.5 (9-C), 71.1 
(9-C), 67.8, 66.7, 65.9, 64.4, 63.7, 55.4 (OMe), 55.4 (OMe), 44.2, 37.9, 37.3, 31.9, 12.6 
(CPr), 12.4 (CPr), 12.1 (CPr), 8.8 (CPr), 8.7 (CPr), 8.5 (CPr); νmax/cm
-1 (film) 3301, 3101, 
2996, 2131, 1706, 1591, 1611, 1526 and 1444; m/z (ES+) 539.3 (100%, [M+H]+); found 
539.2776, C30H38N2O7 requires MH 539.2752  
Full carbon assignment was not possible to mixture of geometric isomers and rotamers 
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(6S,10E,13R)-6-(2,4-Dimethoxyphenyl)-13-(hydroxymethyl)-14-(1-methyl-1H-
imidazole-4-sulfonyl)-2,3,5,6,7,9,12,13,14,15-decahydro-1H-4,8,2,14-
benzodioxadiazacycloheptadecin-3-one 258c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (10.8 mg, 
0.06 mmol), triethylamine (9.1 mg, 0.09 mmol) and amine 245D (31 mg, 0.03 mmol) 
gave the crude product after 9 h. The crude product was purified by F-SPE and 
following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the crude product; on completion of the reaction the crude. The crude product 
was purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
sulfonamide 258c (8 mg, 0.013 mmol, 43%) as a colourless glass; Rf 0.31 (90:10, 
CHCl3−MeOH);     
     2.9 (c. 0.4, MeOH); δH (500 MHZ; DMSO-d6) >80/<20 E/Z; 7.69 
(1H, d, J 1.4, Imid), 7.51 (1H, d, J 1.4, Imid), 7.50-7.43 (1H, m, Ar), 7.20-7.08 (3H, Ar), 
7.03 (1H, d, J 8.4, DMB 6-H), 6.45 (1H, d, J 2.5, DMB 3-H), 6.37 (1H, dd, J 8.4 and 2.5, 
DMB 5-H), 5.37 (1H, br s, 10 or 11-H), 5.21 (1H, br s, 10 or 11-H), 4.59-4.39 (2H, m, 1-
HA and 5-HA), 4.32-4.18 (2H, m, 1-HB and 5-HB), 4.18-4.02 (1H, m, 15-HA), 3.91 (1H, d, 
15-HB), 3.86-3.73 (2H, m, 9-HAB), 3.71 (3H, s, OMe), 3.64 (3H, s, OMe), 3.58-3.35 (5H, 
CHABOH, 7-H2 and 6-H or 13-H), 3.50 (3H, s, NMe), 3.33-3.20 (1H, 6-H or 13-H), 2.34-
2.31 (1H, m, 12-HA), 2.11 (1H, dt, J 15.4 and 9.4, 12-HB); δC (75 MHz; DMSO-d6) 
159.4, 157.6, 155.5, 139.7, 139.5, 129.8, 129.6, 128.3, 127.1, 126.5, 124.6, 120.3, 
105.0, 99.9, 98.7, 69.9, 67.5, 63.9, 55.7, 55.2, 37.3, 33.3, 32.3, 28.9; νmax/cm
-1 (film) 
3056, 2988, 2305, 2257, 2129, 1651; m/z (ES+) 615.2 (95%, [M+NH4]
+) and 637.2 
(100%, [M+Na]+); found 637.2320, C30H38N4O8S requires MNa 637.2303 
Full carbon assignment was not possible to mixture of geometric isomers and rotamers 
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(6S,13R)-6-(2,4-Dimethoxyphenyl)-13-(hydroxymethyl)-2,3,5,6,7,9,12,13,14,15-
decahydro-1H-4,8,2,14-benzodioxadiazacycloheptadecin-3-one 258d 
 
Following general procedure S2, tetra-n-butylammonium fluoride (1M, 0.1 mL) was 
added to the amine 245D (50 mg, 0.048 mmol); on completion of the reaction, the crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the amine 258d (23 mg, 0.048 mmol, 99%) as a pale yellow glass; Rf 0.16 (90:10, 
CHCl3—MeOH);     
     1.7 (c. 1.2, MeOH); δH (500 MHz; CDCl3) >80/<20 E/Z 7.40-
7.22 (5H, m, DMB 6-H and Ar), 7.12-7.03 (1H, m, ), 6.51 (1H, d, J 2.4, DMB 3-H), 6.45-
6.38 (1H, m, DMB 5-H), 5.89 (1H, dt, J 14.1 and 6.7, 11-H), 5.69-5.61 (m, 11-Hmin and 
10-Hmin), 5.57 (1H, dt, J 14.1 and 4.7, 10-H), 4.43-4.29 (2H, m, 1-H2 and 15-H2) 4.06-
3.84 (4H, 9-HAB and 5-HAB), 3.79 (3H, s, OMe), 3.76 (3H, s, OMe), 3.74-3.51 (4H, 
CHABOH and 7-HAB), 2.91 (1H, 13-H), 2.82 (p, 13-H
min), 2.57-2.50 (12-Hmin), 2.45-2.36 
(1H, 12-H), 2.28-2.21 (1H, 12-H); δC (75 MHz; CDCl3) 160.2 (DMB 2 or 4-C
min), 
160.1(DMB 2 or 4-C), 158.4 (DMB 2 or 4-C), 158.4 (DMB 2 or 4-Cmin), 156.9 (C=O), 
138.9, 138.1, 131.1, 131.0, 130.9 (10-C), 130.7 (11-C), 129.7, 129.4, 129.3, 128.6, 
128.4, 127.1, 120.8, 104.5 (DMB 5-C), 99.1 (DMB 3-Cmin), 98.9 (DMB 3-C), 74.0 (min), 
71.7 (9-C), 70.1 (9-Cmin), 67.6 (8-Cmin), 67.1 (8-C), 66.5, 64.4 (CH2OH), 63.3 
(CH2OHmin), 59.9 (13-C), 59.5 (13-C
min), 55.7 (2 × OMe), 50.9 (1-C), 50.3 (1-Cmin), 
45.4 (5-Cmin), 44.6 (5-C), 38.4 (15-C), 37.3 (12-Cmin), 35.0 (12-C), 30.1 (6-C); νmax/cm
-1 
(film) 3278, 2913, 2449, 2414, 1683, 1614, 1507, 1464, 1438; m/z (ES+) 471.3 (100%, 
[M+H]+); found 471.2496, C26H34N2O6 requires MH 471.2490 
Full carbon assignment was not possible to mixture of geometric isomers and rotamers 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({[(2R)-1-
hydroxypent-4-en-2-yl][(pyridin-3-
yl)carbamoyl]amino}methyl)phenyl]methyl}carbamate 266a 
192 
 
 
Following general procedure A1, 3-pyridyl isocyanate (8 mg, 0.066 mmol) and amine 
235D (35 mg, 0.033 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
urea 266a (20.3 mg, 0.033 mmol, 99%) as a colourless glass; Rf 0.13 (70:30, petrol—
EtOAc);     
     −1.5 (c. 1, MeOH); δH (500 MHz; CDCl3) 8.94 (s, Py)
min, 8.84 (1H, s, 
Py), 8.52 (s, Py) min, 8.32 (1H, s, Py), 8.12 (1H, s, Py), 7.54 (1H, s, Py), 7.45-6.54 (5H, 
Ar), 6.45-6.30 (2H, m, DMB 3 and 5-H), 5.81 (1H, ddt, J 17.4, 10.6 and 7.1, propenyl 2-
H), 5.69-5.62 (1H, m, 4-H), 5.17 (1H, dd , J 17.4 and 1.8, propenyl 3-HA), 5.08 (1H, d, J 
10.6, propenyl 3-HB), 5.01-4.91 (2H, m, 5-HAB), 4.64 (1H, s, N(COPy)CH2Ph or 
PhCH2N(CO)), 4.46 (1H, s, N(COPy)CH2Ph or PhCH2N(CO)), 4.39-4.09 (5H, propyl 1-
H2, 2-H, N(COPy)CH2Ph or PhCH2N(CO)), 3.90 (2H, d, J 5.6, propenyl 2-H2), 3.81-3.46 
(11H, 2 x OMe, propyl 3-H2 and propyl 2-H, CH2OH), 2.35-2.12 (2H, m, 3-H); δC (125 
MHz; C6D6/MeOH; 343 K) 160.3 (DMB 2 or 4-C), 158.8 (DMB 2 or 4-C), 138.9, 135.2, 
129.8, 129.33, 129.3, 128.9, 120.5, 119.9 (5-C), 117.5 (propenyl 3-C) min, 116.0 
(propenyl 3-C), 105.1(DMB 5-C), 99.2 (DMB 3-C), 71.9 (propenyl 1-C), 71.0 (propenyl 
1-C)min, 70.9 (propyl 3-C), 66.1 (1-C), 63.1min, 62.5 (2-C) , 56.9, 55.2 (OMe), 54.9 
(OMe), 54.1min, 49.4 (propyl 1-C), 46.4, 43.4min, 41.7, 38.7 (propyl 2-C), 35.8min, 33.9 (3-
C), 32.1min; νmax/cm
-1 (film) 3333, 2930, 2852, 1681, 1613, 1566, 1508, 1466; m/z (ES+) 
619.3 (100%, [M+H]+); found 619.3149 , C34H42N4O7 requires MH 619.3126 
Full carbon assignment was not possible to mixture of rotamers 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({N-[(2R)-1-
hydroxypent-4-en-2-yl]1-methyl-1H-imidazole-4-
sulfonamido}methyl)phenyl]methyl}carbamate 266c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (30 mg, 
0.16 mmol), triethylamine (32 mg, 0.32 mmol) and amine 235D (34 mg, 0.032 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
sulfonamide 266c (14.8 mg, 0.023 mmol, 73%) as a colourless oil; Rf 0.06 (70:30 
petrol—EtOAc);     
     0.8 (c. 0.7, MeOH); δH (500 MHz; CDCl3) 7.46 (2H, s, Ar), 7.35 
(1H, s, Ar), 7.32-7.28 (1H, m, Ar), 7.27-7.19 (2H, m, Ar), 7.10 (1H, d, Ar), 6.44-6.41 
(2H, m, DMB 3 and 5-H), 5.85 (1H, ddt, J 17.3, 10.7 and 5.5, propenyl 2-H), 5.55-5.41 
(2H, 4-H and NH), 5.22 (1H, dd, J 17.3 and 1.8, propenyl 3-HA), 5.12 (1H, dd, J 10.5 
and 1.8, propenyl 3-HB), 4.96-4.90 (2H, m, 5-HAB), 4.46 (1H, d, N(SO2Imid)CHAPh), 
4.39-4.27 (5H, propyl 1-HAB PhCH2N(CO) and N(SO2Imid)CHBPh), 4.04 (1H, t, J 9.5, 2-
H), 3.94 (2H, s, propenyl 1-H2), 3.77 (6H, 2 x OMe), 3.71 (3H, NMe), 3.64-3.57 (5H, 1-
HAB and propyl 3-HAB and propyl 2-H), 2.39-2.31 (1H, 3-HA), 2.15 (1H, dt, J 15 and 7.7, 
3-HB); δC (75 MHz; CDCl3) 159.6 (DMB 2 or 4-C), 158.3 (DMB 2 or 4-C), 156.7 (C=O), 
140.9 (Imid), 138.7 (propenyl 2-C) , 137.2 (Imid), 134.9, 134.8, 133.9, 130.7, 129.6, 
128.9, 128.1, 127.5, 124.5, 120.1, 117.5 (propenyl 3-C), 116.7 (5-C), 104.0 (DMB 5-C), 
98.6 (DMB 3-C); 71.9 (propenyl 1-C), 70.4 (1-C), 65.3 (propyl 1-C), 63.5 (2-C), 62.6 
(propyl 3-C), 55.4 (OMe), 55.3 (OMe), 48.8 (N(SO2Imid)CH2Ph), 42.1 PhCH2N(CO), 
37.9 (propyl 2-C), 36.7 (3-C), 34.2 (NMe); νmax/cm
-1 (film) 3055, 2987, 2305, 1713, 
1612, 1508, 1421 and 1264; m/z (ES+) 665.3 (100%, [M+Na]+); found 665.2584, 
C32H42N4O8S requires MNa 665.2616  
  
194 
 
(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({1-cyclopropyl-
N-[(2R)-1-hydroxypent-4-en-2-yl]formamido}methyl)phenyl]methyl}carbamate 
266b 
 
Following general procedure A2, cyclopropane carbonyl chloride (15 mg, 15 mmol), 
triethylamine (30 mg, 30 mmol) and amine 235D (32 mg, 0.03 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with 90:10 CHCl3—MeOH gave the amide 266b (7.6 mg, 0.017 mmol, 56%) as 
a colourless glass; Rf 0.66 (70:30, petrol—EtOAc);     
    
 1.3  (c. 0.5, MeOH); δH (500 
MHz; C6D6) 7.41 (1H, d, J 7.6, Ar), 7.31-7.20 (1H, m, Ar), 7.12 (1H, t, J 7.8, Ar), 7.06 
(1H, t, J 7.6, Ar), 6.99 (1H, d, J 7.4, Ar), 6.48-6.45 (2H, m, DMB 3 and 5-H), 5.85 (1H, 
ddt, J 17.4, 10.6 and 5.4, propenyl 2-H), 5.76 (1H, ddt, J 17.2, 10.1 and 7.4, 4-H), 5.22 
(1H, dd , J 17.4 and 1.9, propenyl 3-HA), 5.09 (1H, dd, J 17.2 and 1.8, 5-HA), 5.04 (1H, 
d, J 10.6, propenyl 3-HB), 5.01 (1H, d, J 10.1, 5-HB), 4.79 (1H, dd, J 10.7 and 7.2, 
propyl 1-HA), 4.69 (1H, dd, J 10.7 and 6.3, propyl 1-HB), 4.63 (1H, br s, PhCHAN(CO)), 
4.51 (1H, br s, PhCHBN(CO)), 4.16 (2H, d, J 6, propyl 1-H), 4.11 (1H, br s, propyl 2-H), 
3.94 (1H, p, 2-H), 3.89 (2H, s, propenyl 1-H2), 3.76-3.74 (2H, m, N(CO
CPr)CH2Ph), 
3.61 (2H, br s, propyl 3-H), 3.47 (3H, s, OMe), 3.39 (3H, s, OMe), 2.43 (1H, br s, OH), 
1.49-1.11 (3H, m, CPr and 3-H), 0.66-0.44 (2H, m, CPr); δC (75 MHz; CDCl3) 160.4 
(DMB 2 and 4-C), 135.5, 129.5, 128.9, 124.8, 121.0, 117.1 (propenyl 2-C), 115.8 (5-C), 
105.0 (DMB 3-C), 72.0 (propenyl 1-C), 71.3 (1-C), 65.9 (propyl 1-C), 63.9 (propyl 3-C), 
60.3 (2-C), 55.1 (OMe), 54.9 (OMe), 42.6 (PhCHAN(CO), 39.2 (3-C), 12.5 (
CPr), 8.1 
(CPr), 7.9 (CPr), N(COCPr)CH2Ph missing; νmax/cm
-1 (film) 3326, 3006, 2959, 2929, 
1713, 1614, 1508, 1463 and 1439; m/z (ES+) 567.3 (100%, [M+H]+); found 567.3057, 
C32H42N2O7 requires MH 567.3065 
Full carbon assignment was not possible to mixture of rotamers 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-({[(2R)-1-
hydroxypent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 266d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 235D (30 mg, 0.03 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
266d (9.4 mg, 0.019 mmol, 63%) as a pale yellow oil; Rf 0.34 (90:10, petrol—EtOAc); 
   
 
    
 80.4 (c. 0.5, MeOH); δH (500 MHz; CDCl3) 7.36-7.26 (4H, m, Ar), 7.12 (1H, d, 
Ar), 6.48-6.42 (2H, m, DMB 3 and 5-H), 5.88 (1H, ddt, J 16.8, 10.2 and 5.5, propenyl 2-
C), 5.81 (1H, ddt, J 17.1, 9.9 and 7.3, 4-H), 5.24 (1H, d , J 16.8, propenyl 3-HA), 5.18-
5.12 (3H, m, propenyl 3-HB and 5-HAB), 4.46-4.33 (4H, m, propyl 1-H2 and 
PhCH2N(CO)), 3.97 (2H, s, propenyl 1-H2), 3.90-3.80 (8H, m, OMe and NHCH2Ph), 
3.65 (4H, br s, 1-HA, propyl 2-H and propyl 3-HAB), 11.1 and 5.9 (1H, dd , J 11.1 and 
5.9, 1-HA), 2.28 (1H, ap t , J 5.6, 2-H), 2.31 (2H, ap t, J 6.9, 3-H); δC (75 MHz; CDCl3) 
159.5 (DMB 2 and 4-C), 158.4 (C=O), 134.9, 134.5, 132.5, 130.4, 128.9, 127.9, 121.9, 
120.1, 118.1 (propenyl 3-C), 116.7 (5-C), 103.9 (DMB 5-C), 98.6 (DMB 3-C), 71.9 
(propenyl 1-C), 70.6 (1-C), 63.5 (2-C), 55.4 (OMe), 55.3 (OMe), 38.1 (propyl 2-C), 35.5 
(3-C), N(COCPr)CH2Ph  and NHCH2Ph missing; νmax/cm
-1 (film) 3326, 3004, 2922, 
1705, 1614, 1587, 1508, 1464; m/z (ES+) 499.3 (100%, [M+H]+); found 499.2797, 
C28H38N2O6 requires MH 499.2803  
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(3R,9R,10R)-9-Hydroxy-3-(hydroxymethyl)-10-methyl-N-(pyridin-3-yl)-12-
(trifluoromethane)sulfonyl-2,3,4,7,8,9,10,11,12,13-decahydro-1H-2,12-
benzodiazacyclopentadecine-2-carboxamide 259a 
 
Following general procedure A1, 3-pyridyl isocyanate (14 mg, 0.112 mmol) and amine 
247D (63 mg, 0.056 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by mass−directed liquid chromatography and gave the urea 259a (3.8 mg, 
0.0067 mmol, 12%) as a colourless film; Rf 0.4 (EtOAc); νmax/cm
-1 (film) 2921, 2851, 
1667, 1580, 1385, 1260, 1225, 1188, 1107 and 1025; m/z (ES+) 553.2 (100%, 
[M−H2O]
+); found 533.2094, C26H31F3N4O4S requires M−H2O 553.2091 
Unable to obtain 1H and 13C spectra due to insufficient material 
(4R,5R,11R)-12-Cyclopropanecarbonyl-11-(hydroxymethyl)-4-methyl-2-
(trifluoromethane)sulfonyl-2,3,4,5,6,7,10,11,12,13-decahydro-1H-2,12-
benzodiazacyclopentadecin-5-ol 259b 
 
Following general procedure A2, cyclopropane carbonyl chloride (31 mg, 0.29 mmol), 
triethylamine (60 mg, 0.59 mmol) and amine 247D (67 mg, 0.059 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by mass−directed liquid 
column chromatography and gave the amide 259b (12.8 mg, 0.025 mmol, 42%) as a 
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colourless glass; Rf 0.39 (EtOAc);     
    
 11.4 (c. 0.6, MeOH); δH (500 MHz; CDCl3)  
7.64 (d, J 7.8, Armin), 7.40-7.17 (4H, m, Ar), 5.52 (1H, dd, J 10.8 and 5.8, 8 or 9-HZ), 
5.49-5.43 (1H, m, 8 or 9-HZ and E), 5.12 (1H, d, J 14, 1-HA
Z), 5.08-4.99 (m, mix 1-HA
E
B
Z), 
4.92 (1H, d, J 16.7, 1-HB
E), 4.25 (1H, m, J 11.2 and 5.7, CHA
ZOH), 4.18 (1H, dd, J 11.2 
and 5.4, CHB
ZOH), 3.98 (d, J 13.5, 13-HA
E), 3.93 (d, J 13.5, 13-HB
E), 3.83 (1H, d, J 
11.7, 13-HAB
Z), 3.79 (1H, s, 5-HZ), 3.66 (1H, d, J 11.7, 13-HZ), 3.55 (d, J 9.5, CHB
EOH), 
3.45 (1H, dd, J 14.6 and 10.7, 3-HA), 3.13 (1H, dd, J 14.6 and  4.8, 3-HB), 3.01-2.90 
(1H, 11-H), 2.42 (d, J 13.5, 10-HA
E), 2.28 (1H, dt, J 14.7 and 9.5, 10-HAB
Z), 2.14 (2H, s, 
10-HB
E, 7-HAB
Z), 2.08-1.48 (9H, m, CPr, 4-H, 7-HAB, 10-HAB, 6-HAB), 1.06-1.01 (2H, m, 
CPr), 0.94-0.85 (2H, m, CPr), 0.70 (3H, d, J 6.9, MeZ), 0.54 (d, J 6.5, MeE); δC (75 MHz; 
CDCl3) 174.7, 164.9, 138.2, 132.7, 130.7, 129.4, 128.2, 128.0, 127.8, 127.2, 76.7, 
66.7, 65.7, 63.5, 56.9, 56.6, 53.3, 50.1, 49.8, 47.9, 32.5, 30.9, 22.8, 12.8, 9.6, 9.4, 8.4, 
8.3; νmax/cm
-1 (film) 3759, 3586, 2940, 1725, 1456, 1383, 1274, 1266, 1225; m/z (ES+) 
519.2 (100%, [M+H]+); found 519.2155, C24H33F3N2O5S requires MH 519.2135 
full carbon assignment was not possible to mixture of geometric isomers and rotamers 
(4R,5R,11R)-11-(Hydroxymethyl)-4-methyl-12-(1-methyl-1H-imidazole-4-sulfonyl)-
2-(trifluoromethane)sulfonyl-2,3,4,5,6,7,10,11,12,13-decahydro-1H-2,12-
benzodiazacyclopentadecin-5-ol 259c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (52 mg, 
0.29 mmol), triethylamine (58 mg, 0.58 mmol) and amine 247D (65 mg, 0.057 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by mass−directed preparative liquid chromatography, and gave the 
sulfonamide 266c (4.1 mg, 0.007 mmol, 12%) as a colourless glass; Rf 0.12 (CHCl3); 
    
     0.3 (c. 0.4, MeOH); νmax/cm
-1 (film) 3006, 2990, 1462, 1384, 1335; m/z (ES+) 
617.1 (100%, [M+Na]+); found 595.1898, C24H33F3N4O6S2 requires MH 595.1872 
Unable to obtain 1H and 13C spectra due to insufficient material  
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(4R,5R,11R)-11-(Hydroxymethyl)-4-methyl-2-(trifluoromethane)sulfonyl-
2,3,4,5,6,7,10,11,12,13-decahydro-1H-2,12-benzodiazacyclopentadecin-5-ol 259d 
  
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 247D (61 mg, 0.054 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by mass−directed liquid column chromatography, and gave the amine 259d 
(5.2 mg, 0.012 mmol, 22%) as a pale yellow oil; Rf 0.15 (95:5 CHCl3—MeOH);     
     
−1.2 (c. 0.5, MeOH); νmax/cm
-1 (film) 3580, 3387, 2933, 1658, 1457, 1384, 1257; m/z 
(ES+) 451.2 (100%, [M+H]+); found 451.1878, C20H29F3N2O4S requires MH 451.1873 
Unable to obtain 1H and 13C spectra due to insufficent material 
1,1,1-Trifluoro-N-[(2R,3R)-3-hydroxy-2-methylhept-6-en-1-yl]-N-{[2ʹ-({[(2ʹR)-1ʹ-
hydroxypent-4ʹ-en-2ʹ-yl]amino}methyl)phenyl]methyl}methanesulfonamide 268d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 114D (48 mg, 0.042 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by mass−directed liquid column chromatography, and gave the amine 268d 
(15.5 mg, 0.032 mmol, 77.2%) as a colourless oil; Rf 0.21 (CHCl3);     
     3.2 (c. 1.5, 
MeOH); δH (500 MHz; CDCl3) 7.53-7.42 (4H, m, Ar), 5.95-5.77 (2H, m, 4ʹ-H and 6-H), 
5.34 (1H, dd, J 17.3 and 1.6, 7-HA), 5.29 (1H, d , J 10.6, 7-HB), 5.03 (1H, dd, J 17.1 and 
1.7, 5ʹ-HA), 4.98 (1H, dd, J 10.1 and 1.7, 5ʹ-HA), 4.56 (1H, d, J 13.5, PhCHANTf), 4.50 
(1H, d, J 13.5, PhCHBNTf), 4.02 (1H, dd, J 12.3 and 3.6, 1ʹ-HA), 3.84 (1H, dd, J 12.3 
and 5, 1ʹ-HB), 3.54-3.42 (2H, m, NHCHABPh), 3.28 (1H, d, J 7.3, 1-HA), 3.25 (1H, d, J 
7.3, 1-HB), 3.28-3.23 (1H, m, 3-H), 2.66-2.59 (1H, m, 2ʹ-H), 2.12-2.02 (1H, m, 3ʹ-HA), 
1.99-1.91 (1H, m, 3ʹ-HB), 1.47-1.22 (8H, m, CH3, 2-H, 4-HAB and 5-HAB); δC (125 MHz; 
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CDCl3) 139.4, 136.6, 133.8, 132.8, 131.7, 131.4, 130.6, 125.7, 120.3, 115.3, 63.8, 
60.7, 59.0, 48.0, 38.5, 38.0, 33.6, 32.8, 31.5, 28.7, 14.5, 9.3; νmax/cm
-1 (film) 3250, 
3034, 1538 and 1372; m/z (ES+) 479.2 (100%, [M+H]+); found 479.2204, 
C22H33F3N2O4S requires MH 479.2186 
N-{[2-({N-[(2R,3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-N-[(2ʹR)-1ʹ-hydroxypent-
4ʹ-en-2ʹ-yl]cyclopropanecarboxamide 268b 
 
Following general procedure A2, cyclopropane carbonyl chloride (22 mg, 0.21 mmol), 
triethylamine (43 mg, 0.43 mmol) and amine 236D (49 mg, 0.043 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with 90:10 CHCl3—MeOH gave the amide 268b (17.9 mg, 0.033 mmol, 76%) as 
a colourless oil; Rf 0.76 (CHCl3);     
    
 5 (c. 0.9, MeOH); δH (500 MHz; CDCl3) 7.46 
(1H, dd, J 7.3 and 1.3, Ar), 7.41-7.22 (3H, m, Ar), 5.84-5.69 (2H, m, 6-H and 4ʹ-H), 
5.19-5.05 (2H, m, 7-H or 5ʹ-H), 4.99-4.93 (2H, m, 7-H or 5ʹ-H), 4.89 (1H, br s, 
PhCHANTf), 4.63 (1H, br s, PhCHBNTf), 4.16 (1H, dd, J 11.2 and 4.7, 1ʹ-HA), 4.07 (1H, 
dd, J 11.2 and 6.0, 1ʹ-HB), 3.88 (1H, d, J 12.1, NCHAPh), 3.76 (1H, d, J 12.1, NCHBPh), 
3.70-3.18 (3H, m, 3-H and 1-H), 2.95 (1H, p, J 5.9, 2ʹ-H), 2.33 (1H, dt, J 13.1 and 6.3, 
3ʹ-HA), 2.24 (1H, dt, J 13.1 and 7.2, 3ʹ-HB), 2.09-2.00 (1H, m, 5-HA), 1.93-1.85 (1H, m, 
5-HB), 1.75 (1H, br s, 2-H), 1.62 (1H, tt, J 8.1 and 4.7, 
CPr), 1.48-1.40 (2H, m, 4-HAB), 
1.02-0.98 (2H, m, CPr), 0.91-0.86 (2H, m, CPr), 0.66 (3H, br s, Me); δC (75 MHz; CDCl3) 
174.8, 138.3, 137.7, 134.4, 134.2, 130.2, 129.0, 128.5, 128.2, 118.2, 114.8, 77.2, 65.8, 
56.2, 53.5, 51.2, 49.5, 36.9, 36.1, 33.3, 30.5, 12.8 (CPr), 10.2 (CPr), 8.6 (CPr); νmax/cm
-1 
(film) 3424, 3077, 2979, 2939, 1726, 1641, 1455, 1385, 1275 and 1261; m/z (ES+) 
529.6 (100%, [M−OH]+); found 547.2457, C26H37F3N2O3S requires MH 547.2448 
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3-{[2-({N-[(2R,3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-3ʹ-[(2ʹR)-1ʹ-hydroxypent-
4ʹ-en-2ʹ-yl]-1ʹ-(pyridin-3-yl)urea 268a 
 
Following general procedure A1, 3-pyridyl isocyanate (25.2 mg, 0.21 mmol) and amine 
236D (49 mg, 0.043 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 90:10 CH2Cl2—MeOH gave the 
urea 268a (22.6 mg, 0.037 mmol, 88%) as a colourless oil; Rf 0.27 (90:10, 
CHCl3−MeOH);     
     2.3 (c. 1.1, MeOH); δH (500 MHz; CDCl3) 9.78 (1H, br s, NH), 
8.29-8.10 (3H, m, Py), 7.51 (1H, d, Py), 7.43-7.19 (4H, m, Ar), 5.87-5.65 (2H, m, 6-H 
and 4ʹ-H), 5.17 (1H, s, NPyCHAPh), 5.16 (1H, d, J 9.8, 7-HA or 5ʹ-HA), 5.10 (1H, d, J 
17.5, 7-HB or 5ʹ-HB), 4.98 (1H, d, J 16.5, 7-HB or 5ʹ-HB), 4.93 (1H, d, J 10.2, 7-HA or 5ʹ-
HA), 4.65 (2H, s, NTfCHABPh), 4.18 (2H, s, NPyCH2), 3.70 (1H, dd, J 10.8 and 4.8, 1ʹ-
H), 3.66-3.50 (3H, m, 1ʹ-H, 2ʹ-H and 3-H), 3.40-3.25 (2H, 1-HAB), 2.67 (1H, td, J 14.5 
and 7.2, 3ʹ-HA), 2.47 (1H, td, J 14.5 and 7, 3ʹ-HB), 2.18-2.08 (1H, m, 5-HA), 1.98-1.84 
(1H, m, 5-HB), 1.60-1.42 (2H, m, 4-HA and 2-H), 1.29-1.13 (1H, m, 4-HB), 0.72 (3H, J 
6.9, Me); δC (75 MHz; CDCl3) 156.4, 142.6, 139.5, 138.2, 137.2, 136.1, 133.9, 128.7, 
128.5, 128.4, 126.9, 124.1, 118.6, 114.8, 77.2, 64.2, 60.0, 52.9, 50.9, 37.4, 33.5, 30.7; 
νmax/cm
-1 (film) 3287, 3056, 2984, 2939, 2305, 1658, 1539, 1484, 1422 and 1385; m/z 
(ES+) 599.8 (100%, [M+H]+); found 599.2509, C28H37F3N4O3 requires MH 599.2510 
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(2R)-1-Hydroxy-N-{[2-({N-[(2R,3R)-3-hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-S-(1-methyl-1H-
imidazol-4-yl)pent-4-ene-2-sulfonamido 268c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (36 mg, 0.2 
mmol), triethylamine (40 mg, 0.4 mmol) and amine 236D (47 mg, 0.04 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the sulfonamide 268c (12.4 
mg, 0.019 mmol, 49.8%) as a colourless glass; Rf 0.31 (90:10, CHCl3—MeOH);     
    
 
5.2 (c. 0.6, MeOH); δH (500 MHz; CDCl3) 7.57-7.54 (1H, m, Ar), 7.48 (1H, d, J 1.4, Ar), 
7.40-7.37 (1H, m, Ar), 7.35 (1H, d, J 1.5, Ar), 7.33-7.28 (2H, m, Ar), 5.77 (1H, ddt, J 
16.9, 10.1 and 6.6, 6-H), 5.58 (1H, ddt, J 17.1, 10.3 and 7.0, 4ʹ-H), 5.00 (1H, dd , J 17.1 
and 1.8, 5ʹ-HA), 4.98-4.92 (3H, m, 5ʹ-HB and 7-HAB), 4.72 (2H, s, PhCH2NTf), 4.50 (1H, 
d, J 15.8, N(Imid)CHAPh), 4.42 (1H, d, J 15.8, N(Imid)CHBPh), 3.98 (1H, dd, J 12.5 and 
9.6, 1ʹ-HA), 3.81 (1H, s, 2ʹ-H), 3.71 (3H, s, NMe), 3.65 (1H, dd, J 12.5 and 3.7, 1ʹ-HB), 
3.54 (1H, s, 3-H), 3.42 (1H, dd, J 14.5 and 8.8, 1-HA), 3.23 (1H, dd, J 14.5 and 6.3, 1-
HB), 2.35 (1H, dt, J 15 and 6.4, 3ʹ-HA), 2.19 (1H, dt, J 15 and 7.9, 3ʹ-HB), 2.12-2.04 (1H, 
m, 5-HA), 1.98-1.90 (1H, m, 5-HB), 1.54-1.42 (1H, 4-HA), 1.38 (1H, q, J 6.9, 2-H), 1.24-
1.15 (1H, m, 4-HB), 0.70 (3H, d, J 6.9, Me); δC (75 MHz; CDCl3) 141.2, 138.7, 138.2, 
135.0, 134.7, 133.6, 130.6, 128.9, 128.3, 128.1, 124.4, 117.5, 114.8, 76.7, 63.6, 62.6, 
53.6, 51.6, 37.1, 36.5, 33.9, 33.4, 30.4, 10.4; νmax/cm
-1 (film) 3388, 2981, 2940, 1641, 
1533, 1456, 1385, 1337, 1275; m/z (ES+) 645.3 (100%, [M+Na]+); found 645.1983, 
C26H37F3N4O6S2 requires MNa 645.1999 
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(7S,11E,14R)-7-(2,4-Dimethoxyphenyl)-14-(hydroxymethyl)-4-oxo-N-(pyridin-3-yl)-
5,9-dioxa-3,15-diazabicyclo[15.3.1]henicosa-1(20),11,17(21),18-tetraene-15-
carboxamide 260a 
 
Following general procedure A1, 3-pyridyl isocyanate (30.3 mg, 0.252 mmol) and 
amine 248D (52 mg, 0.05 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the urea 260a (7.2 mg, 24 mmol, 24%) as a brown oil; Rf 0.12 (95:5 CHCl3—
MeOH);    
 
    
 5.7 (c. 0.7, MeOH); νmax/cm
-1 (film) 3300, 3006, 2924, 2851, 1711, 1660, 
1612, 1539, 1508, 1483, 1464, and 1422; m/z (ES+) 591.3 (100%, [M+H]+); found 
591.2812, C32H38N4O7 requires MH 591.2813 
Unable to obtain 1H and 13C spectra due to a mix of geometric isomers and conformers 
(7S,11E,14R)-15-Cyclopropanecarbonyl-7-(2,4-dimethoxyphenyl)-14-
(hydroxymethyl)-5,9-dioxa-3,15-diazabicyclo[15.3.1]henicosa-1(20),11,17(21),18-
tetraen-4-one 260b 
 
Following general procedure A2, cyclopropane carbonyl chloride (18.6 mg, 0.179 
mmol), triethylamine (36 mg, 0.36 mmol) and amine 248D (37 mg, 0.036 mmol) gave 
the crude product after 16 h. The crude product was purified by F-SPE and following 
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general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CH2Cl2 gave the amide 260b (3.96 mg, 0.0072 mmol, 
20.4%) as a pale yellow glass; Rf 0.89 (CH2Cl2);     
    
 4.4 (c. 0.2, MeOH); δH (500 
MHz; CDCl3; 323 K) very broad 7.69-7.58 (1H, m, Ar ), 7.51-7.04 (4H, m, Ar and DMB 
6-H), 6.46-6.37 (2H, m, DMB 3 and 5-H), 5.73-4.93 (4H, m, 11-H and 12-H), 4.51-3.36 
(17H, m, 2 × OMe, 7-H, 10-HAB, CHABOH, 8-HAB, 2-HAB and 16-HAB), 2.95-2.83 (1H, m, 
14-H), 2.35-1.95 (2H, m, 13-HAB), 1.66-1.57 (1H, m, 
CPr), 1.02-0.97 (2H, m, CPr), 0.89-
0.83 (2H, m, CPr); δC (125 MHz; CDCl3; 323 K) 174.6, 158.1, 131.5, 131.4, 130.9; 
128.9, 128.5, 127.1, 124.2, 104.9, 104.4, 98.8; 66.4, 66.2, 62.4, 55.4, 55.3, 54.8, 32.9; 
12.8; 8.4; νmax/cm
-1 (film) 3322, 2925, 1720, 1612, 1587, 1543, 1507, 1463, 1402 and 
1344; m/z (ES+) 540.5 (100%, [M+H]+) and 539.3 (17%, [M+Na]+); found 539.2753, 
C30H38N2O7 requires MH 539.2752 
full carbon assignment was not possible to mixture of geometric isomers and rotamers 
(7S,11E,14R)-7-(2,4-Dimethoxyphenyl)-14-(hydroxymethyl)-15-(1-methyl-1H-
imidazole-4-sulfonyl)-5,9-dioxa-3,15-diazabicyclo[15.3.1]henicosa-
1(20),11,17(21),18-tetraen-4-one 260c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (32 mg, 
0.179 mmol), triethylamine (36 mg, 0.359 mmol) and amine 248D (37 mg, 0.0359 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with CHCl3 gave the sulfonamide 260c 
(12.5 mg, 0.020 mmol, 57%) as a colourless oil; Rf 0.37 (CHCl3);     
    
 3.7 (c. 0.6, 
MeOH); δH (500 MHz; CDCl3) 7.83 (1H, dd, J 5.9 and 1.3, Ar), 7.78-7.74 (1H, m, Ar), 
7.43 (1H, s, Ar), 7.37-7.28 (2H, d , Ar), 7.23-7.18 (1H, m, Ar), 7.12 (1H, d, J 8.6, Ar), 
6.55 (1H, dd, J 4.2 and 2.5, DMB), 6.49 (1H, ddd, J 8.5, 3.4 and 2.5, DMB), 5.47-5.22 
204 
 
(2H, m, 11- and 12-H), 4.77 (1H, br s, 2-HA
min), 4.64 (1H, br s, 2-HB
min), 4.46 (1H, d, J 
15.8, 16-HA), 4.44 (1H, br s, 2-HAB), 4.33 (1H, d, J 15.8, 16-HB), 4.24-4.10 (3H, m, 6-HA 
and 10-HAB), 4.09-4.02 (1H, m, 6-HB), 3.79 (3H, s, NMe), 3.77 (3H, s, OMe
min), 3.76 
(3H, s, OMe), 3.75 (3H, s, OMe), 3.74 (3H, s, OMe min); 3.79-3.29 (6H, m, CHABOH, 14-
H, 7-H and 8-HAB), 2.27-2.14 (2H, 13-HAB); δC (75 MHz; CDCl3) 159.8, 158.1, 158.1, 
156.5, 141.8, 141.6, 138.5, 138.1, 129.5, 129.1, 128.8, 128.7, 128.7, 127.7, 124.2, 
120.5, 104.4, 104.35, 98.8, 98.7, 77.1, 66.2, 62.2, 55.4, 55.3, 45.1, 44.8, 37.9, 34.1, 
29.6; νmax/cm
-1 (film) 3304, 2921, 2850, 1712, 1612, 1587, 1531, 1508, 1454, 1332; m/z 
(ES+) 638.1 (100%, [M+Na]+); found , C30H38N4O8S requires MH   
 
(7S,11E,14R)-7-(2,4-Dimethoxyphenyl)-14-(hydroxymethyl)-5,9-dioxa-3,15-
diazabicyclo[15.3.1]henicosa-1(20),11,17(21),18-tetraen-4-one 260d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 248D (38 mg, 0.037 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
260d (7.82 mg, 0.017 mmol, 45%) as a colourless oil; Rf 0.1 (95:5 CHCl3−MeOH); 
νmax/cm
-1 (film) 3319, 2924, 2853, 1701, 1612, 1587, 1507 and 1463, m/z (ES+) 471.3 
(100%, [M+H]+); found 471.2501, C26H34N2O6 requires MH 471.2490 
Unable to obtain 1H and 13C spectra due to geometric isomers 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({[(2R)-1-
hydroxypent-4-en-2-yl][(pyridin-3-
yl)carbamoyl]amino}methyl)phenyl]methyl}carbamate 269a 
 
Following general procedure A1, 3-pyridyl isocyanate (31 mg, 0.26 mmol) and amine 
237D (55 mg, 0.052 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with CHCl3 gave the urea 269a (14.8 
mg, 0.024 mmol, 46%) as a colourless oil; Rf 0.08 (CHCl3);     
    
 6.1 (c. 0.7, MeOH); 
δH (500 MHz; CDCl3) 8.60 (1H, NH), 8.29 (1H, s, Ar), 8.15 (1H, d, J 4.2, Ar), 7.94 (1H, 
d, J 8.1, Ar), 7.35-7.02 (6H, m, Ar), 6.43 (2H, s, Ar), 5.85 (1H, ddt, J 16.2, 10.7 and 5.5, 
propenyl 2-H), 5.74 (1H, ddt, J 17.4, 107 and 6.9, 4-H), 5.27 (1H, br s, NH), 5.21 (1H, 
dd , J 17.4 and 1.7, 5-HA), 5.14-5.07 (3H, m, 5-HB and propenyl 3-HAB), 4.70 (1H, d, J 
16.4, N(Py)CHAPh), 4.48 (1H, d, J 16.4, N(Py)CHBPh), 4.37 (1H, dd, J 10.7 and 5.8, 
propyl 1-HA), 4.31 (1H, dd, J 10.7 and 6.3, propyl 1-HB), 4.25 (2H, s, PhCH2O(CO)), 
3.94 (3H, br s, 2-H and propenyl 1-H2), 3.78 (3H, s, OMe), 3.76 (3H, s, OMe), 3.69 (1H, 
d, J 10.9, propyl 3-HA), 3.65-3.48 (4H, m, propyl 3-HB and 1-HAB and propyl 2-H), 2.48 
(1H, dt, 3-HA), 2.42-2.29 (1H, m, 3-HB); δC (75 MHz; CDCl3) 159.6, 158.3, 157.3, 156.9, 
143.1, 140.5, 139.4, 138.9, 136.8, 134.8, 134.3, 129.0, 128.9, 126.7, 126.6, 126.5, 
126.3, 123.6, 119.9, 117.9, 116.7, 104.1, 98.6, 71.9, 70.4, 65.5, 64.1, 59.6, 55.4, 55.3, 
48.7, 44.9, 38.1, 33.7; νmax/cm
-1 (film) 3318, 3060, 3005, 2936, 1703, 1660, 1613, 1587, 
1537, 1508, 1483, 1465 and 1422; m/z (ES+) 641.4 (100%, [M+Na]+); found 619.3138, 
C34H42N4O7 requires MH 619.3126 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({1-cyclopropyl-
N-[(2R)-1-hydroxypent-4-en-2-yl]formamido}methyl)phenyl]methyl}carbamate 
269b 
 
Following general procedure A2, cyclopropane carbonyl chloride (27.9 mg, 0.269 
mmol), triethylamine (54 mg, 0.54 mmol) and amine 237b (57 mg, 0.054 mmol) gave 
the crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CHCl3 gave the amide 269b (17 mg, 0.030 mmol, 55.6%) 
as a colourless oil; Rf 0.4 (EtOAc);     
    
 3.7 (c. 0.9, MeOH); δH (500 MHz; CDCl3) 
7.41-7.06 (5H, m, Ph and DMB 6-H), 6.44 (1H, d, J 1.8, DMB 5-H), 6.42 (1H, s, DMB 3-
H), 5.86 (1H, ddt, J 17.2, 10.7 and 5.8, propenyl 2-H), 5.75 (1H, ddt, J 17.3, 10.3 and 
7.3, 4-H), 5.21 (1H, dd , J 17.3 and 1.7, propenyl 3-HA), 5.13-5.01 (3H, m, 5-HAB and 
propenyl 3-HB), 4.99-4.53 (3H, m, NH and N(
CPr)CHABPh), 4.42 (1H, dd, J 10.8 and 
5.8, propyl 1-HA), 4.36 (1H, dd, J 10.8 and 6.2, propyl 1-HB), 4.30 (2H, s, 
PhCH2N(CO)O), 4.16-4.00 (2H, m, 1-HAH), 3.96 (1H, dd, J 12.5 and 5, propenyl 1-HA), 
3.91 (1H, dd, J 12.5 and 6.4, propenyl 1-HB); 3.87 (6H, s, 2 × OMe), 3.74-3.56 (3H, m, 
propyl 3-HAB and propyl 2-H), 2.91 (1H, p, 2-H), 2.43 (1H, br s, 3-HA), 2.34-2.24 (1H, m, 
3-HB), 1.06-0.97 (2H, m, 
CPr), 0.89-0.83 (2H, m, CPr), 0.72 (1H, br s, CPr); δC (75 MHz; 
CDCl3) 174.6, 159.7, 158.5, 138.9, 135.0, 135.0, 129.0, 128.7, 120.3, 120.3, 116.4 
(propenyl 3-C or 5-H), 116.3 (propenyl 3-C or 5-H), 104.4 (DMB), 104.4 (DMB), 98.8 
(DMB); 71.9 (propenyl 1-C), 70.7, 66.1, 63.9, 55.4 (2-H), 55.3 (OMe), 51.1, 38.4, 33.2, 
12.9, 12.8, 8.4, 8.3; νmax/cm
-1 (film) 3359, 3075, 3007, 2936, 1721, 1613, 1508, 1463; 
m/z (ES+) 589.4 (100%, [M+Na]+); found 567.3088, C32H42N2O7 requires MH 567.3065 
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({N-[(2R)-1-
hydroxypent-4-en-2-yl]1-methyl-1H-imidazole-4-
sulfonamido}methyl)phenyl]methyl}carbamate 269c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (45 mg, 
0.25 mmol), triethylamine (50 mg, 0.5 mmol) and amine 237D (53 mg, 0.05 mmol) gave 
the crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CHCl3 gave the sulfonamide 269c (23.3 mg, 0.036 mmol, 
73%) as a pale yellow oil; Rf 0.2 (CHCl3);     
     10.2 (c. 1.0, MeOH); δH (500 MHz; 
CDCl3) 7.49-7.08 (7H, m, Ar), 6.44 (2H, d, J 2.3, DMB), 5.86 (1H, ddt, J 17.3, 10.6 and 
5.5, propenyl 2-H), 5.61-5.52 (1H, m, 4-H), 5.47 (1H, br s, NH), 5.22 (1H, dd , J 17.3 
and 1.7, propenyl 3-HA), 5.13 (1H, dd, J 10.6 and 1.7, propenyl 3-HB); 4.97-4.86 (2H, 
m, 5-HAB), 4.45-4.16 (6H, N(Imid)CHABPh, propyl 3-HAB and PhCH2N(CO)O), 4.02-3.86 
(3H, propenyl 1-H2 and 2-H), 3.78 (6H, s, 2 × OMe), 3.68 (3H, Me), 3.66-3.58 (5H, 
propyl 2-H, propyl 3-HAB and 1-HAB), 2.26 (1H, dt, J 13.8 and 6.8, 3-HA), 2.14 (1H, dt, J 
13.8 and 6.9, 3-HB); δC (75 MHz; CDCl3) 159.6, 158.4, 156.6, 141.4, 138.7, 138.5, 
137.3, 134.9, 134.7, 128.9, 128.6, 127.9, 126.7, 124.2, 120.1, 117.3 (5-C), 116.6 
(propenyl 3-C), 104.1 (DMB), 98.6 (DMB); 71.9 (propenyl 1-C), 70.5 (1-C), 65.4 (propyl 
3-C), 63.9 (2-C), 62.4 (propyl 1-C), 55.4 (OMe), 55.3 (OMe), 50.8 (N(Imid)CH2Ph, or 
PhCH2N(CO)O), 44.8 (N(Imid)CH2Ph, or PhCH2N(CO)O), 38.1 (Propyl 2-C), 36.7 (3-
C), 34.1 (NCH3); νmax/cm
-1 (film) 3317, 2938, 1713, 1612, 1531, 1508, 1465, 1334, 1275 
and 1262; m/z (ES+) 665.3 (100%, [M+Na]+); found 665.2629, C32H42N4O8S requires 
MNa 665.2616   
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(2S)-2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[3-({[(2R)-1-
hydroxypent-4-en-2-yl]amino}methyl)phenyl]methyl}carbamate 269d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 237D (53 mg, 0.05 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
269d (8.4 mg, 0.017 mmol, 33.7%) as a pale yellow oil; Rf 0.15 (90:10, CHCl3—
MeOH);     
     7.5 (c. 0.4, MeOH); δH (500 MHz; CDCl3) 7.30-7.25 (2H, Ar), 7.22 (1H, 
d, J 7.4, Ar), 7.14 (1H, d, J 6.3, Ar), 7.11 (1H, d, J 8.6, Ar), 6.44 (2H, s, DMB 3 and 5-
H), 5.86 (1H, ddt, J 16.2, 10.8 and 5.5, propenyl 2-H), 5.75 (1H, ddt, J 17.6, 9.6 and 
7.4, 4-H), 5.23 (1H, dd , J 16.2 and 1.7, propenyl 3-HA), 5.14-5.09 (3H, m, propenyl 3-
HA and 5-HAB), 4.95 (1H, br s, NH), 4.42 (1H, dd, J 10.6 and 5.4, propyl 1-HA), 4.37 
(1H, dd, J 10.6 and 5.6, propyl 1-HB), 4.32 (2H, ap d, J 5.5, PhCH2N(CO)O), 3.95 (2H, 
s, propenyl 1-H2), 3.82 (1H, d, J 13.1, NHCHAPh), 3.78 (6H, s, OMe), 3.76 (1H, d, J 
13.1, NHCHBPh), 3.68-3.59 (5H, m, 1-HA, propyl 2-H, propyl 3-HAB and 2-H), 3.36 (1H, 
dd, 1-HB), 2.77 (1H, p, J 5.6, 2-H), 2.31-2.21 (2H, m, 3-HAB); δC (75 MHz; CDCl3) 159.6, 
158.4, 156.6, 138.9, 134.9, 134.6, 128.9, 128.8, 127.3, 120.1, 118.1, 116.6, 104.1, 
98.6, 71.9, 70.5, 62.8, 57.6, 55.4, 55.3, 50.9, 44.9, 38.1, 36.0; νmax/cm
-1 (film) 3331, 
3054, 3005, 2936, 2839, 1712, 1613, 1508 and 1464, ; m/z (ES+) 499.3 (100%, 
[M+H]+); found 499.2814, C28H38N2O6 requires MH 499.2803 
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(15E,18R)-18-(Hydroxymethyl)-19-(1-methyl-1H-imidazole-4-sulfonyl)-5,13-dioxa-
3,19-diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one 
E-117c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (15.3 mg, 
0.085 mmol), triethylamine (17.1 mg, 0.169 mmol) and amine E-115D (17 mg, 0.017 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 95:5 CH2Cl2—MeOH gave the amine 
E-117c (8.1 mg, 0.014 mmol, 87%) as a colourless glass; Rf 0.4 (EtOAc); νmax/cm
-1 
(film) 3280, 3006, 2919, 2850, 1708, 1605, 1533, 1496, 1456 and 1332; m/z (ES+) 
549.2 (100%, [M+H]+); found 549.1779, C26H30N4O6S requires MH 527.1959  
Unable to obtain 1H and 13C spectra due to excessive H2O contamination   
(15E,18R)-18-(Hydroxymethyl)-4-oxo-N-(pyridin-3-yl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaene-19-
carboxamide E-117a 
 
Following general procedure A1, 3-pyridyl isocyanate (4 mg, 0.034 mmol) and amine 
E-115D (17 mg, 0.017 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
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was purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
urea E-117a (6.7 mg, 0.013 mmol, 79%); Rf 0.1 (CHCl3); νmax/cm
-1 (film) 2922, 2851, 
1710, 1554, 1463, 1380, 1275 and 1083; m/z (ES+) 503.2 (100%, [M+H]+); found 
503.2291, C28H30N4O5 requires MH 503.2289 
Unable to obtain 1H and 13C spectra due to excessive H2O contamination   
(15E,18R)-19-Cyclopropanecarbonyl-18-(hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one E-
117b 
 
Following general procedure A2, cyclopropane carbonyl chloride (12.5 mg, 0.12 mmol), 
triethylamine (24.2 mg, 0.24 mmol) and amine E-115D (24 mg, 0.024 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the amide E-117b (6.5 mg, 
0.014 mmol, 60.2%) as a colourless glass; Rf 0.44 (90:10, CHCl3—MeOH);     
    
 −8.9 
(c. 0.3, MeOH); δH (300 MHz; CDCl3) 8.18 (1H, br s, NH), 7.40-7.25 (5H, m, Ar), 7.15 
(1H, d, J 7.3, Ar), 6.96 (1H, t, J 7.5, 10-H), 6.88 (1H, d, J 8.3, 11-H), 5.88 (1H, dd, J 16 
and 4.4, 15- or 16-H), 5.82 (1H, dd, J 16 and 6.2, 15- or 16-H), 5.30-5.26 (1H, m, OH), 
5.17 (1H, d, J 10.7, 6-HA), 5.11 (1H, d, J 10.7, 6-HB), 5.57-5.48 (2H, m, 14-HAB), 4.46 
(1H, dd, J 15.9 and 7.1, 20-HA), 4.39 (1H, dd, J 15.9 and 6.1, 20-HB), 4.16 (1H, dd, J 
11.6 and 4.6, CHAOH), 4.11 (1H, dd, J 11.6 and 5.6, CHBOH), 4.02 (2H, s, 2-HAB), 
3.01-2.97 (1H, m, 18-H), 2.46-2.38 (2H, m, 17-HAB), 1.66-1.60 (1H, m, 
CPr), 1.03-0.98 
(2H, CPr), 0.92-0.87 (2H, CPr); δC (75 MHz; CDCl3) 174.6, 157.7, 156.8, 139.7, 131.9, 
130.4, 128.7, 127.7, 126.5, 120.7, 112.1, 77.1, 76.8, 67.9, 54.3, 50.3, 31.4, 12.7, 8.5; 
νmax/cm
-1 (film) 3320, 3007, 2920, 2850, 1714, 1606, 1539, 1496, 1455 and 1403; m/z 
(ES+) 451.2 (100%, [M+H]+); found 451.2241, C26H30N2O5 requires MH 451.2227 
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(15E,18R)-18-(Hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one E-
117d   
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine E-115D (15 mg, 0.015 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CH2Cl2—MeOH gave the amine 
E-117d (5.5 mg, 0.0144 mmol, 96.2%) as a colourless film; Rf 0.12 (90:10, CHCl3—
MeOH);    
 
    
 10.7 (c. 0.3, MeOH); δH (500 MHz; CDCl3/MeOD; 333 K) 7.38-7.04 (5H, 
m, Ph), 6.96 (1H, d, J 7.4, Ph), 6.81 (1H, td, J 7.5 and 1.0, 10-H), 6.73 (1H, d, J 8.3, 
11-H), 5.75 (1H, br s, 15 or 16-H), 5.66 (1H, br d, J 15.3, 15 or 16-H), 5.12 (1H, d, J 
10.6, 6-HA), 5.07 (1H, d, J 10.6, 6-HB), 4.30 (1H, dd, J 13.1 and 3.8, 14-HA), 4.27 (1H, 
dd, J 13.1 and 4.7, 14-HB), 4.26-4.14 (2H, m, 2-HAB), 3.74 (2H, s, 20-HAB), 3.53 (1H, dd, 
J 11 and 5.1, CHAOH), 3.45 (1H, dd, J 11 and 5.9, CHBOH), 2.70 (1H, p, 18-H), 2.22 
(2H, s, 17-HAB); δC (125 MHz; C6D6 ; 343 K) 157.8, 131.7, 130.1, 128.3, 126.2, 124.6, 
112.2, 91.9, 68.1, 56.7; νmax/cm
-1 (film) 3304, 2921, 2471, 1682, 1607, 1591, 1548, 
1455; m/z (ES+) 383.2 (100%, [M+H]+); found 383.1974, C22H26N2O4 requires MH 
393.1965 
(15Z,18R)-18-(Hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one Z-
117d 
 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine Z-115D (15 mg, 0.015 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
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purified by column chromatography, eluting with 90:10 CH2Cl2—MeOH gave the amine 
Z-117d (4.4 mg, 0.012 mmol, 72%) as a colourless film; Rf 0.41 (90:10, CHCl3—
MeOH);    
 
    
 15.7 (c. 0.3, MeOH); δH (500 MHz; CDCl3) 7.36-7.25 (3H, m, Ar), 7.20 
(1H, t, J 7, Ar), 7.11 (1H, d, J 7.6, Ar), 7.03 (1H, br s, Ar), 6.95 (1H, td, J 7.4, Ar), 6.92 
(1H, d, J 8.1, Ar), 5.95-5.90 (1H, m, 15-H), 5.56 (1H, br s, 16-H), 5.42 (1H, br s, NH), 
4.91 (2H, br s, 6-HAB), 4.70 (1H, dd, J 11.1 and 8.6, 2 or 20-HAB), 4.55 (1H, br s, 2 or 
20-HAB), 4.49 (1H, dd, J 11.1 and 3.7, 2 or 20-HAB), 4.27 (1H, dd, J 15.4 and 5.9, 2 or 
20-HAB), 3.76 (1H, br s, 18-H), 3.73 (2H, s, 6-HAB), 3.69 (1H, dd, CHAOH), 3.43 (1H, dd, 
CHAOH), 2.81-2.77 (1H, m, OH), 2.43 (1H, dt, J 14.9 and 9.4, 17-HA), 2.23 (1H, d, J 
14.9, 17-HB); νmax/cm
-1 (film) 3318, 3006, 2990, 1686, 1606, 1550, 1497; m/z (ES+) 
383.2 (100%, [M+H]+); found 383.1963, C26H34N2O6 requires MH 383.1965 
Unable to obtain 13C NMR due to insufficient material 
(15Z,18R)-18-(Hydroxymethyl)-4-oxo-N-(pyridin-3-yl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaene-19-
carboxamide Z-117a 
 
 
Following general procedure A1, 3-pyridyl isocyanate (3.83 mg, 0.032 mmol) and 
amine Z-115D (16 mg, 0.016 mmol) gave the crude product after 1 h. The crude 
product was purified by F-SPE and following general procedure S1, hydrofluoric acid 
(0.2 mL, ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 90:10 CHCl3−MeOH gave 
the urea Z-117a (5.6 mg, 0.011 mmol, 70%); Rf 0.4 (EtOAc);  νmax/cm
-1 (film) 3321, 
2925, 2853, 1709, 1605, 1537, 1462 and 1388; m/z (ES+) 503.2 (100%, [M+H]+); found 
503.2285, C28H30N4O5 requires MH 503.2289 
Unable to obtain 1H or 13C spectra due to excessive H2O contamination   
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(15Z,18R)-19-Cyclopropanecarbonyl-18-(hydroxymethyl)-5,13-dioxa-3,19-
diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one Z-
117b 
 
 
Following general procedure A2, cyclopropane carbonyl chloride (8.3 mg, 0.08 mmol), 
triethylamine (16.2 mg, 0.16 mmol) and amine Z-115D (16 mg, 0.016 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 90:10 CH2Cl2—MeOH gave the amide Z-117b (4.9 mg, 
0.011 mmol, 69%); Rf 0.44 (90:10, CHCl3—MeOH);     
    
 7.9 (c. 0.3, MeOH); δH (500 
MHz; CDCl3) 7.46-7.06 (6H, m, Ar), 6.93 (1H, t, J 7.4, Ar), 6.89 (1H, br s, Ar), 5.74 (1H, 
br s, 15 or 14-H), 5.39 (1H, br s, 6-HA), 5.29 (1H, br s, 15 or 14-H), 5.01 (1H, d, J 8.6, 
6-HB), 4.95 (1H, s, NH), 4.82 (1H, br s, 2 or 20-HAB), 4.54 (1H, br s, 2 or 20-HAB), 4.40 
(2H, br s, 2 or 20-HAB), 3.74 (2H, s, 14-HAB), 3.54 (1H, br s, 18-H), 2.77 (1H, br s, 
CHAOH), 2.48-2.41 (1H, m, CHBOH), 1.75 (2H, s, 17-HAB), 1.57 (1H, br s, 
CPr), 1.03 
(2H, s, CPr), 0.79-0.71 (2H, m, CPr); νmax/cm
-1 (film) 3309, 3009, 2930, 1710, 1606, 
1535, 1494, 1456; m/z (ES+) 473.2 (100%, [M+Na]+); found 473.2053, C26H29N2O5 
requires MNa 473.2047 
Unable to obtain 13C NMR due to insufficient material 
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(15E,18R)-18-(Hydroxymethyl)-19-(1-methyl-1H-imidazole-4-sulfonyl)-5,13-dioxa-
3,19-diazatricyclo[19.3.1.07,12]pentacosa-1(24),7,9,11,15,21(25),22-heptaen-4-one 
Z-117c   
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (11.7 mg, 
0.065 mmol), triethylamine (13.1 mg, 0.129 mmol) and amine Z-115D (13 mg, 0.0129 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CH2Cl2—MeOH gave the amine 
Z-117c (4.19 mg, 0.0079 mmol, 62%); Rf 0.12 (CHCl3); νmax/cm
-1 (film) 2922, 2851, 
1701, 1554, 1463 and 1378; m/z (ES+) 549.2 (100%, [M+Na]+); found 549.2674, 
C26H30N4O6 requires MNa 549.1778 
Unable to obtain 1H or 13C spectra due to excessive H2O contamination   
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({[(2R)-1-hydroxypent-4-en-2-
yl][(pyridin-3-yl)carbamoyl]amino}methyl)phenyl]methyl}carbamate 118a 
 
Following general procedure A1, 3-pyridyl isocyanate (23 mg, 0.19 mmol) and amine 
116 (80 mg, 0.077 mmol) gave the crude product after 16 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
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urea 118a (16.9 mg, 0.032 mmol, 41%); Rf 0.11 (80:20, petrol—EtOAc);     
    
 9.3 (c. 
1.5, MeOH); δH (500 MHz; CDCl3) 8.60 (1H, br s, Py), 8.32 (1H, s, Py), 8.18 (1H, d, J 
4.8, Py), 7.98 (1H, dd, J 8.4 and 1.8, Py), 7.39-7.17 (6H, Ar), 6.94 (1H, ap t, J 7.4, Ar 3-
H), 6.89 (1H, d, J 6.9, Ar 5-H), 6.05 (1H, ddt, J 15.9, 10.2 and 5, propenyl 2-H), 5.78 
(1H, ddt, J 16.7, 9.5 and 6.8, 4-H), 5.43 (1H, d, J 16.7, propenyl 3-HA), 5.42 (1H, br s, 
NH), 5.28 (1H, dd, J 10.2 and 1.6, propenyl 3-HB), 5.24 (1H, d, J 12.7, PhCH2O), 5.20 
(1H, d, J 12.7, PhCH2O), 5.12 (1H, d, J 16.7, 5-HA), 5.11 (1H, d, J 9.5, 5-HB), 4.76 (1H, 
d, J 16.3, N(Py)CHAPh), 4.58 (2H, d, J 5, propenyl 1-H2), 4.49 (1H, d, J 16.3, 
N(Py)CHBPh), 4.39-4.29 (2H, m, PhCH2N(CO)O), 4.05-3.99 (1H, m, 2-H), 3.71 (1H, dd, 
J 11.1 and 2.7, 1-HA), 3.54 (1H, dd, J 11.1 and  8.5, 1-HB), 2.51 (1H, dt, J 14.3 and 7.5, 
3-HA), 2.39 (1H, dt, J 14.3 and 7, 3-HB); δC (75 MHz; CDCl3) 157.3, 156.9, 156.4, 142.9, 
140.4, 139.0, 136.9, 134.3, 133.1, 129.6, 129.4, 129.1, 126.8, 126.6, 126.5, 126.4, 
124.9, 123.7, 120.6, 118.0, 117.2, 111.7, 68.8 (propenyl 1-C), 64.1 (1-C), 62.5 
(PhCH2O), 59.6 (2-C), 48.5 (N(Py)CH2Ph), 44.9 (PhCH2N(CO), 33.7 (3-C); νmax/cm
-1 
(film) 3055, 2988, 2305, 1714, 1655, 1604, 1551 and 1422; m/z (ES+) 531.3 (100%, 
[M+H]+); found 531.2593, C30H34N4O5 requires MH 531.2602  
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({1-cyclopropyl-N-[(2R)-1-hydroxypent-
4-en-2-yl]formamido}methyl)phenyl]methyl}carbamate 118b 
 
Following general procedure A3, cyclopropane carbonyl chloride (45 mg, 0.43 mmol), 
triethylamine (87 mg, 0.87 mmol) and amine 116 (86 mg, 0.083 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with EtOAc gave the amide 118b (10.6 mg, 0.022 mmol, 26.7%); Rf 0.81 (80:20, 
petrol—EtOAc);     
     6.2 (c. 0.5, MeOH); δH (500 MHz; CDCl3) 7.28 (1H, d, J 7.4), 
7.25-7.13 (4H, m, Ar), 7.11 (1H, d, J 7.4), 6.87 (1H, ap t, J 7.4), 6.80 (1H, d, J 8.2), 
5.97 (1H, ddt, J 15.8, 10.2 and 5, propenyl 2-H), 5.70 (1H, ddt, J 17.3, 10.4 and 7.1, 4-
H), 5.34 (1H, dd , J 17.3 and 1.7, propenyl 3-HA), 5.21-5.16 (3H, m, propenyl 3-HB, NH 
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and PhCHAO), 5.06-5.00 (3H, m, 5-HAB and PhCHBO), 4.5 (2H, d, J 5, propenyl 1-H2), 
4.32 (2H, d, J 6, PhCH2N(CO)O), 4.03 (1H, dd, J 11.2 and 5.1, 1-HA), 3.98 (1H, dd, J 
11.2 and 5.6, 1-HB), 3.76 (1H, d, J 13.5, N(CO)CHAPh), 3.73 (1H, d, J 13.5, 
N(CO)CHBPh), 2.81 (1H, p, J 5.9, 2-H); 2.23 (1H, dt, J 13.0 and 6.5, 3-HA), 2.16 (1H, J 
13.0 and 7.1, 3-HB) 1.59-1.49 (1H, 
CPr), 0.94-0.89 (2H, CPr), 0.82-0.76 (2H, CPr); δC (75 
MHz; CDCl3) 174.9 (C=O), 159.6 (C=O), 153.4, 140.8, 138.7, 134.6, 133.2, 129.6, 
129.3, 128.8, 127.3, 126.3, 125.1, 120.6, 118.1 (5-C), 117.1 (propenyl 3-C), 111.7 (Ph 
3-C), 68.8 (propenyl 1-C), 65.9 (1-C), 62.3 (2-C), 55.2 (PhCH2O), 51.3 N(CO)CH2Ph, 
45.1 (PhCH2N(CO), 36.3 (3-C), 12.9 (
CPr), 8.6 (CPr); νmax/cm
-1 (film) 3329, 3054, 2987, 
2686, 2305, 1714, 1606, 15165, 1493, 14221361 and 1265; m/z (ES+) 479.3 (80%, 
[M+H]+) and 411.2 (100%, [M− CPr]+); found 479.2537, C28H34N2O5 requires MH 
479.2540 
 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({N-[(2R)-1-hydroxypent-4-en-2-yl]1-
methyl-1H-imidazole-4-sulfonamido}methyl)phenyl]methyl}carbamate 118c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (81 mg, 
0.45 mmol), triethylamine (90 mg, 0.9 mmol) and amine 116 (86 mg, 0.083 mmol) gave 
the crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 90:10 CHCl3—MeOH gave the sulfonamide 118c (33.5 
mg, 0.06 mmol, 73%); Rf 0.41 (90:10, CHCl3—MeOH);     
     3.7 (c. 1.7, MeOH); δH 
(500 MHz; CDCl3) 7.43 (1H, s, Ar), 7.39-7.17 (7H, m, Ar), 6.95 (1H, ap t, J 7.4, Ar 3-H), 
6.87 (1H, d, J 8.2, Ar 5-H), 6.04 (1H, ddt, J 17.2, 10.3 and 5.0, propenyl 2-H), 5.56 (1H, 
ddt, J 17.1, 9.8 and 7.4, 4-H), 5.45 (1H, br s, NH), 5.41 (1H, dd , J 17.2 and 1.8, 
propenyl 3-), 5.26 (1H, dd, J 10.6 and 1.8, propenyl 3-HB), 5.24 (2H, s, PhCH2O), 5.22-
5.17 (1H, br s, OH), 4.94 (1H, d, J 9.8, 5-HA), 4.91 (1H, d, J 17.1, 5-HB), 4.57 (2H, d, J 
5, propenyl 1-H2), 4.36 (1H, d, J 15.8, N(Imid)CHAPh), 4.34 (2H, s, PhCH2N(CO)), 4.23 
(1H, d, J 15.8, N(Imid)CHAPh), 4.00-3.94 (1H, m, 1-HA), 3.91 (1H, br s, 2-H), 3.66 (3H, 
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s, Me), 3.62 (1H, d, J 10.1, 1-HB), 2.27 (1H, dt, J 13.8 and 6.8, 3-HA), 2.14 (1H, dt, J 
13.8 and 7.5, 3-HB); δC (75 MHz; CDCl3) 156.6 (C=O), 156.4 (C=O), 141.3, 138.6, 
138.5, 137.3, 134.7, 133.2 (4-C), 129.6, 129.4, 128.6 (propenyl 2-C), 127.9, 127.8, 
126.7, 125.1, 124.3, 120.7, 117.4 (5-C), 117.3 (propenyl 3-C), 111.7 (Ph 3-C), 68.8 
(propenyl 1-C), 63.9 (2-C), 62.4 (PhCH2O(CO)) 63.3 (1-C), 50.8 (N(Imid)CH2Ph), 44.9 
(PhCH2N(CO)), 36.8 (3-C), 34.1 (CH3); νmax/cm
-1 (film) 3310, 3006, 2987, 2318, 2127, 
1713, 1642, 1605, 1590, 1532, 1493, 1454 and 1333; m/z (ES+) 577.2 (100%, [M+H]+); 
found 577.2104, C28H34N4O6S requires MH 577.2091 
[2-(Prop-2-en-1-yloxy)phenyl]methyl N-{[3-({[(2R)-1-hydroxypent-4-en-2-
yl]amino}methyl)phenyl]methyl}carbamate 118d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 116 (81 mg, 0.078 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
118d (13.5 mg, 0.033 mmol, 42%); Rf 0.3 (EtOAc);     
     4.5 (c. 1.2, MeOH); δH (500 
MHz; CDCl3) 7.38 (1H, d, J 7.4, Ar), 7.35-7.19 (5H, m, Ar), 6.98 (1H, apt, J 7.5, Ar), 
6.90 (1H, d, J 8.3, Ar), 6.07 (1H, ddt, J 15.7, 10.2 and 5.0, propenyl 2-H), 5.77 (1H, ddt, 
J 17.2, 10.3 and 7.2, 4-H), 5.45 (1H, d, J 17.2, propenyl 3-HA), 5.31-5.26 (3H, m, 
PhCH2O and propenyl 3-HB), 5.14 (1H, d, J 15.7, 5-HA), 5.13 (1H, d, J 10.2, 5-HB), 5.08 
(1H, br s, NH), 4.60 (2H, d, J 5.1, propenyl 1-H2), 4.42 (2H, d, J 6, PhCH2N(CO)), 3.87 
(1H, d, J 13.1, NHCHAPh), 3.81 (1H, d, J 13.1, NHCHBPh), 3.69 (1H, dd , J 10.8 and 4, 
1-HA), 3.40 (1H, dd, J 10.8 and 5.8, 1-HB), 2.84-2.79 (1H, m, 2-H), 2.34-2.21 (3H, m, 3-
HAB and OH); δC (75 MHz; CDCl3) 156.6, 156.4, 139.9, 138.9, 134.5, 133.2, 129.6, 
129.4, 128.9, 127.3, 126.5, 125.1, 120.6 (Ar 5-C), 118.2 (5-C), 117.2 (propenyl 3-C), 
111.7 (Ar 3-C); 68.8 (propenyl 1-C), 62.7 (1-C or PhCH2O), 62.4 (1-C or PhCH2O), 57.6 
(2-C), 50.8 (NHCH2Ph), 45.0 (PhCH2N(CO)), 35.9 (3-C); νmax/cm
-1 (film) 3323, 2925, 
1702, 1523, 1493, 1455; m/z (ES+) 411.2 (100%, [M+H]+); found 411.2295, C24H30N2O4 
requires MH 411.2278 
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[(4R,6E)-3-(1-Methyl-1H-imidazole-4-sulfonyl)-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(15),6,12(16),13-tetraen-4-yl]methanol E-261c   
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (33 mg, 
0.181 mmol), triethylamine (36 mg, 0.362 mmol) and amine E-249D (34 mg, 0.036 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:8:1 CH2Cl2—EtOH—NH4OH gave 
the amine E-261c  (16.1 mg, 0.03 mmol, 83%); Rf 0.44 (EtOAc); δH (500 MHz; CDCl3) 
7.83 (1H, s, Imid 3-H), 7.80 (1H, s, Imid 5-H), 7.72 (1H, s, Ar), 7.34-7.23 (3H, m, Ar), 
4.83 (1H, br s, 7-H), 4.58 (1H, d, J 14.7, 2-HA), 4.50-4.42 (2H, m, 2-HB and 11-HA), 4.30 
(1H, d, J 15.9, 11-HB), 4.26 (1H, br s, 6-H), 3.76 (3H, s, Me), 3.75-3.71 (1H, s, 4-H), 
3.68 (1H, dd, J 11 and 5.9, CHAOH), 3.64-3.55 (2H, m, 9-HAB), 3.52 (1H, dd, J 11 and 
6.3, CHBOH), 2.13-2.03 (3H, m, 5-HAB and 8-HA), 1.99-1.87 (1H, m, 8-HB); δC (75 MHz; 
CDCl3) 139.7, 139.6, 131.3, 128.3 (7-C), 128.1, 127.8 (6-C), 127.7, 127.6, 124.9, 79.1 
(CH2OH), 61.7 (4-C), 54.5 (2-C), 51.6 (11-C), 33.8 (5-C), 33.5 (NMe), 32.3 (8-C), 9-C 
missing; νmax/cm
-1 (film) 3295, 2943, 1638, 1612, 1532, 1454, 1386, 1335, 1224; m/z 
(ES+) 545.1 (100%, [M+H]+); found 545.1103, C26H34N2O6 requires MH 545.1111 
 
(4R,6E)-4-(Hydroxymethyl)-N-(pyridin-3-yl)-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(15),6,12(16),13-tetraene-3-carboxamide E-261a 
 
Following general procedure A1, 3-pyridyl isocyanate and amine E-249D (34 mg, 0.067 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
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purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the urea E-
261a (15 mg, 0.03 mmol, 89%); Rf 0.12 (60:40, EtOAc—petrol); νmax/cm
-1 (film) 3319, 
2938, 1662, 1550, 1510, 1382; m/z (ES+) 499.2 (20%, [M+H]+) and 543.2 (100%, 
[M+PEG]+); found 499.1618, C22H25F3N4O4S requires MH 499.1635 
NMR extremely broad compound confirmed by high-resolution mass spectroscopy, see 
E-261d for the free-amine scaffold NMR assignment 
[(4R,6E)-3-Cyclopropanecarbonyl-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(15),6,12(16),13-tetraen-4-yl]methanol E-261b 
 
Following general procedure A2, cyclopropane carbonyl chloride (19 mg, 0.181 mmol), 
triethylamine (36 mg, 0.36 mmol) and amine E-249D (34 mg, 0.036 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with EtOAc gave the amide E-261d (11 mg, 0.025 mmol, 
69%); Rf: 0.77 (EtOAc);     
     2.1 (c. 1.1, MeOH); νmax/cm
-1 (film) 3402, 2050, 1630, 
1459, 1387; m/z (ES+) 447.2 (100%, [M+H]+); found 447.1571, C20H25F3N2O4S requires 
MH 447.1560 
NMR extremely broad; compound confirmed by high-resolution mass spectroscopy, 
see E-261d for the free-amine scaffold NMR 
[(4R,6E)-10-(Trifluoromethane)sulfonyl-3,10-diazabicyclo[10.3.1]hexadeca-
1(15),6,12(16),13-tetraen-4-yl]methanol E-261d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine E-249D (31 mg, 0.033 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with EtOAc gave the amine E-261d (8.6 
mg, 0.023 mmol, 69%); Rf 0.18 (EtOAc);     
     5.3 (c. 0.9, MeOH); δH (500 MHz; 
CDCl3) 7.62 (1H, s, Ar), 7.31 (1H, ap t, J 7.4, Ar), 7.24 (1H, d, J 6.8, Ar), 7.23 (1H, d, J 
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7.4, Ar), 4.74 (1H, dd, J 16 and 5.8, 7-H), 4.69 (1H, dd, J 16 and 5.3, 6- H), 4.61 (1H, d, 
J 15.3, 11-HA), 4.53 (1H, d, J 15.3, 11-HB), 4.04 (1H, d, J 14.2, 2-HA), 3.64 (1H, d, J 
14.2, 2-HB), 3.67-3.64 (1H, m, 9-HA), 3.45 (1H, dd, J 10.7 and 6.1, CHAOH), 3.45-3.40 
(1H, m, 9-HB), 3.39 (1H, dd, J 10.7 and 5.8, CHBOH), 2.52 (1H, 4-H), 2.22-2.14 (1H, m, 
5-HA), 2.07-2.00 (1H, m, 5-HB), 1.97 (1H, d, J 14.2, 8-HA), 1.76-1.69 (1H, m, 8-HB); δC 
(75 MHz; CDCl3) 135.3, 130.5 (6-C), 128.5, 127.7, 127.4 (7-C), 126.9, 63.9 (CH2OH), 
59.7 (4-C), 53.9 (11-C), 51.3 (2-C), 50.7 (9-C), 34.5 (5-C), 31.9 (8-C); νmax/cm
-1 (film) 
3369, 2930, 1610, 1454, 1384; m/z (ES+) 379.1 (100%, [M+H]+); found 379.1316, 
C16H21F3N2O3S requires MH 379.1298 
(4R,6Z)-4-(Hydroxymethyl)-N-(pyridin-3-yl)-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(15),6,12(16),13-tetraene-3-carboxamide Z-261a 
 
Following general procedure A1, 3-pyridyl isocyanate and amine Z-249D (30 mg, 0.032 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:8:1 CH2Cl2—EtOH—NH4OH then 
EtOAc gave the amine Z-261a (11 mg, 0.022 mmol, 69%); Rf 0.5 (EtOAc);     
     3.7 
(c. 1.1, MeOH); δH (500 MHz; DMSO-d6; 343 K) 9.02 (1H, br s, NH), 8.62 (1H, d, J 2.5, 
Ar), 8.18 (1H, dd, J 4.7 and 1.4, Ar), 7.89 (1H, ddd, J 8.3, 2.6 and 1.5, Ar), 7.58 (1H, s, 
Ar), 7.54-7.41 (2H, m, Ar), 7.32 (1H, d, J 7.4, Ar), 7.27 (1H, dd, J 7.4 and 4.7, Ar), 5.49 
(1H, td, J 11.4 and 4.0, 7-H), 5.24 (1H, td, J 11.4 and 3.5, 6-H); 4.82-4.71 (1H, m, 2-HA 
or 11-HA), 4.71-4.50 (3H, m, 2-HA or 11-HA and 2-HB or 11-HB), 3.88-3.82 (1H, m, 
CHAOH), 3.80-3.70 (1H, m, CHBOH), 3.56 (1H, dt , J 13.8 and 6.6, 8-HA), 3.30 (1H, br 
s, 8-HB), 2.11 (1H, br s, 4-H), 1.80-1.61 (4H, m, 5-H and 7-HAB); δC (75 MHz; DMSO-d6; 
343 K) 155.7, 142.7, 141.6, 140.1, 137.2, 135.2, 134.9, 129.3, 129.1, 128.6, 128.3, 
127.6, 126.7, 126.3, 123.0, 120.7 q J 325, 61.7, 53.8, 49.7, 28.6, 28.2, 26.9; νmax/cm
-1 
(film) 3054, 2987, 2305, 1669, 1614, 1559, 1485, 1422, 1387; m/z (ES+) 499.2 (100%, 
[M+H]+); found 499.1623, C22H25F3N4O4S requires MH 499.1621 
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[(4R,6Z)-3-Cyclopropanecarbonyl-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(16),6,12,14-tetraen-4-yl]methanol Z-261b 
 
Following general procedure A2, cyclopropane carbonyl chloride (16 mg, 0.149 mmol), 
triethylamine (30 mg, 0.298 mmol) and amine Z-249D (28 mg, 0.029 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with EtOAc gave the amine Z-261b (9 mg, 0.02 mmol, 70%); 
Rf 0.8 (EtOAc);     
     7.9 (c. 1.8, MeOH);   δH (500 MHz; DMSO-d6; 343 K) very broad 
7.64-7.24 (4H, m, Ar), 5.51-5.38 (1H, m, 6-H), 5.32-5.18 (1H, m, 7-H), 4.87-3.96 (5H, 
m, 2-HAB and 11-HAB and 4-H), 3.75 (1H, s, CHAOH), 3.68-3.37 (2H, m, 9-HA and 
CHBOH), 3.13 (1H, br s, 9-HB), 2.12-1.86 (2H, m, 5-HAB), 1.83-1.56 (2H, m, 8-HAB), 
1.44-1.34 (1H, m, CPr), 0.96-0.70 (4H, m, CPr); νmax/cm
-1  (film) 3369, 3013, 2932, 2883, 
1725, 1611, 1454, 1428, 1386; m/z (ES+) 447.2 (100%, [M+H]+); found 447.1565, 
C26H34N2O6 requires MH 447.1560 
Unable to obtain a 13C spectrum due to interconversion of conformers 
[(4R,6Z)-3-(1-Methyl-1H-imidazole-4-sulfonyl)-10-(trifluoromethane)sulfonyl-3,10-
diazabicyclo[10.3.1]hexadeca-1(16),6,12,14-tetraen-4-yl]methanol Z-261c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (26 mg, 
0.144 mmol), triethylamine (30 mg, 0.29 mmol) and amine Z-249D (27 mg, 0.029 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:8:1 CH2Cl2—EtOH—NH4OH gave 
the amine Z-261c (12 mg, 0.023 mmol, 79%); Rf 0.4 (EtOAc);     
     4.1 (c. 1.2, 
MeOH); δH (500 MHz; DMSO-d6; 343 K) 7.82 (1H, Ar), 7.79 (1H, Ar), 7.66 (1H, Ar), 
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7.41-7.29 (3H, Ar), 5.45 (1H, ap t, J 11, 6-H), 5.29 (1H, ap t, J 11, 7-H), 4.74 (1H, d, J 
14.5, 11-HA), 4.60 (1H, d, J 15.6, 2-HA), 4.48 (1H, d, J 14.5, 11-HB), 4.14 (1H, d, J 15.6, 
2-HB), 3.89 (1H, br s, 4-H), 3.75 (3H, Me), 3.67 (1H, dd, J 11.3 and 7.1, CHAOH), 3.55 
(2H, br s, 9-HAB), 3.51 (1H, dd, J 11.3 and 6.1, CHBOH), 1.80 (1H, d, J 16.4, 5-HA), 1.68 
(1H, d, J 16.4, 5-HB), 1.58-1.40 (2H, m, 8-HAB); δC (125 MHz; DMSO-d6 343 K) 139.7, 
139.5, 138.8, 135.6, 129.6, 128.8, 128.4, 127.8, 126.2, 124.5, 61.4 (CH2OH), 61.1 (4-
C), 54.1 (11-C), 50.3 (9-C), 48.5 (2-C), 33.5 (Me), 29.1 (5-C), 26.6 (8-C); νmax/cm
-1 (film) 
3303, 2936, 1532, 1454, 1384, 1332; m/z (ES+) 545.1 (100%, [M+Na]+); found 
545.1106, C20H22F3N4O5S2 requires MNa 545.1111 
 
[(4R,6Z)-10-(Trifluoromethane)sulfonyl-3,10-diazabicyclo[10.3.1]hexadeca-
1(16),6,12,14-tetraen-4-yl]methanol Z-261d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine Z-249D (32 mg, 0.034 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
Z-261d (9.3 mg, 0.024 mmol, 72%); Rf 0.32 (EtOAc);     
     10.7 (c. 0.9, MeOH); δH 
(500 MHz; DMSO-d6; 343 K) 7.84 (1H, s, Ph), 7.68 (1H, d, J 7.5, Ph), 7.58 (1H, ap t, J 
7.5, Ph), 7.49-7.44 (1H, m, Ph), 5.38 (1H, td, J 10.5 and 5.5, 7-H), 5.34 (1H, td, J 10.5 
and 5.6, 6-H), 4.68-4.48 (2H, m, 11-HAB), 4.29 (1H, d, J 13.5, 2-HA), 4.13 (1H, d, J 13.5, 
2-HB), 3.71 (1H, dd, J 11.8 and 3.3, CHAOH), 3.57-3.50 (3H, m, CHBOH 9-HAB); 2.68 
(1H, s, 4-H), 1.96-1.65 (4H, 5-HAB and 8-HAB); δC (125 MHz; DMSO-d6; 343 K) 135.3, 
132.1, 130.7, 130.1, 129.6, 127.8 (6-C), 126.5 (7-C), 59.9 (CH2OH), 58.9 (4-C), 53.5 
(11-C), 53.3 (9-C), 49.3 (2-C), 48.6 , 27.4 (5-C), 25.6 (8-C); νmax/cm
-1 (film) 3292, 2730, 
2640, 2049, 1597, 1456, 1381, 1359; m/z (ES+) 379.1 (100%, [M+H]+); found 379.1312, 
C16H21F3N2O3S requires MH 379.1298 
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(2R)-N-[(3-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-1ʹ-hydroxy-S-(1-methyl-
1H-imidazol-4-yl)pent-4ʹ-ene-2ʹ-sulfonamido 270c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (80 mg, 
0.49 mmol), triethylamine (89 mg, 0.89 mmol) and amine 238D (86 mg, 0.089 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
sulfonamide 270c (25.5 mg, 0.046 mmol, 52%); Rf 0.56 (EtOAc);     
     8.7 (c. 2.5, 
MeOH); δH (500 MHz; CDCl3) 7.51 (1H, s, Imid), 7.45-7.43 (2H, m, Imid), 7.38 (1H, s, 
Imid), 7.35 (1H, ap t, J 7.6, Ph), 7.28 (1H, d, J 7.6, Ph), 5.61 (1H, ddt, J 17.4, 10.2 and 
6.9, 3-H), 5.55 (1H, ddt, J 17.2, 9.8 and 7, 4ʹ-H), 5.45 (1H, dd, J 8.0 and 4.5, OH), 5.05 
(1H, dd, J 10.2 and 1.6, 4-HA), 5.02 (1H, dd, J 17.4 and 1.6, 4-HB), 4.92 (1H, d, J 9.8, 
5ʹ-HA), 4.90 (1H, d, J 17.2, 5ʹ-HB), 4.51 (2H, br s, PhCH2NTf), 4.39 (1H, d, J 15.7, 
N(Imid)CHAPh), 4.27 (1H, d, J 15.7, N(Imid)CHBPh), 3.99 (1H, ddd, J 12.1, 10.0 and 4, 
1ʹ-HA), 3.88 (1H, td, J 10.0 and 6.7, 2-H), 3.75 (3H, s, Me), 3.64 (1H, ddd, J 12.1, 8 and 
3.6, 1ʹ-HB), 3.33 (2H, t , J 7.7, 1-H2), 2.29 (3H, m, 3ʹ-HA and 2-H2), 2.14 (1H, dt, J 14.3 
and 7.8, 3ʹ-HB); δC (75 MHz; CDCl3) 141.3, 138.6, 138.1, 134.6 (3-C), 134.5, 133.4 (4ʹ-
C), 129.1, 128.8, 127.7, 124.3, 120.1 (q, J 325, CF3), 118.0 (5ʹ-C), 117.4 (4-C), 63.9 
(2ʹ-C), 62.2 (1ʹ-C), 52.0 (PhCH2NTf), 50.9 (N(Imid)CH2Ph), 47.5 (1-C), 37.0 (3-C), 34.2 
(CH3), 32.5 (2-C); νmax/cm
-1 (film) 3278, 3055, 2987, 2686, 2522, 2411, 2305, 2126, 
1720, 1642, 1609, 1532; m/z (ES+) 573.1 (100%, [M+Na]+); found 551.1592, 
C22H29F3N4O5S2 requires MH 551.1604 
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N-[(3-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-N-
[(2ʹR)-1ʹ-hydroxypent-4ʹ-en-2ʹ-yl]cyclopropanecarboxamide 270b 
 
Following general procedure A2, cyclopropane carbonyl chloride (45 mg, 0.43 mmol), 
triethylamine (86 mg, 0.86 mmol) and amine 238D (83 mg, 0.086 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with 90:10 CHCl3—MeOH gave the amide 270b (13.3 mg, 0.028 mmol, 33%); 
Rf 0.56 (90:10, CHCl3—MeOH);     
     15.2 (c. 1.3, MeOH);  δH (500 MHz; CDCl3) 
7.37-7.21 (4H, m, Ar), 5.77 (1H, ddt, J 17.7, 10.8 and 7.7, 4ʹ-H), 5.61 (1H, ddt, J 17.1, 
10.2 and 6.8, 3-H), 5.12 (1H, d , J 17.7, 5-HA), 5.11 (1H, d , J 10.8, 5-HB), 5.04 (1H, d, J 
10.2, 4-HA), 5.01 (1H, d, J 17.1, 4-HB), 4.55 (2H, br s, PhCH2NTf), 4.11 (1H, dd , J 11.2 
and 5.1, 1ʹ-HA), 4.06 (1H, dd, J 11.2 and 5.6, 1ʹ-HB), 3.87 (1H, d, J 13.4, N(
CPr)CHAPh), 
3.84 (1H, d, J 13.4, N(CPr)CHBPh), 3.34 (2H, t, J 7.7, 1-H2), 2.89 (1H, p, J 5.7, 2ʹ-H), 
2.34-2.17 (4H, m, 3ʹ-HAB and 2-H2), 1.66-1.59 (1H, m, 
CPr), 1.02-0.98 (2H, m, CPr), 
0.90-0.86 (2H, m, CPr); δC (75 MHz; CDCl3) 174.8 (C=O), 141.5, 134.5, 134.4, 133.4, 
129.1, 128.4, 128.1, 127.1, 120.0 (q, J 324, CF3), 118.0 (5ʹ-C or 4-C), 117.9 (5ʹ-C or 4-
C), 65.9 (1ʹ-C), 55.3 (2ʹ-C), 52.2 (PhCH2NTf), 51.1 (N(
CPr)CH2Ph), 47.4 (1-C), 36.4 (3ʹ-
C), 32.5 (2-C), 12.8 (CPr), 8.5 (CPr); νmax/cm
-1 (film) 3060, 3006, 2984, 1725, 1641, 
1457, 1387, 1275, 1266, and 1225; m/z (ES+) 475.2 (100%, [M+H]+); found 475.1874, 
C26H34F3N2O6 requires MH 475.1873 
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3-[(3-{[N-(But-3-en-1-yl)(trifluoromethane)sulfonamido]methyl}phenyl)methyl]-3-
[(2ʹR)-1ʹ-hydroxypent-4ʹ-en-2ʹ-yl]-1-(pyridin-3-yl)urea 270a 
 
Following general procedure A1, 3-pyridyl isocyanate (23.8 mg, 0.199 mmol) and 
amine 238D (96 mg, 0.099 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 90:10 CHCl3−MeOH gave 
the urea 270a (21 mg, 0.039 mmol, 40%); Rf 0.1 (EtOAc);     
     1.7 (c. 2.1, MeOH);   
δH (500 MHz; CDCl3) 8.90 (1H, br s, NH), 8.26 (1H, d, J 2.6, Py-2), 8.14 (1H, dd, J 4.8 
and 1.5, Py-6), 8.08 (1H, d, J 8.7, Py-4), 7.39-7.24 (3H, m, Py-5 and Ar), 7.27-7.21 (2H, 
m, Ar), 5.70 (1H, ddt, J 17.1, 8.6 and 7.6, 4ʹ-H), 5.57 (1H, ddt, J 17.1, 10.3 and 6.8, 3-
H), 5.07 (1H, d, J 10.3, 4-HA), 5.08 (1H, d, J 17.1, 4-HB), 5.01 (1H, d, J 8.6, 5ʹ-HA), 4.97 
(1H, d, J 17.1, 5ʹ-HB), 4.59 (2H, s, N(Py)CH2Ph), 4.51 (2H, br s, PhCH2NTf), 3.88 (1H, 
m, 2ʹ-H), 3.83 (1H, dd, J 11.1 and 2.4, 1ʹ-HA), 3.74 (1H, dd, J 11.1 and 6.9, 1ʹ-HB), 3.32 
(2H, t, J 7.7, 1-H2), 2.45 (2H, dq, J 18.3 and 7.2, 3ʹ-H2), 2.20 (2H, br s, 2-H2); δC (75 
MHz; CDCl3) 156.9 (C=O), 142.6 (Py), 139.9 (Py), 139.7 (Py), 137.1 (Py-3), 135.0 (4ʹ-
C), 134.1 (3-C), 133.3, 129.4, 127.8, 127.4, 127.2, 126.9, 123.9, 119.8 (q, J 327, CF3), 
118.2 (4-C or 5ʹ-C), 118.0 (4-C or 5ʹ-C), 63.9 (1ʹ-C), 59.9 (2ʹ-C), 52.1 (PhCH2NTf), 49.7 
(N(Py)CPh), 47.6 (1-C), 33.8 (3ʹ-C), 32.5 (2-C); νmax/cm
-1 (film) 3006, 2988, 1734, 1660, 
1539, 1485, 1423, 1386; m/z (ES+) 527.2 (100%, [M+H]+); found 527.1946, 
C24H29F3N4O4S requires MH 527.1934 
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N-(But-3-en-1-yl)-1,1,1-trifluoro-N-{[3ʹ-({[(2ʹR)-1ʹ-hydroxypent-4ʹ-en-2ʹ-
yl]amino}methyl)phenyl]methyl}methanesulfonamide 270d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 238D (81 mg, 0.084 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
270d (16 mg, 0.039 mmol, 46%); Rf 0.19 (90;10, CHCl3—MeOH);     
     3.7 (c. 1.6, 
MeOH);  δH (500 MHz; CDCl3) 7.39-7.28 (3H, m, Ar), 7.24 (1H, d, J 7.7, Ar), 5.76 (1H, 
ddt, J 16.5, 10.8 and 7.2, 4ʹ-H), 5.62 (1H, ddt, J 17.1, 10.3 and 6.9, 3-H), 5.12 (1H, d, J 
16.5, 5ʹ-HA), 5.11 (1H, d, J 10.8, 5ʹ-HB), 5.05 (1H, dd , J 10.5 and 1.5, 4-HA), 5.01 (1H, 
dd , J 17.1 and 1.5, 4-HB), 4.53 (2H, br s, PhCH2Ntf), 3.86 (1H, d, J 13.3, NHCHAPh), 
3.80 (1H, d, J 13.3, NHCHBPh), 3.66 (1H, dd, J 10.8 and 4.1, 1ʹ-HA), 3.37 (1H, dd, J 
10.8 and 6.4, 1ʹ-HB), 3.34 (2H, t, J 8.1, 1-H2), 2.80-2.74 (1H, m, 2ʹ-H), 2.32-2.19 (3H, m, 
3ʹ-HAB and 2-HA), 2.01 (2H, br s, 2-HB and OH); δC (75 MHz; CDCl3) 141.2, 134.7 (4ʹ-C), 
134.6 (3-C), 133.4, 129.2, 128.4, 128.1, 127.2, 119.9 (q, J 325, CF3), 118.1 (5ʹ-C or 4-
C), 117.9 (5ʹ-C or 4-C), 62.9 (1ʹ-C), 57.5 (2ʹ-C), 52.1 (PhCH2NTf), 50.8 (NHCH2Ph), 
47.5 (1-C), 36.2 (3ʹ-C), 32.5 (2-C); νmax/cm
-1 (film) 3300, 3079, 3005, 2982, 2933, 1642, 
1457, 1387; m/z (ES+) 407.2 (100%, [M+H]+); found 407.1621, C18H25F3N2O2 requires 
MH 407.1611 
(5R,6R,9Z,12R)-12-(Hydroxymethyl)-5-methyl-3-(trifluoromethane)sulfonyl-3,13-
diazabicyclo[13.3.1]nonadeca-1(18),9,15(19),16-tetraen-6-ol 262d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 250D (119 mg, 0.106 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
262d (10 mg, 0.022 mmol, 21%); Rf 0.18 (90:10, CHCl3—MeOH);     
     −14.9 (c. 1, 
MeOH);  δH (500 MHz; CDCl3) 7.38-7.17 (4H, m, Ar), 5.39 (1H, dd, J 11 and 6.3, 9-H), 
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5.35 (1H, dd, J 11 and 7.3, 10-H), 4.68 (1H, d, J 15, 2-HA), 4.48 (1H, d, J 15, 2-HB); 
4.30 (1H, br s, 6-H), 4.05 (1H, d, J 5.5, CH2OH), 3.92 (1H, d, J 13.7, 14-HA), 3.67 (1H, 
d, J 13.7, 14-HB), 4.45-4.30 (3H, m, CHAOH, 4-HAB), 3.28-3.19 (1H, m, CHBOH), 2.56 
(1H, p, J 5.9, 12-H), 2.09 (1H, dt, J 13.3 and 6.7, 11-HA), 2.02 (1H, dt, J 13.3 and 6.1, 
11-HB), 1.85-1.79 (2H, m, 8-HAB), 1.44-1.29 (2H, m, 7-HAB), 1.11-0.97 (1H, m, 5-H), 
0.66 (3H, d, J 6.6); δC (75 MHz; CDCl3) 135.1, 131.6 (10-C), 128.7, 128.3, 127.9 (9-C), 
126.4, 68.9 (CH2OH), 62.9 (4-C), 58.9 (12-C), 53.9 (2-C), 52.8 (14-C), 34.5, 33.4 (11-
C), 25.6 (7-C), 22.8 (8-C), 21.9, (5-C), 10.2 (Me), 6-C missing; νmax/cm
-1 (film) 2925, 
2854, 2318, 1462, 1377; m/z (ES+) 451.2 (100%, [M+H]+); found 451.1894, 
C20H29F3N2O3S requires MH 451.1873 
(4R,6E,10R,11R)-10-Hydroxy-4-(hydroxymethyl)-11-methyl-N-(pyridin-3-yl)-13-
(trifluoromethane)sulfonyl-3,13-diazabicyclo[13.3.1]nonadeca-1(19),6,15,17-
tetraene-3-carboxamide 262a 
 
Following general procedure A1, 3-pyridyl isocyanate (27.5 mg, 0.229 mmol) and 
amine 250D (129 mg, 0.115 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 90:10 CHCl3—MeOH 
gave the urea 262a (14 mg, 0.024 mmol, 21.4%); Rf 0.31 (90:10, CHCl3—MeOH); 
    
     −17.9 (c. 1.4, MeOH); δH (500 MHz; DMSO-d6; 343 K) 8.66 (1H, d, J 2.4, Py), 
8.18 (1H, dd, J 4.7 and 1.5, Py), 7.95-7.88 (1H, m, Py), 7.44-7.37 (3H, m, Ar and Py), 
7.34 (1H, d, J 7.8, Ar), 7.28 (1H, dd, J 8.2 and 4.5, Ar), 5.36 (1H, dt, J 11.1 and 6.7, 6-
H), 5.29 (1H, dt, J 11.1 and 7.2, 7-H), 5.00 (1H, br s, OH), 4.85 (1H, d, J 16.7, 2-HA), 
4.65 (1H, d, J 15.4, 14-HA), 4.62 (1H, d, J 15.4, 14-HB), 4.49 (1H, d, J 16.7, 2-HB), 4.06 
(1H, br s, 4-H), 3.67-3.58 (2H, m, CH2OH), 3.52 (1H, dd, J 13.9 and 10.9, 12-HA), 3.21 
(1H, dd, J 13.9 and 4.8, 12-HB), 3.15-3.10 (1H, m, 10-H), 2.17 (1H, dt, J 14.1 and 8.4, 
5-HA), 1.96 (1H, dt, J 14.1 and 5.5, 5-HB), 1.65-1.47 (3H, m, 11-H and 8-H2), 1.36-1.31 
(2H, m, 9-H2), 0.71 (3H, d, J 6.8, Me); δC (75 MHz; DMSO-d6; 343 K) 156.2 (C=O), 
142.7 (6-Py), 141.7 (2-Py), 141.0 (3-Py), 135.2, 130.9 (9-C), 128.8, 127.5 (10-C), 
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126.7, 126.6, 125.9, 123.0; 61.1 (CH2OH), 59.2 (12-C), 53.8 (2-C), 46.7 (14-C), 45.9 
(4-C), 33.6 (11-C), 32.9 (7-C), 28.8 (5-C), 22.4 (8-C), 9.3 (Me); νmax/cm
-1 (film) 3289, 
2931, 1662, 1609, 1384, 1275; m/z (ES+) 571.1 (100%, [M+H]+); found 571.2185, 
C26H33FN2O6 requires MH 571.2197 
(5R,6R,9E,12R)-13-Cyclopropanecarbonyl-12-(hydroxymethyl)-5-methyl-3-
(trifluoromethane)sulfonyl-3,13-diazabicyclo[13.3.1]nonadeca-1(18),9,15(19),16-
tetraen-6-ol 262b 
 
Following general procedure A2, cyclopropane carbonyl chloride (31 mg, 0.3 mmol), 
triethylamine (62 mg, 0.61 mmol) and amine 250D (69 mg, 0.061 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with 90:10 CHCl3−MeOH gave the amide 262b (11.1 mg, 0.021 mmol, 34%); Rf  
0.26 (80:20, petrol—EtOAc);     
     −22 (c. 1.1, MeOH);  δH (500 MHz; DMSO-d6; 343 
K) 7.41-7.20 (4H, m, Ar), 5.44 (1H, dt, J 11 and 7.0, 9-H), 5.36 (1H, dt, J 11 and 7.9, 
10-H), 4.69 (1H, d , J 15.2, 2-HA), 4.48 (1H, d , J 15.2, 2-HB), 4.07-4.03  (2H, m, 
CH2OH), 3.91 (1H, d, J 13.5, 14-HA); 3.68 (1H, d, J 13.5, 14-HB), 3.34 (1H, dd, J 14 and 
8.3, 4-HA), 3.25 (1H, dd, J 14 and 6.3, 4-HB), 3.20 (1H, dd, J 10.3 and 5.4, 6-H), 2.78 
(1H, p, J 5.9, 12-H), 2.17-2.05 (2H, m, 11-H2), 1.88-1.82 (2H, m, 8-H2), 1.74 (1H, br s, 
OH), 1.68-1.63 (2H, m, CPr), 1.42-1.31 (2H, m, 7-H2), 1.09-1.05 (1H, m, OH), 0.91-0.85 
(4H, m, CPr); 0.67 (3H, d, J 6.8, Me); δC (125 MHz; DMSO-d6, 343K) 173.7 (Ar), 141.5 
(Ar), 135.1 (Ar), 132.3 (9-C), 128.8 (Ar), 128.2 (Ar), 127.9 (Ar), 126.4 (10-C), 125.7 
(Ar), 119.1 (q, J 325, CF3), 68.9 (6-C), 65.9 (CH2OH), 55.6 (12-C), 53.9 (4-C), 52.9 (2-
C), 50.9 (14-C), 34.7 (7-C), 29.6 (11-C), 22.9 (8-C), 12.5 (CH3), 9.8 (
CPr), 7.8 (CPr); 
νmax/cm
-1 (film) 3585, 3388, 3011, 2938, 1724, 1610, 1454, 1384; m/z (ES+) 519.2 
(100%, [M+H]+); found 519.2154, C24H33F3N2O5S1 requires MH 519.2135 
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(5R,6R,9E,12R)-12-(Hydroxymethyl)-5-methyl-13-(1-methyl-1H-imidazole-4-
sulfonyl)-3-(trifluoromethane)sulfonyl-3,13-diazabicyclo[13.3.1]nonadeca-
1(18),9,15(19),16-tetraen-6-ol 262c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (59 mg, 
0.33 mmol), triethylamine (68 mg, 0.67 mmol) and amine 250D (76 mg, 0.067 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 95:5 CHCl3—MeOH gave the 
sulfonamide 262c (24.1 mg, 0.041 mmol, 60.6%); Rf 0.28 (95:5, CHCl3—MeOH);     
    
 
−0.3 (c. 1.2, MeOH); δH (500 MHz; DMSO-d6; 343 K) 7.81 (1H, d, J 1.4, Imid), 7.78 
(1H, d, J 1.4, Imid), 7.47-7.40 (2H, m, Ar), 7.40 (1H, t, J 7.8, Ar), 7.36-7.32 (1H, m, Ar), 
5.27 (1H, dd, J 10.8 and 5.1, 9-H or 10-H), 5.24 (1H, dd, J 10.8 and 6.3, 9-H or 10-H), 
4.66 (1H, d, J 15.8, 2-HA), 4.57 (1H, d, J 15.8, 2-HB), 4.54 (1H, d, J 16.2, 14-HA), 4.31 
(1H, d, J 16.2, 14-HB), 4.14 (1H, br s, OH), 3.79 (1H, ddt, J 9.7, 7.1 and 5.0, 12-H), 
3.72 (3H, s, NMe), 3.52 (2H, m, 4-HA an CHAOH), 3.44 (1H, dd, J 11.6 and 4.4, 
CHBOH), 3.24 (1H, dd, 13.9 and 4.7, 4-HB), 3.09 (2H, s, OH and 6-H), 2.07-1.99 (1H, 
m, 11-HA), 1.88 (1H, dt, 10.5 and 5, 11-HB), 1.59-1.51 (1H, m, 8-HA), 1.49-1.40 (2H, m, 
8-HB and 5-H), 1.34-1.23 (2H, m, 7-H2), 0.73 (d, J 6.7, Me <10% trans), 0.69 (3H, d, J 
6.7, Me); δC (125 MHz; DMSO-d6; 343 K) 139.7 (Imid), 139.6 (Imid), 139.5 (Ar), 135.4 
(Ar), 130.7 (9- or 10-C); 128.7 (Ar), 128.1 (Ar), 127.9 (Ar), 126.5 (9- or 10-C), 126.4 
(Ar), 124.7 (Imid); 120.1 (q J 325, CF3), 68.8 (6-C), 60.8 (12-C), 60.7 (CH2OH), 54.6 (4-
C), 52.9 (2-C), 48.2 (14-C); 33.5 (Me), 33.0 (7-C), 33.0 (11-C), 30.4 (5-C), 22.4 (8-C), 
9.3 (Me); νmax/cm
-1 (film) 3401, 2941, 1639, 1533, 1491, 1448, 1384; m/z (ES+) 617.2 
(100%, [M+H]+); found 617.1684, C24H33F3N4O6S2 requires MH 617.1686 
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(2R)-1-Hydroxy-N-{[3-({N-[(2R,3R)-3-hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-S-(1-methyl-1H-
imidazol-4-yl)pent-4ʹ-ene-2ʹ-sulfonamido 271c 
  
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (64 mg, 
0.36 mmol), triethylamine (72 mg, 0.71 mmol) and amine 239D (82 mg, 0.071 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 95:5 CHCl3—MeOH gave the 
sulfonamide 271c (18 mg, 0.028 mmol, 40.8%); Rf 0.35 (95:5, CHCl3—MeOH);     
    
 
−3.1 (c. 0.9, MeOH);  δH (500 MHz; CDCl3) 7.51 (1H, d, J 1.4, Ar), 7.44 (1H, d, J 1.4, 
Ar), 7.41 (1H, s, Ar), 7.40-7.30 (4H, m, Ar), 5.77 (1H, ddt, J 16.9, 10.2 and 6.7, 6-H), 
5.57 (1H, ddt, J 17.1, 10.2 and 7.1, 4ʹ-H), 5.45 (1H, br s, OH), 5.01 (1H, dd , J 17.1 and 
1.6, 7-HA), 4.98 (3H, m, 7-HB and 5ʹ-HAB), 4.64 (2H, br s, PhCH2NTf), 4.38 (1H, d, J 
15.8, N(SO2)CHAPh), 4.28 (1H, d, J 15.8, N(SO2)CHBPh), 3.99-3.88 (2H, m, 1ʹ-HA and 
2ʹ-H), 3.75 (3H, s, CH3), 3.64 (1H, d, J 11.2, 1ʹ-HB), 3.56 (1H, br s, 3-H), 3.44 (1H, br s, 
1-HA), 3.15 (1H, br s, 1-HB), 2.28-2.08 (3H, m, 3ʹ-HAB and 5-HA), 2.01-1.93 (1H, 5-HA); 
1.64-1.45 (2H, 2-H and 4-HA), 1.21 (1H, 4-HB), ch3 (3H, CH3); δC (75 MHz; CDCl3) 
141.2, 138.6, 138.3, 137.9, 134.9, 134.6, 129.1, 128.9, 128.0, 124.3; 117.6 (7-C or 5ʹ-
C), 114.9 (7-C or 5ʹ-C), 79.9 (3-C), 63.7 (2ʹ-C), 62.2 (1ʹ-C), 53.4 (PhCH2NTf), 52.1 (1-
C), 50.6 (N(SO2)CH2Ph), 36.9 (5-C or 3ʹ-C), 36.3 (4-C), 34.25 (me), 32.9 (5-C or 3ʹ-C), 
30.6 (2-C), 10.6 (CH3 extracted from HMQC); νmax/cm
-1 (film) 3370, 2977, 2939, 1641, 
1533, 1450, 1384, 1335; m/z (ES+) 645.3 (100%, [M+Na]+); found 623.2163, 
C26H37F3N4O6S2 requires MH 623.2179 
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3-{[3-({N-[(2R,3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-3ʹ-[(2ʹR)-1ʹ-hydroxypent-
4ʹ-en-2ʹ-yl]-1ʹ-(pyridin-3-yl)urea 271a 
 
Following general procedure A1, 3-pyridyl isocyanate (16.3 mg, 0.14 mmol) and amine 
239D (78 mg, 0.067 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 90:10 CH2Cl2—MeOH gave the 
urea 271a (35 mg, 0.058 mmol, 87.4%); Rf 0.15 (90:10, CH2Cl2—MeOH);     
     −2.2 
(c. 3.5, MeOH); δH (300 MHz; CDCl3) 8.96 (1H, br s, NH), 8.20 (1H, d, J 2.7, 2-Py), 8.12 
(1H, dd, J 4.8 and 1.4, 4-Py), 8.00 (1H, ddd, J 8.4, 2.7 and 1.4, 5-Py), 7.41-7.17 (5H, 
m, Ar and 6-Py), 5.81-5.65 (2H, m, 4ʹ-H and 6-H), 5.09 (1H, d, J 10.4, 7-HA or 5ʹ-HA), 
5.08 (1H, d, J 16, 7-HB or 5ʹ-HB), 4.99 (1H, d, J 17, 7-HB or 5ʹ-HB), 4.97 (1H, d, J 9.4, 7-
HA or 5ʹ-HA), 4.62 (1H, d, J 15.8, N(CO)CHAPh), 4.54 (1H, d, J 15.8, N(CO)CHBPh), 
4.53 (2H, br s, PhCH2NTf), 3.96-3.86 (1H, m, 2ʹ-H), 3.80-3.63 (2H, m, 1ʹ-H2), 3.52 (1H, 
br s, 3-H), 3.34 (1H, dd, J 13.7 and 8, 1-HA), 3.17 (1H, br s, 1-HB), 2.55-2.34 (2H, m, 3ʹ-
HAB), 2.14-1.88 (2H, m, 5-HAB), 1.67 (1H, d, J 6.8, 2-H), 1.44 (1H, d, J 7.1, 4-HA), 1.32-
1.17 (1H, m, 4-HB), 0.71 (3H, d, J 6.8, Me); δC (75 MHz; CDCl3) 157.1 (CO), 142.7, 
139.9, 139.4, 138.1, 136.9, 135.4, 134.1, 129.5, 127.9, 127.8, 127.0, 123.9, 122.3, 
118.3 (5ʹ-C), 115.1 (7-C), 77.2 (3-C), 63.9 (1ʹ-C), 60.0 (2ʹ-C), 53.6 (N(CO)CH2Ph), 52.0 
(PhCH2NTf), 49.2 (1-C), 36.4 (5-C), 33.8 (3ʹ-C), 33.0 (2-C), 30.5 (4-C), CF3 missing; 
νmax/cm
-1 (film) 3316, 3054, 2980, 2937, 1730, 1662, 1587, 1540, 1484, 1384; m/z (ES+) 
599.3 (100%, [M+H]+); found 599.2506, C28H37F3N4O5S requires MH 599.2510 
 
  
232 
 
N-{[3-({N-[(2R,3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]methyl}-N-[(2R)-1ʹ-hydroxypent-
4ʹ-en-2ʹ-yl]cyclopropanecarboxamide 271b 
 
Following general procedure A2, cyclopropane carbonyl chloride (41 mg, 0.4 mmol), 
triethylamine (80 mg, 0.8 mmol) and amine 239D (90 mg, 0.08 mmol) gave the crude 
product after 16 h. The crude product was purified by F-SPE and following general 
procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude product 
and on reaction completion was quenched with methoxytrimethylsilane (0.5 mL) and 
stirred for a further 16 h. The crude product was purified by column chromatography, 
eluting with 95:5 CHCl3−MeOH gave the amide 271b (9.7 mg, 0.018 mmol, 22.2%); Rf 
0.64 (90:10, CHCl3—MeOH);     
     1.2 (c. 0.9, MeOH);  δH (500 MHz; CDCl3; 323 K) 
Mixture of rotamers 7.41-7.26 (4H, m, Ar), 5.82-5.70 (2H, m, 4ʹ-H and 6-H), 5.14-4.94 
(4H, m, 5ʹ-HAB and 7-HAB), 4.67-4.38 (4H, m, N(CO)CH2Ph and PhCH2NTf), 4.13-4.04 
(1H, m, 3-H), 3.72-3.41 (4H, m, 1-HAB and 1ʹ-HAB), 3.20-3.10 (1H, m, 2ʹ-H), 2.41 (1H, s, 
3ʹ-HA), 2.35-2.20 (1H, m, 3-HB), 2.21-2.02 (1H, m, 5-HA), 2.01-1.92 (1H, m, 5-HB), 1.69-
1.52 (2H, m, 4-HAB), 1.39-0.69 (6H, m, 
CPr and 2-H); 0.75 (3H, d, J 6.8, Me); δC (125 
MHz; DMSO-d6; 343 K) 138.5, 131.9, 128.4, 127.8, 126.6, 116.2 (5-C), 114.4 (7-C), 
69.5 (3-C), 65.7 (1ʹ-C), 58.1 (2ʹ-C), 54.9 (N(CO)CH2Ph), 52.6 (PhCH2NTf), 50.2 (1-C), 
35.8 (2-C), 33.6 (3ʹ-C), 29.7 (4-C), 12.5 (CPr), 10.2 (Me), 7.7 (CPr), CF3 missing; 
νmax/cm
-1 (film) 3386, 3055, 2981, 2938, 2306, 1725, 1640, 1546, 1450 and 1384; m/z 
(ES+) 547.3 (100%, [M+H]+); found 547.2461, C26H37F3N2O5S requires MH 547.2448 
1,1,1-Trifluoro-N-[(2R,3R)-3-hydroxy-2-methylhept-6-en-1-yl]-N-{[3-({[(2R)-1ʹ-
hydroxypent-4ʹ-en-2ʹ-yl]amino}methyl)phenyl]methyl}methanesulfonamide 271d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 239D (79 mg, 0.069 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
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purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
271d (22 mg, 0.046 mmol, 67%); Rf 0.2 (90:10, CHCl3—MeOH);     
    
 6.8 (c. 1.1, 
MeOH); δH (500 MHz; CDCl3) 7.49-7.34 (4H, m, Ar), 5.87 (1H, ddt, J 17.4, 10.3 and 7.1, 
4ʹ-H), 5.81 (1H, ddt, J 16.9, 10.6 and 5.4, 6-H), 5.15 (1H, dd , J 17.4 and 1.9, 5ʹ-HA), 
5.12 (1H, dd, J 10.3 and 1.7, 5ʹ-HB), 5.02 (1H, ddd, J 16.9, 1.4 and 1.4, 7-HA), 4.97 (1H, 
ddd, J 10.6, 1.4 and 1.4, 7-HB), 4.67 (1H, d, J 14.5, PhCHANTf), 4.61 (1H, d, J 14.5, 
PhCHBNTf), 3.93 (1H, d, J 13.3, NHCHAPh), 3.89 (1H, d, J 13.3, NHCHBPh), 3.66 (1H, 
dd, J 11.1 and 4.7, 1ʹ-HA), 3.53 (1H, dd, J 11.1 and 6.3, 1ʹ-HB), 3.49-3.47 (3H, m, 3-H 
and 1-HAB), 2.79 (1H, qd, J 6.3 and 4.7, 2ʹ-H), 2.33-2.29 (2H, m, 3ʹ-HAB), 2.14-2.06 (1H, 
m, 5ʹ-HA), 2.02-1.92 (1H, m, 5ʹ-HB), 1.76-1.68 (1H, m, 2-H), 1.53-1.44 (1H, m, 4-HA), 
1.36-1.26 (1H, m, 4-HB), 0.82 (3H, d, J 6.9, Me); δC (75 MHz; CDCl3) 141.8 (Ar 1- or 3-
C), 139.5 (Ar 1- or 3-C), 136.9 (6ʹ-C), 136.4 (4-C), 130.1 (Ar ), 129.8 (Ar), 129.6 (Ar), 
128.6 (Ar), 121.8 (q, J 324, CF3); 117.8 (7-C), 115.1 (5ʹ-C), 71.7 (3-C), 64.1 (1ʹ-C), 59.4 
(2ʹ-C), 54.6 (1-C), 54.5 (PhCH2NTf), 51.8 (NHC), 37.7 (2-C), 36.6 (3ʹ-C), 34.9 (5-C), 
31.3 (4-C), 10.8 (Me); νmax/cm
-1 (film) 3390, 3054, 3005, 2986, 2937, 1640, 1451 and 
1384; m/z (ES+) 479.2 (100%, [M+H]+); found 479.2199, C22H33F3N2O4S requires MH 
479.2186 
2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-(2-{[(1-hydroxypent-4-
en-2-yl)[(pyridin-3-yl)carbamoyl]amino]methyl}phenyl)phenyl]methyl}carbamate 
 
Following general procedure A1, 3-pyridyl isocyanate (11.2 mg, 0.093 mmol) and 
amine 240D (53 mg, 0.046 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 95:5 CHCl3—MeOH gave 
the urea 272a (12.5 mg, 0.018 mmol, 39%); Rf 0.2 (70:30, petrol—EtOAc);     
    
 16.2 
(c. 0.6, MeOH); δH (300 MHz; CDCl3) very broad and atropisomers denoted in italics 
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where possible 8.41-8.32 (1H, m, Py), 8.24-8.13 (1H, m, Py), 7.98-7.86 (1H, m, Py), 
7.81-7.69 (1H, m, Ar), 7.50 (1H, ap t, J 6.6, Ar), 7.45-7.23 (4H, m, Ar), 7.22-7.07 (3H, 
m, Ar), 7.00 (1H, dd, J 8.2 and 6.6, DMB 6-H), 6.46-6.36 (2H, m, DMB 3-H and 5-H); 
5.81 (1H, ddt, J 16.1, 10.5 and 5.5, propenyl 2-H), 5.69 (1H, ddt, J 17, 9.9 and 6.9, 4-
H), 5.32 (1H, br s, NH), 5.19 (1H, dd, J 17 and 1.5, propenyl 3-HA), 5.11 (1H, d, J 9.9, 
propenyl 3-HB), 5.07-4.93 (2H, m, 5-CAB), 4.40-3.86 (9H, propenyl 1-H2, 2 x Benzylic 
CH2, propyl 1-H and 2-H), 3.78 (3H, s, OMe), 3.74 (3H, s, OMe), 3.69-3.45 (5H, 1-H, 
propyl 3-H and 2-H ), 2.44-2.30 (2H, 3-H); δC (75 MHz; CDCl3) 159.6 (DMB 4-C), 158.3 
(DMB 2-C), 157.0 (C=O), 156.8 (C=O), 143.5, 136.6, 134.9, 134.6, 128.9, 128.3, 127.6, 
127.5, 127.4, 123.3, 117.7 (5-C or propenyl 3-C), 116.7 (5-C or propenyl 3-C), 104.1 
(DMB 5-C), 98.6 (DMB 3-C), 71.9 (propenyl 1-C), 70.5 (1-C), 65.6 (propyl 3-C), 62.4 
(propyl 1-C), 59.5 (2-C); 55.3 (OMe), 50.5 (N(CO)CPh), 45.7 (NPyCPh), 38.2 (propyl 2-
C), 33.6 (3-C); νmax/cm
-1 (film) 3332, 2937, 1711, 1623, 1598, 1534, 1357, 1208, 1159, 
and 1099 ;m/z (ES+) 695.3 (100%, [M+H]+); found 695.3441, C40H46N4O7 requires MH 
695.3439 
 
2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-(2-{[N-(1-hydroxypent-
4-en-2-yl)1-methyl-1H-imidazole-4-
sulfonamido]methyl}phenyl)phenyl]methyl}carbamate 272c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (52 mg, 
0.29 mmol), triethylamine (58.6 mg, 0.59 mmol) and amine 240D (65 mg, 0.057 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with CHCl3 gave the amine sulfonamide 
272c (9.1 mg, 0.013 mmol, 22.2%); Rf 0.4 (EtOAc);     
    
 4.8 (c. 0.5, MeOH); δH (500 
MHz; CDCl3; 323 K) atropisomers denoted where possible 7.82 (1H, d, J 7.9), 7.66-
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7.22 (7H, m, ), 7.20-7.02 (3H, m, ), 6.44-6.38 (2H, m, ), 5.84 (1H, ddt, J 16.8, 11 and 
5.4, propenyl 2-H), 5.84 (ddt, J 16.1, 10.2 and 5.2, propenyl 2-Hatrop), 5.55 (1H, ddt, J 
17.3, 10 and 6.9, 4-H), 5.55 (ddt, J 17.1, 10.2 and 6.6, 4-Hatrop), 5.20 (1H, dd , J 17.3 
and 1.8, 5-HA), 5.10 (1H, dd, J 10.2 and 1.6, 5-HB), 4.94-4.81 (2H, m, propenyl 3-HAB), 
4.44-4.27 (2H, m, propyl 1-HAB), 4.10 (1H, dd, J 16.8 and 5.6, N(SO2)CHAPh or 
PhCHAN(CO)O), 4.08-3.97 (1H, m, N(SO2)CHBPh or PhCHBN(CO)O), 3.95-3.87 (2H, 
m, propenyl 1-H), 3.78-3.74 (6H, m, 2 × OMe), 3.66 (3H, s, NMe), 3.64 (s, NMeatrop), 
3.63-3.43 (8H, propyl 2-H and 3-HAB, 2-H, 1-HAB and N(SO2)CH2Ph or PhCH2N(CO)O), 
2.31-2.20 (1H, 3-HA), 2.18-2.05 (1H, 3-HB); δC (125 MHz; CDCl3; 323 K) 159.7, 158.4 
(atrop), 157.1 (atrop), 138.5, 135.0, 134.8, 129.8, 129.8, 129.6, 129.0, 128.9, 128.3, 128.1, 
128.0, 127.8, 127.8, 127.02, 127.0, 124.2, 120.4, 117.2, 117.1, 116.4, 104.4, 98.8, 
71.9, 70.6, 63.8, 62.6, 62.2, 55.4, 55.3, 38.3, 33.9 (Me); νmax/cm
-1 (film) 3691, 3056, 
2987, 2685, 2411, 2306, 1714, 1607, 1550, 1508, 1422, 1277; m/z (ES+) 741.3 (100%, 
[M+Na]+); found 741.2919, C38H46N4O8S requires MNa 741.2929 
full carbon assignment was not possible to mixture of atropisomers 
2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-(2-{[1-cyclopropyl-N-
(1-hydroxypent-4-en-2-yl)formamido]methyl}phenyl)phenyl]methyl}carbamate 
272b 
 
Following general procedure A2, cyclopropane carbonyl chloride (36.4 mg, 0.35 mmol), 
triethylamine (70.4 mg, 0.69 mmol) and amine 240D (79 mg, 0.069 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with 50:50 petrol—EtOAc gave the amide 272b (19.9 mg, 
0.031 mmol, 45%); Rf 0.5 (70:30, petrol—EtOAc);     
    
 −5.9 (c. 1, MeOH); δH (300 
MHz; CDCl3; 323 K) very broad 7.95-7.25 (5H, m, Ar), 7.21-7.03 (4H, m, Ar), 6.44 (2H, 
s, DMB), 5.84 (1H, 16.1, 10.7 and 5.4, propenyl 2-H), 5.70-5.59 (1H, 4-H), 5.21 (1H, 
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16.1, propenyl 3-HA), 5.12 (1H, 10.7, propenyl 3-HB), 5.06-4.83 (2H, 5-HAB), 4.67-3.28 
(20H, N(CO)CH2Ph, PhCH2N(CO)O, 2 × OMe, 2-H, 1-H, propenyl 1-H, Propyl 1HAB, 2-
H and 3-HAB), 2.46-1.85 (2H, 3-H), 1.54-1.45 (1H, 
CPr), 1.05-0.63 (4H, CPr); δC (75 
MHz; CDCl3) 159.7 (DMB 4-C), 158.3 (DMB 2-C), 146.1 (C=O), 138.9, 134.9 (propenyl 
2-C), 131.6, 129.8, 129.8, 128.9, 128.4, 128.3, 128.2, 127.6, 127.5, 127.2, 117.5 
(propenyl 3-C or 5-C), 116.7 (propenyl 3-C of 5-C), 104.1 (DMB 5-C), 98.6 (DMB 3-C), 
71.9 (propenyl 1-C), 70.6 (1-C), 65.4 (propyl 1-C), 64.0 (propyl 3-C), 63.9 
(N(CO)CH2Ph), 59.9 (2-C), 55.4 (OMe), 55.3 (OMe), 49.2 (PhCH2N(CO)O), 38.2 
(propyl 2-C), 33.1 (3-C), 12.3 (CPr), 8.4 (CPr); νmax/cm
-1 (film) 3332, 3061, 3006, 2937, 
1713, 1614, 1588, 1544, 1508, 1463, 1358, 1261, 1208, 1159, and 1099; m/z (ES+) 
665.3 (100%, [M+Na]+); found 643.3395, C38H46N2O7 requires MH 643.3378 
3-({2-[2-({N-[(3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]phenyl}methyl)-3-(1-
hydroxypent-4-en-2-yl)-1-(pyridin-3-yl)urea 274a 
 
Following general procedure A1, 3-pyridyl isocyanate (21.5 mg, 0.179 mmol) and 
amine 242 (110 mg, 0.089 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:50 petrol—EtOAc gave the urea 
274a (37.7 mg, 0.056 mmol, 63%); Rf 0.25 (50:50 EtOAc—petrol);     
    
 10.9 (c. 1.1, 
MeOH);δH (500 MHz; CDCl3) 9.52 (0.5H, br s, NH), 9.23 (0.5H, br s, NH), 8.22 (1H, d, J 
11.7), 8.10 (2H, m, Ar), 7.68-7.06 (9H, Ar), 5.74 (1H, ddt, J 17.1, 10.4 and 6.7, 6-H), 
5.63-5.54 (1H, m, 4ʹ-H), 5.02-4.84 (4H, m, 5ʹ-HAB and 7-HAB), 4.68 (0.5H, d, J 16.8, 
PhCHANTf), 4.40 (0.5H, d, J 16.5, PhCHANTf
atrop), 4.35 (1H, br s, PhCHBNTf), 4.18-
3.99 (1H, m, 3-H), 3.89-3.38 (5H, m, 1ʹ-HAB, 2ʹ-H, N(COPy)CH2Ph), 3.34 (1H, dd , J 
14.4 and 9.2, 1-HA), 3.20 (1H, dd, J 14.4 and 6.6, 1-HB), 2.45 (0.5H, dt, J 13.8 and 6.9, 
3ʹ-HA), 2.38-2.23 (1.5H, m, 3ʹ-HB and 3ʹHAB
atrop), 2.15-1.83 (2H, m, 5-HAB), 1.64-1.53 
(0.5H, 4-HA
atrop), 1.51-1.41 (1.5H, 2-H and 4-HB
atrop), 1.32-1.19 (1H, 4-HAB), 0.69 (3H, d, 
J 6.9, Me); δC (75 MHz; CDCl3) 157.2, 156.9, 142.4, 142.3, 139.7, 139.6, 139.3, 139.2, 
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138.5, 138.3, 138.2, 135.8, 134.0, 133.8, 133.2, 129.7, 129.6, 129.7, 128.6, 128.4, 
128.0, 127.5, 127.4, 127.3, 127.1, 124.1, 118.3, 118.2, 114.9, 114.8, 63.7, 63.6, 60.9, 
60.1, 54.5, 52.6, 51.2, 48.9, 36.8, 33.8, 33.6, 33.4, 33.2, 30.6, 30.4, 10.5; νmax/cm
-1 
(film) 3285, 3063, 2979, 2939, 1663, 1588, 1546, 1484, 1424, 1385 and 1341; m/z 
(ES+) 675.3 (100%, [M+H]+); found 675.2833, C34H41F3N4O5S requires MH 675.2823 
1-Hydroxy-N-({2-[2-({N-[(3R)-3-hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]phenyl}methyl)-S-(1-methyl-1H-
imidazol-4-yl)pent-4-ene-2-sulfonamido 274c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (93 mg, 
0.517 mmol), triethylamine (104 mg, 1.03 mmol) and amine 242 (127 mg, 0.103 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 50:50 EtOAc—petrol gave the 
sulfonamide 274c (50.7 mg, 0.071 mmol, 69.2%); Rf 0.35 (50:50, EtOAc—petrol); δH 
(500 MHz; CDCl3) 7.95 (1H, d, J 7.8, Imid 2-H), 7.89 (1H, d, J 7.8, Imid 2-H
atrop), 7.57 
(1H, d, J 7.7, Aratrop), 7.50-7.30 (6.5H, m, Ar), 7.17-7.12 (1H, m, Ar), 7.07-7.01 (1H, m, 
Ar), 5.74 (1H, ddt, J 16.8, 9.8 and 6.7, 4ʹ-H), 5.61 (0.5H, ddt, J 16.8, 10.2 and 7.6, 6-H), 
5.43 (0.5H, br s, 6Hatrop), 5.03-4.72 (4H, m, 5ʹ-HAB and 7-HAB), 4.67-4.04 (4H, m, 
N(Imid)CH2Ph and PhCH2NTf ), 3.97 (d, J 17, N(Imid)CH2Ph or PhCH2NTf ), 3.92-3.84 
(1H, 3-H); 3.73 (3H, s, NMe), 3.71 (s, NMeatrop), 3.60-3.36 (5H, 1ʹ-H2, 2ʹ-H and 1-H2), 
3.33 (1H, dd , 1-HA
atrop), 3.29 (1H, br s, 1-HB
atrop), 2.32-1.84 (4H, 3ʹ-H2 and 5-H2), 1.79-
1.60 (0.5H, 4-HA), 1.53-1.37 (2H, 2-H and 4-HB and 4-HA
atrop), 1.30-1.17 (0.5H, 4-
HB
atrop), 0.65 (3H, d , J 6.7, CH3); δC (75 MHz; CDCl3) 140.6, 140.5, 139.3, 139.0, 138.8, 
138.7, 138.3, 138.1, 137.8, 135.9, 135.4, 134.7, 134.6, 133.8, 132.4, 130.1, 129.9, 
129.5, 128.8, 128.7, 128.5, 128.4, 128.3, 128.1, 127.6, 127.4, 124.6, 117.7, 117.3, 
115.1, 114.9, 63.1, 62.5, 61.7, 54.4, 51.5, 60.1, 47.0, 36.9, 36.2, 34.2, 34.1, 32.9, 30.5, 
30.4, 16.6,  12.3, 12.1, 10.6; νmax/cm
-1 (film) 3368, 3146, 3061, 2942, 2307, 1941, 1830, 
1713, 1640, 1600, 1532 and 1447; m/z (ES+) 721.2 (100%, [M+Na]+); found 721.2324, 
C32H41F3N4O6S requires MNa 721.2312 
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N-({2-[2-({N-[(3R)-3-Hydroxy-2-methylhept-6-en-1-
yl](trifluoromethane)sulfonamido}methyl)phenyl]phenyl}methyl)-N-(1ʹ-
hydroxypent-4ʹ-en-2ʹ-yl)cyclopropanecarboxamide 274b 
 
Following general procedure A2, cyclopropane carbonyl chloride (52 mg, 0.49 mmol), 
triethylamine (98.9 mg, 0.98 mmol) and amine 242 (122 mg, 0.099 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CHCl3 gave the amide 274b (40.7 mg, 0.065 mmol, 66%); 
Rf 0.4 (CHCl3);  δH (500 MHz; DMSO-d6) 7.59-7.30 (6H, m, Ar), 7.22-7.17 (1H, m, Ar), 
7.09 (1H, ap t, J 7.6, Ar), 5.8-5.59 (2H, m, 6-H and 4ʹ-H), 4.99-4.87 (4H, m, 5ʹ-HAB and 
7-HAB), 4.49 (0.5H, d, J 16.4, PhCHANTf), 4.44 (0.5H, d, J 16.3, PhCHANTf
atrop), 4.27-
4.10 (1H, m, PhCHBNTf), 3.88-3.74 (2H, m, N(CO)CHABPh), 3.48-3.06 (5H, m, 3-H, 1-
HAB and 1ʹ-HAB), 2.64 (1H, ap t, J 5.4, 2ʹ-H), 2.11-1.97 (3H, m, 3’-HA and 5-HAB), 1.93-
1.84 (1H, m, 3ʹ-HB), 1.54-1.02 (4H, m, 
CPr , 2-H and 4-HAB), 0.87-0.77 (4H, m, 
CPr), 
0.64 (3H, d, Me); δC (75 MHz; CDCl3) 173.57, 173.54, 139.8, 139.7, 138.8, 138.7, 
138.5, 138.4, 135.1, 132.9, 132.8, 129.9, 129.2, 129.1, 128.9, 127.9, 127.8, 127.5, 
127.3, 126.6, 116.8, 116.7, 114.4, 114.3, 69.5, 69.4, 65.7, 55.5, 54.1, 53.5, 50.9, 50.4, 
48.2, 48.1, 36.4, 36.1, 33.6, 33.5, 29.7, 12.4, 10.3, 10.2, 7.7; νmax/cm
-1 (film) 3402, 
3075, 2979, 2254, 2127, 1998, 1827, 1708, 1640, 1545, 1448 and 1383; m/z (ES+) 
623.3 (100%, [M+H]+); found 623.2786, C32H41F3N2O5S requires MH 623.2761 
Full 13C assignment was not possible due to atropisomers 
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2-(2,4-Dimethoxyphenyl)-3-(prop-2-en-1-yloxy)propyl N-{[2-(2-{[(1-hydroxypent-4-
en-2-yl)amino]methyl}phenyl)phenyl]methyl}carbamate 272d 
 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 240D (63 mg, 0.055 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by preparative mass−directed column chromatography and gave the amine 
272d (15.9 mg, 0.028 mmol, 50.4%); Rf 0.21 (EtOAc); νmax/cm
-1 (film) 3441, 3056, 3005, 
2936, 2305, 1711, 1614, 1587, 1544, 1508 and 1465; m/z (ES+) 575.3 (100%, [M+H]+); 
found 575.3142, C34H42N2O6 requires MH 575.3116 
Unable to obtain 1H or 13C spectra, see 272c and 272b for spectra of the same 
scaffolds 
1,1,1-trifluoro-N-[(3R)-3-hydroxy-2-methylhept-6-en-1-yl]-N-{[2-(2-{[(1-
hydroxypent-4-en-2-yl)amino]methyl}phenyl)phenyl]methyl}methanesulfonamide 
274d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 242 (90 mg, 0.073 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by preparative mass−directed column chromatography and gave the amine 
274d (40 mg, 0.072 mmol, 99%); RF 0.33 (EtOAc); νmax/cm
-1 (film) 3591, 3424, 3063, 
2979, 2937, 2320, 1936, 1829, 1713, 1640, 1546, 1447 and 1384; m/z (ES+) 555.3 
(100%, [M+H]+); found 555.2514, C28H37F3N2O4S requires MH 555.2499 
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Unable obtain 1H and 13C due to severe atropisomers 
(17E)-13-(2,4-Dimethoxyphenyl)-20-(hydroxymethyl)-10-oxo-N-(pyridin-3-yl)-
11,15-dioxa-9,21-diazatricyclo[21.4.0.02,7]heptacosa-1(27),2,4,6,17,23,25-heptaene-
21-carboxamide 263a 
 
Following general procedure A1, 3-pyridyl isocyanate (5.28 mg, 0.44 mmol) and amine 
251D (24.3 mg, 0.022 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by column chromatography, eluting with 50:50 petrol−EtOAc gave the 
urea 263a (11.9 mg, 0.018 mmol, 82%); Rf 0.12 (CH2Cl2);     
    
 4.1 (c. 1.2, MeOH); 
νmax/cm
-1 (film); m/z (ES+) 667.3 (100%, [M+H]+); found 667.3126, C38H42N4O7 requires 
MH 667.312610 
Unable obtain 1H and 13C due to severe atropisomers 
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(17E)-13-(2,4-Dimethoxyphenyl)-20-(hydroxymethyl)-21-(1-methyl-1H-imidazole-4-
sulfonyl)-11,15-dioxa-9,21-diazatricyclo[21.4.0.02,7]heptacosa-1(27),2,4,6,17,23,25-
heptaen-10-one 263c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (18.9 mg, 
0.105 mmol), triethylamine (21.2 mg, 0.21 mmol) and amine 251D (23.5 mg, 0.21 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with CH2Cl2 gave the amine 263c (11.4 
mg, 0.016 mmol, 76%); Rf 0.1 (CH2Cl2);     
    
 3.1 (c. 1.1, MeOH); νmax/cm
-1 (film) 3321, 
3005, 2924, 2852, 1711, 1612, 1586, 1531, 1507, 1463 and 1335; m/z (ES+) 713.3 
(20%, [M+H]+); found 713.2614, C36H42N4O8S requires MH 713.2616 
Unable to obtain a 1H or 13C spectra due to geometric isomers and atropisomers 
(17E)-21-Cyclopropanecarbonyl-13-(2,4-dimethoxyphenyl)-20-(hydroxymethyl)-
11,15-dioxa-9,21-diazatricyclo[21.4.0.02,7]heptacosa-1(27),2,4,6,17,23,25-heptaen-
10-one 263b 
 
Following general procedure A2, cyclopropane carbonyl chloride (10.9 mg, 0.105 
mmol), triethylamine (21.2 mg, 0.21 mmol) and amine 251D (22.7 mg, 0.021 mmol) 
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gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with CHCl3 gave the amide 263b (11.1 mg, 
0.018 mmol, 86%); Rf 0.32 (CHCl3);     
     3.2 (c. 0.7, MeOH); δH (500 MHz; CDCl3) 
8.01 (1H, s, Ar), 7.82 (0.1H, br s, Aratrop), 7.56-7.04 (8H, m, Ar), 6.46-6.37 (2H, m, 
DMB), 5.60-5.20 (2H, m, 17 and 18 H), 4.65-2.99 (21H, m, 2 × OMe, 20-H, CHABOH, 
16-HAB, 14-HAB, 13-H, 12-HAB, 8-HAB and 22-HAB), 2.44 (1H, br s, 19-HA), 2.25-1.88 (1H, 
19-HB), 1.26 (2H, 
CPr), 1.10-0.67 (3H, CPr); δC (75 MHz; CDCl3) 162.4, 130.7, 129.5, 
129.1, 128.7, 128.2, 127.5, 127.3, 127.3, 126.3, 104.4, 68.9, 65.6, 63.9, 63.9, 60.8, 
55.4, 55.3, 36.3, 31.7, 31.4, 29.6, 16.5, 12.3, 12.2, 8.6; νmax/cm
-1 (film) 3388, 3060, 
3006, 2926, 2854, 2255, 2127, 1712, 1614, 1587, 1536, 1508 and 1436; m/z (ES+) 
615.3 (100%, [M+H]+); found 637.2875, C36H42N2O7 requires MNa 637.2884 
3-{[2-(2-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)phenyl]methyl}-3-(1-
hydroxypent-4-en-2-yl)-1-(pyridin-3-yl)urea 273a 
 
Following general procedure A1, 3-pyridyl isocyanate (13.8 mg, 0.114 mmol) and 
amine 241D (60.3 mg, 0.057 mmol) gave the crude product after 1 h. The crude product 
was purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, 
ca. 45-51%) was added to the crude product and on reaction completion was 
quenched with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude 
product was purified by column chromatography, eluting with 95:5 CHCl3—MeOH gave 
the urea 273a (25.2 mg, 0.041 mmol, 72%); Rf 0.23 (95:5, CHCl3—MeOH);     
    
 4.9 
(c. 1, MeOH); δH (500 MHz; CDCl3) 8.27 (1H, s, Pyridyl 2-H), 8.17 (1H, d, J 4.7, Pyridyl 
6-H), 8.10 (1H,  Pyridyl 4-Hatrop), 8.03-7.94 (2H, m, Pyridyl 4-H and NH), 7.61-7.56 (2H, 
m, Ar), 7.48-7.33 (3H, m, Ar), 7.19 (2H, dd, J 7.4 and 1.6, pyridyl 5-H), 7.15 (1H, dd, J 
7.4 and 1.4, Ar), 5.61 (1H, ddt, J 17.1, 10.6 and 6.7, 4ʹ-H), 5.57-5.47 (1H, m, 3-H), 
5.00-4.88 (4H, m, 4-HAB and 5ʹ-HAB), 4.56-4.47 (1H, br d, J 16.2, NTfCH2Bn), 4.45 
(0.5H, d, J 16.8, NPyCHA
atrop), 4.35 (0.5H, d, J 16.9, NPyCHA), 4.15 (1H, br s, 
NTfCH2Bn
atrop), 4.10 (0.5H, d, J 16.9, NPyCHB), 3.99 (0.5H, d, J 16.8, NPyCHB
atrop), 
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3.84-3.78 (1H, m, 2ʹ-H), 3.77-3.72 (m, 1-HAB
atrop), 3.69-3.64 (1H, m, 1-HA), 3.57 (1H, dd, 
J 11.2 and 7, 1-HB), 3.36-3.28 (1H, m, 1ʹ-HA), 3.19 (1H, dt, J 14.5 and 7.3, 1ʹ-HB), 2.38-
2.24 (2H, m, 3ʹ-HAB), 2.09-2.02 (2H, m, 2-HAB); δC (75 MHz; CDCl3) 156.9, 156.8, 142.7, 
139.9, 139.8, 139.7, 138.4, 137.1, 134.1, 133.2, 133.2, 132.8, 129.9, 129.8, 129.6, 
128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 127.5, 127.5, 127.1, 127.0, 123.9, 118.1, 
118.0, 117.9, 117.8, 63.7, 60.2, 59.9, 49.4, 48.1, 48.0, 46.9, 33.7, 33.6, 32.4; νmax/cm
-1 
(film) 3291, 3053, 3006, 2872, 1665, 1588, 1541, 1422, 1275, 1261, 1225 and 1198; 
m/z (ES+) 603.2(100%, [M+H]+); found 603.2259, C30H33F3N4O4S requires MH 
603.2247 
N-{[2-(2-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)phenyl]methyl}-1-hydroxy-S-(1-
methyl-1H-imidazol-4ʹ-yl)pent-4ʹ-ene-2ʹ-sulfonamido 273c 
 
Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (45.9 mg, 
0.25 mmol), triethylamine (51.5 mg, 0.510 mmol) and amine 241D (53.3 mg, 0.051 
mmol) gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with CHCl3 gave the sulfonamide 273c 
(23.2 mg, 0.037 mmol, 73%); Rf 0.15 (CHCl3);     
    
 3.9 (c. 1.2, MeOH); δH (500 MHz; 
DMSO-d6; 343 K) 7.79 (1H, d, J 7.8, Ar), 7.71-7.69 (1H, m, Ar), 7.59-7.56 (1H, m, 
Imid), 7.55-7.49 (2H, m, Imid and Ar), 7.48-7.38 (2H, m, Ar), 7.38-7.31 (1H, m, Ar), 
7.21 (1H, d, J 7.1, Ar), 7.09 (1H, dt, J 7.3 and 1.7, Ar), 5.62-5.52 (2H, m, 3-H and 4ʹ-H), 
5.44 (ddt, J 17.1, 10.2 and 7, 3-Hatrop), 4.97-4.93 (1H, m, 4-HA), 4.89 (0.5H, dd, J 17.3 
and 1.7, 4-HB), 4.88 (0.5H, J 17.3 and 1.7, 4ʹ-HB
atrop), 4.84 (0.5H, d, J 10.2 and 1.9, 5ʹ-
HA), 4.78 (0.5H, d , J 16.9, 5ʹ-HB), 4.75 (0.5H, d , J 10, 5ʹ-HA
atrop), 4.66 (0.5H, dd, J 17.1 
and 1.8, 5ʹ-HB
atrop), 4.57-4.40 (2H, m, N(SO2)CH2Ph or PhCH2NTf), 4.33-4.16 (2H, m, 
N(SO2)CH2Ph or PhCH2NTf); 3.91 (d, J 17.3, N(SO2)CH2Ph
atrop), 3.76-3.67 (1H, m, 2ʹ-
H), 3.66 (3H, s, Me), 3.37-3.11 (4H, m, 1-H2 and 1ʹ-HAB), 2.20-1.94 (3H, m, 2-H and 3ʹ-
HA), 1.92-1.83 (1H, m, 3ʹ-HB); δC (125 MHz; DMSO-d6; 343 K) 139.5 (Imid), 139.3 (min 
Imid), 139.2 (Imid), 137.2, 137.1, 137.1, 136.9, 135.3 (3ʹ-C or 4-C atrop), 135.2 (3ʹ-C or 4-
C), 133.8, 133.7, 132.7, 132.6 (Imid atrop), 130.1 (Bip atrop), 130.0, 129.0, 129.9, 128.2 
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(3ʹ-C or 4-C), 128.1, 128.0, 127.7, 127.5, 126.7, 126.6 , 124.7 , 124.6, 119.6 q J 325, 
CF3), 117.4 (5ʹ-C
atrop), 117.3 (5ʹ-C), 116.4 (min 4-C), 116.3 (4-C), 62.4 (1ʹ-C), 61.7 (1ʹ-
Catrop), 60.4 (2ʹ-Catrop), 60.1 (2ʹ-C), 49.5 (PhCH2NTf
atrop), 49.4 (PhCH2NTf), 48.4 (1-
Catrop), 48.2 (1-C), 45.7 (N(SO2)CH2Ph
atrop), 45.5 (N(SO2)CH2Ph), 33.9 (3-C
atrop), 33.5 
(3ʹ-C), 33.4 (Me), 31.9 (2-C); νmax/cm
-1 (film) 3301, 3146, 3061, 3005, 2984, 2941, 2306, 
1716, 1642, 1531, 1446, 1422, 1386 and 1338; m/z (ES+) 649.2 (100%, [M+Na]+); 
found 649.1755, C28H33F3N4O5S requires MNa 649.1737 
N-{[2-(2-{[N-(But-3-en-1-
yl)(trifluoromethane)sulfonamido]methyl}phenyl)phenyl]methyl}-N-(1ʹ-
hydroxypent-4ʹ-en-2ʹ-yl)cyclopropanecarboxamide 273b 
 
Following general procedure A2, cyclopropane carbonyl chloride (24.9 mg, 0.24 mmol), 
triethylamine (48.5 mg, 0.48 mmol) and amine 241D (49.8 mg, 0.048 mmol) gave the 
crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CHCl3 gave the amide 273b (23.1 mg, 0.042 mmol, 88%); 
Rf 0.56 (CHCl3);     
    
 1.6 (c. 0.8, MeOH); δH (500 MHz; CDCl3) 7.79-7.06 (8H, m, Ar), 
5.62 (1H, ddt, 3-H), 5.50 (1H, ddt, 4ʹ-H), 5.07-4.94 (3H, m, 5ʹ-HA and 4-HAB), 4.87 (1H, 
d , J 17.3, 5ʹ-HB), 4.50 (1H, PhCHANTf), 4.12 (1H, PhCHBNTf), 3.95 (1H, dd , J 11.3 
and 4.7, 1ʹ-HB), 3.89-3.82 (1H, m, 1ʹ-HB), 3.56-3.36 (2H, m, C(CO)CHABPh), 3.33-3.08 
(2H, m, 1-H2), 2.71-2.63 (1H, m, 2ʹ-H), 2.14-1.93 (4H, m, 3ʹ-HAB and 2-H2), 1.61-1.52 
(1H, m, CPr), 1.00-0.93 (2H, m, CPr), 0.91-0.82 (2H, m, CPr); δC (75 MHz; CDCl3) 174.8 
(C=O), 140.3, 134.5, 133.3, 128.4, 127.9, 127.3, 117.8, 104.9, 68.2 (1ʹ-C), 65.9 (2ʹ-C), 
55.7, 49.2, 49.2, 47.6, 36.2, 35.9, 32.2, 30.9, 12.7 (CPr), 8.6 (CPr); νmax/cm
-1 (film) 3327, 
3061, 3006, 2985, 2850, 1841, 1726, 1641, 1531, 1445, 1387, 1275, 1262, 1225 and 
1191; m/z (ES+) 551.2 (100%, [M+H]+); found 551.5188, C28H34F3N2O4S requires MH 
551.2186 
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(12Z)-10-(Hydroxymethyl)-N-(pyridin-3-yl)-16-(trifluoromethane)sulfonyl-9,16-
diazatricyclo[16.4.0.02,7]docosa-1(18),2,4,6,12,19,21-heptaene-9-carboxamide 
264a 
 
Following general procedure A1, 3-pyridyl isocyanate (6.8 mg, 0.062 mmol) and amine 
252D (32.1 mg, 0.031 mmol) gave the crude product after 1 h. The crude product was 
purified by F-SPE and following general procedure S1, hydrofluoric acid (0.2 mL, ca. 
45-51%) was added to the crude product and on reaction completion was quenched 
with methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product 
was purified by preparative mass−directed column chromatography, to give the amine 
264a (16.6 mg, 0.029 mmol, 93%); Rf 0.14 (90:10, CHCl3—MeOH);     
     2.7 (c. 1.7, 
MeOH);  δH (500 MHz; CDCl3) 8.67 (1H, s, Ar), 8.43 (1H, s, Ar), 8.23 (1H, s, Ar), 8.09 
(1H, d, J 7.9, Ar), 7.66 (1H, d, J 7.9, Ar), 7.64 (1H, d , J 7.6, Ar), 7.49 (1H, td, J 7.6 and 
1.4, Ar), 7.38 (2H, t, J 8, Ar), 7.32 (1H, t, J 7.4, Ar), 7.30 (1H, br s, Ar), 7.19 (1H, dd, J 
7.7 and 1.4, Ar), 7.09 (1H, dd, J 7.7 and 1.4, Ar), 5.52 (1H, d , J 16.8, 8-HA), 5.48 (1H, 
dd, J 10.2 and 6.8, 13-H), 5.45 (1H, dd, J 10.2 and 4.7, 12-H), 4.97 (1H, d, J 16.7, 17-
HA), 4.32 (1H, d, J 16.7, 17-HB), 4.01 (1H, d, J 16.8, 8-HB), 3.89-3.82 (1H, m, 10-H), 
3.62 (1H, dd, J 10.5 and 2.5, CHAOH), 3.53-3.50 (1H, m, 15-HA), 3.24 (1H, ap t, J 10.5, 
CHBOH), 2.84-2.77 (1H, m, 15-HB), 2.08-1.97 (3H, m, 11-HA and 14-HAB), 1.97-1.91 
(1H, m, 11-HB); δC (75 MHz; CDCl3) 157.6, 138.4, 136.9, 136.7, 132.0, 131.5, 131.1, 
129.4, 128.8, 128.4, 127.4, 126.8, 126.7, 64.1 (CH2OH), 59.1 (10-C), 48.7 (17-C), 46.9 
(15-C), 43.6 (8-C), 28.1 (11-C), 25.1 (14-C); νmax/cm
-1 (film) 3279, 3058, 3024, 2951, 
2250, 1667, 1588, 1539, 1483, 1422 and 1386; m/z (ES+) 575.2 (100%, [M+H]+); found 
575.1935, C28H29F3N4O4S requires MH 575.1934 
 
[(12Z)-9-(1-Methyl-1H-imidazole-4-sulfonyl)-16-(trifluoromethane)sulfonyl-9,16-
diazatricyclo[16.4.0.02,7]docosa-1(18),2,4,6,12,19,21-heptaen-10-yl]methanol 264c 
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Following general procedure A3, 1-methyl-1H-imidazole-4-sulfonyl chloride (29.7 mg, 
0.165 mmol), triethylamine (33 mg, 0.33 mmol) and amine 252D (33.7 mg, 0.033 mmol) 
gave the crude product after 16 h. The crude product was purified by F-SPE and 
following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the crude product and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the 
sulfonamide 264c (10.2 mg, 0.017 mmol, 51%); Rf 0.47 (90:10, CHCl3—MeOH); δH 
(500 MHz; CDCl3/MeOD; 323 K) 8.11 (1H, dt, J 8.0 and 1.1, Ar), 7.65 (1H, d , Ar), 7.50 
(1H, td, J 7.7 and 1.4, Ar), 7.47 (1H, d, J 1.5, Ar), 7.45 (1H, d, J 1.5, Ar), 7.44 (1H, td, J 
7.5 and 1.5, Ar), 7.36-7.30 (2H, m, Ar), 7.06 (1H, dd, J 4.1 and 1.4, Ar), 7.05 (1H, dd, J 
4.1 and 1.4, Ar), 5.38 (1H, dtd, J 10.3, 7.6 and 1.7, 13-H), 5.32 (1H, td, J 10.3 and 4.9, 
12-H), 4.93 (1H, d, J 16.7, 8-HA), 4.85 (1H, d, J 16.5, 17-HA), 4.33 (1H, d, J 16.7, 8-HB), 
4.12 (1H, d, J 16.5, 17-HB), 3.74 (3H, s, NMe), 3.73-3.67 (1H, m, 10-H), 3.43 (1H, dd, J 
12 and 3.1, CHAOH), 3.41-3.35 (1H, m, 15-HA), 3.27 (1H, dd, J 12 and 7.5, CHBOH), 
2.97-2.89 (1H, m, 15-HB), 2.16 (1H, tdd, J 12.8, 7.8 and 4.9, 14-HA), 2.03-1.91 (2H, m, 
14-HB and 11-HA), 1.80-1.73 (1H, m, 11-HB); δC (75 MHz; CDCl3) 140.8, 138.9, 138.1, 
137.4, 136.0, 132.3, 131.9, 130.9, 129.9, 129.4, 128.8, 128.5, 127.7, 127.2, 127.0, 
126.7, 124.2, 120.1 (q, J 325, CF3), 62.9 (CH2OH), 61.6 (10-C), 50.7 (Me), 49.4 (17-C), 
47.9 (15-C), 46.0 (8-C), 27.7 (11-C), 25.5 (14-C); νmax/cm
-1 (film) 2988, 1836, 1649, 
1529, 1469, 1384, 1336, 1275, 1261, 1225 and 1188; m/z (ES+) 599.2 (100%, [M+H]+); 
found 599.1612, C26H29F3N4O5S2 requires MH 599.1604 
[(12Z)-9-Cyclopropanecarbonyl-16-(trifluoromethane)sulfonyl-9,16-
diazatricyclo[16.4.0.02,7]docosa-1(18),2,4,6,12,19,21-heptaen-10-yl]methanol 264b 
 
Following general procedure A2, cyclopropane carbonyl chloride (17.2 mg, 0.165 
mmol), triethylamine (33 mg, 0.33 mmol) and amine 252D (33.3 mg, 0.033 mmol) gave 
the crude product after 16 h. The crude product was purified by F-SPE and following 
general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to the crude 
product and on reaction completion was quenched with methoxytrimethylsilane (0.5 
mL) and stirred for a further 16 h. The crude product was purified by column 
chromatography, eluting with CHCl3 → 95:5 CHCl3—MeOH gave the amide 264b (13.1 
mg, 0.025 mmol, 76%); Rf 0.46 (CHCl3);     
     1.7 (c. 1.3, MeOH); δH (500 MHz; 
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CDCl3) 7.71 (1H, d, J 7.9, Ar), 7.59 (1H, d, J 7.8, Ar), 7.45 (1H, t, J 7.6, Ar), 7.39 (1H, t, 
J 7.5, Ar), 7.34 (1H, t, J 7.5, Ar), 7.30 (1H, t, J 7.4, Ar), 7.17 (1H, d, J 7.5, Ar), 7.02 (1H, 
d, J 7.5, Ar), 5.33-5.22 (2H, m, 12- and 13-H), 4.75 (1H, d, J 15.8, 8-HA), 4.08-3.99 (3H, 
m, CHABOH and 8-HB), 3.75 (1H, d, J 13.1, 17-HA), 3.67 (1H, d, J 13.1, 17-HB), 3.40 
(1H, t, J 12.1, 15-HA), 2.89 (1H, s, 15-HB), 2.77 (1H, s, 10-H), 2.15-1.86 (4H, 11-HAB 
and 14-HAB), 1.65-1.59 (1H, 
CPr); 1.01-0.99 (2H, CPr), 0.90-0.85 (2H, CPr); δC (75 MHz; 
CDCl3) 174.5 (C=O), 139.6, 138.2, 133.2, 130.6, 129.9, 128.8, 128.4, 128.3, 128.1, 
127.3, 126.8, 126.7, 119.4 (q, J 325, CF3), 65.7 (CH2OH), 57.9 (10-C), 51.3 (8-C), 51.1 
(17-C), 50.5 (15-C), 28.5 (11-C), 28.2 (14-C), 12.8 (CPr), 8.4 (CPr), 8.3 (CPr); νmax/cm
-1 
(film) 3014, 2951, 1728, 1456, 1387, 1275, 1261, 1226 and 1183; m/z (ES+) 523.1 
(100%, [M+H]+); found 523.1874, C26H29F3N2O4S requires MH 523.1873 
[(12Z)-16-(Trifluoromethane)sulfonyl-9,16-diazatricyclo[16.4.0.02,7]docosa-
1(18),2,4,6,12,19,21-heptaen-10-yl]methanol 264d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 252D (35 mg, 0.034 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 90:10 CHCl3—MeOH gave the amine 
264d (13.2 mg, 0.029 mmol, 85%); Rf 0.11 (90:10, CHCl3—MeOH);     
     3.5 (c. 1.3, 
MeOH);  δH (500 MHz; CDCl3/MeOD; 323 K) 7.79 (1H, br s, Ar), 7.74 (1H, d, J 7.9, Ar), 
7.49 (1H, ap t, J 7.6, Ar), 7.43 (1H, br s, Ar), 7.39 (1H, d, J 8, Ar), 7.36 (1H, d, J 7.7, 
Ar), 7.15 (1H, d, J 7.8, Ar), 7.07 (1H, d, J 7.6, Ar), 5.29 (1H, td, J 11.2 and 7.4, 12-H), 
5.23 (1H, br s, 13-H), 4.80 (1H, d, J 16, 17-HA), 4.12 (1H, d, J 16, 17-HB), 3.99 (2H, br 
s, 8-HAB), 3.70 (1H, br s, CHAOH), 3.56 (1H, br s, CHBOH), 3.38 (1H, br s, 10-H), 2.98 
(1H, br s, 15-HA), 2.81 (1H, br s, 15-HB), 2.18-1.96 (4H, m, 11-HAB and 14-HAB); δC (125 
MHz; CDCl3/MeOD; 323 K) 138.1, 133.1, 130.9, 130.6, 129.4, 129.3, 128.7, 128.6, 
127.8, 127.8, 125.7, 120.1 (q, J 325, CF3), 77.1 (CH2OH), 51.1 (17-C or 8-C), 50.7 (17-
C or 8-C), 27.5 (11-C), 14-C, 15-C, 10-C missing; νmax/cm
-1 (film) 3371, 3052, 3025, 
2925, 2255, 2127, 1662, 1440, 1386, 1226 and 1190; m/z (ES+) 455.2 (100%, [M+H]+); 
found 455.1619, C22H25F3N2O3S requires MH 455.1611 
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N-(But-3-en-1-yl)-1,1,1-trifluoro-N-{[2-(2-{[(1ʹ-hydroxypent-4ʹ-en-2ʹ-
yl)amino]methyl}phenyl)phenyl]methyl}methanesulfonamide 273d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 241D (51 mg, 0.049 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified by column chromatography, eluting with 95:5 CHCl3—MeOH gave the amine 
273d (17.8 mg, 0.037 mmol, 77%); Rf 0.31 (95:5, CHCl3—MeOH);     
     10.7 (c. 1.7, 
MeOH);  δH (300 MHz; CDCl3) 7.58 (1H, d, Ar), 7.48 (1H, d, Ar), 7.46-7.32 (4H, m, Ar), 
7.25-7.19 (1H, m, Ar), 7.12 (1H, d, J 7.5, Ar), 5.59 (1H, ddt, J 17.4, 10.5 and 7.1, 4ʹ-H), 
5.53 (1H, J 17.1, 10.1 and 6.9, 3-H), 5.05-4.94 (3H, m, 4-HA and 5ʹ-AB), 4.88 (1H, ddd, J 
17.1, 3.4 and 1.7, 4-HB), 4.48 (1H, br s, PhCHANTf), 4.11 (1H, br s, PhCHBNTf), 3.54 
(1H, d, J 12.5, NHCHAPh), 3.48 (1H, d, J 13.5, 1-H), 3.41 (1H, d, J 13.5, 1-H), 3.35 
(1H, d, J 12.5, NHCHBPh), 3.34-3.12 (2H, m, 1ʹ-HAB), 2.58-2.48 (1H, m, 2ʹ-H), 2.11-1.94 
(3H, m, 3ʹ-HAB and 2-HA), 1.68 (1H, br s, 2-HB); δC (75 MHz; CDCl3) 140.3, 139.3, 
134.6, 134.5, 133.2, 132.5, 132.1, 130.2, 129.9, 129.6, 129.3, 128.5, 128.4, 128.1, 
128.0, 127.6, 127.4, 127.4, 122.1, 117.9, 117.9, 117.8, 62.8 (1ʹ-C), 57.9 (2ʹ-C), 57.7 (2ʹ-
C), 49.2 (PhCH2NTf), 49.0 (PhCH2NTf), 48.9 (1-C), 48.6 (1-C), 47.6 (NHCH2Ph), 47.5 
(NHCH2Ph), 36.1 (3ʹ-C), 35.9 (3ʹ-C), 32.2 (2-C), 30.9 (2-C); νmax/cm
-1 (film) 3055, 3006, 
2988, 2305, 1641, 1457, 1387, 1275 and 1262; m/z (ES+) 483.2 (100%, [M+H]+); found 
483.1934, C24H29F3N2O3S requires MH 483.1924 
full carbon assignment was not possible to mixture of atropisomers 
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(17E)-13-(2,4-Dimethoxyphenyl)-20-(hydroxymethyl)-11,15-dioxa-9,21-
diazatricyclo[21.4.0.02,7]heptacosa-1(27),2,4,6,17,23,25-heptaen-10-one 263d 
 
Following general procedure S1, hydrofluoric acid (0.2 mL, ca. 45-51%) was added to 
the amine 251D (24.4 mg, 0.022 mmol) and on reaction completion was quenched with 
methoxytrimethylsilane (0.5 mL) and stirred for a further 16 h. The crude product was 
purified mass−directed preparative liquid chromatography and gave the amine 263d 
(8.2 mg, 0.015 mmol, 68%); Rf 0.42 (95:5, CHCl3—MeOD);     
     15.7 (c. 0.8, MeOH);  
δH (500 MHz; C6D6; 343 K) Z/E <20>80; 7.48 (d, J 7.5, Z), 7.38 (d, J 7.5, Ar), 7.29-7.25 
(2H, m, Ar), 7.22-7.16 (1H, m, Ar), 7.16-6.95 (6H, m, Ar), 6.40-6.34 (2H, m, DMB), 5.54 
(1H, dt, J 15.5 and 7.0, 18-H), 5.49-5.43 (2H, m, 18-H and 17-H Z), 5.40 (1H, dt, J 15.5 
and 5.6, 17-H E), 4.51-4.34 (3H, m, 8- and 12-H E), 4.28 (1H, dd, J 10.7 and 8.6, 8-H), 
4.17-4.10 (m, 12-H Z), 4.04 (1H, dd, J 14 and 4.2, 12-H), 3.83-3.64 (4H, m, 16-H and 
14-H), 3.62 (1H, d, J 11.5, 22-H), 3.45 (1H, d, J 11.5, 22-H), 3.40 (3H, s, OMe E), 3.39 
(s, OMe Z), 3.36-3.30 (1H, m, 13-H), 3.29 (s, OMe Z), 3.28 (3H, s, OMe E), 3.20 (1H, 
dd, J 11 and 4.8, CHBOH), 3.11 (1H, dd, J 11. and 6.4, CHBOH), 2.42-2.35 (1H, m, 20-
H), 2.06-1.94 (2H, m, 19-H); δC (125 MHz; C6D6; 343 K) 160.2, 158.6, 155.9, 151.7, 
140.7, 130.1, 129.8, 129.5, 129.2, 127.2, 121.0, 112.9, 104.9, 99.2, 64.2, 63.8, 59.5, 
54.9, 49.9, 44.6, 38.6, 37.7; νmax/cm
-1 (film) 2929, 2852, 1709, 1613, 1587, 1542, 1508, 
1465, 1275, 1261 and 1037; m/z (ES+) 547.3 (100%, [M+H]+); found 547.2816, 
C32H38N2O6 requires MH 547.2803 
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Appendix 1 Example NMR spectra from final compound 
The fluorous tag allowed the expedient and efficient purification of the intermediates at 
multiple steps throughout the series; this is exemplified in Spectra 1-5. Spectrum 1 
shows the product of the first coupling reaction, mediated by the Fukuyama—
Mitsunobu reaction followed by deacetylation. Spectrum 2 shows the product of the 
final coupling reaction to append the capping building block. Spectrum 3 shows the 
purified product (246) from a ring closing metathesis reaction; notably, the spectrum is 
broad, suggesting slow interconversionbetween conformers. Spectrum 4 shows the 
product 246D after removal of the 2-nitrobenzenesulfonamide group; the spectrum is 
sharp suggesting faster interconversion between conformers. Finally, Spectrum 5 is 
that of a final compound after diversification and release from the fluorous tag. 
 
Spectrum 1 500 MHz 
1
H NMR spectrum following a Fukuyama—Mitsunubo reaction, F-SPE and 
deacetylation  
251 
 
 
Spectrum 2 500 MHz 
1
H NMR spectrum following a Fukuyama—Mitsunubo reaction and F-SPE  
 
 
Spectrum 3 500 MHz 
1
H NMR spectrum following ring-closing metathesis followed by column 
chromatography 
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Spectrum 4 500 MHz 
1
H NMR spectrum following removal of the 2-nitrobenzenesulfonamide and F-SPE 
 
Spectrum 5 500 MHz 
1
H NMR spectrum following the reaction between the amine 246
D
 and 3-pyridyl 
isocyanate followed by F-SPE; removal of the silyl protecting group with HF, followed by column 
chromatography to give the macrocycle 159a 
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Appendix 2 Crystal structure of 159a 
 
View of 159a. Ellipsoid probability: 50%. 
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Table 1.  Crystal data and structure refinement for 159a. 
 
Archive code 11_04_13 
Identification code 159a                                            
Formula C22H25F3N4O4S 
Formula weight 498.52 
Size 0.53 x 0.06 x 0.06 mm 
Crystal morphology Colourless needle 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Tetragonal 
Space group P41 
Unit cell dimensions a = 11.6528(4) Å  = 90° 
 b = 11.6528(4) Å  = 90° 
 c = 17.6255(6) Å  = 90° 
Volume 2393.33(14) Å
3
 
Z 4 
Density (calculated) 1.384 Mg/m
3
 
Absorption coefficient 0.194 mm
-1
 
F(000) 1040 
Data collection range 1.75  28.31° 
Index ranges -15  h 15,  -10  k  15,  -19  l  23 
Reflections collected 18591 
Independent reflections 5631 [R(int) = 0.0503] 
Observed reflections 4660 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9884 and 0.7039 
Refinement method Full 
Data / restraints / parameters 5631 / 1 / 308 
Goodness of fit 1.011 
Final R indices  [I >2(I)] R1 = 0.0397, wR2 = 0.0780 
R indices (all data) R1 = 0.0554, wR2 = 0.0846 
Largest diff. peak and hole 0.172 and -0.214e.Å
-3
 
Absolute structure parameter 0.03(6) 
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Table 2. Atomic co-ordinates (x 10
4
) and equivalent isotropic displacement parameters 
(Å
2
 x 10
4
) with standard uncertainties (s.u.s) in parentheses. Ueq is defined as 
1
/3 of the 
trace of the orthogonalized Uij tensor. 
_____________________________________________________________________ 
 
  x y z Ueq 
_____________________________________________________________________ 
 
 N(1) -2775.3(13) 5806.2(13) 2054.8(9) 206(3) 
 C(2) -2085.6(16) 5305.1(16) 1448.6(11) 206(4) 
 C(3) -1535.2(15) 6181.9(16) 922.9(11) 218(4) 
 C(4) -1770.2(17) 7346.8(17) 987.1(13) 274(4) 
 C(5) -1230.7(19) 8149.8(19) 518.1(14) 332(5) 
 C(6) -461.2(18) 7784.6(19) -22.6(14) 353(5) 
 C(7) -235.8(17) 6618.2(18) -101.3(12) 285(5) 
 C(8) -761.3(15) 5806.9(17) 364.4(12) 225(4) 
 C(9) -500.1(17) 4553.6(17) 231.7(12) 258(4) 
 N(10) 197.0(13) 4035.1(14) 856.3(10) 250(4) 
 C(11) 1359.8(15) 4543.3(17) 990.9(13) 277(5) 
 C(12) 1539.6(18) 5025.6(18) 1785.5(13) 309(5) 
 C(13) 648.0(17) 5865.3(18) 2034.9(13) 295(5) 
 C(14) -94.6(17) 5658.5(18) 2589.8(13) 288(5) 
 C(15) -1048.7(17) 6441.2(17) 2830.9(12) 266(4) 
 C(16) -2280.1(16) 5937.6(17) 2822.6(11) 234(4) 
 C(17) -2357.6(18) 4790(2) 3226.4(13) 317(5) 
 O(18) -1860.2(14) 4887.9(17) 3960.3(10) 473(5) 
 O(21) -4470.8(11) 6577.2(11) 2454.4(8) 230(3) 
 C(21) -3880.4(15) 6141.6(16) 1947.8(11) 203(4) 
 N(22) -4321.9(13) 5970.2(14) 1229.7(9) 225(4) 
 C(23) -5375.4(15) 6403.4(16) 965.4(11) 210(4) 
 C(24) -5951.6(18) 7331.4(18) 1283.7(12) 298(5) 
 C(25) -6944.2(18) 7712.5(19) 935.4(13) 330(5) 
 C(26) -7338.6(17) 7180.3(18) 293.8(12) 280(5) 
 N(27) -6810.3(14) 6274.4(15) -11.9(10) 281(4) 
 C(28) -5854.7(17) 5902.5(17) 326.5(12) 258(4) 
 S(31) -51.7(4) 2737.1(5) 1099.8(3) 320.7(13) 
 O(31) 608.6(15) 2459.1(14) 1749.8(11) 478(5) 
 F(32) 57.8(19) 2054.1(16) -317.5(11) 809(6) 
 O(32) -1251.3(12) 2517.5(13) 1064.0(11) 414(4) 
 C(32) 555(3) 1829(2) 347(2) 553(8) 
 F(33) 372.9(18) 728.1(13) 500.9(14) 847(6) 
 F(34) 1658.6(16) 1992.3(17) 276.3(15) 981(8) 
_____________________________________________________________________ 
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Table 3. Anisotropic displacement parameters (Å
2
 x 10
3
). The anisotropic displacement 
factor exponent takes the form: 
 
-22[h2a*2U11 + ... + 2 h k a* b* U12] 
_____________________________________________________________________ 
 
  U11 U22 U33 U23 U13 U12 
_____________________________________________________________________ 
 
 N(1) 20.9(8) 23.7(8) 17.1(8) -0.3(6) -1.3(7) 1.2(6) 
 C(2) 18.6(9) 23.3(10) 20.0(10) -1.0(8) 1.0(7) 1.5(7) 
 C(3) 16.9(9) 25.4(10) 23.1(10) 3.0(8) -3.0(7) 0.6(7) 
 C(4) 24.9(10) 28.2(10) 29.1(11) 1.9(9) 1.3(8) 1.7(8) 
 C(5) 33.4(12) 27.0(11) 39.1(13) 4.8(9) -2.2(10) -0.6(9) 
 C(6) 27.3(11) 38.0(13) 40.6(14) 16.3(11) 0.5(10) -4.1(9) 
 C(7) 21.4(10) 38.8(12) 25.4(12) 5.9(9) 0.6(8) 0.5(9) 
 C(8) 15.6(9) 30.1(10) 21.7(10) 2.2(8) -2.1(8) 1.6(8) 
 C(9) 20.1(10) 32.8(11) 24.4(11) 0.0(9) -0.4(8) 2.4(8) 
 N(10) 19.7(8) 24.7(8) 30.4(10) 2.4(7) -0.4(7) 0.7(6) 
 C(11) 14.3(9) 29.2(10) 39.7(13) 4.9(9) 1.2(9) -1.1(7) 
 C(12) 21.0(10) 33.8(12) 37.8(13) 4.5(10) -3.0(9) -4.4(8) 
 C(13) 23.3(11) 27.5(11) 37.8(13) 4.2(9) -7.2(9) -3.2(8) 
 C(14) 21.3(10) 29.8(11) 35.2(13) 3.0(9) -6.4(9) -3.3(8) 
 C(15) 25.0(10) 29.3(11) 25.5(11) -2.2(9) -5.1(8) -3.8(8) 
 C(16) 22.2(10) 31.6(11) 16.5(10) -3.0(8) -0.9(8) 2.9(8) 
 C(17) 24.6(11) 43.9(13) 26.8(12) 10.6(10) -4.6(9) -5.0(10) 
 O(18) 34.5(9) 80.4(14) 27.0(9) 25.0(9) -8.1(7) -17.4(8) 
 O(21) 23.1(7) 28.5(7) 17.4(7) -2.9(6) 3.1(6) 2.1(6) 
 C(21) 18.4(9) 20.8(9) 21.7(11) 0.2(8) -0.4(8) -3.0(7) 
 N(22) 18.4(8) 29.4(9) 19.7(9) -4.5(7) -1.0(6) 4.2(7) 
 C(23) 16.7(9) 25.1(10) 21.2(10) 3.0(8) 1.0(7) -2.3(7) 
 C(24) 30.6(11) 31.9(11) 26.7(12) -7.5(9) -4.8(9) 5.8(9) 
 C(25) 29.8(11) 34.4(12) 34.9(13) -4.7(10) -0.6(9) 8.4(9) 
 C(26) 17.3(9) 33.3(11) 33.5(13) 4.9(9) -3.2(9) -0.9(8) 
 N(27) 24.5(9) 30.4(9) 29.3(10) 1.5(8) -5.8(7) -5.0(7) 
 C(28) 23.6(10) 25.9(10) 27.9(12) -2.0(8) 0.5(9) -0.9(8) 
 S(31) 27.4(3) 27.1(3) 41.7(3) 4.0(2) -2.4(2) -2.9(2) 
 O(31) 46.7(10) 37.8(10) 58.9(13) 17.7(8) -19.0(9) -8.3(8) 
 F(32) 113.2(16) 69.8(12) 59.6(13) -26.6(10) 5.2(11) 11.0(11) 
 O(32) 28.4(8) 40.8(9) 55.0(11) 6.8(8) -1.5(8) -11.7(7) 
 C(32) 49.4(17) 36.7(15) 80(2) -15.2(15) 6.9(15) 0.9(12) 
 F(33) 98.4(15) 30.7(9) 125.0(17) -16.1(10) -2.1(13) 0.7(9) 
 F(34) 52.2(11) 82.1(14) 160(2) -58.3(14) 34.7(12) 1.3(9) 
_____________________________________________________________________ 
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Table 4. Hydrogen atom co-ordinates (x 10
3
) and isotropic displacement parameters 
(Å
2
 x 10
2
) with s.u.s in parentheses. 
_____________________________________________________________________ 
 
  x y z Ueq 
_____________________________________________________________________ 
 
 H(2a) -2579. 4790. 1143. 25. 
 H(2b) -1473. 4830. 1679. 25. 
 H(4) -2307. 7602. 1356. 33. 
 H(5) -1395. 8944. 572. 40. 
 H(6) -86. 8326. -340. 42. 
 H(7) 287. 6369. -480. 34. 
 H(9a) -1231. 4126. 184. 31. 
 H(9b) -78. 4472. -253. 31. 
 H(11a) 1486. 5166. 618. 33. 
 H(11b) 1946. 3945. 897. 33. 
 H(12a) 1555. 4380. 2150. 37. 
 H(12b) 2299. 5405. 1805. 37. 
 H(13) 610. 6585. 1783. 35. 
 H(14) -15. 4955. 2857. 35. 
 H(15a) -1038. 7123. 2496. 32. 
 H(15b) -882. 6710. 3352. 32. 
 H(16) -2782. 6486. 3106. 28. 
 H(17a) -3171. 4555. 3272. 38. 
 H(17b) -1946. 4197. 2930. 38. 
 H(18) -2291. 4573. 4281. 57. 
 H(22) -3911. 5557. 912. 27. 
 H(24) -5670. 7694. 1729. 36. 
 H(25) -7353. 8345. 1142. 40. 
 H(26) -8013. 7466. 57. 34. 
 H(28) -5479. 5253. 116. 31. 
_____________________________________________________________________ 
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 Table 5.   Interatomic distances (Å) with s.u.s in parentheses. 
_____________________________________________________________________ 
 
 N(1)-C(21) 1.359(2) N(1)-C(2) 1.459(2) 
 N(1)-C(16) 1.479(2) C(2)-C(3) 1.521(3) 
 C(3)-C(4) 1.389(3) C(3)-C(8) 1.405(3) 
 C(4)-C(5) 1.398(3) C(5)-C(6) 1.376(3) 
 C(6)-C(7) 1.391(3) C(7)-C(8) 1.394(3) 
 C(8)-C(9) 1.510(3) C(9)-N(10) 1.496(3) 
 N(10)-C(11) 1.498(2) N(10)-S(31) 1.5986(17) 
 C(11)-C(12) 1.523(3) C(12)-C(13) 1.493(3) 
 C(13)-C(14) 1.328(3) C(14)-C(15) 1.500(3) 
 C(15)-C(16) 1.550(3) C(16)-C(17) 1.518(3) 
 C(17)-O(18) 1.422(3) O(21)-C(21) 1.236(2) 
 C(21)-N(22) 1.381(2) N(22)-C(23) 1.407(2) 
 C(23)-C(28) 1.386(3) C(23)-C(24) 1.391(3) 
 C(24)-C(25) 1.383(3) C(25)-C(26) 1.369(3) 
 C(26)-N(27) 1.335(3) N(27)-C(28) 1.336(3) 
 S(31)-O(31) 1.4175(17) S(31)-O(32) 1.4226(15) 
 S(31)-C(32) 1.838(3) F(32)-C(32) 1.333(4) 
 C(32)-F(34) 1.306(3) C(32)-F(33) 1.328(3) 
_____________________________________________________________________ 
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 Table 6.   Angles between interatomic vectors (°) with s.u.s in parentheses. 
_____________________________________________________________________ 
 
 C(21)-N(1)-C(2) 122.38(16) C(21)-N(1)-C(16) 117.83(15) 
 C(2)-N(1)-C(16) 119.77(15) N(1)-C(2)-C(3) 114.17(15) 
 C(4)-C(3)-C(8) 119.17(18) C(4)-C(3)-C(2) 121.58(17) 
 C(8)-C(3)-C(2) 119.25(17) C(3)-C(4)-C(5) 121.1(2) 
 C(6)-C(5)-C(4) 119.7(2) C(5)-C(6)-C(7) 119.6(2) 
 C(6)-C(7)-C(8) 121.4(2) C(7)-C(8)-C(3) 118.93(18) 
 C(7)-C(8)-C(9) 118.45(18) C(3)-C(8)-C(9) 122.60(17) 
 N(10)-C(9)-C(8) 112.71(16) C(9)-N(10)-C(11) 116.63(16) 
 C(9)-N(10)-S(31) 118.77(13) C(11)-N(10)-S(31) 119.71(13) 
 N(10)-C(11)-C(12) 114.58(17) C(13)-C(12)-C(11) 114.62(18) 
 C(14)-C(13)-C(12) 123.5(2) C(13)-C(14)-C(15) 125.6(2) 
 C(14)-C(15)-C(16) 116.95(16) N(1)-C(16)-C(17) 108.34(16) 
 N(1)-C(16)-C(15) 114.13(16) C(17)-C(16)-C(15) 112.60(16) 
 O(18)-C(17)-C(16) 109.36(18) O(21)-C(21)-N(1) 123.05(17) 
 O(21)-C(21)-N(22) 120.93(17) N(1)-C(21)-N(22) 116.02(16) 
 C(21)-N(22)-C(23) 125.23(16) C(28)-C(23)-C(24) 117.42(18) 
 C(28)-C(23)-N(22) 118.01(17) C(24)-C(23)-N(22) 124.52(18) 
 C(25)-C(24)-C(23) 118.32(19) C(26)-C(25)-C(24) 120.1(2) 
 N(27)-C(26)-C(25) 122.45(19) C(28)-N(27)-C(26) 117.43(18) 
 N(27)-C(28)-C(23) 124.21(19) O(31)-S(31)-O(32) 121.88(11) 
 O(31)-S(31)-N(10) 109.56(9) O(32)-S(31)-N(10) 109.66(9) 
 O(31)-S(31)-C(32) 104.06(13) O(32)-S(31)-C(32) 104.01(12) 
 N(10)-S(31)-C(32) 106.33(12) F(34)-C(32)-F(33) 108.5(2) 
 F(34)-C(32)-F(32) 108.4(3) F(33)-C(32)-F(32) 107.5(2) 
 F(34)-C(32)-S(31) 111.3(2) F(33)-C(32)-S(31) 110.3(2) 
 F(32)-C(32)-S(31) 110.74(19) 
_____________________________________________________________________ 
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 Table 7.   Torsion angles (°) with s.u.s in parentheses. 
_____________________________________________________________________ 
 
 C(21)-N(1)-C(2)-C(3) 82.7(2) C(16)-N(1)-C(2)-C(3) -98.72(19) 
 N(1)-C(2)-C(3)-C(4) -5.5(3) N(1)-C(2)-C(3)-C(8) 173.77(17) 
 C(8)-C(3)-C(4)-C(5) -1.5(3) C(2)-C(3)-C(4)-C(5) 177.81(19) 
 C(3)-C(4)-C(5)-C(6) 0.7(3) C(4)-C(5)-C(6)-C(7) 0.6(3) 
 C(5)-C(6)-C(7)-C(8) -0.9(3) C(6)-C(7)-C(8)-C(3) 0.1(3) 
 C(6)-C(7)-C(8)-C(9) 178.33(18) C(4)-C(3)-C(8)-C(7) 1.1(3) 
 C(2)-C(3)-C(8)-C(7) -178.22(17) C(4)-C(3)-C(8)-C(9) -177.05(18) 
 C(2)-C(3)-C(8)-C(9) 3.6(3) C(7)-C(8)-C(9)-N(10) 110.6(2) 
 C(3)-C(8)-C(9)-N(10) -71.3(2) C(8)-C(9)-N(10)-C(11) -61.2(2) 
 C(8)-C(9)-N(10)-S(31) 143.63(14) C(9)-N(10)-C(11)-C(12) 120.77(19) 
 S(31)-N(10)-C(11)-C(12) -84.3(2) N(10)-C(11)-C(12)-C(13) -53.0(2) 
 C(11)-C(12)-C(13)-C(14) 112.5(2) C(12)-C(13)-C(14)-C(15)-176.15(19) 
 C(13)-C(14)-C(15)-C(16) 123.6(2) C(21)-N(1)-C(16)-C(17) 97.9(2) 
 C(2)-N(1)-C(16)-C(17) -80.7(2) C(21)-N(1)-C(16)-C(15) -135.81(17) 
 C(2)-N(1)-C(16)-C(15) 45.6(2) C(14)-C(15)-C(16)-N(1) -74.4(2) 
 C(14)-C(15)-C(16)-C(17) 49.6(3) N(1)-C(16)-C(17)-O(18) 178.58(16) 
 C(15)-C(16)-C(17)-O(18) 51.4(2) C(2)-N(1)-C(21)-O(21) -179.30(17) 
 C(16)-N(1)-C(21)-O(21) 2.1(3) C(2)-N(1)-C(21)-N(22) 0.6(3) 
 C(16)-N(1)-C(21)-N(22) -177.97(16) O(21)-C(21)-N(22)-C(23) 9.8(3) 
 N(1)-C(21)-N(22)-C(23) -170.08(17) C(21)-N(22)-C(23)-C(28)-161.77(18) 
 C(21)-N(22)-C(23)-C(24) 20.8(3) C(28)-C(23)-C(24)-C(25) -1.6(3) 
 N(22)-C(23)-C(24)-C(25) 175.87(19) C(23)-C(24)-C(25)-C(26) 0.0(3) 
 C(24)-C(25)-C(26)-N(27) 1.3(3) C(25)-C(26)-N(27)-C(28) -1.0(3) 
 C(26)-N(27)-C(28)-C(23) -0.7(3) C(24)-C(23)-C(28)-N(27) 2.0(3) 
 N(22)-C(23)-C(28)-N(27) -175.59(18) C(9)-N(10)-S(31)-O(31) -173.64(15) 
 C(11)-N(10)-S(31)-O(31) 31.92(19) C(9)-N(10)-S(31)-O(32) -37.41(18) 
 C(11)-N(10)-S(31)-O(32) 168.15(16) C(9)-N(10)-S(31)-C(32) 74.47(18) 
 C(11)-N(10)-S(31)-C(32) -79.97(19) O(31)-S(31)-C(32)-F(34) -55.5(3) 
 O(32)-S(31)-C(32)-F(34) 176.0(2) N(10)-S(31)-C(32)-F(34) 60.2(3) 
 O(31)-S(31)-C(32)-F(33) 65.1(2) O(32)-S(31)-C(32)-F(33) -63.5(2) 
 N(10)-S(31)-C(32)-F(33) -179.3(2) O(31)-S(31)-C(32)-F(32)-176.09(19) 
 O(32)-S(31)-C(32)-F(32) 55.3(2) N(10)-S(31)-C(32)-F(32) -60.4(2) 
_____________________________________________________________________ 
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 Table 9.   Hydrogen bonded distances (Å) and angles (°). Standard uncertainties  
 are included in parentheses for values which do not involve constrained hydrogen  
 atoms. 
__________________________________________________________________ 
  
 Atoms (D-H…A) D-H H…A D…A DHA 
__________________________________________________________________ 
 
 O(18)-H(18)...N(27)
(b)
 0.84 1.9 2.742(2) 174.4 
 N(22)-H(22)...O(21)
(a)
 0.88 2.19 3.034(2) 161.8 
__________________________________________________________________ 
 
Key giving operations for symmetry related atoms:  
 
  (a) -1-y, +x, -1/4+z         
  (b) -1-x, 1-y, 1/2+z         
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